!

!

!

!

Università degli Studi di Padova Department of Biomedical Sciences

!

!

School of Bioscience and Biotechnology

Curriculum: Biotechnology

XXV Cycle

STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF

SARCOENDOPLASMIC RETICULUM Ca2+-ATPases (SERCA)

!

!

Director of PhD School: Ch.mo Prof. Giuseppe Zanotti

Coordinator of the curriculum: Ch.mo Prof. Giorgio Valle

Supervisor: Ch.mo Prof. Giuseppe Zanotti

!

PhD candidate: Sara Giannetti

!

!

!

December 2012

!

!

!

!

!

!

!

!

!

!

CONTENTS

3

CONTENTS

SUMMARY 5

RIASSUNTO 10

1. INTRODUCTION 15 1.1 CALCIUM SIGNALING 17 1.1.1 HOW DOES THE CA2+-SIGNAL WORK? 18 1.1.2 THE CORE OF CALCIUM SIGNALING NETWORK 20 1.2 THE SERCA PUMP 22 1.2.1 THE P-TYPE ATPASE FAMILY 22 1.2.2 ISOFORMS OF THE SERCA PUMP 24 1.2.3 SERCA REGULATORY PROTEINS 24 1.2.4 REGULATION OF SERCA 2A ACTIVITY 25 1.3 STRUCTURAL PROPERTIES OF SERCA PUMP. A DETAILED OVERVIEW 26 1.3.1 E1 VERSUS E2: THE FIRST STEPS INSIDE THE MOLECULAR UNDERSTANDING OF REACTION CYCLE 26 1.3.2 E1-P PHOSPHO-INTERMEDIATE STRUCTURES AS A RESPONSE TO ATP-BINDING SITE CONTROVERSY 28 1.3.3 E2-P PHOSPHO-INTERMEDIATE STRUCTURES AND THE CATALYTIC CYCLE IS COMPLETED 32 1.3.4 INSIGHT INTO THE TRANSPORT MECHANISM COUPLED TO ATP HYDROLYSIS 33 1.4 THE HUMAN SERCA PUMPS GENE MUTATIONS 36 1.5 THE EF-HAND AS THE STRUCTURAL MOTIF OF THE CA2+-BINDING PROTEINS FAMILY 37 1.5.1 SWIPROSIN-1/EFHD2 AND SWIPROSIN-2/EFHD1 39

2. CRYSTAL STRUCTURE OF ENDOPLASMIC RETICULUM CA2+-ATPASE (SERCA) FROM BOVINE MUSCLE 41

2.1 INTRODUCTION 43 2.2 MATERIALS AND METHODS 44 2.2.1 PROTEIN EXTRACTION, PURIFICATION AND CRYSTALLIZATION 44 2.2.2 STRUCTURE DETERMINATION AND REFINEMENT 45 2.2.3 ACTIVITY MEASUREMENTS 47 2.3 RESULTS 47 2.3.1 SERCA1A ISOFORM 47 2.3.2 SERCA 1A ACTIVITY 48 2.3.3 CRYSTAL STRUCTURE OF BOVINE SERCA 1A 48 2.4 DISCUSSION 50 2.4.1 SERCA MUTATIONS 56 2.5 CONCLUSIONS 57 2.6 ACCESSION NUMBERS 58

4

2.7 ACKNOWLEDGMENTS 58 2.8 SUPPLEMENTARY FIGURES 59

3. HETEROLOGOUS EXPRESSION AND AFFINITY PURIFICATION OF HUMAN SERCA 2A IN SACCHAROMYCES CEREVISIAE 65

3.1 INTRODUCTION 67 3.2 MATERIALS AND METHODS 68 3.2.1 HETEROLOGOUS EXPRESSION OF HUMAN SERCA 2AR863G IN S. CEREVISIAE 68 3.2.2 PROTEIN EXPRESSION 70 3.2.3 ISOLATION OF YEAST MEMBRANES 70 3.2.4 SOLUBILIZATION OF MEMBRANE FRACTIONS 71 3.2.5 FORMATION OF PHOSPHO-INTERMEDIATE ENZYME ON MEMBRANE FRACTION 71 3.2.6 PURIFICATION OF H SERCA 2AR863G 72 3.2.7 BATCH PURIFICATION WITH AVIDINE AGAROSE 72 3.2.8 GEL-FILTRATION 72 3.2.9 PROTEIN RECONSTITUTION AND CRYSTALLIZATION TRIALS 73 3.2.10 SODIUM DODECYL SULFATE-POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE) 73 3.2.11 WESTERN BLOTTING 73 3.3 RESULTS AND DISCUSSION 74 3.3.1 OVER-EXPRESSION OF H SERCA 2AR863G IN S. CEREVISIAE 74 3.3.2 HUMAN SERCA, ISOFORM 2A, PURIFICATION 77 3.3.3 CRYSTALLIZATION TRIALSFRONTESPIZIO 80 3.4 CONCLUSIONS 80 3.5 ACKNOWLEDGEMENTS 80

4. EXPRESSION AND PURIFICATION OF SWIPROSIN1/EFHD2, A NOVEL HUMAN TAU-ASSOCIATED PROTEIN 81

4.1 INTRODUCTION 83 4.2 MATERIALS AND METHODS 83 4.2.1 HETEROLOGOUS EXPRESSION OF HUMAN EFHD2 IN E. COLI 83 4.2.2 IMAC PURIFICATION AND SIZE EXCLUSION CHROMATOGRAPHY 84 4.2.3 SDS-PAGE AND WESTER BLOT ANALYSIS 84 4.2.4 LIMITED PROTEOLYSIS 85 4.2.5 CRYSTALLIZATION 85 4.3 RESULTS AND DISCUSSION 86

ACKNOWLEDGEMENTS 91

APPENDIX 93

REFERENCES 105

SUMMARY

5

SUMMARY

!"#$% &'% ()*% +,'(% -*.'"(&/*% "+,01% ()*% '*2,03% +*''*01*.'% "03% &'% .*'4,0'&5/*% 6,.%

2,0(.,//&01%'*-*."/%2*//7/".%4.,2*''*'8%9.,+%2*//%1.,:()%"03%4.,/&6*."(&,0%(,%4.,1."++*3%2*//%

3*"();% &('% -*.'"(&/&(<% &'% *+4/,<*3% (,% .*17/"(*% 4.,2*''*'% "'% 3&-*.'*% "'% +7'2/*% 2,0(."2(&,0;%

'*2.*(&,0;% *0*.1*(&2% +*("5,/&'+% "03% '<0"4(&2% 4/"'(&2&(<8% =)*.*6,.*;% ()*% &0-,/-*+*0(% ,6%

2"/2&7+%&0%2,0(.,//&01%'*-*."/%"'4*2('%,6%2*//%4)<'&,/,1<%3*+"03'%()*%7'*%,6%"%',4)&'(&2"(*3%

+*2)"0&'+%5"'*3%,0%"%:&3*%'*(%,6%4.,(*&0%2,+4,0*0('% >(,,/?&(@;%"5/*% (,%7'*%,'2&//"(&,0'% &0%

2"/2&7+% 2,02*0(."(&,0% "'% "% '&10"/% (,% .*17/"(*% "% -".&*(<% ,6% !"#$%&'(&)*)+', -./0'&&'&1%

A,0*()*/*'';%2*//'%".*%70"5/*%(,%'7'("&0%4.,/,01*3%&02.*"'*%,6% &0(."2*//7/".%2"/2&7+8%9,.%()&'%

+,(&6% *7?".<,(&2% 2*//'% )"-*% *-,/-*3% "0% *66&2&*0(% (."0'4,.(% '<'(*+% >!"#$, 2/3'/&*"&)&@% (,%

+"&0("&0%()*%&0(."2*//7/".%2,02*0(."(&,0%,6%2"/2&7+%:&()&0%"%."01*%#BCDBB%0E8%F'%"%.*'4,0'*%

(,%"%'4*2&6&2%*G(."2*//7/".%'(&+7/7';%"%."4&3%&02.*"'*%,6%6.**%!"#$%>HBBCDBBB%0E@%.*'7/('% &0%"0%

&++*3&"(*%(&''7*%'4*2&6&2%2*//7/".%.*'4,0'*;%()"0?'%(,%()*%"5&/&(<%,6%!"#$%&'()*()+&,-./0()1%(,%

5&03% 2"/2&7+% 5<% ()*% I9C)"03%+,(&6% "03% "2(&-"(*% '*-*."/% 3,:0'(.*"+% *66*2(,.'% &0-,/-*3% &0%

,()*.% '&10"/&01% 4"():"<8% =)*% 2,,.3&0"(*3% .*+,-"/% ,6% 2<(,',/&2% 6.**%!"#$% ,7(% ,6% ()*%4/"'+"%

+*+5."0*%"03%&0(,%&0(*.0"/%,.1"0*//*'%>IJKLJ@%-&"%()*%23!4%47+4%>4/"'+"%+*+5."0*%!"#$C

F=M"'*@%"03%()*%4"$5!"#$'602"(7'.;%"03%-&"%()*%567!4%47+4%>'".2,4/"'+&2%.*(&27/7+%!"#$C

F=M"'*@%.*'(,.*'%!"#$%(,%&('%.*'(&01%/*-*/8%

=)*% +,'(% '4*2&"/&N*3% +*2)"0&'+% ,6% 2,,.3&0"(&,0% ,6% 2"/2&7+% '&10"/&01% 0*(:,.?% 2"0%

4,''&5/<%5*% 6,703% &0% '?*/*("/%+7'2/*;%:)*.*% ()*% &02.*"'*% &0% 2<(,',/&2%!"#$% .*'7/('% &0%+7'2/*%

2,0(."2(&,0% "03% .*+,-"/% ,6% !"#$% &0372*'% +7'2/*% .*/"G"(&,08% L&02*% &0% )7+"0% "5,7(% OBP% ,6%

2<(,',/&2% !"#$% .*(7.0'% (,% ()*% '".2,4/"'+&2% .*(&27/7+% >LJ@% "03% '&02*% &(% .*4.*'*0('% ()*%+"Q,.%

',7.2*%,6%!"#$% '(,.*;% ()*%LIJ!F%47+4% &'%2,0'*R7*0(/<% &0-,/-*3% &0% .*17/"(&01% ()*%*G2&("(&,0C

2,0(."2(&,0%2,74/*3%+*2)"0&'+%&0%'?*/*("/%"03%2".3&"2%+7'2/*8%%

=)*%LIJ!F%4.,(*&0%')".*'%()*%2"("/<(&2%4.,4*.(&*'%,6%&,0C+,(&-*%F=M"'*'%,6%()*%MC(<4*%

6"+&/<;%2)"."2(*.&N*3%5<%()*%6,.+"(&,0%,6%"0%*0*.1&N*3%&0(*.+*3&"(*;%.*'7/(&01%6.,+%()*%"7(,C

6

4),'4),.</"(&,0% ,6% "% ?*<% &0-".&"0(% "'4".("(*% .*'&37*% &0% "% )&1)/<% 2,0'*.-*3% '*R7*02*8%

S"'&2"//<;% ()*% MC(<4*% 6"+&/<% +*+5*.'% 2,74/*% ()*% "2(&-*% (."0'4,.(% ,6% &,0'% "2.,''% ()*%

+*+5."0*% (,% ()*%)<3.,/<'&'%,6%F=M% ().,71)%"% .*"2(&,0%2<2/*%4.,4,'*3%+,.*% ()"0%TB%<*".'%

"1,;% 2"//*3% 8/&*%9:;'.&, 0<0:'8%U&()% .*'4*2(% (,% ,()*.%+*+5*.'% ,6% MC(<4*% 6"+&/<;% ()*% LIJ!F%

47+4% 3&66*.'% &0% (&''7*% 3&'(.&57(&,0;% .*17/"(&,0;% (."0'4,.(% '4*2&6&2&(&*'% "03% .,/*% &0% !"#$%

),+*,'("'&'8%V(%&'%*02,3*3%5<%"%6"+&/<%,6%().**%1*0*';%LIJ!F%D;%#;%T%"03%&('%&',6,.+'%3&-*.'&(<%

&'%)&1)/<%&02.*"'*3%5<%"/(*.0"(&-*%'4/&2&01%,6%()*%(."0'2.&4(';%4.&02&4"//<%"(%()*%!WWXC(*.+&0"/8%

F(%4.*'*0(;%+,.*%()"0%DB%3&66*.*0(%LIJ!F%&',6,.+'%)"-*%5**0%3*(*2(*3%"(%()*%4.,(*&0%/*-*/;%

57(%,0/<%()*%TY%'(.72(7.*%,6%&',6,.+%D"%6.,+%."55&(%)"'%5**0%3*(*.+&0*38%%

%=)*%6&.'(%ZC."<%2.<'("/%'(.72(7.*%,6%LIJ!F%',/-*3%5<%()*%1.,74%,6%=,<,')&+"%"5,7(%DT%

<*".'%"1,%.*4.*'*0('%"%+&/*'(,0*%&0%()*%703*.'("03&01%,6%()*%+,/*27/".%+"2)&0*%.*'4,0'&5/*%

6,.% 2"/2&7+% 47+4&018% V(% )"'% *'("5/&')*3% ()*% 5"'*+*0(% 6,.% ()*% 57&/3&01% ,6% "//% ()*% 6,//,:&01%

?0,:/*31*%"5,7(% ()*%MC(<4*%F=M"'*% 6"+&/<8%L&02*%()*0;%2.<'("//,1."4)*.'%)"-*%:,.?*3%-*.<%

)".3% (.<&01% (,%*/72&3"(*% ()*%MC(<4*%47+4%2"("/<(&2% 2<2/*8% V0%4".(&27/".;% (:,% .*'*".2)%1.,74'%

>()*% 1.,74'% ,6% !8% =,<,')&+"% &0% ["4"0% "03% M8%A&''*0% &0%Y*0+".?@% )"-*%+,-*3% ()*&.% *66,.('%

(,:".3'% ()*% 703*.'("03&01% ,6% ()*% F=MC3.&-*0% &,0% (."0'4,.(% +*2)"0&'+;% 4.,372&01% "03%

"0"/<N&01%"(%"(,+&2%.*',/7(&,0%>#;TCT%\@%()*%TY%2.<'("/'%,6%'*-*."/%&0(*.+*3&"(*'%,6%LIJ!FD"8%

=)*&.% '(73&*'% )"-*% ,4*0*3% ()*% :"<% (,% ()*% .*2*0(% "3-"02*'% &0% +*+5."0*% 4.,(*&0'%

2.<'("//,1."4)<8%V0%6"2(;%"5,7(%]]%2.<'("/%'(.72(7.*'%,6%."55&(%LIJ!FD";%4,''&5/<%+&+&2?&01%"//%

()*% 2,06,.+"(&,0"/% '("(*'% ,6% ()*% *0N<+*% 2<2/*;% )"-*% 5**0% ',% 6".% 3*4,'&(*3% &0% ()*% M.,(*&0%

Y"("%S"0?%>MYS@%"03%()*%().**C3&+*0'&,0"/%'(.72(7.*%,6%LIJ!FD"%6.,+%."55&(%'?*/*("/%+7'2/*%

2,0(&07*'%(,%5*%2,0'&3*.*3%()*%".2)*(<4*%,6%()*%MC(<4*%F=M"'*'%6"+&/<8%

L&02*%LIJ!F%47+4'%4/"<%"%?*<%.,/*%&0%()*%.*17/"(&,0%,6%2"/2&7+%),+*,'("'&';%"/(*."(&,0%

,6% ()*&.% "2(&-&(<% )"'% 5**0% &0-*'(&1"(*3% &0% .*/"(&,0% (,% (:,% )7+"0% 3&'*"'*'% "'',2&"(*3% :&()%

LIJ!F%47+4%1*0*%3*6*2('^% ()*%S.,3<_'%"03%Y".&*._'%3&'*"'*8%=)*% 6,.+*.% &'%"% .".*% .*2*''&-*%

+7'27/".% 2,03&(&,0% 2)"."2(*.&N*3% 5<% "0% *G*.2&'*C&0372*3% &+4"&.+*0(% ,6%+7'2/*% .*/"G"(&,08%

=)*% 703*./<&01% 2"7'*% 6,.%+7'2/*% 2,0(."2(7.*% )"'% 5**0% 6,703% (,% 5*% "'',2&"(*3% (,% "% LIJ!F%

SUMMARY

7

.*372*3%"2(&-&(<;% .*'7/(&01% 6.,+%"%3*6*2(% &0% ()*%1*0*%2,3&01% 6,.%LIJ!FD"% &',6,.+%>F=M#FD@8%

A,0*()*/*'';% ()*% ,.&1&0% ,6% ()*% LIJ!F% 3*6&2&*02<% &'% '(&//% 2,0(.,-*.'&"/8% =)*% '*2,03% 1*0*(&2%

4"(),/,1<%?0,:0%"'%Y".&*._'%3&'*"'*%&'%"%.".*%"7(,',+"/%3,+&0"0(%'?&0%3&',.3*.%2)"."2(*.&N*3%

5<%/,''%,6%2*//C(,C2*//%"3)*'&,0%"03%"50,.+"/%?*."(&0&N"(&,0%,6%()*%*4&3*.+&'8%E,.*%()"0%DTB%

+7("(&,0'% &0% ()*% 1*0*% 2,3&01% 6,.% ()*% LIJ!F#% &',6,.+'% >F=M#F#@% )"-*% 5**0% &3*0(&6&*3% &0%

)7+"0%4"(&*0('8%Y&66*.*0(/<%6.,+%S.,3<_'%3&'*"'*;%()*%2/&0&2"/%'<+4(,+'%".*%.*'(.&2(*3%(,%()*%

*4&3*.+&'%"03%'4*2&6&2%".*"%,6%()*%'?&0%"03%&(%&'%(),71)(%()"(%()&'%/,2"/&N"(&,0%.*6/*2('%1*0*(&2%

+,'"&2&'+8%%

W7.% '(.72(7."/% 2,0(.&57(&,0% (,% ()*%703*.'("03&01%,6% ()*%*66*2('%,6%4,&0(%+7("(&,0'%,0%

()*%4.,(*&0% 2,06,.+"(&,0% 2,+*% 6.,+% ()*% 2.<'("/% '(.72(7.*%,6%5,-&0*%LIJ!F%47+4;% .*2*0(/<%

',/-*3%"(%#8`%\%.*',/7(&,08%L&02*%"0%JDa]X%'75'(&(7(&,0%)"'%5**0%&3*0(&6&*3%&0%2,:'%"66*2(*3%

5<%2,01*0&("/%4'*73,+&,(,0&"%"03%"%X701".&"0%4"(&*0(%"66*2(*3%5<%S.,3<_'%3&'*"'*%:"'%6,703%

(,%2"..<%()*%'"+*%+7("(&,0;%()&'%"0&+"/%2,7/3%5*%7'*3%"'%"%'7&("5/*%+,3*/%6,.%'(73<&01%)7+"0%

4"(),/,1<8% V0%"33&(&,0;% ()&'%4.,(*&0% .*4.*'*0('% ()*% 6&.'(% 2.<'("/% '(.72(7.*%,6%LIJ!FD"% 6.,+%"%

',7.2*%3&66*.*0(%6.,+%."55&(8%

=)*%4.,(*&0%:"'%*G(."2(*3%6.,+%"%4,.(&,0%,6%!=*"('=&,*.=(0)%+7'2/*%"03%),+,1*0&N*3%

"03%',/75&/&N*3%:&()%3*,G<2),/"(*%,.%!D#Ib%3*(*.1*0(8%!.<'("/'%:*.*%,5("&0*3%5<%7'&01% ()*%

)"01&01%3.,4%-"4,.%3&667'&,0%(*2)0&R7*%"03%()*%'(.72(7.*%',/-*3%5<%+,/*27/".%.*4/"2*+*0(8%

ZC."<%3"("%2,//*2(&,0%:"'%4*.6,.+*3%"(%()*%I7.,4*"0%L<02).,(.,0%J"3&"(&,0%9"2&/&(<%>ILJ9@%&0%

c.*0,5/*;% 9."02*8% =)*% 2.<'("//,1."4)&2% J% 6"2(,.% ,6% ()*% .*6&0*3% 6&0"/% '(.72(7.*% &'% B8#T8% =)*%

,-*."//%+,/*27/".%+,3*/%&'%-*.<%'&+&/".%(,%()"(%,6%()*%."55&(%*0N<+*;%"'%*G4*2(*3%5<%()*%)&1)%

"+&0,%"2&3%'*R7*02*%&3*0(&(<8%A*-*.()*/*'';%()*%5,-&0*%*0N<+*%)"'%.*372*3%2"("/<(&2%"2(&-&(<%

:&()%.*'4*2(%(,%()*%."55&(%*0N<+*8%L75(/*%'(.72(7."/%+,3&6&2"(&,0';%&0%4".(&27/".%&0%()*%.*1&,0%

,6%()*% /,01% /,,4%()"(%4.,(.73*'% &0(,%()*%LJ% /7+*0%2,00*2(&01%(."0'+*+5."0*%dC)*/&2*'%EO%

"03%Eb;%*G4/"&0%()*%3&66*.*02*8%

F5,7(% ()*%4"(),/,1&2"/%+7("0(;% '&02*% ()*%+7("(&,0% &'% /,2"(*3% &0% ()*%F%3,+"&0%,6% ()*%

47+4;% :)&2)% &'% &0-,/-*3% &0% /".1*% +,-*+*0('% ,6% ()*% 47+4% 37.&01% &('% .*"2(&,0% 2<2/*;% &(% &'%

8

4,''&5/*%(,%'4*27/"(*%"5,7(%()*%*66*2(%,6%()*%+7("(&,0%,0%()*%4.,(*&0%2,06,.+"(&,0;%,0%()*%

5"'&'%,6%,7.%'(.72(7.*8%V0%()*%ID8FEMM!M%'("(*;%()*%0*1"(&-*/<%2)".1*3%c/7#%2,70(*.5"/"02*'%

()*%4.,(,0"(*3%'&3*%2)"&0%,6%F.1Da]%()"(%"2('%"'%"%2*0(."/% e"02),.%4,&0(e% 6,.%().**%3&66*.*0(%

'(.*(2)*'% ,6% ()*%FC3,+"&0% 6,/38% =)*% '75'(&(7(&,0%,6% ()*% '&3*% 2)"&0% ,6% ()*% ".1&0&0*%:&()% ()*%

&+&3"N,/*%,6%()*%X&'%.*'&37*%2,7/3%3*'("5&/&N*%()*%2,06,.+"(&,0%,6%()*%47+4%37.&01%()*%IDCI#%

(."0'&(&,0;%4.,5"5/<%*0)"02&01%()*%'*0'&5&/&(<%,6%()*%4.,(*&0%(,%4.,(*,/<(&2%3*1."3"(&,08%

L&02*% ()*% "&+% ,6% +<% M)Y% 4.,Q*2(% &'% ()*% '(73<% ,6% ()*% LIJ!F% 47+4% 1*0*% 3*6*2('%

.*'4,0'&5/*% 6,.%)7+"0%1*0*(&2%3&'*"'*;% ()*%LIJ!F%#"% &',6,.+%.*4.*'*0('%"0,()*.% &+4,.("0(%

(".1*(% 6,.% ,7.% '(.72(7."/% &0-*'(&1"(&,0'8% =)&'% 4.,(*&0% &'% ()*% +"Q,.% 4/"<*.% &0-,/-*3% &0% ()*%

.*17/"(&,0% ,6% ()*% *G2&("(&,0C2,0(."2(&,0% 2,74/&01% ,6% ()*% )*".(8% I-&3*02*'% 6.,+% )7+"0% "03%

*G4*.&+*0("/% +,3*/'% ,6% )*".(% 6"&/7.*% )"-*% 3*+,0'(."(*3% ()"(% "/(*."(&,0'% &0% LJ% 2"/2&7+%

)"03/&01%".*%"'',2&"(*3%:&()%"0%&+4"&.*3%2,0(."2(&/&(<8%W()*.%*-&3*02*'%"/',%'**+%(,%'711*'(%

()"(% +7("(&,0'% ,6% ()*% &',6,.+% #"% +"<% 4.*3&'4,'*% (,% 2".3&"2% 3&'*"'*'8% J*2*0(/<;% LIJ!F#"%

47+4% 1*0*% (."0'6*.% :"'% 3*+,0'(."(*3% (,% 5*% '"6*% "03% *66*2(&-*% &0% .*'(,.&01% 2,0(."2(&/*%

6702(&,0% -&"% ,-*.C*G4.*''&,0% ,6% LIJ!F#"% 703*.% 4)<'&,/,1&2"/% "03% 4"(),C4)<'&,/,1&2"/%

2,03&(&,0'8%=)*%3*(*.+&0"(&,0%,6%()*%2.<'("/%'(.72(7.*%,6%()*%LIJ!F#"%2,7/3%)*/4%(,%*/72&3"(*%

()*%+,/*27/".%+*2)"0&'+'%.*'4,0'&5/*%6,.%!"#$%'&10"/&01%3<'6702(&,0%"'%:*//%"'%(,%3*'&10%"03%

'(73<%'4*2&6&2%&0)&5&(,.'%,6%()*%)*".(%LIJ!F#"%*0N<+*8%%

V0% ,7.% :,.?;% ()*% )7+"0% LIJ!F#"% :"'% *G4.*''*3% &0% >"002"./3<0'&, 0'.'+)&)"'% "'% "%

.*2,+5&0"0(% 4.,(*&0% :&()% "% 5&,(&0% "22*4(,.% 3,+"&0% >SFY@% /&0?*3% (,% ()*% !C(*.+&07'%

>)LIJ!F#"CSFY@%5<%"%().,+5&0%2/*"-"1*%'&(*8%W:&01%(,%()*%4.*'*02*%,6%"%().,+5&0%2/*"-"1*%

'&(*%:&()&0%()*%4.,(*&0%'*R7*02*;%"%4,&0(%+7("0(%>JbaTc@%:"'%1*0*."(*3%"03%()*%4.,(*&0%:"'%

'722*''67//<% *G4.*''*38% V0% -&-,% <*"'(% 5&,(&0</"(&,0% ,6% SFY% "33*3% "'% "% ("1% (,% LIJ!F#"% )"'%

,66*.*3%5,()%"% 6"'(%"03%*66&2&*0(%"66&0&(<%47.&6&2"(&,0%'(."(*1<%"03%"%4,'&(&-*% '*/*2(&,0%,6% ()*%

4.,4*./<% 6,/3*3% *0N<+*8% =,% ,5("&0% '766&2&*0(% "+,70(% ,6% 4.,(*&0% (,% 4*.6,.+% 2.<'("//&N"(&,0%

(.&"/';% "% 4.,(,2,/% 6,.% 5"(2)% 6*.+*0("(&,0% ,6% >1, 0'.'+)&)"'% :"'% ,4(&+&N*3% &0% "% ),+*% +"3*%

5&,.*"2(,.8% =)*% 4.,(*&0% :"'% ',/75&/&N*3% :&()% "% 5766*.% 2,0("&0&01% 0C3,3*2</% fCYC+"/(,'&3*%

SUMMARY

9

>YYE@%"(% ()*% "44.,4.&"(*%!E!8% 9&0"//<;% ()*% *0N<+*%:"'%47.&6&*3%5<% "-&3&0C"66&0&(<% '(."(*1<;%

7'&01%(:,%3&66*.*0(%47.&6&2"(&,0%(,,/'%>()*%"-&3&0%.*'&0%"03%()*%"-&3&0%+"10*(&2%0"0,4".(&2/*'@8%

9&0"//<;%"%0*:%4.,(*&0%(".1*(%)"'%5**0%()*%,5Q*2(%,6%'(.72(7."/%&0-*'(&1"(&,0'^%()*%I9)3#%

2"/2&7+C5&03&01%4.,(*&08% =)&'%4.,(*&0% .*4.*'*0('%"%0,-*/% ("7C"'',2&"(*3%4.,(*&0% &3*0(&6&*3% &0%

()*% [AMgT% ("7,4"()<% +,7'*% +,3*/;% :)&2)% 3*-*/,4'% 0*7.,3*1*0*."(&,0% &0% "1*C3*4*03*0(%

+"00*.8% =)&'% *-&3*02*% )"'% 5**0% "/',% -"/&3"(*3% &0% )7+"0% "66*2(*3% 5<% F/N)*&+*._'% 3&'*"'*;%

:)*.*% ()*% "'',2&"(&,0% 5*(:**0% ("7% "03% ()*% 0,-*/% 2"/2&7+C5&03&01% 4.,(*&0% :"'% 6,703%

*0)"02*38% =)*% ("7% 4.,(*&0% 4/"<'% "% ?*<% .,/*% &0% ()*% "44*"."02*% ,6% ("7,4)"()&*';% :)&2)% ".*%

3*'2.&5*3% "'% "% 1.,74% ,6% 0*7.,/,1&2"/% 3&',.3*.'% 2)"."2(*.&N*3% 5<% ()*% "11.*1"(&,0% ,6%

)<4*.4),'4),.</"(*3% "03% 6&/"+*0(,7'% ("7% 4.,(*&0'% ,.1"0&N*3% &0% 0*7.,6&5.&//".<% ("01/*'8%

Y*'4&(*% ()*% ("7% 4),'4),.</"(&,0% 4.,2*''% )"'% 5**0% &0(*0'*/<% '(73&*3;% ()*% +,/*27/".%

+*2)"0&'+% 703*./<&01% ()*% ("7C+*3&"(*3% 0*7.,3*1*0*."(&,0% &'% 4,,./<% 703*.'(,,38% =)*%

&3*0(&6&2"(&,0% ,6% ()*% 0*:% ("7C"'',2&"(*3% 4.,(*&0% I9)3#% "03% &('% '(.72(7."/% 2)"."2(*.&N"(&,0%

2,7/3% )*/4% (,% */72&3"(*% ()*% +*2)"0&'+'% .*'4,0'&5/*% 6,.% ("7,4"()&*'8% V0% ,7.% :,.?;% ()*%

.*2,+5&0"0(%I9XY#%4.,(*&0%:"'%*G4.*''*3%&0%?&02'.)02)",0/:),"'%"%4,/<C)&'(&3&0*C("11*3%67'&,0%

4.,(*&08% =)*% 4.,(*&0% )"'% 5**0% 47.&6&*3;% 2,02*0(."(*3% "03% 7'*3% 6,.% 2.<'("//&N"(&,0% (.&"/'8%

Y*'4&(*% 3&66."2(&01% 2.<'("/'% )"-*% 0,(% 5**0% ,5("&0*3% <*(;% 4.*/&+&0".<% (*'('% "44*".% R7&(*%

4.,+&'&018%%%

%

10

RIASSUNTO

!"# $%&'# (# )"# *)+# ,-./%0)"-# 0.%# )# /-1234)# 5-//%66-.)# -4# (# .-/*23/%7)"-# 4-"# 1230.2""2# 4)#

385-.2/)#*.21-//)#1-""8"%.)9#:%""%#1.-/1)0%#-#*.2");-.%<)23-#1-""8"%.-#%""%#52.0-#*.26.%55%0%=#"%#

/8%# ,-./%0)")0># (# )5*)-6%0%# *-.# .-62"%.-# 4),-./-# 0)*2"26)-# 4)# *.21-//)# ?8%")# "%# 1230.%<)23-#

58/12"%.-=# "%#/-1.-<)23-=# )"#5-0%72")/52#-3-.6-0)12#-# "%#*"%/0)1)0>#/)3%*0)1%9# !"#12)3,2"6)5-302#

4-"#1%"1)2#3-"#1230.2""2#4)#4),-./)#%/*-00)#4-""%#;)/)2"26)%#1-""8"%.-#.)1@)-4-=#*-.0%302=#"A80)")<<2#4)#

83#/2;)/0)1%02#5-11%3)/52#7%/%02#/8#83#/-0#4)#125*23-30)#*.20-)1)#B022"C)0D=#)3#6.%42#4)#8/%.-#"-#

2/1)""%<)23)# 3-""%# 1231-30.%<)23-#4-"# 1%"1)2# 125-# /-63%"-#*-.# .-62"%.-#83%# ,%.)-0>#4)# *.21-//)#

$%&'# /-3/)7)")# B!"#$% &'(&)*)+'% ,-./'&&'&D9# E800%,)%=# "-# 1-""8"-# 323# /232# )3# 6.%42# 4)# /2/0-3-.-#

)31.-5-30)# *.2"836%0)# 4)# 1%"1)2# )30.%1-""8"%.-9# F-.# ?8-/02# 520),2# "-# 1-""8"-# -81%.)20-# @%332#

-,2"802#83#-;;)1)-30-#/)/0-5%#4)#0.%/*2.02#B!"#$%0.1'.&*"&)&D#*-.#5%30-3-.-#"%#1231-30.%<)23-#

)30.%1-""8"%.-# 4)# 1%"1)2# -30.2# 83# )30-.,%""2# 0.%# )# &GHIGG# 3J9# !3# .)/*2/0%# %4# 832# /0)52"2#

-K0.%1-""8"%.-=# 83# .%*)42# )31.-5-302# 4-"# $%&'# ")7-.2# BLGGHIGGG# 3JD# *.2481-# 83A)55-4)%0%#

.)/*2/0%# 1-""8"%.-# 0-//802H/*-1);)1%=# 6.%<)-# %""A%7)")0># 4-""-# ,-.*')('% /0'% 2'3"(.% )2% /"2/).# B!"#$%

&'(&)*)+'%,-.*')(&D#4)#%00),%.-#4),-./-#*.20-)3-#7-./%6")2#12)3,2"0-#)3#%"0.-#,)-#4)#/-63%"%<)23-=#)3#

/-68)02#%"# "2.2# "-6%5-#%00.%,-./2# )"#520),2#/0.8008.%"-#%#5%3)#MN9#O%#122.4)3%0%#.)52<)23-#4-"#

$%&'#1)02/2")12#;82.)#4%""%#5-57.%3%#*"%/5%0)1%#-#4-30.2#6")#2.6%3-"")#)30-.3)#BMPQRPD#%00.%,-./2#

"%# *25*%# FJ$S# B$%&'HSEF%/-# 4-""%# 5-57.%3%# *"%/5%0)1%D# -# "2# /1%57)%02.-# T%'Q$%&'# -#

%00.%,-./2# "%# *25*%#RMP$S# B$%&'HSEF%/-#4-"# .-0)12"2# /%.12-342*"%/5%0)12D# .)*.)/0)3%# )"# "),-""2#

7%/%"-#4-"#$%&'9#!"#*)+#/*-1)%")<<%02#5-11%3)/52#4)#122.4)3%<)23-#4-""%#.-0-#4)#/-63%"%<)23-#4-"#

1%"1)2# *8U# -//-.-# *.27%7)"5-30-# 0.2,%02# 3-"# 58/12"2# /1@-"-0.)12=# 42,-# 83# %85-302# 4-""%#

1231-30.%<)23-#4-"# $%&'# *.2481-# "%# 1230.%<)23-#58/12"%.-#5-30.-# "%# /8%# .)52<)23-# )3481-# )"#

.)"%//%5-302#58/12"%.-9#F2)1@V#3-6")#85%3)#1).1%#)"#WGX#4-"#$%&'#1)02/2")12#.)02.3%#3-"#.-0)12"2#

/%.12*"%/5%0)12# BRPD#-#*2)1@V#?8-/0A8"0)52#.%**.-/-30%# "%#5%66)2.-#.)/-.,%#4)#$%&'=# "%#*25*%#

RMP$S# (# 123/-68-30-5-30-# 12)3,2"0%# 3-""%# .-62"%<)23-# 4-"# 5-11%3)/52# %112**)%02# 4)#

1230.%<)23-#-#.)"%//%5-302#3-"#58/12"2#/1@-"-0.)12#-#1%.4)%129#

RIASSUNTO

11

O%#*.20-)3%#RMP$S#1234),)4-#"-#*.2*.)-0>#1%0%")0)1@-#4-"#520),2#)23)12#4-""%#;%5)6")%#4-""-#

FH0Y*-# SEF%/)=# 1%.%00-.)<<%0%# 4%""%# ;2.5%<)23-# 4)# 83# )30-.5-4)2# ;2/;2.)"%02=# 4-.),%30-#

4%""A%802;2/;2.)"%<)23-#4)#83#.-/)482#4)#%/*%.0%02#3-""%#"2.2#/-?8-3<%#%"0%5-30-#123/-.,%0%9#!3#

/)30-/)=# )# 5-57.)# 4-""%# ;%5)6")%# FHEY*-# %112**)%32# )"# 0.%/*2.02# %00),2# 4)# )23)# %00.%,-./2# "%#

5-57.%3%#%""A)4.2")/)#4-""ASEF#0.%5)0-#83#1)1"2#4)#.-%<)23-#*.2*2/02#ZG#%33)#;%=#1@)%5%02#4.&*5

627'-&%/8/2'9#P)/*-002#%6")#%"0.)#5-57.)=# "%#*25*%#RMP$S#/)#4);;-.-3<)%#*-.# "%#/8%#4)/0.)78<)23-#

0)//80%"-=# "%# .-62"%<)23-=# "%# /*-1);)1)0>#-# )"# .82"2#3-""A25-2/0%/)#4-"# 1%"1)29#M//%#(# 124);)1%0%#4%#

83%#;%5)6")%#4)#0.-#6-3)=#RMP$S#I=#&=#Z#-#"%#,%.)%7)")0>#4-""-#/8-#)/2;2.5-#(#"-6%0%#%4#832#/*")1)36#

%"0-.3%0),2#4-"#0.%/1.)002#*.)5%.)2=#/*-1)%"5-30-#%"#$[[\H0-.5)3%"-9#N)32.%=#*)+#4)#IG#)/2;2.5-#

/232#/0%0-#)4-30);)1%0-#%#"),-""2#*.20-)12=#5%#/2"2#"%#/0.8008.%#0.)4)5-3/)23%"-#4-""A)/2;2.5%I%#4)#

123)6")2#(#/0%0%#4-0-.5)3%0%9##

O%#*.)5%# /0.8008.%# 1.)/0%""26.%;)1%#4-""%# RMP$S=# .)/2"0%#4%"# 6.8**2#4)# E2Y2/@)5%#1).1%#IZ#

%33)# ;%=# .%**.-/-30%# 83%# *)-0.%# 5)")%.-# 3-""%# 125*.-3/)23-# 4-""%# 5%11@)3%# 52"-12"%.-#

.-/*23/%7)"-#4-"#0.%/*2.02#%00),2#4-"#1%"1)29#M//%#@%#/0%7)")02#"-#7%/)#*-.#"%#12/0.8<)23-#4)#0800-#"-#

%008%")# 1232/1-3<-# .-"%0),-# %""%# ;%5)6")%# 4-""-# FH0Y*-# #SEFH%/)9#:%# %""2.%=# )# 1.)/0%""26.%;)# @%332#

"%,2.%02# ;%0)12/%5-30-# 3-"# 1-.1%.-# 4)# 1@)%.).-# )"# 1)1"2# 1%0%")0)12# 4-""%# *25*%# FH0Y*-9# !3#

*%.0)12"%.-=#48-#6.8**)#4)#.)1-.1%#B)"#6.8**2#4)#$9#E2Y2/@)5%#)3#])%**23-#-#?8-""2#4)#T)//-3# )3#

:%3)5%.1%D# @%332# 52//2# )# "2.2# /;2.<)# ,-./2# "%# 125*.-3/)23-# 4-"# 5-11%3)/52# 4)# 0.%/*2.02#

)23)12# %00),%02# 4%""ASEF=# *.2481-342# -# %3%")<<%342# %# "),-""2# %025)12# B&=ZHZ# SD# "-# /0.8008.-#

1.)/0%""26.%;)1@-#4)#4),-./)#)30-.5-4)#4-""%#RMP$SI%9#!#"2.2#/084)#@%332#%*-.02#"%#/0.%4%#%)#.-1-30)#

*.26.-//)# 3-""%# 1.)/0%""26.%;)%# 4-""-# *.20-)3-# 4)# 5-57.%3%9# !3;%00)=# 1).1%# ^^# /0.8008.-# 4-""%#

RMP$SI%#4)#123)6")2=#1@-#1-.1%32#4)#/)58"%.-#0800)#6")#/0%0)#123;2.5%<)23%")#4-"#1)1"2#-3<)5%0)12=#

/232# /0%0-# 4-*2/)0%0-# 3-""%# _%31%# :%0)# F.20-)1%# BF:_D# -# "%# /0.8008.%# 0.)4)5-3/)23%"-# 4-""%#

RMP$SI%#4%"#58/12"2#/1@-"-0.)12#1230)38%#%4#-//-.-#123/)4-.%0%#"A%.1@-0)*2#4-""%#;%5)6")%#4-""%#

FH0Y*-#SEF%/)9##

F2)1@V# "-# *25*-# RMP$S# /,2"6232# 83# .82"2# 1@)%,-# 3-""%# .-62"%<)23-# 4-""A25-2/0%/)# 4-"#

1%"1)2=# ,%.)%<)23)# 3-""%# "2.2# %00),)0># *.20-)1%# /232# /0%0-# )4-30);)1%0-# )3# 48-# 5%"%00)-# 85%3-#

12

%//21)%0-#%#4);-00)#3-)#6-3)#124);)1%30)#*-.#"%#*25*%#RMP$S`#"%#5%"%00)-#4)#_.24Y#-#4)#:%.)-.9#O%#

*.)5%# (# 83%# .%.%# -# .-1-//),%# 1234)<)23-# 58/12"%.-# 1%.%00-.)<<%0%# 4%# 83%# .)48<)23-# 3-"#

.)"%//%5-302# 58/12"%.-# )34200%# 4%""A-/-.1)<)29# O%# 1%8/%# 4-""%# 1230.%008.%# (# %//21)%0%# %4# 83%#

.)48<)23-#3-""A%00),)0>#4-""%# RMP$S=#4-.),%30-#4%#83#4);-002#3-"# 6-3-# 124);)1%30-# "A)/2;2.5%#I%#

BSEF&SID9# E800%,)%=# "A2.)6)3-# 4)# ?8-/0%# .)48<)23-# (# %312.%# 1230.2,-./%9# O%# /-1234%# *%02"26)%#

6-3-0)1%=#320%#125-#5%"%00)%#4)#:%.)-.=#(#83#.%.2#4)/08.72#%802/25)12#425)3%30-#4-""%#*-""-=#

1%.%00-.)<<%02# 4%# 83A%//-3<%# 4)# %4-/)23-# 0.%# "-# 1-""8"-# -# 83A%325%"%# 1@-.%0)3)<<%<)23-#

4-""A-*)4-.5)4-9# R232# /0%0-# )4-30);)1%0-# *)+# 4)# IZG# 580%<)23)# 3-"# 6-3-# 124);)1%30-# *-.# "-#

)/2;2.5-#&%# BSEF&S&D# )3#*%<)-30)#85%3)9#S#4);;-.-3<%#4-""%#5%"%00)%#4)#_.24Y=# )# /)3025)#1")3)1)=#

.)/0.-00)#%""A-*)4-.5)4-#-#%#/*-1);)1@-#%.--#4-""%#*-""-=#*.27%7)"5-30-#.);"-00232#83#52/%)1)/52#

4)#0)*2#6-3-0)129#!"#32/0.2#1230.)7802#/0.8008.%"-#%""%#125*.-3/)23-#4-6")#-;;-00)#4-""-#580%<)23)#

*830);2.5)# /8""%# 123;2.5%<)23-# *.20-)1%# 4-.),%# 4%""%# /0.8008.%# 1.)/0%""26.%;)1%# 4-""%# *25*%#

RMP$SI%#72,)3%=#.-1-30-5-30-#.)/2"0%#%#&9a#b#4)#.)/2"8<)23-9#F2)1@V#83%#580%<)23-#4%#%.6)3)3%#

%# )/0)4)3%# 3-""%# *2/)<)23-# Ic^# (# /0%0%# )4-30);)1%0%# )3# 83%# 5811%# %;;-00%# 4%# */-842# 5)2023)%#

1236-3)0%# -# "%# /0-//%# 580%<)23-# (# /0%0%# )4-30);)1%0%# )3# 83# *%<)-30-# 836@-.-/-# %;;-002# 4%""%#

5%"%00)%#4)#_.24Y=#?8-/02#%3)5%"-#*20.-77-#-//-.-#8/%02#125-#524-""2#125*%0)7)"-#%""2#/084)2#

4-""-#*%02"26)-#85%3-9##

O%# *.20-)3%# (# /0%0%# -/0.%00%# 4%# 83%# *2.<)23-# 4-"#58/12"2#!9*"('9&% *-9(/)=# 1@-# (# /0%02#

2526-3-)<<%02# -# /2"87)")<<%02# 123# )# 4-0-.6-30)# 4-2//)12"%02# -# $I&Md9# !# 1.)/0%"")# *.20-)1)# /232#

/0%0)#200-380)#0.%5)0-#"%#0-13)1%#4-""A@%36)36#4.2*#123#)"#5-0242#4-""%#4);;8/)23-#4)#,%*2.-#-#"%#

/0.8008.%# (# /0%0%# .)/2"0%# 123# )"# 5-0242# 4-""%# /2/0)08<)23-# 52"-12"%.-9# O%# .%112"0%# 4-)# 4%0)#

1.)/0%""26.%;)1)# (# /0%0%# -/-68)0%# 3-""%# /0.8008.%# 4-"# /)31.20.23-# -8.2*-2# BMRPND# %# ].-327"-=#

N.%31)%9# !"# ;%002.-# 1.)/0%""26.%;)12# P# 4-"#524-""2# /0.8008.%"-# .%;;)3%02# (# G9&Z9# T-"# 125*"-//2# )"#

524-""2#(#/)5)"-#%#?8-""2#4-""A-3<)5%#4)#123)6")2=#125-#%00-/2#4%""A%"0%#)4-30)0>#4-""%#/-?8-3<%#

%55)32%1)4)1%9#E800%,)%=#"A-3<)5%#72,)32#52/0.%#83%#.)4200%#%00),)0>#1%0%")0)1%#.)/*-002#%#?8-""%#

4-"#123)6")29#e8%"1@-#*)112"%#524);)1%<)23-=# )3#*%.0)12"%.-#3-""%#.-6)23-#4-"# "22*#1@-#*.20.84-#

RIASSUNTO

13

3-"#"85-#4-"#.-0)12"2#/%.12*"%/5%0)12#-#1@-#1233-00-#"-#!H-")1@-#JW#-#Jd=#*20.-77-#/*)-6%.-#"%#

4);;-.-3<%9##

P)68%.42# %""-# ;2.5-#*%02"26)1@-=# *2)1@V# "%#580%<)23-# (# "21%")<<%0%# 3-"# 425)3)2#S# 4-""%#

*25*%=#1.81)%"-#3-"#1)1"2#4)#.-%<)23-=#/8""%#7%/-#4-""%#32/0.%#/0.8008.%#(#/0%02#*2//)7)"-#;%.-#4-""-#

/*-18"%<)23)# /86")# -;;-00)# 1@-# "%# 580%<)23-# *20.-77-# *.248..-# /8""%# 123;2.5%<)23-# *.20-)1%9#

T-""2#/0%02#MIH#SJJFF$F=#)"#.-/)482#4)#%1)42#6"80%55)12#1%.)12#3-6%0),%5-30-#1230.27)"%31)%#

"%# 1%0-3%# "%0-.%"-# *.2023%0%# 4-""AS.6Ic^# 1@-# %6)/1-# 125-# *-.32# 1-30.%"-# *-.# 0.-# 4);;-.-30)#

/0).%5-30)#4-"#425)3)2#S9#O%#/2/0)08<)23-#4-""%#1%0-3%#"%0-.%"-#4-""A%.6)3)3%#123#"A)5)4%<2"2#4-"#

.-/)482#4A)/0)4)3%#*20.-77-#4-/0%7)")<<%.-#"%#123;2.5%<)23-#4-""%#*25*%#48.%30-#"%#0.%3/)<)23-#

0.%#6")#/0%4)#MIHM&=#%85-30%342#*.27%7)"5-30-#"%#/8/1-00)7)")0>#4-""%#*.20-)3%#%""%#4-6.%4%<)23-#

*.20-2")0)1%9#

F2)1@V# "2# /12*2#4-"#5)2#*.26-002#4)#42002.%02#(# "2# /084)2#4-)#4);-00)# 6-3)1)# .-/*23/%7)")#

4-""-#5%"%00)-#85%3-=#"A)/2;2.5%#RMP$S&%#.%**.-/-30%#83#%"0.2#)5*2.0%30-#7-./%6")2#4-)#32/0.)#

/084)# /0.8008.%")9# e8-/0%# *.20-)3%# /,2"6-# 83# .82"2# 1@)%,-# 3-""%# .-62"%<)23-# 4-"# 5-11%3)/52#

%112**)%02# 4)# 1230.%<)23-# -# .)"%//%5-302# 4-"#58/12"2# 1%.4)%129# P)/8"0%0)# 200-380)# 4%# *%<)-30)#

12"*)0)# 4%# )3;%.02# 1%.4)%12# -# 4%# 524-"")# /*-.)5-30%")# @%332# 4)52/0.%02# 1@-# %"0-.%<)23)# 3-""%#

.-62"%<)23-# 4-"# ;"8//2# 4)# 1%"1)2# /232# %//21)%0-# %# 83%# .)4200%# 1230.%00)")0>9# S"0.-# -,)4-3<-#

/-57.%32=# )32"0.-=# /866-.).-# 1@-# %"183-# 580%<)23)# 3-""A)/2;2.5%&%# *2//232# *.-4)/*2..-# %#

5%"%00)-# 1%.4)%1@-9# P-1-30-5-30-=# "%# 0-.%*)%# 4)# 0.%/;-.)5-302# 6-3)12# 4-""%# RMP$S&%# /)# (#

4)52/0.%0%#/)18.%#-4#-;;)1%1-#3-"#.)*.)/0)3%.-#"%#;83<)23-#1230.%00)"-#4-"#182.-=#%00.%,-./2#"A2,-.#

-/*.-//)23-#4-""%#RMP$S&%#)3#1234)<)23)#;)/)2"26)1@-#-#*%02H;)/)2"26)1@-9#O%#4-0-.5)3%<)23-#4-""%#

/0.8008.%# 1.)/0%""26.%;)1%# 4-""%# RMP$S&%# *20.-77-# ?8)34)# %)80%.-# %# 1@)%.).-# )# 5-11%3)/5)#

52"-12"%.)# .-/*23/%7)")# 4-""%# 4)/;83<)23-# 3-"# *.21-//2# 4)# /-63%"%<)23-# 4-"# 1%"1)2=# 12/f# 125-#

%*.).-#"%#*2//)7)")0>#4)#)4-30);)1%.-#-#/084)%.-#6")#)3)7)02.)#*.20-)1)#/*-1);)1)#*-.#"%#RMP$S&%9#

T-"#32/0.2#"%,2.2=#"A)/2;2.5%&%#85%3%#(#/0%0%#-/*.-//%#)3#:"//0"-.18/'&%/'-'+)&)"'#125-#

*.20-)3%# .)1257)3%30-# 123# 83# 425)3)2# %11-002.-# 4)# 7)20)3%# B_S:D# "-6%02# %"# $H0-.5)3%"-##

B@RMP$S&%H_S:D#4%#83#/)02#4)# 0%6")2#*-.# "%# 0.257)3%9#F2)1@V#?8-/0A8"0)52#-.%#*.-/-30-#%31@-#

14

4-30.2#"%#/-?8-3<%#*.20-)1%=#83%#580%<)23-#*830);2.5-#BPdcZ]D#(#/0%0%#6-3-.%0%#-#"%#*.20-)3%#

(#/0%0%#-/*.-//%#123#/811-//29#!3#,),2=#"%#7)20)3)"%<)23-#4-"#_S:#%66)8302#125-#/)02#g7-./%6")2h#

%""%#RMP$S&%#@%#2;;-.02#/)%#83%#,-"21-#-4#-;;)1)-30-#/0.%0-6)%#4)#*8.);)1%<)23-#1@-#83%#/-"-<)23-#

*2/)0),%# 4-""A-3<)5%# *.2*.)%5-30-# ;2"4%029# F-.# 200-3-.-# 83%# /8;;)1)-30-# ?8%30)0># 4)# -3<)5%#

*8.);)1%02#)3#5242#4%#.-%")<<%.-#*.2,-#4)#1.)/0%"")<%<)23-=#)3#83#.-%002.-#12/0.8)02#)3#"%72.%02.)2=#

(#/0%02#200)5)<<%02#83#*.20212""2#*-.# "%# ;-.5-30%<)23-# )3#7%01@# )3#:;%/'-'+)&)"'9# O%#*.20-)3%#(#

/0%0%# ?8)34)# /2"87)")<<%0%# )3# 83# 0%5*23-# 123# ::J# %""%# %**.2*.)%0%# 1231-30.%<)23-# 1.)0)1%#

5)1-""%.-9#S""%#;)3-=#"A-3<)5%#(#/0%02#*8.);)1%02#%00.%,-./2#"%#*8.);)1%<)23-#*-.#%;;)3)0>#%""A%,)4)3%=#

8/%342#48-# 4);;-.-30)# /)/0-5)# 4)# *8.);)1%<)23-# B%,)4)3%# 123)86%0%# %""%# .-/)3%# -# 3%32#*%.0)1-""-#

.),-/0)0-#4)#%,)4)3%D9#

F-.#;)3).-=#83#382,2#0%.6-0#(#/0%02#266-002#4-)#32/0.)#/084)#/0.8008.%")`#"%#*.20-)3%#1@-#"-6%#

)"# 1%"1)2# MN\:&9# e8-/0%# .%**.-/-30%# 83%# 382,%# *.20-)3%# %//21)%0%# %""%# 0%8# 1@-# (# /0%0%#

)4-30);)1%0%#3-"#524-""2#/*-.)5-30%"-#4)#02*2#BiTFOZD=#/*-1);)12#*-.#"2#/084)2#4-""-#0%82*%0)-9#!"#

524-""2#/*-.)5-30%"-#/,)"8**%# )3;%00)#3-8.2#4-6-3-.%<)23-# )3#5%3)-.%#4)*-34-30-#4%6")#%33)9#

e8-/0%#-,)4-3<%#(#/0%0%#%31@-#.)/1230.%0%#)3#*%<)-30)#%;;-00)#4%#S"<@-)5-.=#3-)#?8%")#(#.)/8"0%0%#

*)+# -"-,%0%# "A%//21)%<)23-# 0.%# "%# 0%8# -# "%# MN\:&9# O%# *.20-)3%# 0%8# /,2"6-# 83# .82"2# 1@)%,-# 3-""%#

125*%./%# 4-""-# 0%82*%0)-=# 1@-# /232# 4-/1.)00-# 125-# 83# 6.8**2# 4)# 5%"%00)-# 3-8.2"26)1@-#

1%.%00-.)<<%0-# 4%""A%66.-6%<)23-# 4)# *.20-)3-# 0%8# )*-.;2/;2.)"%0-# -# ;)"%5-302/-=# 2.6%3)<<%0-# )3#

625)02")# 4)# 3-8.2;)7.)""-9# T232/0%30-# )"# *.21-//2# 4)# ;2/;2.)"%<)23-# /)%# /0%02# /084)%02#

)30-3/),%5-30-=# )"#5-11%3)/52#52"-12"%.-#%""%#7%/-#4-""%#3-8.2#4-6-3-.%<)23-#5-4)%02#4%""%#

0%8#(#%312.%#*212#/084)%029#OA)4-30);)1%<)23-#4-""%#382,%#*.20-)3%#MN@4&#%//21)%0%#%""%#0%8#-#"%#

/8%#1%.%00-.)<<%<)23-#/0.8008.%"-#*20.-77-.2#%)80%.-#%#1@)%.).-# )#5-11%3)/5)# .-/*23/%7)")#4-""-#

0%82*%0)-9#T-"#32/0.2#"%,2.2=#"%#*.20-)3%#.)1257)3%30-#MN@4&#85%3%#(#/0%0%#-/*.-//%#)3#<;%/.2)#

125-#*.20-)3%#4)# ;8/)23-# 123#83# 0%6#4)# )/0)4)3-9# O%#*.20-)3%# (# /0%0%#*8.);)1%0%=# 1231-30.%0%# -#

8/%0%# *-.# "-# *.2,-# 4)# 1.)/0%"")<<%<)23-9# T232/0%30-# 323# /)%32# %312.%# /0%0)# 200-380)# 1.)/0%"")#

4);;.%36-30)=#"-#*.2,-#*.-")5)3%.)#%**%)232#,-.%5-30-#*.25-00-30)9#

#

CHAPTER I

INTRODUCTION

16

CONTENTS

1.1 CALCIUM SIGNALING 17

1.1.1 HOW DOES THE CA2+-SIGNAL WORK? 18

1.1.2 THE CORE OF CALCIUM SIGNALING NETWORK 20

1.2 THE SERCA PUMP 22

1.2.1 THE P-TYPE ATPASE FAMILY 22

1.2.2 ISOFORMS OF THE SERCA PUMP 24

1.2.3 SERCA REGULATORY PROTEINS 24

1.2.4 REGULATION OF SERCA2A ACTIVITY 25

1.3 STRUCTURAL PROPERTIES OF SERCA PUMP. A DETAILED OVERVIEW 26

1.3.1 E1 VERSUS E2: THE FIRST STEPS INSIDE THE MOLECULAR UNDERSTANDING OF REACTION CYCLE 26

1.3.2 E1-P PHOSPHO-INTERMEDIATE STRUCTURES AS A RESPONSE TO ATP-BINDING SITE CONTROVERSY 28

1.3.3 E2-P PHOSPHO-INTERMEDIATE STRUCTURES AND THE CATALYTIC CYCLE IS COMPLETED 32

1.3.4 INSIGHT INTO THE TRANSPORT MECHANISM COUPLED TO ATP HYDROLYSIS 33

1.4 THE HUMAN SERCA PUMPS GENE MUTATIONS 36

1.5 THE EF-HAND AS THE STRUCTURAL MOTIF OF THE CA2+-BINDING PROTEINS FAMILY 37

1.5.1 SWIPROSIN-1/EFHD2 AND SWIPROSIN-2/EFHD1 39

INTRODUCTION

17

1.1 CALCIUM SIGNALING

!"##$% &""'% ()% *)++,&-*.("% ()% $,/0-0"1% 2,/-&3% (4"% "0)#,(-)&5%+,#(-6*"##,#./% )/3.&-$+$%

4.0"% .')7("'% $)74-$(-*.("'% +"*4.&-$+$% ()% 3"&"/.("% .&'% "#.8)/.("% -&9)/+.(-)&% (4/),34%

+"$$"&3"/$% *.//:-&3% 7/-+./:% $-3&.#$% ()% *"##$% ;!"#$%& '($$()*(#$<% .&'% '"*)'-&3% (4"-/%

-&9)/+.(-)&% -&$-'"% (4"+% ;$(+,)-& '($$()*(#$<% ;!./.9)#-5% =>>?<1% !.=@% -$% .+)&3% (4"% +)$(%

0"/$.(-#"% $"*)&'% +"$$"&3"/$5% $-&*"% -(% (/-33"/$% .% A-'"% /.&3"% )9% $7.(-.#% .&'% ("+7)/.#%

-&(/.*"##,#./% $-3&.#$1% B4.&C$% ()% -($% .8-#-(-"$% ()% .#("/% #)*.#% "#"*(/)$(.(-*% 9-"#'$% .&'% 7/)("-&%

*)&9)/+.(-)&$%)9% $7"*-9-*%+)#"*,#./% (./3"($5% -(% *)&(/)#$% $"0"/.#% *"##,#./%7/)*"$$"$% ;!#.74.+5%

?DDE<1% F/)+% *"##% 3/)A(4% .&'% 7/)#-9"/.(-)&% ()% 7/)3/.++"'% *"##% '".(45% -($% 0"/$.(-#-(:% -$%

"+7#):"'% ()% /"3,#.("% 7/)*"$$"$% .$% '-0"/$"% .$% +,$*#"% *)&(/.*(-)&5% $"*/"(-)&5% "&"/3"(-*%

+"(.8)#-$+%.&'%$:&.7(-*%7#.$(-*-(:%',/-&3%#"./&-&3%.&'%+"+)/:%;G"//-'3"5%?DDH<1%%

B)% *))/'-&.("% ".*4% )9% (4"$"% 9,&*(-)&$5% !.=@% $-3&.#% +,$(% 8"% "99-*-"&(#:% .&'% 7/"*-$"#:%

*)&(/)##"'1%BA)%8/).'%*#.$$"$%)9% $7"*-.#-I"'%7/)("-&$%7"/9)/+%(4-$% (.$C5% (4"%!"#$%&'(()*%"+,%

-.)% !"#$%/)+/0*% 1*0-)2+/1% G)(4% )9% (4"+% 8-&'% *.#*-,+% A-(4% 3/".(% $7"*-9-*-(:% .&'% .99-&-(:% -&%

-&(/.*"##,#./% "&0-/)&+"&(% +.-&(.-&-&3% -($% *:()$)#-*% *)&*"&(/.(-)&% ./),&'% ?>>% &J% ;G/-&-5%

!./.9)#-5% =>>D<1% K)&"(4"#"$$5% (4":% 7#.:% .% '-99"/"&(% /)#"% -&% (4"% !.=@% $-3&.#-&3% &"(A)/C1% B4"%

9)/+"/% -&*#,'"$% -&(/-&$-*%+"+8/.&"%7/)("-&$%(4.(%+)0"%*.#*-,+%-)&$%.*/)$$%(4"%+"+8/.&"5%

+)',#.(-&3%(4"%!.=@%$-3&.#%8)(4%$7.(-.##:%.&'%("+7)/.##:1%B4":%8"#)&3%()%$"0"/.#%$,8*#.$$"$%)9%

!.=@67,+7$%.&'%"L*4.&3"/$%(4.(%'-99"/% -&%.99-&-(:% 9)/%!.=@%.&'%(/.&$7)/(%+"*4.&-$+$1% %M-&*"%

(4":%*)&(/)#%!.=@%*)&*"&(/.(-)&%A-(4),(%7/)*"$$-&3%-($%+"$$.3"5%(4":%./"%&.+"'%./01&23!!(#&

4#,%(")$1% N&% (4"% *)&(/./:5% !.=@% $"&$)/% 7/)("-&$% '"*)'"% (4"% -&(/.*"##,#./% !.=@% $-3&.#% -&()%

$"0"/.#% *"##,#./% /"$7)&$"$% .&'% ./"% 3"&"/.##:% *4./.*("/-I"'% 8:% .% 4"#-LO#))7O4"#-L% $(/,*(,/.#%

+)(-9%("/+"'%(4"%PF64.&'1%B4"$"%7/)("-&$%8"#)&3%()%(4"%PF64.&'%!"#$%&'()*()+&,-./0()1&2"3(45%

(4.(%*)&(.-&$%)0"/%Q>>%+"+8"/$1%%

B4"% 9,&*(-)&.#% /"#.(-)&$4-7% 8"(A""&% .##% (4"$"% 7/)("-&$% $,33"$($% .% $)74-$(-*.("'% !.=@%

$-3&.#-&3%+"*4.&-$+%8.$"'%)&% .%A-'"% $"(% )9% 7/)("-&% *)+7)&"&($% ;())#C-(<5% .8#"% ()%A)/C% -&%

18

*))7"/.(-)&%()%"&$,/"%(4"%7,&*(,.#%.&'%"L.*(%(/.&$+-$$-)&%)9%!.=@%$-3&.#%-&$-'"%(4"%*"##1%B4-$%

())#C-(% -$% .#$)% .8#"% ()% -&("/.*(% A-(4% )(4"/% $-3&.#-&3% 7.(4A.:1% B4.&C$% ()% (4"% 7#,/.#-(:% )9%

*)+8-&.(-)&% (4.(% *.&% 8"% 3"&"/.("'5% '-99"/"&(% *"##% (:7"$% *.&% $"#"*(% .% ,&-R,"% $"(% )9%

*)+7)&"&($% -&%)/'"/%()%*/".("%(4"-/%)A&%.77/)7/-.("%$:$("+%)9%*.#*-,+%$-3&.#-&3%;G"//-'3"5%

=>>S<1% F-&.##:5% (4"% .**,/.("% *)+8-&.(-)&% .&'% (4"% 7/"*-$"% .$$"+8#:% )9% (4-$% "L("&$-0"% !.=@%

$-3&.#-&3%())#C-(%.&'%-($%-&("/.*(-)&%A-(4%)(4"/%$-3&.#-&3%7.(4A.:%.##)A$%*.#*-,+%$-3&.#%()%7#.:%

.%7-0)(.#%/)#"%-&%*"##%8-)#)3:%;G"//-'3"5%=>>><1%

1.1.1 HOW DOES THE CA2+-SIGNAL WORK?

!)&$-'"/-&3%.%$-&3#"%9,&*(-)&.#%,&-(5%9)/%-&$(.&*"%.%&)&6$(-+,#.("'%*"##5%(4"%'-$(/-8,(-)&%

)9%*.#*-,+%$-3&.#%*.&%8"%".$-#:%'"7-*("'%-&%("/+$%)9%*)&*"&(/.(-)&%0./:-&3%-&%(-+"1%T&%9.*(5%-&%

/"$(-&3%*"##$%(4"%-&(/.*"##,#./%*)&*"&(/.(-)&%)9%*.#*-,+%-$%+.-&(.-&"'%A-(4-&%(4"%/.&3"%=>6?>>%

&J1%U% /.7-'% -&*/".$"%)9%!.=@% (4/),34% (4"% *))/'-&.("'%)7"&-&3%)9% $7"*-9-*&!"#$34."++)5/% )&%

(4"%7#.$+.%+"+8/.&"%;67!18&9.4/"+0%.,0-"/0*&:;"))041<&=7!18&-0:0,/.-%.,0-"/0*&:;"))041<&

>7!18&1/.-0%.,0-"/0*&:;"))041<&100&?05@.-*1&2.-&*02()(/(.)1A&.&'%8:%-($%/"#".$"%9/)+%-&("/&.#%

$()/"$% ;B=C>=<% (4/),34% (4"%!"#$3*)5)"/)% 4."++)5/% /"$,#($% -&% .&% -++"'-.("% *"##,#./% /"$7)&$"%

(4.(%'"7"&'$%)&%*"##%(:7"%.&'%*)&("L(%;G"//-'3"5%=>>S<1%%

BA)% 9.+-#-"$% )9% -&(/.*"##,#./% *.#*-,+% *4.&&"#$% *)&(/)#% (4"% /"#".$"% )9% *.#*-,+% 9/)+%

-&("/&.#% $()/"$V% (4"% /:.&)'-&"% /"*"7()/% ;=5=<% .&'% (4"% -&)$-()#% ?5W5E6(/-74)$74.("% /"*"7()/%

;T)1DE=<%9.+-#-"$1%M"0"/.#%$"*)&'%+"$$"&3"/$%'"/-0"'%9/)+%(4"%.*(-0.(-)&%)9%'-99"/"&(%$-3&.#-&3%

7.(4A.:% )&% (4"% 7#.$+.% +"+8/.&"% .*(-0.("% (4"+1% K)&"(4"#"$$5% (4"% 7/-+./:% .*(-0.()/% )9%

(4"$"%*4.&&"#$% -$% (4"%*.#*-,+% -($"#9% (4/),34%(4"%.,()6/"3,#.()/:%+"*4.&-$+%C&)A&%.$%!.=@6

-&',*"'% !.=@6/"#".$"% ;!F=!<1% B4-$% 7)$-(-0"% 9""'8.*C% $:$("+% *)&0"/($% .&% "#"+"&(./:% $-3&.#%

"0"&(%-&%.%3#)8.#%*.#*-,+%/"$7)&$"%;!"#$&/-")1(0)/<5%/"$7)&$-8#"%9)/%*)&(/)##-&3%)9%'-0"/$"%(:7"$%

)9% *"##,#./% 7/)*"$$"$% ;G"//-'3"5% ?DDH<1% U$% .% *)&$"R,"&*"5% $-3&.#$% 9/)+% $"0"/.#% *"##,#./%

7.(4A.:$%*.&%.*(-0.("%.&'%+)',#.("%)&"%)/%+)/"%*"##,#./%7/)*"$$"$1% T&%),/%*.$"5% (4.&C$%()%

(4"%.8-#-(:%)9%!"#$%&'()*()+&,-./0()1%()%8-&'%*.#*-,+%8:%(4"%PF64.&'%+)(-9%.&'%.*(-0.("%$"0"/.#%

INTRODUCTION

19

')A&$(/".+% "99"*()/$% -&0)#0"'% -&% )(4"/% $-3&.#-&3% 7.(4A.:5% (4"% *.#*-,+% $-3&.#% -$% .8#"% ()%

+)',#.("%.%0./-"(:%)9%!"#$%10)1(/(90&,-.:01101&(4.(%)7"/.("%)0"/%.%A-'"%("+7)/.#%$7"*(/,+1%

K)&"(4"#"$$5%*"##$%./"%,&.8#"%()%$,$(.-&%.&%"L("&$-0"%.&'%7"/$-$("&(%-&*/".$"%)9%*.#*-,+%

*)&*"&(/.(-)&1% X/)#)&3"'% "#"0.(-)&% )9% *:()$)#-*% !.=@% /"$,#(% -&% +-()*4)&'/-.#% )0"/#).'-&35%

.*(-0.(-)&%)9%7/)(".$"$5%.&'%.*(-0.(-)&%)9%2KU69/.3+"&(-&3%"&I:+"$1%B)%.0)-'%(4"$"%*:()()L-*%

"99"*($5% ",C./:)(-*% *"##$% 4.0"% "0)#0"'% .&% "99-*-"&(% (/.&$7)/(% $:$("+% ()% +.-&(.-&% .'"R,.("%

-&(/.*"##,#./%*)&*"&(/.(-)&%)9%*.#*-,+5%(4"%$)6*.##"'%!.=@%4)+")$(.$-$1%B4-$%+"*4.&-$+%/"$,#($%

9/)+%(4"%*))/'-&.("'%/"+)0.#%)9%*:()$)#-*%!.=@%),(%)9%(4"%7#.$+.%+"+8/.&"%.&'%-&()%-&("/&.#%

)/3.&"##"$% ;PYZMY<1% B4"%+.-&% 7/)("-&$% -&0)#0"'% -&% (4"% *)&(/)#% )9% !.=@% 4)+")$(.$-$% ./"V% (4"%

G"$C!"

#$0H:;")+0-% .&'% (4"% DI!J% 7,+7% ;7#.$+.% +"+8/.&"% !.=@6UBX.$"<% )&% (4"% 7#.$+.%

+"+8/.&"5% .&'% (4"% >B=!J% 7,+7% ;$./*)7#.$+-*% /"(-*,#,+%!.=@6UBX.$"<% /"$7)&$-8#"% 9)/% (4"%

*.#*-,+% /",7(.C"% -&()% (4"% $./*)7#.$+-*% /"(-*,#,+% ;MY<1% U$% .% /"$,#(5% (4"% 7"/9"*(% 8.#.&*"%

8"(A""&% (4"% "&(/:% )9% *.#*-,+% -&% (4"% *:()7#.$+% .&'% (4"% *)&$(.&(% /"+)0.#% "-(4"/% 8:% -($%

"L(/,$-)&% .*/)$$% XJ% )/% 8:% -($% $()/.3"% -&% (4"% $./*)7#.$+-*% .##)A$% *"##$% ()% ,$"% )$*-##.(-)&% -&%

*.#*-,+%*)&*"&(/.(-)&%.$%.% $-3&.#-&3%+"*4.&-$+%()% /"3,#.("%.&'%*))/'-&.("%".*4% -&$(.&(%)9%

*"##,#./%#-9"1%%

%

K(+&LM&>:;03"/(:&-0,-010)/"/(.)&.2&2N):/(.)"4&N)(/1&.2&!"#$&1(+)"4()+&)0/@.-?M&J*",/0*&2-.3O&P0--(*+0O&IM&0/&"4O&#QQQM&

20

%

K(+M&#M&>:;03"/(:&-0,-010)/"/(.)&.2&!"#$&1(+)"4()+&/..4?(/M&F)/-":044N4"-&!"

#$&;.30.1/"1(1&(1&":;(090*&'5&'"4"):()+&

/;0&0)/-5&")*&-03.9"4&.2&!"#$(.)M&67!O&9.4/"+0%.,0-"/0*&:;"))041<&=7!O&-0:0,/.-&.,0-"/0*&:;"))041<&>7!O&1/.-0%

.,0-"/0*& :;"))041<& F)1DE=1O& ().1(/.4& LOROS%/-(1,;.1,;"/0& -0:0,/.-1<& =5=1O& -5").*()0& -0:0,/.-1O& DI!JO& ,4"13"&

303'-")0&!"#$%JTD"10<&>B=!JO&1"-:.,4"13(:&-0/(:N4N3&!"

#$%JTD"10M&J*",/0*&2-.3&P0--(*+0O&IM&0/&"4O&LUUVM&

1.1.2 THE CORE OF CALCIUM SIGNALING NETWORK

B4"% +)$(% $7"*-.#-I"'% +"*4.&-$+% )9% *))/'-&.(-)&% )9% *.#*-,+% $-3&.#-&3% ())#C-(% *.&%

7)$$-8#:% 8"% 9),&'% -&% $C"#"(.#% +,$*#"5% A4"/"% (4"% [6(:7"% \)#(.3"6N7"/.("'% !4.&&"#$% ./"%

'-/"*(#:% *),7#"'% ()% (4"%Y]Y?5% $)% (4.(% (4"% (/.&$+-$$-)&%)9%!"#$%$-3&.#%)**,/$%8:%.&%.##)$("/-*%

0./-.(-)&%)9%7/)("-&%*)&9)/+.(-)&$% ;B$,3)/C.%"(%.?DDQ^%_#"-&%"(%.#1?DDQ<1%!)&$"R,"&(#:5% (4"%

+"+8/.&"% '"7)#./-I.(-)&% *.,$"$% (4"% /"#".$"% )9% *.#*-,+% 9/)+% MY% (4/),34% (4"% A"##6C&)A&%

!"#$%()*N:0*&!"

#$%-040"10&+"*4.&-$+1%B4-$%-&*/".$"%-&%*.#*-,+%*)&*"&(/.(-)&%-$%/"*)3&-I"'%8:%

$7"*-9-*%!"#$%10)1.-1%-&%$C"#"(.#%+,$*#"V%(4"%T-.,.)()!%;B7!<%.&'%(4"%!"43.*N4()&W!"IAM%B4":%

./"%*)&$-'"/"'%7/)()(:7"$%)9%(4"%!"#$&'()*()+&,-./0()&2"3(45M&G)(4%)9%(4"+%4.0"%9),/%PF4.&'%

$(/,*(,/.#% +)(-9$% 9)/% 8-&'-&3% *.#*-,+% .&'% (4":% /"3,#.("% '-99"/"&(% $("7$% )9% (4"% "L*-(.(-)&6

/"#.L.(-)&% *),7#"'%+"*4.&-$+1% B4"% B7!% *)&(/)#$% (4"% C":% "0"&(% )9%+,$*#"% *)&(/.*(-)&5% (4"%

+:)$-&6.*(-&% -&("/.*(-)&1% B4-$% -$% #)*C"'% 8:% (4"% 7/"$"&*"% )9% (/)7)+:)$-&6(/)7)&-&% *)+7#"L5%

A4-*4%-$%/"+)0"'%-&%/"$7)&$"%()%*)&9)/+.(-)&.#%*4.&3"$%)9%(/)7)&-&%.$%.%*)&$"R,"&*"%)9%(4"%

INTRODUCTION

21

*.#*-,+%8-&'-&31% T&%(4-$%A.:5%(4"%.*(-&68-&'-&3%$-("%8"*)+"$%.0.-#.8#"%.&'%+:)$-&%*.&%+)0"%

)&%9-#.+"&($%.(%(4"%"L7"&$"%)9%UBX%4:'/)#-$-$1%N&%(4"%)(4"/%4.&'5%!UJ%$(-+,#.("$%(4"%"&I:+"%

74)$74)/:#.$"% C-&.$"% ()% "&$,/"% .% 7./.##"#% -&*/".$"% -&% UBX% 7/)',*(-)&% 0-.% +-()*4)&'/-.5%

*)&9-/+-&3% (4"% (4"$-$% (4.(% (4"% $.+"% *"##% *.&% ,$"% '-99"/"&(% $"&$)/$% ()% /"3,#.("% $"7./.("#:%

*))/'-&.("'%7/)*"$$"$1%Y",7(.C"%)9%*:()$)#-*%*.#*-,+%-&()%MY%8:%MPY!U%7,+7%.&'%/"+)0.#%()%

(4"%"L(/.*"##,#./%$7.*"%8:%K!`%.&'%XJ!U%7,+7%/"$,#($%-&%+,$*#"%/"#.L.(-)&1%B4-$%+"*4.&-$+%

-$%+)/"%*)&$"/0"'%-&%)(4"/%(:7"%)9%",C./:)(-*%*"##$%$,*4%.$%4"./(%*"##$5%A4"/"%-&%/"$7)&$"%)9%

+"+8/.&"%'"7)#./-I.(-)&%.%$+.##%.+),&(%)9%*.#*-,+%"&("/$%(4/),34%(4"%[6(:7"%*4.&&"#%.&'%

.*(-0"$%(4"%/"#".$"%9/)+%-&("/&.#%$()/"%(4/),34%Y]Y=1%U%7/)7)/(-)&%)9%(4-$%!.=@%(/.0"#$%(4/),34%

(4"%+-()*4)&'/-.5%.&'%',/-&3%(4-$%(-+"%-(%$(-+,#.("$%(4"%+"(.8)#-$+%()%7/)0-'"%(4"%UBX%(4.(%-$%

&"*"$$./:%()%+.-&(.-&%*)&(/.*(-)&1%

%

%

K(+M&EM&>:;03"/(:&-0,-010)/0/(.)&.2&/;0&3"X.-&,4"50-1&(3,4(:"/0*&()&0H(/"/(.)%:.)/-":/(.)&:.N,4()+&.2&/;0&;0"-/M&&

Y%/5,0& !"#$& :;"))04& WYT!!AO& /;0& -5").*()0& -0:0,/.-& W=5=AO& /;0& 1"-:.W0)*.A,4"13(:& -0/(:N4N3& !"

#$& JTD"10&

W>B=!J#"A& ,N3,& ")*& /;0& ,4"13"%303'-")0& !"#$& JTD"10& WDI!JA& ")*& /;0& G"

$C& !"

#$& 0H:;")+0-& WG!ZAM& DYG&

,;.1,;.4"3'")O&[GT&XN):/(.)O&T=F&/-("*()O&!>\&:"410]N01/-()M&J*",/0*&2-.3&6"2("*"?(O&BM&0/&"4O&#QQ^M&

%

22

1.2 THE SERCA PUMP

1.2.1 THE P-TYPE ATPASE FAMILY

T&% +.++.#$5% (4/""% *.#*-,+% 7,+7$% 4.0"% 8""&% '"$*/-8"'V% (4"% $./*)7#.$+-*% /"(-*,#,+%

;MPY!U<5%7#.$+.%+"+8/.&"% ;XJ!U<%.&'% (4"%a)#3-%&"(A)/C% ;MX!U<%7,+7$1%U##% (4/""%7,+7$%

8"#)&3% ()% (4"% X6(:7"% UBX.$"$% 9.+-#:5% *4./.*("/-I"'% 8:% (4"% 9)/+.(-)&% )9% .&% "&"/3-I"'%

-&("/+"'-.("5%/"$,#(-&3%9/)+%(4"%.,()674)$74)/:#.(-)&%)9%.%C":%-&0./-.&(%.$7./(.("%/"$-',"%-&%

.%4-34#:%*)&$"/0"'%$"R,"&*"V%M6_BaB[B1%%

U% $"R,"&*"% .#-3&+"&(% )9% 9),/% +.-&% /"7/"$"&(.(-0"$% )9% (4"% 9.+-#:% 9/)+% ,&/"#.("'%

)/3.&-$+$%;_,4#8/.&'(5%=>>W<%$4)A$%*)&$"/0"'%/"3-)&$% -&%*:()7#.$+-*%')+.-&$5%$,*4%.$%(4"%

$-("% A4"/"% (4"% 74)$74)/:#.("'% -&("/+"'-.("% -$% 9)/+"'5% (4"% UBX68-&'-&3% 7)*C"(5% .&'% (4"%

/"3-)&% -&0)#0"'% -&% (4"% '"74)$74)/:#.(-)&% )9% (4"% "&I:+"1% 2"$7-("% (4"% #)A% '"3/""% ;?Eb<% )9%

3"&"/.#% -'"&(-(-"$5% (4"$"% *)&$"/0"'% /"3-)&$% ./"% $(/,*(,/.##:% .&'% 9,&*(-)&.##:% $-3&-9-*.&(% .&'%

./"%*)&$"/0"'%(4/),34),(%(4"%X6(:7"%UBX6.$"%9.+-#:1%T&%.''-(-)&%()%(4"$"%9".(,/"$5%(4"%9.+-#:%

+"+8"/$%$4./"%(4"%"$$"&(-.#%7/)7"/(-"$%)9%+"+8/.&"%()7)#)3:%;9/)+%Q%()%??%(/.&$+"+8/.&"%

4"#-*"$5%A4"/"%(4"%-)&68-&'-&3%$-("$%./"%#)*.("'<%.&'%/".*(-)&%+"*4.&-$+5%8,(%(4":%*.&%'-99"/%

-&% /"3,#.(-)&% 7/)*"$$"$5% -&4-8-(-)&% +"*4.&-$+$% .&'% (/.&$7)/(% $7"*-9-*-(-"$1% G.$-*.##:5% (4":%

*),7#"%(4"%.*(-0"%(/.&$7)/(%)9%-)&$%.*/)$$%(4"%+"+8/.&"%()%(4"%4:'/)#:$-$%)9%UBX%(4/),34%.%

/".*(-)&%*:*#"%7/)7)$"'%+)/"%(4.&%S>%:"./$%.3)1%N/-3-&.##:5% (4"%*:*#"%A.$%'"$*/-8"'%.$%(A)%

'-$(-&*(%*)&9)/+.(-)&.#%$(.("$5%8.$"'%)&%(4"%'-99"/"&(%.99-&-(:%)9%(4"%"&I:+"%9)/%(/.&$7)/("'%

-)&$V% P?% $(.("% ;4-34% .99-&-(:5% 9.*"'% )&% *:()7#.$+<% .&'% P=% $(.("% ;-)&% #)A% .99-&-(:5% 9.*"'% )&%

"L(/.*"##,#./%$7.*"<%;U#8"/$5%Qc<1%[.("/5%C-&"(-*%'.(.%$4)A"'%(4.(%(4"%"&"/3:%/"R,-/"'%9)/%(4"%

*),7#-&3% )9% 4:'/)#:(-*% .&'% 0"*()/-.#% (/.&$7)/(% 7/)*"$$"$% /"$,#("'% 9/)+% (A)% 74)$74)/:#.("'%

-&("/+"'-.("% $(.("$V% P?!X% ;4-346"&"/3:% -&("/+"'-.("<% .&'% P=6X% ;#)A6"&"/3:% -&("/+"'-.("<%

;d4-((.+5%?DH><1%

G.$"'% )&% C-&"(-*$% '.(.% )8$"/0"'% 9/)+% K.@Z_@6UBX.$"% "L7"/-+"&($5% X)$(% .&'% U#8"/$%%

;U#8"/$5%?DQH^%X)$(%"(%.#15%?DQD<%7/)7)$"'%.%3"&"/.#%-)&6(/.&$#)*.(-)&%*:*#"%)9%X6(:7"%UBX.$"$1%

INTRODUCTION

23

U**)/'-&3% ()% (4"% +)'"#% ;$""% 8)L?<5% 74)$74)/:#.(-)&% .&'% '"74)$74)/:#.(-)&% 7/)*"$$"$%

"L*#,$-0"#:%)**,//"'%A4"&%(4"%"&I:+"%A.$%#-&C"'%()%K.@5%.&'%()%_@%/"$7"*(-0"#:5%A4-#"%(4"%-)&%

+)0"+"&(% .*/)$$% (4"% +"+8/.&"% ())C% 7#.*"% ',/-&3% (4"% B?6X% ()% B=6X% .&'% (4"% B=% ()% B?%

(/.&$-(-)&$5%$-+,#(.&"),$#:1%T&%(4-$%A.:5%(4"%/-34(%$"R,"&*"%)9%+)#"*,#./%"0"&($5%A4"/"8:%(4"%

7,+7%(/.&$7)/("'%-)&$%.(%(4"%"L7"&$"%)9%UBX5%A"/"%'"$*/-8"'1%K)&"(4"#"$$5%(4"$"%"0-'"&*"$%

A"/"%-&$,99-*-"&(%()%/"*)&$(/,*(%A-(4%/".$)&.8#"%*)&9-'"&*"%(4"%+)#"*,#./%+"*4.&-$+$%(4.(%

*)&0"/(% (4"% *4"+-*.#% "&"/3:5% '"/-0"'% 9/)+%UBX%4:'/)#:$-$5% -&()% .% 0"*()/-.#% (/.&$7)/(5% )/% ()%

'"$*/-8"%(4-$%7/)*"$$"$%.(%(4"%.()+-*%'"(.-#1%F-&.##:5%(4"%+)#"*,#./%,&'"/$(.&'-&3%)9%(4"%UBX6

'/-0"&%-)&%(/.&$7)/(%+"*4.&-$+%4.'%.%(,/&-&3%7)-&(%(4.&C$%()%(4"%'"("/+-&.(-)&%)9%(4"%(4/""6

'-+"&$-)&.#% $(/,*(,/"%)9%MY%!.=@6UBX.$"% ;MPY!U<% 9/)+%/.88-(% $C"#"(.#%+,$*#"5%A4-*4% -$%&)A%

*)&$-'"/"'%(4"%./*4"(:7"%)9%(4"%X6(:7"%UBX.$"$%;B):)$4-+.5%=>>><1%

%

&

K(+M&RM&T;0&D.1/%J4'0-1&:5:40M&T;0&:"/"45/(:&:5:40&:")&'0&*01:-('0*&"1&2.44.@8&()&/;0&BL&1/"/0O&/;0&;(+;&"22()(/5&(.)%

'()*()+&1(/0&(1&"::011('40&2-.3&:5/.,4"13M&!"#$&'()*()+&/-(++0-1&/;0&,;.1,;.-54"/(.)&.2&/;0&:"/"45/(:&_%-01(*N0&'5&

/;0&I+#$&:..-*()"/0*&+%,;.1,;"/0&.2&JTD&")*&/;0&1N'10]N0)/&/-")1(/(.)&/.&/;0&BL`D&1/"/0M&T;(1&(1&.)0&.2&/;0&-"/0%

4(3(/()+& 1/0,1&.2& /;0& :5:40O& ")*&N)*0-& 2"9.-"'40& :.)*(/(.)1& /;0& ()/0-30*("/0& :")& /-")120-& /;0&,;.1,;.-54& +-.N,&

'":?&/.&J_DM&T;0&2"1/&/-")1(/(.)&/.&/;0&B#%D&1/"/0&()*N:01&/;0&!"#$&-040"10&()/.&/;0&0H/-":044N4"-&1(/0M&J/&/;(1&,.()/O&

/;0&(.)%'()*()+&1(/0&;"1&"&;(+;&"22()(/5&2.-&a$O&@;(:;&:")&'()*&2-.3&/;0&.N/1(*0M&T;0&)0H/&;5*-.451(1&.2&/;0&0)b530&

-0+0)0-"/01&/;0&:.)2.-3"/(.)&B#&")*&/;0&*(11.:("/(.)&.2&/;0&().-+")(:&,;.1,;"/0&")*&3"+)01(N3&-090-/1&/.&/;0&

BL&1/"/0O&@;0-0&/;0&a$&(1&-040"10&()/.&/;0&:0441M&T;0&2-00&(.)%0)b530&:")&/;N1&1/"-/&")*&")./;0-&:5:40M&T"?0)&2-.3&

P-()(O&IM&0/&"4O&#QLQM&

24

1.2.2 ISOFORMS OF THE SERCA PUMP

T&%+.++.#$5%.%9.+-#:%)9%(4/""%*)&$"/0"'%3"&"$5%MPY!U%?5%=5%.&'%S5%"&*)'"$%(4/""%+.-&%

MPY!U%7,+7$%.&'%(4"%.#("/&.(-0"%$7#-*-&3%.(%(4"%!NNe6("/+-&.#%)9%(/.&$*/-7($%"&4.&*"$%(4"%

&,+8"/%)9% 7/)("-&% 0./-.&($1%2"0"#)7+"&(.##:% .#("/&.(-0"% $7#-*-&3%)9% MPY!U?%3"&"% /"$,#($% -&%

(A)% (/.&$*/-7(% 0./-.&($% "&*)'-&3% '-99"/"&(% -$)9)/+$V% (4"% MPY!U?.% .&'% MPY!U?8% 7/)("-&$5%

A4-*4%./"%"L7/"$$"'%-&%.',#(%.&'%-&%&")&.(.#%9.$(6(A-(*4%$C"#"(.#%+,$*#"5%/"$7"*(-0"#:1%F)/%(4"%

MPY!U=% 3"&"5% .% (-$$,"6'"7"&'"&(% 7/)*"$$-&3% )9% 7/-+./:% (/.&$*/-7(% -$% /"$7)&$-8#"% 9)/% (4"%

"L7/"$$-)&% )9% (A)% +.-&% -$)9)/+$V% (4"% MPY!U=.% .&'% (4"% MPY!U=8% 7/)("-&$1% B4"% 9-/$(% -$%

"L7/"$$"'% 7/"')+-&.&(#:% -&% *./'-.*% .&'% $#)A6(A-(*4% $C"#"(.#% +,$*#"5% A4-#"% (4"% $"*)&'% -$%

*)&$-'"/"'% (4"% 4),$"C""7-&3% -$)9)/+5% 8"*.,$"% -(% -$% "L7/"$$"'% .(% #)A% #"0"#$% -&%+,$*#"% .&'%

&)&6+,$*#"%*"##$1%U&)(4"/%0./-.&(%)9%(4"%MPY!U%=%3"&"%;MPY!U=*<%4.$%8""&%9),&'%-&%4,+.&%

+)&)*:("$% .&'% 9"(.#% 4"./(1% F-&.##:5% $-L% 7)$$-8#"% 0./-.&($% ;.69<% )9% MPY!US% 3"&"% 4.0"% 8""&%

'"$*/-8"'5% 8,(% )&#:% S% -$)9)/+$% ;.6*<% 4.0"%8""&%'"("*("'% -&% 4,+.&$% .(% 7/)("-&% #"0"#1% B4"$"%

#.(("/% ./"% "L7/"$$"'% -&% .% &,+8"/% )9% &)&6+,$*#"% *"##$1% B4"% "L7/"$$-)&% 7.(("/&% )9% MPY!U%

-$)9)/+$5%A4-*4% *4.&3"$%',/-&3%'"0"#)7+"&(% .&'% (-$$,"%'-99"/"&(-.(-)&5% $,33"$($% (4.(% ".*4%

MPY!U%-$)9)/+%7#.:$%.%$7"*-9-*%9,&*(-)&%-&$-'"%(4"%(-$$,"%-&%A4-*4%-(%-$%"L7/"$$"'1%T&%.''-(-)&5%

$)+"%/"3,#.()/:%+)#"*,#"$%)9%(4"%MPY!U%7,+7%*),#'%"&4.&*"%(4"$"%9,&*(-)&.#%'-99"/"&*"$1%

1.2.3 SERCA REGULATORY PROTEINS

BA)%"&')3"&),$%+)#"*,#"$%+)',#.("%(4"%.*(-0-(:%)9%(4"%MPY!U%7,+7V%74)$74)#.+8.&%

;X[G<%.&'%$./*)#-7-&%;M[K<5%A4-*4%./"%"L7/"$$"'%-&%*./'-.*%.&'%$C"#"(.#%+,$*#"$5%/"$7"*(-0"#:1%

d4-#"%(4"%+"*4.&-$+%)9%.*(-)&%)9%X[G%)&%MPY!U%-$%A"##%*4./.*("/-I"'5%(4.(%)9%M[K%)&#:%8"3-&$%

()%8"%,&'"/$())'1%

X4)$74)#.+8.&%-$%.%$+.##%7/)("-&%)9%)&#:%E=%.+-&)%.*-'$5%A4-*4%4.$%8""&%9),&'%)&%(4"%

MY%+"+8/.&"%-&%(A)%'-99"/"&(%*)&9)/+.(-)&$V%(4"%,&74)$74)/:#.("'%X[G%+)&)+"/%)9%Q%C2.5%

/"$7)&$-8#"% 9)/% (4"%MPY!U%7,+7% -&4-8-(-)&5% .&'% (4"%74)$74)/:#.("'%X[G%4)+)7"&(.+"/%)9%

.8),(%==C2.%A)/C-&3% .$% .% /"$"/0)-/1% P.*4%+)&)+"/%4.$%8""&%7/"'-*("'% ()%8"%'-0-'"'% -&()%

INTRODUCTION

25

(A)% A-'"% ')+.-&$V% .% 4:'/)74-#-*% ')+.-&% ;.+-&)% .*-'$% /"$-',"$% ?6S><5% A4-*4% *)&(.-&$% (4"%

/"3,#.()/:%$-("$5%.&'%.%4:'/)74)8-*%')+.-&%;.+-&)%.*-'$%S?6E=<5%A4-*4%-$%.&*4)/"'%-&()%(4"%

*./'-.*%$./*)7#.$+-*%/"(-*,#,+%+"+8/.&"1%2"(.-#"'%*/)$$6#-&C-&3%.&'%$-("6'-/"*(%+,(.3"&"$-$%

$(,'-"$%4.0"%-'"&(-9-"'%(4"%-&("/.*(-)&%$-("$%8"(A""&%(4"%X[G%.&'%(4"%MPY!U%7/)("-&1%B4"%9-/$(%

-&("/.*(-)&%A.$% -'"&(-9-"'%8:% (4"%*/)$$6#-&C-&3%)9%[:$S% -&% (4"%X[K%')+.-&%()% (4"%[:$SDH%.&'%

[:$W>>%)9% (4"% $"R,"&*"%_22_X\% -&% (4"% *:()$)#-*%K%')+.-&%)9% (4"% MPY!U%7,+7% ;f.+"$5% X15%

?DcD<1%B4-$%$"R,"&*"%-$%*)&$"/0"'%-&%(4"%MPY!U%?%.&'%=%7/)("-&$%.&'%7/)8.8#:%-$%/"$7)&$-8#"%

9)/% (4"%"L*#,$-)&%)9% MPY!U%S% -$)9)/+$% 9/)+% (4"%X[G% -&4-8-()/:% $:$("+1% B4"% $"*)&'% $-("%4.$%

8""&%9),&'%-&%$7"*-9-*%/"$-',"$%)9%(4"%X[K%(/.&$6+"+8/.&"%')+.-&%;=c6E=%/"$-',"$<%(4.(%./"%

/"$7)&$-8#"% 9)/% (4"% 7,+7% -&4-8-(-)&5% /"',*-&3% -($% .77./"&(% *.#*-,+% .99-&-(:1% B4-$% -&4-8-()/:%

9,&*(-)&% )9% (/.&$6+"+8/.&"% ')+.-&% 4.$% 8""&% 9),&'% ,$-&3% X[G% +)#"*,#"$% -&% A4-*4% (4"%

*:()$)#-*%')+.-&$%A"/"%'"#"("'5%$,33"$(-&3%(4.(%X[K6MPY!U%(/.&$6+"+8/.&"%-&("/.*(-)&%4.$%

.%C":%-&4-8-()/:%/)#"%;_-+,/.5%]15%?DDQ<1%%

B4"%4)+)#)3,"%)9%X[K%-$%M./*)#-7-&%;MK[<%(4.(%"L*#,$-0"#:%-&4-8-($%(4"%MPY!U?.%-$)9)/+%

-&%$C"#"(.#%+,$*#"%*"##$1%F/)+%$"R,"&*"%.#-3&+"&(5%(4"%(/.&$6+"+8/.&"%')+.-&%)9%M[K%$4./"$%

&"./#:% S>b% -'"&(-(:%A-(4% (4.(% )9% 74)$74)#.+8.&% ;X[K<5% *)&9-/+-&3% -($% /)#"% .$% .&% -&4-8-()/:%

$-("1%Y"*"&(%)8$"/0.(-)&$%4.0"%'"+)&$(/.("'%(4.(%M[K%-$%*)6"L7/"$$"'%A-(4%MPY!U=.%-&%+)'"#%

*"##$% .&'% (4-$% -$% /"#.("'% ()% .% $,7"/6-&4-8-(-)&% )9% (4"% 7,+71% T&% .''-(-)&5% KJY% $(,'-"$% 4.0"%

$,33"$("'%(4.(%(4"%(A)%/"3,#.()/:%7/)("-&$%8-&'%()%MPY!U%-&%.%$-+-#./%+.&&"/1%e)A"0"/5%(4"%

74:$-)#)3-*.#%$-3&-9-*.&*"%)9%(4"%MPY!U%7,+7%/"3,#.(-)&%8:%M[K%/"+.-&$%()%8"%"#,*-'.("'1%

1.2.4 REGULATION OF SERCA2A ACTIVITY

U$%+"&(-)&"'5%X[K%-$%(4"%+.g)/%/"3,#.()/%)9%MPY!U=.%.*(-0-(:%.&'%$)%9./%-$%(4"%)&#:%)&"%

(4.(% A.$% 7/)0"&% ()% 8"% -&0)#0"'% -&% *./'-.*% '"0"#)7+"&(5% -&*#,'-&3% 4"./(% 9.-#,/"1% B4"% X[K6

+"'-.("'% -&4-8-(-)&% )9% MPY!U=.% -$% 9-&"#:% /"3,#.("'% 8:% 74)$74)/:#.(-)&% )9% (4/""% '-$(-&*(%

74)$74)/:#.(-)&% $-("$% ;M"/% ?>5% M"/% ?Q5% B4/% ?H<% -&% (4"% /"3,#.()/:% ')+.-&% )9% X[K5%A4-*4% ./"%

*)&(/)##"'% 8:% (4/""% '-99"/"&(% 7/)("-&% C-&.$"$% ;7/)("-&% C-&.$"% !% ;X_!<5% *UJX6'"7"&'"&(%

7/)("-&% C-&.$"% ;X_U<% .&'% !.=@6*.#+)',#-&% 7/)("-&% C-&.$"% ;!.J_TT<1% X4)$74)/:#.(-)&% )9% ".*4%

26

/"$-',"% -$% /"#.("'% ()% .&% -&*/".$"% -&% MPY!U=.% .*(-0-(:% .$% .% /"$,#(% )9% (4"% .$$)*-.(-)&% )9% X[G%

+)&)+"/$% -&()% 7"&(.+"/1%N&% (4"% )(4"/% "&'5% '"74)$74)/:#.(-)&% 0-.% 7/)("-&% 74)$74.(.$"% T%

;XXT<% /"$()/"$% (4"% -&4-8-()/:% "99"*($% )9% X[K% )&% MPY!U=.1% B4-$% /"$,#($% -&% .% '"*/".$"% -&% !.=@%

.99-&-(:%.$%.%*)&$"R,"&*"%)9%MPY!U=.ZX[K%-&("/.*(-)&5%A4-*4%$(.8-#-I"$%(4"%"&I:+"%-&%(4"%P=%

*)&9)/+.(-)&5% *.,$-&3% (4"% -&4-8-(-)&% .&'% (4"% .33/"3.(-)&% )9% (4"% 7,+71% B4"% .*(-0-(:% )9% (4"%

MPY!U%7,+7%-$%+)',#.("'%8:%h%.'/"&"/3-*%$-3&.##-&3%7.(4A.:%(4/),34%(4"%74)$74)/:#.(-)&%)9%

-&4-8-()/%T%0-.%7/)("-&%C-&.$"%U1%U'/"&.#-&"%.&'%)(4"/%h6.3)&-$($%-&-(-.("%.&%-+7)/(.&(%$-3&.#6

(/.&$',*(-)&% 7.(4A.:5% A4"/"% (4"% -&*/".$"% -&% (4"% *UJX% *)&*"&(/.(-)&% .*(-0.("$% *UJX6

'"7"&'"&(%7/)("-&%C-&.$"%;X_U<5%A4-*4%(4"&%74)$74)/:#.("$%.&'%.#("/$%(4"%9,&*(-)&%)9%.%9"A%

*./'-.*% 7/)("-&$1% T&% 9.*(5% (4"% $"/-&"?Q% $-("% .77"./$% ()% 8"% (4"%+)$(% -+7)/(.&(%+"'-.()/% ()%

"&4.&*"%*./'-.*%*)&(/.*(-#-(:%.&'%4.$%8""&%$,33"$("'%()%8"%(4"%+.-&%/"3,#.()/%)9%(4"%.*(-0-(:%

)9%74)$74)#.+8.&1%

1.3 STRUCTURAL PROPERTIES OF SERCA PUMP. A DETAILED OVERVIEW

1.3.1 E1 VERSUS E2: THE FIRST STEPS INSIDE THE MOLECULAR UNDERSTANDING OF REACTION CYCLE

M-&*"% (4"% 9-/$(% 7/"'-*(-)&% )9% (4"% $(/,*(,/"% )9% (4"% MY% !.=@6UBX.$"% ;MPY!U<% 4.$% 8""&%

7/)7)$"'%+)/"%(4.&%=>%:"./$5%.%4,3"%&,+8"/%)9%8-)*4"+-*.#%.&'%+,(.(-)&.#%.&.#:$"$%4.0"%

8""&% .**,+,#.("% ()% *#./-9:% (4"% +)#"*,#./% .$7"*($% )9% (4"% /".*(-)&% *:*#"% .&'% (4"% /"3-)&%

-&0)#0"'% -&% (4"%"&I:+.(-*% *.(.#:$-$1% F/)+%(4-$% $*"&./-)5% (4"%MPY!U%"+"/3"'% #-C"%.&% -&("3/.#%

+"+8/.&"% 7/)("-&% )9% .8),(% ??>% _2.5% *)&$-$(-&3% )9% (4/""% *:()7#.$+-*% ')+.-&$% g)-&"'% ()% .%

3/),7%)9%?>%(/.&$+"+8/.&"%;BJ<%4"#-*"$%;J?6J?><%8:%.%$4)/(%1/"4?%$"3+"&(%;J.*["&&.&%"(%

.#15%?DcE^%G/.&'#%"(%.#15%?DcQ^%B.:#)/%.&'%a/""&5%?DcD<1%B4"%*/-(-*.#%/"$-',"$%9)/%!.=@%8-&'-&3%

.&'% (4)$"% 9)/% UBX% 4:'/)#:$-$5% -'"&(-9-"'% 8:%+,(.3"&"$-$% $(,'-"$5% 4.0"% 8""&% #)*.("'% -&% (4"%

+-''#"% )9% (4"% (/.&$+"+8/.&"% 4"#-*"$% ;!#./C"% "(% .#15% ?DcD^% !4"&% "(% .#15% ?DDQ<5% .&'% -&% (4"%

*:()7#.$+-*%')+.-&%8"(A""&%(4"%JW%.&'%JE%4"#-*"$% ;J./,:.+.%"(%.#15%?DcD^%!#./C"%"(%.#15%

?DD>.^%\-#$"&%"(%.#15%?DD?<5%/"$7"*(-0"#:1%U%&,+8"/%)9%8-)*4"+-*.#%'.(.%4.0"%8""&%*)##"*("'%()%

7/)7)$"% .% $(/,*(,/.#% .//.&3"+"&(% )9% (4"% UBX% 8-&'-&3% 7)*C"(% ;B.:#)/% .&'% a/""&5% ?DcD<5%

INTRODUCTION

27

9)/+"'% 8:% (A)% '-$(-&*(% ')+.-&$% *)&&"*("'% 8:% .% 4-&3"1% U% $+.##"/% *:()7#.$+-*% ')+.-&%

8"(A""&%J=%.&'%JS%4.$%8""&%7)$(,#.("'%()%8"%/"$7)&$-8#"%9)/%(4"%*),7#-&3%)9%UBX%4:'/)#:$-$%

()%-)&%(/.&$7)/(%;U&'"/$"&%"(%.#15%?DcD^%!#./C"%"(%.#15%?DD>8<1%

U##%(4"$"%'.(.%4.0"%8""&%*)+7#"("'%.&'%*)&9-/+"'%8:%(4"%'"$*/-7(-)&%)9%(4"%9-/$(%`6/.:%

*/:$(.#% $(/,*(,/"% )9% !.=@68),&'% MPY!U% .(% =1Q% i% /"$)#,(-)&5% $)#0"'% 8:% B):)$4-+.j$% 3/),7%

;B):)$4-+.5% !1% "(% .#5% =>>><1% T(% 4.$% /"7/"$"&("'% .% +-#"$()&"% -&% (4"% ,&'"/$(.&'-&3% )9% (4"%

+)#"*,#./%+.*4-&"%/"$7)&$-8#"%9)/%(4"%*.#*-,+%7,+7-&3%.&'%-(%4.$%7,(%(4"%8.$"+"&(%9)/%(4"%

8,-#'-&3% )9% .##% (4"% 9)##)A-&3% C&)A#"'3"% .8),(% (4"% X6(:7"% UBX.$"% 9.+-#:1% MPY!U% */:$(.#%

$(/,*(,/"%4.$%*)&9-/+"'%(4"%3"&"/.#%./*4-("*(,/"%)9%(4"%7,+75%*)&$-$(-&3%-&%(4/""%*:()7#.$+-*%

')+.-&$5% K% ;&,*#")(-'"% 8-&'-&3<5% X% ;74)$74)/:#.(-)&% /"$-',"<5% .&'% U% ;.*(,.()/<5% .&'% ?>%

(/.&$+"+8/.&"%4"#-*"$%;J?6J?><%$,//),&'-&3%(A)%*.#*-,+68-&'-&3%$-("1%%

T&% (4"% */:$(.##)3/.74-*% $(/,*(,/"% )9% !"378% $(.("% (4/""% *:()7#.$+-*% ')+.-&$% ./"% A"##%

$"7./.("'%()%9)/+%.&%.,0)&;0"*,(0:05% -&%A4-*4%(4"%*"&(/.#%7./(%)9%(4"%*:()7#.$+-*%/"3-)&%-$%

)**,7-"'%8:%')+.-&%X5%*)&(.-&-&3%(4"%*)&$"/0"'%74)$74)/:#.(-)&%/"$-',"%;U$7SE?<1%U/),&'%

(4-$% $-("5% (4"% /"$-',"$% */-(-*.#% 9)/% UBX% 4:'/)#:$-$% -$% *#,$("/"'5% 9)/+-&3% .% 4-34#:% &"3.(-0"#:%

*4./3"'% $,/9.*"5% .**"$$-8#"% ()% (4"% $)#0"&(1% B4"% ')+.-&% K% -$% (4"% #./3"$(% )9% (4"% (4/""%

*:()7#.$+-*%')+.-&$5%.&'%*)&(.-&$%(4"%&,*#")(-'"68-&'-&3%$-("%;X4"%WcH<1%2)+.-&%U5%(4"%$)6

*.##"'%":/N"/.-&*.3"()5% -$% (4"% $+.##"$(%)9% (4"% (4/""%.&'% -$% *)&&"*("'% ()% (4"%J?6JS% (/.&$6

+"+8/.&"%4"#-*"$%8:%#)&3%9#"L-8#"%#))7$1%T&%.''-(-)&5%-(%*)&(.-&$%.&)(4"/%$-3&.(,/"%$"R,"&*"%

)9% X6(:7"% UBX6.$"% 9.+-#:5% (4"% BaPM%+)(-91% B4"% (A)% !.=@% 8-&'-&3% $-("$% ;T% .&'% TT<% ./"% -&'""'%

"+8"''"'%$-'"%8:%$-'"%-&%(4"%(/.&$6+"+8/.&"%')+.-&1%M-("%T%-$%#)*.("'%-&%(4"%$7.*"%8"(A""&%

4"#-*"$%JE% .&'%JQ5% A-(4% *)&(/-8,(-)&% 9/)+%Jc% .(% .% /.(4"/% '-$(.#% 7)$-(-)&^% (4"% $-'"% *4.-&%

)L:3"&%.()+$%)9%U$&HQc5%a#,HH?%;JE<5%B4/HDD5%U$7c>>%;JQ<%.&'%a#,D>c%;Jc<%*)&(/-8,("%()%

(4-$% $-("5% -&%.3/""+"&(%A-(4%+,(.(-)&.#% $(,'-"$1%M-("% TT% -$% 9)/+"'%.#+)$(%)&%4"#-L%JW%8:% (4"%

+.-&6*4.-&% *./8)&:#% )L:3"&% .()+$% )9% \.#S>W5% U#.S>E% .&'% T#"S>H% ;JW<% .&'% (4"% $-'"6*4.-&%

)L:3"&%.()+$%)9%U$&HDQ5%U$7c>>%;JQ<%.&'%a#,S>D%;JW<%;c<1%B4"%JW%.&'%JE%4"#-*"$%./"%(4"%

#./3"$(% )9% (/.&$6+"+8/.&"% ')+.-&% .&'% (4"-/% *:()7#.$+-*%+)-"(:% ./"% '-/"*(#:% *)&&"*("'% ()%

28

(4"%*.(.#:(-*% *)/"%)9% (4"%X6')+.-&1% T&% 9.*(5% (4"%JE%4"#-L% -$% *)&$-'"/"'% (4"%8.*C8)&"%)9% (4"%

MPY!U%$(/,*(,/"1%

M,/7/-$-&3#:5% (4"% #)&3% '-$(.&*"% 8"(A""&% (4"% &,*#")(-'"68-&'-&3% .&'% 74)$74)/:#.(-)&%

$-("$% ;=E%i<5% .&'% (4.(%8"(A""&% (4"%74)$74)/:#.(-)&%.&'% -)&68-&'-&3% $-("$% -&% (4"%+"+8/.&"%

;.8),(% WE% i<% )7"&"'% ,&$)#0"'% R,"$(-)&$% .8),(% (4"%+)#"*,#./%+"*4.&-$+% (4.(% *),7#"% (4"%

74)$74)/:#.(-)&%7/)*"$$%()%(4"%*.#*-,+%/"#".$"1%e)A%')"$%(4"%UBX%8-&'-&3%)&%(4"%K%')+.-&%

(/.&$9"/%(4"%74)$74.("%()%(4"%U$7SE?%#)*.("'%-&%.&)(4"/%')+.-&k%U&'%4)A%*.&%(4-$%/".*(-)&%

8"% .$$)*-.("'% A-(4% (4"% *.#*-,+% /"#".$"% -&% (4"% #,+"&% )9% $./*)7#.$+-*% /"(-*,#,+k% U$% (4"% X%

')+.-&%7/"$"&(%$(/,*(,/.#%$-+-#./-(:%A-(4%(4"%*.(.#:(-*%*)/"%)9%4.#).*-'%'"4.#)3"&.$"5% -(%A.$%

$,33"$("'% (4.(% .% 7)$$-8#"% /".//.&3"+"&(% )9% (4"% )0"/.##% $(/,*(,/"5% -&% (4"% 7/"$"&*"% )9% !.=@5%

*),#'%$4.7"%.&%KZX%')+.-&%-&("/9.*"%A4"/"%(4"%74)$74)/:#.(-)&%7/)*"$$%*.&%(.C"%7#.*"1%U$%.%

*)&$"R,"&*"%)9% (4-$% -&("/.*(-)&5% (4"%U%')+.-&% *),#'% (/.&$+-(% (4"%+"*4.&-*.#% $-3&.#% ()% (4"%

(/.&$6+"+8/.&"%')+.-&5%(4.(%-&%(,/&%/"#".$"$%(4"%!.=@%8),&'%-&%(4"%MY%#,+"&1%%

M(/,*(,/.#% "0-'"&*"$5% /"$,#(-&3% 9/)+% (4"% *)+7./-$)&% )9% (4-$% $(/,*(,/"% A-(4% .% #)A6

/"$)#,(-)&% "#"*(/)&% '"&$-(:% +.7% )9% (4"% $.+"% "&I:+"% -&% (4"% 0.&.'.("6-&4-8-("'% P=OX%

*)&9)/+.(-)&% ;l4.&35% X15% ?DDc<5% 4.0"% $,33"$("'% (4.(% /-3-'68)':% /".//.&3"+"&($% )9%

*:()7#.$+-*%')+.-&$%(.C"%7#.*"%',/-&3%.*(-0"%(/.&$7)/(5%-&%.3/""+"&(%A-(4%8-)*4"+-*.#%'.(.1%

B4-$%-&("/7/"(.(-)&%A.$%9-&.##:%*)&9-/+"'%8:%(4"%*/:$(.#%$(/,*(,/"%)9%!.=@%9/""%MY%!.=@6UBX.$"%

-&% (4"% (4.7$-3./3-&6$(.8-#-I"'% P=% $(.("5% $)#0"'% .(% S1?i% /"$)#,(-)&% ;B):)$4-+.5% =>>=<1% d-(4%

/"$7"*(% ()%!.=@68),&'%P?%+)#"*,#./%+)'"#5% -(%'-$7#.:$%.%'-99"/"&(%.//.&3"+"&(%)9% (4"%(4/""%

*:()7#.$+-*%')+.-&$5%)/3.&-$"'%.$%.%:.3,":/&;0"*,(0:05%.&'%#./3"6$*.#"%/".//.&3"+"&($%)9%

$-L%(/.&$6+"+8/.&"%4"#-*"$%;J?6JQ<5%"&$,/-&3%(4"%!.=@%/"#".$"%-&()%(4"%MY%#,+"&1%B4"%#.(("/%

.#$)%3"&"/.("$%.%7.(4A.:%9)/%(4"%"&(/:%)9%&"A%*.#*-,+%-)&$%9/)+%(4"%*:()7#.$+-*%$-'"1%

1.3.2 E1-P PHOSPHO-INTERMEDIATE STRUCTURES AS A RESPONSE TO ATP-BINDING SITE CONTROVERSY

G-)*4"+-*.#%$(,'-"$%4.'%A"##%"$(.8#-$4"'%(4.(%(4"%*.(.#:(-*%*:*#"%)9%MPY!U%7,+7%(.C"$%

7#.*"% (4/),34% (A)% 74)$74)/:#.("'% -&("/+"'-.("$% .&'% (4.(% (4"% "&"/3:% '"+.&'"'% 9)/% -)&6

(/.&$#)*.(-)&%/"$,#($%9/)+%(4"%4:'/)#:$-$%)9%.%74)$74)6-&("/+"'-.("%"&I:+"1%M(/,*(,/"$%-&%P?%

INTRODUCTION

29

.&'%P=%$(.("$%4.0"%*)&9-/+"'%(4"%3"&"/.#%./*4-("*(,/"%)9%(4"%7,+7%.&'%7)$(,#.("'%.%7)$$-8#"%

/".*(-)&%+"*4.&-$+5%A4"/"8:%/".//.&3"+"&($%)9%(4/""%*:()7#.$+-*%')+.-&$%-$%+"*4.&-*.##:%

(/.&$+-(("'% ()% (4"% (/.&$6+"+8/.&"% ')+.-&% -&% )/'"/% ()% /"#".$"% (4"% *.#*-,+% -&()% (4"% MY%

#,+"&5% .$% /"$7)&$"% ()% 74)$74)/:#% (/.&$9"/1% N&% (4"% )(4"/% 4.&'5% (4":% 4.0"% .#$)% $7./C"'% .%

'"8.("% .8),(% (4"% $(/,*(,/.#% 8.$-$% )9% (4"% UBX% 8-&'-&3% 7)*C"(% .&'% 4.0"% #"9(% ,&$)#0"'% (4"%

+)#"*,#./%,&'"/$(.&'-&3%)9%+"*4.&-$+$%(4.(%*),7#"%(4"%74)$74)/:#%(/.&$9"/%/".*(-)&%()%(4"%

!.=@%)**#,$-)&%-&%(4"%P?6X%$(.("1%

B4"% 9-/$(% $(/,*(,/.#%"0-'"&*"% (4.(% (/-"'% ()%8/-'3"% (4"$"%3.7$% /"$,#("'% 9/)+%(A)%*/:$(.#%

$(/,*(,/"$%)9%MPY!U5%$)#0"'%8:%K-$$"&j$%3/),7%.(%=1Q%.&'%=1D%i5%/"$7"*(-0"#:V%(4"%!.=@%8),&'%

MPY!U% ;!"#7839:;;!;<% -&% *)+7#"L% A-(4% .% &)&64:'/)#:$.8#"% UBX% .&.#)3,"5% UJXX!X%

m.'"&)$-&"% ;"6#% +"(4:#"&"<6(/-74)$74.("n5% .&'% (4.(% ;!"#78396;<95=>3<% -&% *)+7#"L% A-(4%

.'"&)$-&"%'-74)$74.("%7#,$%.#,+-&-,+%9#,)/-'"5%.&%-&)/3.&-*%74)$74.("%.&.#)3,"%;M)/"&$"&5%

=>>W<1% B4":% +-+-*% (4"% *)&9)/+.(-)&.#% $(.("% )9% (4"% "&I:+"% A-(4% (4"% UBX% 8),&'% .&'% (4"%

(/.&$-(-)&%$(.("%)9%74)$74)/:#%(/.&$9"/5%/"$7"*(-0"#:1%B4"%)0"/.##%*)&9)/+.(-)&%)9%(4"%7,+7%-&%

(4"$"%(A)%9)/+$%-$%.#+)$(%(4"%$.+"5%"L*"7(%9)/%#)*.#%.'g,$(+"&($%.(%(4"%*.(.#:(-*%$-("5%.&'%-$%

*4./.*("/-I"'%8:%(-34(%.$$)*-.(-)&%)9%*:()7#.$+-*%')+.-&$%#-&C"'%()%(4"%(/.&$-"&(#:%)**#,$-)&%

)9%!.=@%8),&'%-&%(/.&$6+"+8/.&"%/"3-)&5%.$%-(%A.$%$,33"$("'%8:%8-)*4"+-*.#%'.(.1%M(/,*(,/.#%

*)+7./-$)&% )9% !.=6P?% .&'% !.=6P?6UJXX!X%+)#"*,#./%+)'"#$% "&.8#"'% ()% "&("/% -&()% .()+-*%

'"(.-#$%)9%(4"$"%*:()7#.$+-*%/".//.&3"+"&($5%$4)A-&3%4)A%(4"%8-&'-&3%)9%UBX%()%(4"%-&0./-.&(%

/"$-',"%X4"WcH%/"$,#($%-&%(4"%.$$"+8#-&3%)9%(4"%&,*#")(-'"68-&'-&3%7)*C"(5%8:%.%D>o%/)(.(-)&%

)9%(4"%K%')+.-&%()A./'%(4"%X%')+.-&1%B4-$%/".//.&3"+"&(%8/-&3$%(4"%EHQ6Ec?%#))7%)9%(4"%K%

')+.-&%*#)$"%()%(4"%H=>6H=E%#))7%)9%(4"%X%')+.-&%-&%)/'"/%()%9)/+%.%*/"0-*"5%A4"/"%(4"%?EE6

?Q>%#))7%)9%(4"%U%')+.-&%*.&% -&$"/(5%.$%/"$7)&$"%()%.%$,8$"R,"&(%/)(.(-)&%)9%WEo1%U$%(4"%U%

')+.-&%-$%g)-&"'%()%(/.&$6+"+8/.&"%4"#-*"$%J?6JS5%(4-$%/)(.(-)&%/"$,#($%-&%(A)%*))/'-&.("'%

"99"*($%(4.(%)**#,'"%(4"%!.=@%8),&'%-&%(4"%(/.&$6+"+8/.&"%')+.-&V%(4"%$(/"(*4-&3%)9%(4"%J=%

4"#-L% ()A./'$% (4"% *:()7#.$+5% .&'% (4"% 8"&'-&3% )9% (4"% J?% -&% .% 7./.##"#% 7)$-(-)&% ()% (4"%

+"+8/.&"% $,/9.*"% ;C-&C% .(% [",Q><5% /"$7"*(-0"#:1% [)*.#% '-99"/"&*"$% -&% *))/'-&.(-)&% )9% (4"%

30

UJXX!X% .&'% U#FW6% .&.#)3,"$% .(% (4"% *.(.#:(-*% *)/"% "&.8#"'% ()% -'"&(-9:% */-(-*.#% /"$-',"$% 9)/%

&,*#")(-'"% 8-&'-&35% $,33"$(-&3% .% 7)$$-8#"% *4"+-*.#% /".*(-)&%+"*4.&-$+% 9)/% (4"% 74)$74)/:#%

(/.&$9"/5% -&%.3/""+"&(%A-(4%+,(.(-)&.#%'.(.1%U$%(4"%&,*#")(-'"68-&'-&3%7)*C"(% -$%.$$"+8#"'%

.(% (4"% -&("/9.*"%8"(A""&% (4"%K%.&'%X%')+.-&$5%.$%.% /"$7)&$"% ()% (4"%$% $(.*C-&3% -&("/.*(-)&%

8"(A""&% ./)+.(-*% /-&3$% )9% .'"&-&"% .&'% X4"WcH5% (4/""% U/3-&-&"% % ;WcD5% EQ>5% QcH<% /"$-',"$%

$(.8-#-I"%(4"%%6%.&'%"674)$74.("%3/),7$%)9%UJXX!X%-&%.%8"&(%*)&9)/+.(-)&1%B4"%#674)$74.("5%

9./%S%i%9/)+%U$7SE?5%-$%-&%(,/&%$(.8-#-I"'%8)(4%8:%(4"%*))/'-&.(-)&%)9%J3=@%A-(4%(4"%*./8)&:#%

)9%B4/SES%.&'%(4"%$-'"%*4.-&$%)9%U$7H>S%.&'%U$7SE?%7#,$%(A)%A.("/%+)#"*,#"$5%.&'%8:%(4"%

$-'"%*4.-&$%)9%[:$QcW5%B4/SES%.&'%B4/Q=E%.$%A"##%.$%8:%(4"%+.-&%*4.-&%)9%a#:Q=Q1%N&%(4"%)(4"/%

4.&'5%-&%(4"%!.=P?6U2XVU#FW6%$(/,*(,/"%.&)(4"/%J3=@%-)&%(.C"$%7./(%-&%(4"%$(.8-#-I.(-)&%)9%(4"%

%6%.&'%"674)$74.("$%)9%U2X%.(%(4"%&,*#")(-'"%8-&'-&3%7)*C"(1%B4"%7#.&./%.#,+-&-,+%9#,)/-'"%

+)#"*,#"% 8/-'3"$% 8"(A""&% (4"% "674)$74.("% .&'% (4"% $-'"% *4.-&% )9% U$7SE?5% +)'-9:-&3% (4"%

-&("/.*(-)&$%)9%(4"%.+-&)%.*-'%/"$-',"$%-&0)#0"'%-&%74)$74)/:#%(/.&$9"/5%8:%(4"%*))/'-&.(-)&%

)9% (A)% J3=@% -)&$1% M,/7/-$-&3#:5% 8)&'-&3% '-$(.&*"$% ;!=% i<% )9% (4"% .()+$% (4.(% */)$$6#-&C%

.#,+-&-,+%A-(4%"674)$74.("%.&'%U$7SE?%)L:3"&%.()+$%./"%-&%.3/""+"&(%A-(4%(4"%4:7)(4"$-$%

)9% .% 7)$$-8#"% &,*#")74-#-*% /".*(-)&% +"*4.&-$+% ;MK=<% (4.(% A.$% 9-&.##:% $,33"$("'% ()% 8"%

/"$7)&$-8#"%9)/%(4"%.$7./(:#674)$74)/:#.("'%-&("/+"'-.("%9)/+.(-)&1%

T&%.''-(-)&5%B):)$4-+.j$%3/),7%7,8#-$4"'%(4"%*/:$(.#%$(/,*(,/"%)9%!.=@%8),&'%MPY!U%-&%.%

*)+7#"L%A-(4% UJXX!X% ;78•9:;;!;<% .(% =1D% i% -&% (4"% $.+"% :"./% ;B):)$4-+.5% =>>W<1% T&% (4-$%

7.7"/5% (4"% $(/,*(,/"% -$% 0"/:% $-+-#./% ()% (4.(% 7/"0-),$#:% '"$*/-8"'5% 8,(% (4"% .,(4)/$% ,$"'%

"0-'"&*"$% '"/-0"'% 9/)+% $(/,*(,/.#% $,7"/-+7)$-(-)&% ()% "+74.$-I"% (4"% /)#"% )9% UBX% .$% (4"%

7/-+./:%+)'-9-"/% )9% (4"% 7/)("-&% *)&9)/+.(-)&5% .&'% (4)$"% )9% a#,S>D5% .$% (4"% 3.(-&3% /"$-',"%

/"$7)&$-8#"% 9)/% *:()7#.$+-*% )**#,$-)&% )9% (/.&$+"+8/.&"% !.=@% 8-&'-&36$-("1% G:% (4"%

$,7"/-+7)$-(-)&% )9% (4"% P?p=!.=@% .&'% P?pUJXX!X% *)&*#,$-)&$% .8),(% (4"% 7/)("-&%

/".//.&3"+"&($% (4.(% +"'-.("'% -&("/.*(-)&$% 8"(A""&% *:()7#.$+-*% .&'% (/.&$+"+8/.&"%

')+.-&$%A"/"%'/.A&5%$,33"$(-&3%.%+"*4.&-$+%9)/%(4"%)**#,$-)&%)9%(4"%*:()7#.$+-*%3.("1%

%

INTRODUCTION

31

%

K(+M&SM&>/-N:/N-"4& :.3,"-(1.)& &'0/@00)&BL!"#$&")*&B#WTcA& 1/-N:/N-01M&!.4.N-1&:;")+0& 2-.3&/;0&"3().& /0-3()N1&

W'4N0A& /.& /;0& :"-'.H5& /0-3()N1M& & F)& BL!"#$O& /@.& !"

#$& (.)1& "-0& 1;.@)& "1& ,N-,40& 1,;0-01O&@;0-0"1& ()& B#WTcA& -0*&

:5:401& ()*(:"/0& 0H/-"& ;5*-.+0)& '.N)*M& DN-,40& "--.@1& ()& BL!"#$& -0,-010)/& /;0& *(-0:/(.)& .2& -0"--")+030)/1& .2&

:5/.,4"13(:&*.3"()1&*N-()+&/;0&/-")1(/(.)&2-.3&BL&/.&B#&1/"/01M&J*",/0*&2-.3&T.5.1;(3"O&!M&0/&"4&#QQ#M&

&

K(+M& dM& !..-*()"/(.)& .2& /;0& /@.& /5,01& .2& )N:40./(*0& ")"4.+N01& '5& I+#$& WJO& PO& !AM& !.3,"-(1.)& .2& BLJID%D!D&

>B=!JL"&1/-N:/N-0&@(/;&/;0&BL!"#$&2.-3&")*&/;0&B#Tc&2.-3&W_AM&J*",/0*&2-.3&>e-0)10)O&TM&YM%IM&0/&"4O&#QQRM&

32

1.3.3 E2-P PHOSPHO-INTERMEDIATE STRUCTURES AND THE CATALYTIC CYCLE IS COMPLETED

M(/,*(,/.#% "0-'"&*"% .8),(% #)A% "&"/3:% -&("/+"'-.("$% -&0)#0"'% -&% !.=@% /"#".$"% .&'%

*),&("/6(/.&$7)/(% .//-0"'% -++"'-.("#:% .9("/1% T&% =>>W5% B):)$4-+.% 7/"$"&("'% (4"% */:$(.#%

$(/,*(,/"% )9% !.=@69/""% /.88-(% MPY!U% ;7#3:?=>#3<% -&% .% *)+7#"L% A-(4% +.3&"$-,+% 9#,)/-'"5% .%

$(.8#"%74)$74.("%.&.#)3,"5%.&'%(.7$-3./3-&%;Ba<5%.&%-&4-8-()/5%.(%=1S%i%/"$)#,(-)&%;B):)$4-+.5%

=>>W<1%B4-$%$(/,*(,/"%*.&%8"%*)&$-'"/"'%()%/"7/"$"&(%(4"%P=6X%$(.("%)9%(4"%"&I:+"%.9("/%(4"%

4:'/)#:$-$% )9% .$7./(:#674)$74.("5% 8,(% 8"9)/"% (4"% /"#".$"% )9% (4"% -&)/3.&-*% 74)$74.("1%d-(4%

/"$7"*(% ()% (4"% !.=@68),&'% P?6U#FWpU2X% $(/,*(,/"5% $)#0"'% 8:% (4"% $.+"% 3/),7% -&% (4"% $.+"%

:"./$5%(4-$%+)#"*,#./%+)'"#%$4)A$%.%(-34(%.$$)*-.(-)&%8"(A""&%(4"%U%.&'%X%')+.-&$%.$%/"$,#(%

)9% (4"% U% ')+.-&% /)(.(-)&% 8:% ??>o% ./),&'% .&% .L-$% 7"/7"&'-*,#./% ()% (4"% +"+8/.&"1%

!)&$"R,"&(#:5% /".//.&3"+"&($% )9% $-L% ;J?6JQ<% (/.&$+"+8/.&"% 4"#-*"$% '"$(/):% (4"% 4-34%

.99-&-(:% !.=@% 8-&'-&3% $-("% .&'% )7"&% (4"% #,+-&.#% 3.("5% 9)/+"'% 8:% J?% .&'% J=% 4"#-*"$1% B4"%

'/.$(-*%*4.&3"%A-(4%/"$7"*(%()%(4"%"./#-"/%$(/,*(,/"$%-$%/"#.("'%()%(4"%/"#".$"%)9%U2X%9/)+%(4"%

&,*#")(-'"68-&'-&3% 7)*C"(1% B4-$% '-$$)*-.(-)&% +)'-9-"$% (4"% K% .&'% X% ')+.-&$% -&("/.*(-)&$5%

*/".(-&3%.% $7.*"% 9)/% (4"%$,8$"R,"&(% -&$"/(-)&%)9% (4"%U%')+.-&%8:% (4"%BaPM%$-3&.(,/"% #))71%

B4"% #.(("/% &)A% *)&(/-8,("$% ()% (4"% *))/'-&.(-)&% 8"(A""&% J3=@% .&'% .$7./(:#674)$74.("5%

.0)-'-&3%(4"%'"74)$74)/:#.(-)&%)9%(4"%"&I:+"1%B4"%(/.&$6+"+8/.&"%4"#-*"$%#-&C"'%()%(4"%U%

')+.-&5% -&%7./(-*,#./%J?%.&'%J=5%/"9#"*(%(4"$"%*:()7#.$+-*%/".//.&3"+"&($%7,$4-&3%)&%JE%

.&'%JW1%B4-$%+)0"+"&(%/"$,#(%-&%(4"%/"#".$"%)9%!.=@%8),&'%-&()%(4"%#,+"&5%.$%.%*)&$"R,"&*"%

)9% (A)% *))/'-&.("'% "99"*($V% (4"% '"$(/,*(-)&% )9% (4"% 4-34% .99-&-(:% *)&9)/+.(-)&% )9% (4"% !.=@%

8-&'-&3%$-("5%.$%.%*)&$"R,"&*"%)9%(4"%8"&'-&3%)9%JE%()A./'$%J?%.&'%)9%)&"%(,/&%)9%JW%%6

4"#-L5% .&'% (4"% )7"&-&3% )9% -($% #,+-&.#% 3.("1% B4"% /)#"% )9% (4"% U% ')+.-&5% .$% (4"% .*(,.()/% )9%

(/.&$+"+8/.&"%3.("5%A.$%*#./-9-"'%)&*"%.3.-&1%%

T&%(4"%$.+"%A)/C5%(4"%7#3:?=>#3%+)#"*,#./%+)'"#%A.$%$,7"/-+7)$"'%()%(4.(%)9%P=%;Ba<%

$(/,*(,/"% -&% )/'"/% ()% *#./-9:% (4"% +)#"*,#./% /".//.&3"+"&($% (4.(% (.C"% 7#.*"% ',/-&3% (4"% P=6

X&P=% (/.&$-(-)&1% B4"%+)$(% -+7)/(.&(% "0-'"&*"%A.$% 9),&'% -&% (4"% (/.&$6+"+8/.&"%')+.-&1%

X./(-*,#./#:5% (4"% $(/,*(,/"% ./),&'% (4"% !.=@68-&'-&3% $-("$% A.$% 9),&'% 4./'#:% *4.&3"'5% .$% .%

INTRODUCTION

33

/"$7)&$"% ()% .% 9,/(4"/% (-#(-&3% )9% (4"% U% ')+.-&% 8:% S>o% *.,$"'% 8:% (4"% /"#".$"% )9% J3=@1% B4"%

#,+"&.#%4.#9%)9% (4"%JW%4"#-L% ;JW[<% -$% (,/&"'%8:%q=>o% -&%P=;Ba<%.&'% $4)A$%.% *4.&3"% -&% (4"%

)/-"&(.(-)&%)9% (4"% #))7%*)&(.-&-&3%a#,S>D% (4.(% *#)$"$% (4"% #,+-&.#% 3.("1% F-&.##:5% .% $*4"+.(-*%

/".*(-)&% )9% (4"% *)+7#"("% *:*#"% 8.$"'% )&% 9-0"% /"7/"$"&(.(-0"% */:$(.#% $(/,*(,/"$% 4.$% 8""&%

7/)7)$"'1%%

%

K(+M&VM&>/-N:/N-"4&:.3,"-(1.)&'0/@00)&B#Tc&")*&B#%I+KR#%&1/-N:/N-01M&!.4.N-1&:;")+0&2-.3&/;0&"3().&/0-3()N1&

W'4N0A& /.& /;0& :"-'.H5& /0-3()N1M& & F)& './;& /;0& 1/-N:/N-01O& /;",1(+"-+()& (1& -0,-010)/0*& "1& ,N-,40& //-(")+40M& DN-,40&

"--.@1&()&B#%I+KR#%&-0,-010)/1&/;0&*(-0:/(.)&.2&J&*.3"()&-0"--")+030)/&*N-()+&/;0&/-")1(/(.)&2-.3&B#%D&/.&B#&

1/"/01M&J*",/0*&2-.3&T.5.1;(3"O&!M&0/&"4O&#QQRM&

1.3.4 INSIGHT INTO THE TRANSPORT MECHANISM COUPLED TO ATP HYDROLYSIS

B)%,&'"/$(.&'%(4"%'"74)$74)/:#.(-)&%+"*4.&-$+%(4.(%*)&*#,'"$%(4"%UBX%4:'/)#:$-$5%-&%

=>>W% K-$$"&% "(% .#1% '"("/+-&"'% (4"% */:$(.#% $(/,*(,/"% )9% (4"% 7/)()&68),&'% P=% /.88-(% MPY!U5%

$(.8-#-I"'%8:%.#,+-&,+%9#,)/-'"%;U#FW6%<%.&'%(.7$-3./3-&%;Ba<5%.(%Si%/"$)#,(-)&%;N#"$"&5%!1%"(%.#5%

=>>W<% d-(4% /"$7"*(% ()% (4"% )(4"/% $(.8#"% 74)$74.("% .&.#)3,"% ;J3FW=6<5% (4"% *))/'-&.(-)&% )9%

/"$-',"$%-&0)#0"'%-&%(4"%74)$74)/:#.(-)&%7/)*"$$%A.$%R,-("%'-99"/"&(5%'"+)&$(/.(-&3%(4.(%(4"%

7#395=>3% $(/,*(,/"% /"7/"$"&(% (4"% (/.&$-(-)&% $(.("% )9% (4"% #)A% "&"/3:% 74)$74)6"&I:+"% ;P=6X<%

A-(4%)**#,'"'%*.(-)&68-&'-&3%$-("$%-&%.%7/)()&.("'%$(.("1%;P=6X&P=6XV%e=N&P=%(/.&$-(-)&<1%

34

!)+7./"'% ()% !"#78!96;<95=>@5% (4"% 74)$74)/:#.("'% /"$-',"% ;U$7SE?<% -&% (4"% 7#395=>

@%

$(/,*(,/"% -&("/.*($%A-(4%(4"%BaPM%+)(-9%)9% (4"%U%')+.-&5%.$%.%*)&$"R,"&*"%)9%.&%U%')+.-&%

/)(.(-)&% 8:% ??>o% ',"% ()% (4"% U2X% /"#".$"1% B4"% 74)$74.("% .&.#)3,"% *))/'-&.(-)&% A-(4% (4"%

*./8)L:#%3/),7%)9%a#,?cS%.&'%(4"%+.-&%*4.-&%*./8)&:#%)9%B4/?c?%9("%.%A.("/%+)#"*,#"% -$% -&%

.3/""+"&(% A-(4% (4"% .$$)*-.(-0"% MK=% /".*(-)&% 7/)7)$"'% 9)/% '"74)$74)/:#.(-)&5% *)&9-/+-&3%

a#,?cS%.$%.% *.(.#:(-*%8.$"5%.8#"% ()%"L(/.*(%.%7/)()&% 9/)+%.%A.("/%+)#"*,#"1% T($% $,8$"R,"&(%

.((.*C% ()% (4"% 74)$74.("% 3/),7% -$% -&% .3/""+"&(%A-(4%+,(.(-)&.#% '.(.1% U% $-+-#./% .$$)*-.(-0"%

/".*(-)&% +"*4.&-$+% 4.$% 8""&% 7/)7)$"'% .#$)% 9)/% (4"% 74)$74)/:#% (/.&$9"/% 9/)+% UBX% .&'%

/"7/"$"&($%(4"%C":%"#"+"&(%9)/%"L7#.-&-&3%(4"%*),7#-&3%+"*4.&-$+$%)9%MPY!U1%T(%/"$(/-*($%(4"%

9-"#'% )9% 7)$$-8#"% *)&9)/+.(-)&.#% $(.("$% -&% A4-*4% (4"% 74)$74)Z'"74)$74)/:#.(-)&% /".*(-)&$%

*),#'%)**,/1%%

T&%.''-(-)&5%$(/,*(,/.#% /".//.&3"+"&($%)9% (4"%"&I:+"% -&% (4"%7#395=>@%+)#"*,#./%+)'"#%

A-(4%/"$7"*(%()%(4)$"%-&%!"#78!96;<95=>@%/"0".#"'%(4"%-+7)/(.&(%/)#"%)9%(4"%U%')+.-&%.$%(4"%

.*(,.()/% )9% (4"% (/.&$#)*.(-)&Z'"74)$74)/:#.(-)&% *),7#"'%+"*4.&-$+1%Y".//.&3"+"&($% )9% .%

9-0"%4"#-*"$%*#,$("/5%9)/+"'%8:%(4"%/"$-',"$%)9%(4"%!6("/+-&.#%7./(%)9%(4"%X6')+.-&%.&'%8:%U6

J=%.&'%U6JS%*4.-&$%.&'%(4"%*)//"$7)&'-&3%$"3+"&($%)9%(4"%U6')+.-&5%()3"(4"/%A-(4%(4"%_@%

-)&% 8),&'% .(% a#,HS=% ;["0:5% 21% "(% .#5% ?DD><% A"/"% 9),&'% */-(-*.#% 9)/% *),7#-&3% (4"% !.=@Ze@%

"L*4.&3"%.&'%(4"%'"74)$74)/:#.(-)&%"0"&($1%P0-'"&*"$%.8),(%)**#,'"'%7/)()&$%*),#'%&)(%8"%

)8$"/0"'%'-/"*(#:5%8"*.,$"%(4"%.()+-*%-&("/.*(-)&$%A-(4%(4"%(.7$-3./3-&%-&4-8-()/%7/)',*"'%.%

$(/,*(,/.#% ./(-9.*(5% 8,(% (4"%A"/"% '"',*"'% 9/)+% $"0"/.#% 8-)*4"+-*.#% '.(.1% F)/% -&$(.&*"5% (4"%

9),/% *./8)L:#.("% /"$-',"$% -&0)#0"'% -&% (4"% -)&6*)&',*(-&3%7.(4A.:% ;a#,HH?5%U$7c>>5%a#,D>c%

.&'%a#,S>D<%$""+%()%8"%-&%.%7/)()&.("'%$(.("5%/"$,#(-&3%-&%.%4:'/)74)8-*%8.//-"/%(4.(%*),#'%

"L7#.-&%(4"%)**#,$-)&%)9% (4"% #,+-&.#%3.("1%J)/")0"/5%(4"$"%/"$-',"$%./"%$"7./.("'%9/)+%(4"%

#,+-&.#%$7.*"%8:%9-0"%7)$-(-0"%*4./3"'%/"$-',"$%;[:$=DH5%[:$DEc5%[:$DH=5%[:$DQ>5%./3=D><%(4.(%

7/)8.8#:%-&4-8-(%(4"%8.*C9#)A%)9%#,+-&.#%!.=@%8:%"#"*(/)$(.(-*%/"7,#$-)&1%%

N&% (4"% 8.$-$% )9% $(/,*(,/.#% .&.#:$-$% .&'% 8-)*4"+-*.#% '.(.5% (4"% .,(4)/$% 7/)7)$"'% .%

3"&"/.#%+"*4.&-$+%)9% !.=@% (/.&$7)/(% .&'%e@% *),&("/6(/.&$7)/(% *),7#"'% ()% 74)$74)/:#.(-)&%

INTRODUCTION

35

.&'% '"74)$74)/:#.(-)&5% /"$7"*(-0"#:5% 9)*,$"'% )&% (4"% (/.&$-"&(% 9)/+.(-)&% )9% )**#,'"'% -)&6

8-&'-&3%$-("$5%*)&(/)##"'%8:%(4"%7-$()&6#-C"%+)0"+"&($%)9%(4"%U%')+.-&1%BA)%3.("$%9.*"'%)&%

*:()7#.$+%.&'%$./*)7#.$+-*%#,+"&5%/"$7"*(-0"#:5%A"/"%-'"&(-9-"'1%M(/,*(,/.##:5%(4"%9)/+.(-)&%

)9% .% 4-346"&"/3:% 74)$74)6"&I:+"% -&("/+"'-.("% A.$% /"#.("'% ()% (4.(% )9% (4"% )**#,'"'%

-&("/+"'-.("%A-(4%!.=@%8),&'%-&%(4"%(/.&$6+"+8/.&"%')+.-&%.$%.%/"$,#(%)9%(4"%*:()7#.$+-*%

3.("%#)*C-&31%Y"#".$"%)9%U2X%-&',*"$%(4"%)7"&-&3%)9%(4"%#,+-&.#%3.("%A-(4%$,8$"R,"&(%!.=@Ze@%

"L*4.&3"1%F-&.##:5%(4"%4:'/)#:$-$%/".*(-)&%*#)$"$%(4"%#,+-&.#%3.("5%)**#,'-&3%(4"%e@%-&$-'"%(4"%

+"+8/.&"^% (4"%$,8$"R,"&(% /"#".$"%)9% (4"% -&)/3.&-*%74)$74.("%)7"&$% (4"%*:()7#.$+-*%3.("%

9)/%(4"%e@Z!.=@%"L*4.&3"1%

%

%

K(+M& ^M& >:;03"/(:& -0,-010)/"/(.)& .2& +0)0-"4&30:;")(13& .2& !"#$& /-")1,.-/& ")*& a

$& :.N)/0-%/-")1,.-/& :.N,40*& /.&

,;.1,;.-54"/(.)&")*&*0,;.1,;.-54"/(.)O&-01,0:/(9045O&.)&/;0&'"1(1&.2&?05&2N):/(.)"4&()/0-30*("/01&.2&>B=!JM&=0*O&

G& *.3"()<& '4N0O& D& *.3"()<& 5044.@O& J& *.3"()<& ,N-,40O& /-")1303'-")0& 10+30)/1& L& ")*& #& WILfI#A& @(/;& /;0(-&

:5/.1.4(:&0H/0)1(.)1<&.-")+0O&IEfIR<&+-00)O&ISfILQM&T"?0)&2-.3&I.440-O&[M&DM&0/&"4O&#QQSM&

36

1.4 THE HUMAN SERCA PUMPS GENE MUTATIONS

BA)% 4,+.&% '-$".$"$% .$$)*-.("'% A-(4% (4"% MPY!U% 7,+7% 3"&"% '"9"*($% 4.0"% 8""&%

'"$*/-8"'% ,&(-#% &)A5% G/)':j$% .&'%2./-"/j$% '-$".$"1% B4"% 9)/+"/% -$% .% /./"% /"*"$$-0"%+,$*,#./%

*)&'-(-)&% *4./.*("/-I"'% 8:% .&% "L"/*-$"6-&',*"'% -+7.-/+"&(% )9%+,$*#"% /"#.L.(-)&% ;G/)':% TU5%

?DQD<1% B4"% ,&'"/#:-&3% *.,$"% 9)/%+,$*#"% *)&(/.*(,/"% 4.$% 8""&% 9),&'% ()% 8"% .$$)*-.("'% ()% .%

MPY!U% /"',*"'% .*(-0-(:5% /"$,#(-&3% 9/)+% .% '"9"*(% )9% (4"% 3"&"% *)'-&3% 9)/% MPY!U?.% -$)9)/+%

;UBX=U?<1% K)&"(4"#"$$5% (4"% )/-3-&% )9% (4"% MPY!U% '"9-*-"&*:% -$% $(-##% *)&(/)0"/$-.#% ;_./7.(-% a5%

?DcQ^%G"&'"/$%UUaJ5%?DDW<1%!#-&-*.##:5% (4"%'-.3&)$-$% -$%+.'"%'-99-*,#(%)A-&3% ()% (4"%3"&"(-*%

4"("/)3"&"-(:% )9% (4"% $:+7()+$1% N/-3-&.##:5% (4/""% +,(.(-)&$% 4.0"% 8""&% -'"&(-9-"'% -&% (4"%

UBX=U?%3"&"%)9%G/)':%+:)7.(4:6.99"*("'%+"+8"/$%9.+-#-"$%.$%/"$7)&$-8#"%9)/%(4"%7.(4)#)3:1%

B4"$"% +,(.(-)&$% #".'% ()% 7/"+.(,/"% $()7% *)')&$5% (/,&*.(-&3% (4"% 7,+7% .&'% (4,$% '"#"(-&3%

"$$"&(-.#%')+.-&$%;N'"(("/+.&%U1%"(%.#5%?DDQ<5%)/%()%.%+-$$"&$"%$,8$(-(,(-)&%)9%X/)HcD%()%[",%

;N'"(("/+.&%U1%"(%.#5%=>>><1%e)A"0"/5%.##%(4"$"%'.(.%$""+%()%.3/""%A-(4%(4"%$,33"$(-)&%(4.(%

(4"% /"',*(-)&% -&% (4"% MPY!U?.% .*(-0-(:% *),#'% 8"% *)+7"&$.("'% .(% *"##,#./% #"0"#% 8:% (4"%

"L7/"$$-)&%)9%(4"%-$)9)/+$%=%.&'%S% -&%9.$(6(A-(*4%$C"#"(.#%+,$*#"%.&'Z)/%8:%(4"%*))/'-&.("'%

!.=@%/"+)0.#%),(%)9%(4"%7#.$+.%+"+8/.&"%0-.%(4"%XJ!U%7,+7%.&'%K.@Z!.=@%"L*4.&3"/%;G/-&-%

"(%.#5%=>?><1%Y"*"&(#:5%.%+,(.(-)&% #".'-&3%()%(4"%Y?QWe%/"7#.*"+"&(% -&%(4"%3"&"%*)'-&3%9)/%

(4"%MPY!U?.%7/)("-&%4.$%8""&%-'"&(-9-"'%-&%*.((#"%8"#)&3-&3%()%(4"%!4-.&-&.%9.+-#:%.99"*("'%8:%

*)&3"&-(.#%7$",')+:)()&-.%;XJB<%;M.**4"(()%"(%.#5%=>>D<1%B4-$%+,(.(-)&% -&',*"$%$:+7()+$%

0"/:% $-+-#./% ()% (4)$"%)9% (4"%G/)':% $:&'/)+"5% $,33"$(-&3% (4.(% (4-$% .&-+.#% *.&%8"%,$"'% .$% .%

$,-(.8#"%+)'"#%9)/%$(,':-&3%4,+.&%7.(4)#)3:1%B4"%MPY!U?.%7/)("-&%*)&("&(%4.$%8""&%9),&'%

()% 8"% $-3&-9-*.&(#:% /"',*"'% -&% (4"% .99"*("'% +,$*#"% '"$7-("% (4"% +YKU% A.$% 7/"$"&(% -&%

"R,-0.#"&(%.+),&($%A-(4%/"$7"*(%()%A-#'6(:7"%*),&("/7./(1%B4-$%"0-'"&*"%*),#'%$,33"$(%(4.(%.%

'"9"*(% -&% (/.&$*/-7(-)&% -$%&)(% -&0)#0"'% -&% (4"%."(-)#)3:%)9% (4"%'-$".$"1%M-&*"% (4"%+,(.(-)&% -$%

#)*.("'% -&% (4"% U% ')+.-&% )9% (4"% 7,+75%A4-*4% -$% -&0)#0"'% -&% #./3"%+)0"+"&($% )9% (4"% 7,+7%

',/-&3% -($% /".*(-)&% *:*#"5% (4"% /"7#.*"+"&(% )9% Y% A-(4% e% $-'"% *4.-&% *),#'% '"$(.8-#-I"% (4"%

*)&9)/+.(-)&%)9%(4"%7,+7%',/-&3%(4"%P?6P=%(/.&$-(-)&5%7/)8.8#:%"&4.&*-&3%(4"%0,#&"/.8-#-(:%

INTRODUCTION

37

)9% (4"% 7/)("-&% ()% 7/)(")#:(-*% '"3/.'.(-)&% ;M.**4"(()% "(% .#5% =>?=<1% T&% .''-(-)&5% .% e,&3./-.&%

7.(-"&(% .99"*("'% 8:% G/)':j$% '-$".$"% A.$% 9),&'% ()% *.//:% .% +-$$"&$"% +,(.(-)&% -&% (4"% $.+"%

7)$-(-)&% )9% (4"% 7/)("-&% $"R,"&*"1% B4-$% "0-'"&*"% )&*"% .3.-&% *)&9-/+$% !4-.&-&.% *.((#"% .$% .%

+)'"#%9)/%$(,':-&3%(4-$%3"&"(-*%'-$".$"1%%

B4"%$"*)&'%3"&"(-*%7.(4)#)3:%.$$)*-.("'%A-(4%MPY!U%7,+7%3"&"%+,(.(-)&$%-$%C&)A&%.$%

2./-"/j$%'-$".$"1%B4-$%-$%.%/./"%.,()$)+.#%')+-&.&(%$C-&%'-$)/'"/%*4./.*("/-I"'%8:%#)$$%)9%*"##6

()6*"##%.'4"$-)&%.&'%.8&)/+.#%C"/.(-&-I.(-)&%)9%(4"%"7-'"/+-$%;YPF<1%B4"%*#-&-*.#%74"&)(:7"%-$%

*4./.*("/-I"'%8:%7"/$-$("&(%"/,7(-)&%)9%C"/)()7-*%7.7,#"$%-&%$"8)//4)-*%/"3-)&$%.&'%9#"L,/"$5%

7.#+-(./%7-($%.&'%&.-#%':$(/)74:1%J)/"%(4.&%?S>%+,(.(-)&$%-&%(4"%3"&"%*)'-&3%9)/%(4"%MPY!U=%

-$)9)/+$% ;UBX=U=<% 4.0"% 8""&% -'"&(-9-"'% -&% 4,+.&% 7.(-"&($1% B4"$"% +,(.(-)&$% 4.0"% .%

A-'"$7/".'%'-$(/-8,(-)&%.&'%(4":%./"%7/-&*-7.##:%#)*.("'%-&%/"3-)&$%(4.(%./"%*)++)&%()%(4"%=.%

.&'%=8%-$)9)/+$1%2-99"/"&(#:%9/)+%G/)':j$%'-$".$"5%(4"%*#-&-*.#%$:+7()+$%./"%/"$(/-*("'%()%(4"%

"7-'"/+-$%.&'%$7"*-9-*%./".%)9%(4"%$C-&%.&'%-(%-$%(4),34(%(4.(%(4-$%#)*.#-I.(-)&%/"9#"*($%3"&"(-*%

+)$.-*-$+1%B4"% *#.$$-*.#% 3"&)(:7"% /"7)/("'% -&% (4/""% 9.+-#-"$% .99"*("'%8:%2./-"/j$%'-$".$"% -$%

4"("/)I:3),$% 9)/%.%+,(.(-)&% #)*.("'% -&%.% /"3-)&%(4.(% -$% $7"*-9-*% 9)/%MPY!U=81%B4-$%+,(.(-)&%

#".'$% ()%7/"+.(,/"% $()7% *)')&$% (4.(% /"$,#(% -&%.%+-$9)#'"'%.&'% -&.*(-0"%7,+71%B4"/"% -$%&)(%

"0-'"&*"% .8),(% 7)$$-8#"% *)+7"&$.(-)&% 9)/% -($% "L7/"$$-)&5% .&'% (4"% $,77/"$$-)&% -&% MPY!U=8%

.*(-0-(:%-$%.8#"%()%'"("/+-&"%$C-&%'-$)/'"/$%;G/-&-%"(%.#5%=>?=<1%U#(4),34%-(%&)(%0"/:%*#"./%4)A%

(4"% #)$$%)9%MPY!U% 9,&*(-)&%*.,$"$%2./-"/j$%'-$".$"5% $-3&-9-*.&(%.'0.&*"$%4.0"%8""&%+.'"% -&%

"#,*-'.(-&3%(4"%+)#"*,#./%8.$-$%)9%(4-$%'-$)/'"/%',/-&3%(4"% #.$(%'"*.'"1%G"*.,$"%)9%(4"%A-'"%

3"&"(-*%0./-.8-#-(:%9),&'%-&%9.+-#:%+"+8"/$%(4.(%"L4-8-(%'-99"/"&*"$%-&%(4"%*#-&-*.#%$"0"/-(:%)9%

(4"%'-$".$"5%7/)8.8#:%)(4"/%3"&"$%)/%"&0-/)&+"&(.#%9.*()/$%*),#'%-&9#,"&*"%(4"%"L7/"$$-)&%)9%

(4"%7.(4)#)3:1%

1.5 THE EF-HAND AS THE STRUCTURAL MOTIF OF THE CA2+-BINDING PROTEINS FAMILY

U$%'"$*/-8"'%-&%(4-$%*4.7("/5%(4"%"99"*()/$%)9%(4"%!.=@%$-3&.#-&3%&"(A)/C%./"%/"7/"$"&("'%

8:%!.=@68-&'-&3%7/)("-&$5%A4-*4%/"$7)&'%()%*4.&3"$%-&%(4"%-&(/.*"##,#./%*.#*-,+%*)&*"&(/.(-)&%

38

8:% .$$)*-.(-&3% .&'% .*(-0.(-&3% $"0"/.#% ')A&$(/".+% 7/)("-&$% -&0)#0"'% -&% '-99"/"&(% $-3&.#-&3%

7.(4A.:1% !.#+)',#-&% /"7/"$"&($% .% A"##6*4./.*("/-I"'% "L.+7#"% )9% .% *.#*-,+% r$"&$)/s1%

J)/")0"/5% !.=@68-&'-&3% 7/)("-&$% *.&% "L4-8-(% .% +)',#.()/% /)#"5% $7.(-.##:% .&'% ("+7)/.##:%

*)&(/)##-&3% (4"% *:()7#.$+-*% !.=@% *)&*"&(/.(-)&1% B4"% *.#8-&'-&% 2D_% 7/)("-&% -$% .% *#.$$-*.#%

*.#*-,+% r8,99"/s% "L.+7#"1% U&:A.:5% (4"$"% (A)% *#.$$"$% )9% 7/)("-&$% ./"% #-&C"'% (4/),34% .%

*)++)&%$(/,*(,/.#%9".(,/"5%(4"%PF64.&'%+)(-91%B4-$%+)(-9%/"7/"$"&($%.&%"0)#,(-)&./:%*4)-*"%

/"#.("'% ()% (4"% 7)$$-8-#-(:% )9% 7#.:-&3% $"0"/.#% 9,&*(-)&$% .(% #)A% "&"/3:% *)$(1% U**)/'-&3% ()% (4"%

3"&"/.#% *)&$"&$,$5%!.=@6-&',*"'%*)&9)/+.(-)&.#% *4.&3"$% /"7/"$"&(%)&"%)9% (4"%4.##+./C$%)9%

(4"%$-3&.#%(/.&$',*(-)&1%B4-$%7/)7"/(:%-$%$(/-*(#:%/"#.("'%()%(4"%.8-#-(:%()%8-&'%!.=@%(4/),34%.&%

PF64.&'% $(/,*(,/.#%+)(-9V% (4"% #.(("/% -$% '"9-&"'%8:% -($%4"#-L6#))764"#-L% $"*)&'./:% $(/,*(,/"%.$%

A"##%.$%8:%(4"%#))7%(4.(%8-&'$%(4"%!.=@%-)&1%B4-$%+)(-9%-$%*)&$"/0"'%.+)&3%(4"%+"+8"/$%)9%.%

#./3"%.&'%9,&*(-)&.##:%'-0"/$"%7/)("-&%9.+-#:5%A4-*4%)A"$%-($%&.+"%()%-(1%B4"%$(/,*(,/.#%,&-(%)9%

(4"$"%7/)("-&$%*)&$-$(%)9%(A)%4"#-*"$%)9%.8),(%?>%.+-&)%.*-'$5% #-&C"'%8:%.% #))7%)9%?=%.+-&)%

.*-'% /"$-',"$% (4.(% *))/'-&.("$% (4"% !.=@% 8-&'-&3% -)&1% M)+"% $"R,"&*"% 0./-.8-#-(:% *.&% 8"% )&#:%

()#"/.("'%-&%(4"%/"3-)&%&)(%-&0)#0"'%-&%!.=@%8-&'-&31%B4"%+)$(%*.&)&-*.#%PF64.&'%!.=@68-&'-&3%

#))7%$(./($%A-(4%.&%-&0./-.&(%.$7./(-*%.*-'%.&'%"&'$%A-(4%.%3#,(.+-*%.*-'1%M"0"&%)L:3"&%.()+$%

)/3.&-I"'%-&%.%7"&(.3)&.#%8:7:/.+-'%9)/+%(4"%7/"9"//"'%*)6)/'-&.(-)&%3")+"(/:%)9%*.#*-,+%

-)&$1%B4"%$-'"%*4.-&$%)9%9),/%*)&$"/0"'%/"$-',"$% #)*.("'%.(%(4"%0"/(-*"$%)9%.&%)*(.4"'/)&%-&%

7)$-(-)&% ?5% S5% E5% .&'% ?=% 7/)0-'"% (4"% )L:3"&% /"$-',"$5%A-(4% .% '),8#"% *)&(/-8,(-)&% 9/)+% (4"%

*./8)L:#% 3/),7% )9% (4"%a#,% /"$-',"% -&% (4"% #.$(% 7)$-(-)&% )9% (4"% #))71% B4"% *./8)&:#% )L:3"&% )9%

0./-.8#"%/"$-',"$%.(%7)$-(-)&%H%.#)&3%A-(4%(4"%$-'"%*4.-&%)L:3"&%)9%.%3#,(.+-*%.*-'%-&%7)$-(-)&%

D% )/% .% A.("/% )L:3"&% *)&(/-8,("% ()% (4"% /"+.-&-&3% (A)% *))/'-&.(-&3% .()+$1% B4-$% !.=@%

*))/'-&.(-)&%$*4"+"%*4./.*("/-I"$%(4"%*.&)&-*.#%PF6#))75%A4-*4%*4./.*("/-I"$%(4"%+.g)/-(:%)9%

(4"% PF64.&'% 7/)("-&$1% \./-.(-)&$% -&% (4"% A.:$% (4"% 7"&(.3)&.#% 8:7:/.+-'.#% *))/'-&.(-)&% -$%

.*4-"0"'%*4./.*("/-I"%(4"%&)&6*.&)&-*.#%PF64.&'%#))7$%(4.(%4.0"%8""&%9),&'%-&%.%0./-"(:%)9%

9.+-#:%+"+8"/$1%B4"%PF64.&'%+)(-9$%.#A.:$%)**,/%-&%7.-/$%.&'%(4"%4"#-L6#))764"#-L%+)(-9%*.&%

8"%/"7".("'%9/)+%=%()%?=%(-+"$1%B4"%$+.##"$(% 9,&*(-)&.#%PF64.&'%,&-(% -$%'-+"/-*5%A4"/"%(4"%

INTRODUCTION

39

(A)%$(/,*(,/.#%+)(-9$%./"%$(.8-#-I"'%8:%.&%.&(-7./.##"#%h6$4""(%9)/+"'%8"(A""&%(4"%(A)%#))7$%

.&'%8:%&,+"/),$%4:'/)74)8-*%*)&(.*($%8"(A""&%(4"%4"#-*"$1%G-&'-&3%)9%!.=@%9,/(4"/%$(.8-#-I"$%

(4"%$(/,*(,/"%-&%.%9),/64"#-L%8,&'#"5%9)/+"'%8:%.%4:'/)74)8-*%*)/"%.&'%.%4:'/)74-#-*%$,/9.*"%

(4.(%+.C"%*)&(.*($%A-(4%$)#0"&(%+)#"*,#"$1%B4"%(A)%PF64.&'$%-&%(4"%')+.-&%./"%&)(%-'"&(-*.#5%

.$% $,33"$("'% 8:% (4"% 7/"9"/"&(-.#% 9)/+.(-)&% )9% .% $(.8#"% 4"("/)'-+"/1% e)A"0"/5% .&%

.77/)L-+.("%=69)#'%$:++"(/:%.L-$%/"#.("$%(4"+1%M(/,*(,/.#%.''-(-)&$%()%(4"%K6("/+-&,$%)9%(4"%

!.=@68-&'-&3% ')+.-&% .&'% +)'-9-*.(-)&$% )9% (4"% #"&3(4% .&'% *)+7)$-(-)&% )9% (4"% #-&C"/%

*)&&"*(-&3%(4"%(A)%PF64.&'$%"&4.&*"%(4"%$(/,*(,/.#%0./-.8-#-(:%A-(4-&%(4"%7/)("-&%9.+-#:1% T&%

.''-(-)&5%(4"%)/3.&-I.(-)&%)9%(4"%PF64.&'%')+.-&$%-&%.%7/)("-&%-&*/".$"$%(4"%#"0"#%)9%'-0"/$-(:1%

1.5.1 SWIPROSIN-1/EFHD2 AND SWIPROSIN-2/EFHD1

Y"*"&(#:% .% &"A% *#.$$% )9% PF64.&'% 7/)("-&$% 4.$% 8""&% '"$*/-8"'1% U**)/'-&3% ()% (4"-/%

/"$7"*(-0"%3"&"%$:+8)#$5%-(%4.$%8""&%7/)7)$"'%()%/"9"/%()%MA-7/)$-&6?ZPF4'=%.&'%MA-7/)$-&6

=ZPF4'?% .$% PF4'=% .&'% PF4'?5% /"$7"*(-0"#:1% B4"$"% 7/)("-&$% ./"% /"#.("'% ()% .&)(4"/% PF64.&'%

7/)("-&5% .##)3/.9(% -&9#.++.()/:% 9.*()/6?1% M"*)&'./:% $(/,*(,/"% 7/"'-*(-)&$% 9)/% 8)(4% 7/)("-&$%

$,33"$(% '-$)/'"/"'% /"3-)&$% .(% (4"%K6("/+-&,$5% 7)("&(-.#% MeS6')+.-&% 8-&'-&3% $-("$5% (A)% PF6

4.&'$% +)(-9$% .&'% .% *)-#"'6*)-#% ')+.-&% .(% (4"% !6("/+-&,$1% 2"$7-("% (4"% 7/"'-*("'% )0"/.##%

$(/,*(,/"%-$%$-+-#./%;.8),(%QEb%)9%$"R,"&*"%-'"&(-(:<5%(4":%"L4-8-(%.%$-3&-9-*.&(%'-99"/"&*"%-&%.%

$(/"(*4%)9%Q>%.+-&)%.*-'$%*#)$"%()%(4"%PF64.&'%+)(-95%A4-*4%7/)8.8#:%-$%/"$7)&$-8#"%9)/%$7"*-9:%

'-$(-&*(% 9,&*(-)&$%)9%PF4'=%.&'%PF4'?1%B4"$"%7/)("-&$%4.0"%8""&% -'"&(-9-"'%8)(4% -&%&"/0),$%

.&'% -++,&"% *"##% #-&"$5% 8,(% ,&(-#% &)A% (4"/"% ./"% &)(% "0-'"&*"$% .8),(% .% 7)$$-8#"% -&("/.*(-)&%

8"(A""&% (4"% (A)% 7/)("-&$1% M"0"/.#% 9,&*(-)&$% 4.0"% 8""&% 7/)7)$"'% 9)/% (4"+5% 8,(% ,&(-#% &)A%

&)&"%)9%(4"+%-$%$,77)/("'%8:%*)&*#,$-0"%"0-'"&*"1%B4"%PF4'=%7/)("-&%A.$%7/)7)$"'%()%.*(%.$%

.%*:()$C"#"()&%.$$)*-.("'%.'.7()/%7/)("-&%-&0)#0"'%-&%-++,&"%.&'%8/.-&%*"##%9,&*(-)&%,&'"/%

8.$.#%.&'%-&9#.++.()/:%*)&'-(-)&$%;2,((-&3%"(%.#5%=>??<1%N(4"/%"0-'"&*"$%'/.A%(4"%.(("&(-)&%

)&% (4"% 7)$$-8#"% /)#"% )9% PF4'=% .$% .% +"'-.()/% )9% G!Y6-&',*"'% .7)7()$-$% ;U0/.+-'),% "(% .#1%

=>>H<1%N&%(4"%)(4"/%"&'5%(4"%PF4'?%7/)("-&%-$%-&0)#0"'%-&%&",/)&.#%'-99"/"&(-.(-)&5%7/)8.8#:%

(4/),34% .&% .$$)*-.(-)&% A-(4%+-()*4)&'/-.1% F,/(4"/+)/"5% PF4'?% *),#'% 8"% 7./(% )9% .% *"##,#./%

40

/"$7)&$"%()%(4"%)L-'.(-0"%$(/"$$%;2,((-&3%"(%.#5%=>??<1%e)A"0"/5%(4"%74:$-)#)3-*.#%/)#"%)9%(4"$"%

7/)("-&$% -$% $)% 9./% 7))/#:% ,&'"/$())'% .&'% $"0"/.#% -&0"$(-3.()/$% ./"% (/:-&3% ()% "#,*-'.("% (4"-/%

-&0)#0"+"&(%-&%7.(4)#)3-*.#%':$9,&*(-)&$1%

%

%

%

%

%

%

%

%

%

%

&

K(+M& UM& >0:.)*"-5& 1/-N:/N-0& ,-0*(:/(.)& .2& >@(,-.1()%LCBK;*#M& T;(1& ,-0*(:/(.)& 1N++01/1& *(1.-*0-0*& -0+(.)1& "/& /;0&&&

G%/0-3()N1O&,./0)/("4&>aE%*.3"()&'()*()+&1(/01O&/@.&BK%;")*1&3./(21&")*&"&:.(40*%:.(4&*.3"()&"/&/;0&!%/0-3()N1M&

CHAPTER II

CRYSTAL STRUCTURE OF ENDOPLASMIC RETICULUM

CA2+-ATPASE (SERCA) FROM BOVINE MUSCLE

ROBERTA SACCHETTO, ILENIA BERTIPAGLIA, SARA GIANNETTI, LAURA CENDRON, FRANCESCO

MASCARELLO, ERNESTO DAMIANI, ERNESTO CARAFOLI AND GIUSEPPE ZANOTTI

!

!

!!

!

Journal of Structural Biology 178 (2012) 38-44

42

CONTENTS

2.1 INTRODUCTION 43

2.2 MATERIALS AND METHODS 44

2.2.1 PROTEIN EXTRACTION, PURIFICATION AND CRYSTALLIZATION 44

2.2.2 STRUCTURE DETERMINATION AND REFINEMENT 45

2.2.3 ACTIVITY MEASUREMENTS 46

2.3 RESULTS 47

2.3.1 SERCA1A ISOFORM 47

2.3.2 SERCA1A ACTIVITY 47

2.3.3 CRYSTAL STRUCTURE OF BOVINE SERCA1A 48

2.4 DISCUSSION 50

2.4.1 SERCA MUTATIONS 55

2.5 CONCLUSIONS 56

2.6 ACCESSION NUMBERS 57

2.7 ACKNOWLEDGMENTS 57

2.8 SUPPLEMENTARY FIGURES 58

!

!

CRYSTAL STRUCTURE OF ENDOPLASMIC RETICULUM CA2+-ATPASE (SERCA) FROM BOVINE MUSCLE

43

2.1 INTRODUCTION

"#$! %&'()*"+&,$! -.! ,&/0-1$23-456&,780! /$980:6:7! 1;<=%*! 5:75>! <?%?! @?A?@?B4! 8,! &!

5/-9$82! -.! &C-:9! DDE! FG&! 1H&0I$22&2! $9! &6?>! DJBK4?! L9! 9/&2,5-/9,! 9M-! %&'(! 8-2,! ./-7! 9#$!

0N9-56&,7!9-!9#$!6:7$2!-.!9#$!,&/0-56&,780!/$980:6:7!&9!9#$!$O5$2,$!-.!9#$!#N3/-6N,8,!-.!-2$!

*"+!7-6$0:6$!1.-/!&!/$P8$M>!,$$!Q/828!&23!%&/&.-68>!'EEJ4?!"#$!7$0#&28,7!-.!9#$!9/&2,5-/9!#&,!

C$$2!$O56&82$3!82!9$/7,!-.!&!0N06$!0#&/&09$/8R$3!CN!9M-!7&S-/!0-2.-/7&98-2&6!,9&9$,>!0&66$3!

<D!&23!<'?!%-2.-/7&98-2!<D>!M#80#!8,!9#$!.-/7!M89#!9#$!#8T#$,9!&..8289N!.-/!0&608:7>!C823,!%&'(!

./-7!9#$!0N9-56&,7>!M#86,9!0-2.-/7&98-2!<'>!M#80#!#&,!6-M$/!&..8289N!.-/!9#$!8-2>!/$6$&,$,!89!

829-!9#$!6:7$2!1G$!H$8,!&23!U&,,$6C&0#>!DJVD4?!!

"#$!9#/$$)387$2,8-2&6!,9/:09:/$!-.!;<=%*D&>!9#$!8,-.-/7!5/$,$29!7&826N!82!.&,9!9M890#!

,F$6$9&6! 7:,06$>! M&,! ,-6P$3! CN! "-N-,#87&! $9! &6?! 1'EEE4>! &23! #&,! C$$2! $O9$2,8P$6N!

0#&/&09$/8R$3!82!/&CC89W!XX!0/N,9&6!,9/:09:/$,>!5-,,8C6N!78780F82T!&66!9#$!0-2.-/7&98-2&6!,9&9$,!

-.! 9#$!$2RN7$! 0N06$>! #&P$!C$$2!3$5-,89$3! 82! 9#$!+/-9$82!G&9&!Q&2F! 1+GQ4! 1"-N-,#87&!&23!

Y-7:/&>!'EE'Z![:!$9!&6?>!'EE'Z!"-N-,#87&!&23!H8R:9&28>!'EEXZ!;-/$2,$2!$9!&6?>!'EEXZ!\C&/&!

$9!&6?>! 'EEKZ! ]$2,$2!$9!&6?>! 'EEAZ!\6$,$2!$9!&6?>! 'EEVZ!"&F&#&,#8!$9!&6?>! 'EEVZ!H-20-^!$9!&6?>!

'EEVZ!I&:/,$2!$9!&6?>!'EEJZ!_829#$/!$9!&6?>!'EDEZ!"-N-,#87&!$9!&6?>!'EDD4?!"#$!5/-9$82!0-2,8,9,!

-.! 9#/$$! 0N9-56&,780! 3-7&82,>! 0&66$3! *>! Y! &23! +>! &23! &! 3-7&82! H>! M#80#! 8206:3$,! 9#$!

9/&2,7$7C/&2$!#$680$,!&23!9#$!,#-/9!6:782&6!6--5,?!G-7&82!*!8,!/$.$//$3!9-!&,!9#$!&09:&9-/!

3-7&82! -.! %&'(! C82382T! &23! /$6$&,$?! "#$! Y! 3-7&82! 0-29&82,! 9#$! 2:06$-983$)C82382T! ,89$?!

G-7&82!+!8206:3$,!*,5@KD>!9#$!/$,83:$!9#&9!8,!5#-,5#-/N6&9$3!3:/82T!9#$!/$&098-2!0N06$?!"#$!

2:06$-983$!8,!C-:23!82!C$9M$$2!3-7&82,!Y!&23!+>!82!,:0#!&!M&N!9#&9!89,!`)5#-,5#&9$!8,!06-,$!

9-!*,5@KD?!"#$!9M-!%&'()C82382T!,89$,!&/$!6-0&9$3!82!a)#$680$,!HX>!HK>!HA!&23!HB!-.!3-7&82!

H?! "#$! 9#/$$! 0N9-56&,780! 3-7&82,! :23$/T-! &! 3/&,980! /$&//&2T$7$29! .-66-M82T! &,5&/9&9$!

5#-,5#-/N6&98-2>!&2!$P$29!9#&9!8,!9#$!F$N!9-!%&'(!/$6$&,$!829-!9#$!6:7$2!1"-N-,#87&!&23!L2$,8>!

'EEX4?!

;<=%*!,9/:09:/$,!-.!,5$08$,!38..$/$29!./-7!/&CC89!&/$!2-9!F2-M2>!&23!82!9#8,!5&5$/!M$!

5/$,$29! 9#$! ,9/:09:/$! -.! 9#$! %&'()*"+&,$! ./-7! C-P82$! 7:,06$?! \:/! 829$/$,9! 82! 9#$! C-P82$!

44

$2RN7$! ,9$7,! ./-7! 9#$! M-/F! 82! 5/-T/$,,! 82! -:/! 6&C-/&9-/N! -2! ,5-29&2$-:,! ;<=%*! 5:75!

7:9&98-2,! /$,5-2,8C6$! .-/! T$2$980! 38,$&,$,! 82! 0-M,! 1;&00#$99-! $9! &6?>! 'EEJ4?! "#$! C-P82$!

*"+&,$! 8,! &! 5/-9$82! -.! JJ@! &782-! &083,! 9#&9! ,#&/$,! JBb! ,$^:$20$! 83$2989N!M89#! 9#$! /&CC89!

$2RN7$?!G$,589$!9#$!P$/N!#8T#!,8786&/89N>!9#$!C-P82$!5:75!#&,!&!6-M$/!0&9&6N980!&098P89N!M89#!

/$,5$09!9-!9#$!/&CC89!;<=%*?!U$/$!M$!3$,0/8C$!9#$!0/N,9&6!,9/:09:/$!-.!C-P82$!;<=%*!&23!9/N!

9-!0-//$6&9$!9#8,!/$3:0$3!&098P89N!9-!9#$!7-6$0:6&/!7-3$6?!

2.2 MATERIALS AND METHODS

2.2.1 PROTEIN EXTRACTION, PURIFICATION AND CRYSTALLIZATION

"#$! "#$%&'#(! $)#&"*! 7:,06$! M&,! :,$3! &,! &! /$5/$,$29&98P$! C-P82$! .&,9)9M890#! ,F$6$9&6!

7:,06$! 1"-96&23! &23! c/NP8>! DJJD4?! ;&/0-56&,780! /$980:6:7! 780/-,-7$,! M$/$! 5/$5&/$3!

&00-/382T! 9-! 9#$!7$9#-3!5/$P8-:,6N! 3$,0/8C$3!CN!G$!H$8,! &23!U&,,$6C&0#! 1DJVD4?! +&/98&66N!

5:/8.8$3! %&'(! 5:75! 5/-9$82! M&,! -C9&82$3! CN! 5&/98&6! $O9/&098-2! -.! ,&/0-56&,780! /$980:6:7!

P$,806$,! M89#! 6-M! 0-20$29/&98-2! -.! 3$-ON0#-6&9$>! &00-/382T! 9-! 9#$! 7$9#-3! 3$,0/8C$3! CN!

H$8,,2$/!$9!&6?>!1DJV@4?!"-!-C9&82!<D!%&'()*"+&,$!5/-9$82>!9#8,!5/$5&/&98-2!M&,!,-6:C868R$3!82!

''!7Td76!-09&$9#N6$2$T6N0-6!7-2-)&)3-3$0N6!$9#$/!1%D'<B4!82!BB!7H!H\+;)c\U!5U!A?B>!VE!

7H!c%6>!DVb!T6N0$/-6!1PdP4>!DE!7H!%&%6'>!@!7H!HT%6'>!D7H!*H++%+?!"#$!,-6:C868,&98-2!M&,!

.-66-M$3!CN!:69/&0$29/8.:T&98-2!&9!V'?EEE!O!T!.-/!@K!782!&9!Xe%!1;:556$7$29&/N!f8T?!;D4?!"#$!

#&2T82T!3/-5! P&5-/)38..:,8-2! 9$0#28^:$!M&,!:,$3! .-/! 0/N,9&668R&98-2?! %/N,9&6,! T/$M! 82! &! .$M!

3&N,!&9!DJe%!,9&/982T!./-7!&!,-6:98-2!-.!;<=%*!-.!&C-:9!DE)D'!7Td76>!:,82T!&,!5/$08589&29!&!

,-6:98-2! 0-29&8282T! ''E7H! ,-38:7! &0$9&9$>! Xb! 9)C:9&2-6>! K7H! !)7$/0&59-$9#&2-6>! DKb!

T6N0$/-6>! A)Vb+<g! AEEE?! "#$! *"+&,$! &098P89N! M&,! 7$&,:/$3! &.9$/! $P$/N! 5:/8.80&98-2! ,9$5?!

=&CC89! ,&/0-56&,780! /$980:6:7! 780/-,-7$,! M$/$! 8,-6&9$3! ./-7! %++#"$,)! -%.&#(! CN! 9#$!

7$9#-3! -.! %#:! $9! &6?>! 1DJBV4?! "#8,! 5/-0$3:/$! N8$63,! 7&826N! P$,806$,! 3$/8P$3! ./-7!

2-2S:2098-2&6!,&/0-56&,780!/$980:6:7!&,!5/$P8-:,6N!3$,0/8C$3!1;&00#$99-!$9!&6?>!'EEK4?!+/-9$82!

0-20$29/&98-2!-.!./&098-2,!M&,!3$9$/782$3!CN!9#$!7$9#-3!-.!I-M/N!$9!&6?!1DJKD4>!:,82T!C-P82$!

,$/:7!&6C:782!&,!&!,9&23&/3?!

CRYSTAL STRUCTURE OF ENDOPLASMIC RETICULUM CA2+-ATPASE (SERCA) FROM BOVINE MUSCLE

45

2.2.2 STRUCTURE DETERMINATION AND REFINEMENT

%/N,9&6,!38../&09!9-!'?JKh!/$,-6:98-2!&23!C$6-2T!9-!9#$!7-2-068280!,5&0$!T/-:5!%'>!M89#!

:289!0$66!5&/&7$9$/,!"iDKA?@K>!h>!#iVK?@A>!h>!$iDK'?JB>!h>!!iDEB?Ae?!"#8,!0-//$,5-23,!9-!9#$!

,&7$!,5&0$!T/-:5!-.!-2$!-.! 9#$! .-/7,!-.! 9#$! /&CC89!$2RN7$! 1+GQ! LG!D"K;!&23!D"K"4>!M89#!

,7&66! 38..$/$20$,! 82! :289! 0$66! 387$2,8-2,?! "#$! &,N77$9/80! :289! 8,! 0-75/8,$3! -.! -2$! ;<=%*!

7-2-7$/>! M89#! &! ,-6P$29! 0-29$29! -.! &55/-O87&9$6N! ABb?! "#$! 3&9&! ,$9,! :,$3! 82! 9#$! .82&6!

/$.82$7$29! M$/$! 7$&,:/$3! ./-7! 9M-! 0/N,9&6,! &9! 9#$! LG'J! C$&7682$! -.! 9#$! <:/-5$&2!

;N20#/-9/-2! =&38&98-2! f&08689N>! g/$2-C6$>! f/&20$?! Q$.-/$! ./$$R82T! 0/N,9&6,! 82! 68^:83! 289/-T$2!

.-/!3&9&!0-66$098-2>!T6N0$/-6!0-20$29/&98-2!M&,!820/$&,$3!82!9#$!/$,$/P-8/!9-!5/-9$09!9#$7!.-/!

0/N-)0--682T?! G&9&! M$/$! 823$O$3! &23! 829$T/&9$3! M89#! ,-.9M&/$! H-,.67! 1I$,68$>! 'EEA4! &23!

7$/T$3!&23!,0&6$3!M89#!;0&6&!1<P&2,>!'EEA4>!0-29&82$3!82!9#$!%%+X!0/N,9&66-T/&5#80!5&0F&T$!

1%-66&C-/&98P$! %-75:9&98-2&6! +/-S$09>! Y:7C$/! X>! DJJX4?! "#$! ,9/:09:/$! M&,! ,-6P$3! CN!

7-6$0:6&/!/$56&0$7$29!:,82T!,-.9M&/$!+#&,$/!1H0%-N!$9!&6?>!'EEV4!,9&/982T!./-7!9#$!,9/:09:/$!

-.!9#$!7-2-068280!<D!.-/7!1+GQ!LG!0-3$!D"K;!1;-/$2,$2!$9!&6?>!'EEX44?!=$.82$7$29!M&,!0&//8$3!

-:9!:,82T!,-.9M&/$!%Y;!1Q/:2T$/!$9!&6?>!DJJB4?!;$P$/&6!,9$5,!-.!7&2:&6!/$C:86382T>!5$/.-/7$3!

M89#!T/&5#80!,-.9M&/$!%--9!1<7,6$N!&23!%-M9&2>!'EEX4>!M$/$!2$0$,,&/N!82!-/3$/!9-!/$&0#!9#$!

.82&6!7-3$6?!;-6P$29!7-6$0:6$,!M$/$!&33$3!M89#!9#$!&:9-7&9$3!5/-0$3:/$!-.!+#$28O!!1*3&7,!

$9!&6?>!'EDE4?!

"#$!.82&6!7-3$6!0-29&82,!VA'D!5/-9$82!&9-7,>!@K!68T&23,!&9-7,!&23!@X!M&9$/!7-6$0:6$,?!

"#$!.82&6!0/N,9&66-T/&5#80!=!.&09-/!8,!E?'EK!1=./$$!E?'VV4?!g$-7$9/80&6!5&/&7$9$/,!-.!9#$!7-3$6>!

0#$0F$3!M89#!+/-0#$0F!1I&,F-M,F8!$9!&6?>!DJJ@4>!&/$!&,!$O5$09$3!-/!C$99$/!.-/!9#8,!/$,-6:98-2?!!

!

!""#$%&'"#(#)*+#,-%-.,-./,#*0#1%-%#/*''"/-.*0#%01#+").0"2"0-3#

!

!

!

!

46

%"#&'!(!

G&9&!0-66$098-2!&23!/$.82$7$29!,9&98,980,?!

!

/%$%!",00'"$*,&%!

;5&0$!T/-:5!%$66!387$2,8-2,!

%1!21!"!3451!!365!=$,-6:98-2!1h4!=,N7!-/!=7$/T$!

" I!d#1I4$!%-756$9$2$,,!1b4!=$3:23&20N!!

!

%'!!DKA?@K>!VK?@A>!DK'?JB>!DEB?A!VA?AD)'?JK!1@?DD)'?JK4!E?DEA!1E?AJ'4!DX?D!1@?K4!JJ?D!1JB?X4!V?X!1V?K4!

7'8*&'-'&$!

Y-?!/$.6$098-2,!=M-/Fd=./$$!Y-?!&9-7,!

+/-9$82!L-2,d68T&23!_&9$/!

Q).&09-/,!+/-9$82!I8T&23d8-2!_&9$/!

=?7?,!3$P8&98-2,!Q-23!6$2T9#,!1h4!Q-23!&2T6$,!1e4!

=&7&0#&23/&2!56-9!1b4!*66-M$3!g$2$/-:,6N!&66-M$3!G8,&66-M$3!\P$/&66!g!.&09-/!

!

!

@K?KXA!E?'EKdE?'VV!!VA'D!@A!@X!!BE!XJ!K'!!E?EEV!D?@!!JV?@!D?V!D?E!E?'!

%! 9:,! ");($%0(! :')'! #('+! $,! ",00'"$! %00! +*88)%"$*,&! +%$%<! =*.>'($?)'(,0#$*,&! (>'00! *(! (>,:&! *&! @%)'&$>'('(<! A!:%B'0'&.$>!,8!C<CDEC!4!:%(!#('+<!

!

2.2.3 ACTIVITY MEASUREMENTS

*"+&,$!&098P89N!M&,!7$&,:/$3!CN!,5$09/-5#-9-7$9/80!3$9$/782&98-2!-.!Y*GU!-O83&98-2!

0-:56$3!9-!&2!*"+!/$T$2$/&982T!,N,9$7>!&,!5/$P8-:,6N!3$,0/8C$3!1;&00#$99-!$9!&6?>!'EEJ4?!"#$!

&,,&N! M&,! 5$/.-/7$3! &9! @Ve%>! 82! &! .82&6! P-6:7$! -.! D! 76! -.! &! 78O9:/$! 0-29&8282T! 'E! 7H!

#8,98382$>!5U!V?'>!K!7H!HT%6'>!E?K!7H!<g"*>!E?D!H!c%6>!E?K!7H!5#-,5#-$2-65N/:P&9$>!E?DK!

7H!Y*GU>!D?X!:289,!-.!5N/:P&9$!F82&,$d6&0980!3$#N3/-T$2&,$>!'!7H!*"+>!E?Db!Y&Y@>!82!9#$!

CRYSTAL STRUCTURE OF ENDOPLASMIC RETICULUM CA2+-ATPASE (SERCA) FROM BOVINE MUSCLE

47

5/$,$20$!-.!'!µTd76!*'@DBV!%&'()8-2-5#-/$>!&9!5%&K?!"#$!*"+&,$!&098P89N>!3$9$09$3!&9!@XE!

27!1GjAXE!;5$09/-5#-9-7$9$/>!Q$0F7&2!%-:69$/4>!M&,!2-/7&68R$3!9-!%&'(!5:75!$O5/$,,8-2!

6$P$6,! 82! ,&/0-56&,780! /$980:6:7!P$,806$,!&23!M&,!$O5/$,,$3! 82!780/-7-6$,!-.!+8d782d7T!-.!

%&'()*"+&,$!5/-9$82!17-6$,!-.!5#-,5#&9$!-/8T82&9$3!./-7!9#$!*"+!#N3/-6N,8,4?!

"#$! %&'()*"+&,$! 5/-9$82! 0-29$29! 82! C-P82$! &23! /&CC89! ,&/0-56&,780! /$980:6:7!

780/-,-7$!./&098-2,>!5/$5&/$3!&,!3$,0/8C$3!&C-P$>!M&,!^:&298.8$3!CN!3$2,89-7$9/N?!f/&098-2,!

M$/$!,$5&/&9$3!CN!$6$09/-5#-/$,8,!-2!;G;!5-6N&0/N6&783$!T/&38$29!T$6,!1K)DEb4!&23!9#$!T$6,!

M$/$!,9&82$3!M89#!%--7&,,8$!C6:$!1;:556$7$29&/N!f8T?!;D4?! L2!$&0#!,$/8$,!-.!$O5$/87$29,>!&!

0&68C/&98-2! 0:/P$! M&,! 0-2,9/:09$3! :,82T! 0-77$/08&6! C-P82$! ,$/:7! &6C:782?! G$2,89-7$9/80!

,0&2282T!-.!%&'()*"+&,$!5/-9$82!C&23!M&,!0&//8$3!-:9!:,82T!&2!*7$/,#&7!+#&/7&08&!Q8-9$0#!

L7&T$!;0&22$/>!$^:855$3!M89#!&55/-5/8&9$!,-.9M&/$?!

2.3 RESULTS

2.3.1 SERCA1A ISOFORM

"#$!$2RN7$!M&,!5:/8.8$3!./-7!C-P82$!"#$%&'#(!$)#&"*>!&!.&,9)9M890#!7:,06$!:,$3!.-/!.&,9!

,F82! 9M890#82T?! L77:2-C6-9982T!$O5$/87$29,!M89#! &298C-38$,! &T&82,9! ;<=%*D&!&23!;<=%*'&!

8,-.-/7,!1f8T?!D4!06$&/6N!,#-M$3!9#&9!9#$!5:/8.8$3!$2RN7$!0-//$,5-23,!2$&/6N!$298/$6N!9-!9#$!

;<=%*D&!8,-.-/7>!9#$!;<=%*'&!5/$,$20$!C$82T!68789$3!9-!6$,,!9#&2!Kb?!"#8,!M&,!0-2.8/7$3!CN!

0-2.-0&6! 780/-,0-5N! 87&T$,! -.! 7:,06$! 0/N-,$098-2,! 877:2$)6&C$6$3! M89#! 7-2-06-2&6!

&298C-38$,!&T&82,9!;<=%*D>!;<=%*'!&23!5#-,5#-6&7C&2!1;:556$7$29&/N!.8T:/$!;'4!!

2.3.2 SERCA1A ACTIVITY

"#$!,5$08.80!&098P89N!-.!C-P82$!;<=%*D&!M&,!A?KK!k!E?'A!l7-6$,d782d7T?!"#&9!-.!/&CC89!

;<=%*D&! 7$&,:/$3! :23$/! 9#$! ,&7$! $O5$/87$29&6! 0-23898-2,! M&,! DE?EA! k! E?AD!

l7-6$,d782d7T?!"#$!cE?K! .-/! 9#$!%&'(!&098P&98-2!-.! 9#$!*"+&,$! 1;:556$7$29&/N!f8T?!;@4!M&,!

,8786&/!.-/!C-P82$!&23!/&CC89!7$7C/&2$!,&756$,!15%&!A?ADkE?EK>!;&00#$99-!$9!&6?>!'EEJ>!&23!

48

5%&!&/-:23!A>!g-:63!$9!&6?>!DJBA>!H&/:N&7&!&23!H&0I$22&2>!DJBB>!/$,5$098P$6N4>!&23!,8786&/!

9-!9#&9!-.!9#$!#:7&2!;<=%*D!5/-9$82!15%&!A?XAkE?EK>!\3$/7&99!$9!&6?>!'EEE4?!

2.3.3 CRYSTAL STRUCTURE OF BOVINE SERCA1A

"#$!0/N,9&6!,9/:09:/$!-.!9#$!%&'()C-:23!.-/7!-.!C-P82$!;<=%*!8206:3$,!/$,83:$,!./-7!D!

9-!JJ'>!M89#!9#$!$O0$598-2!-.! .$M!38,-/3$/$3!&782-!&083,! 82!9#$!,9/$90#!BVA!9-!BBE!13:$!9-!

9#$!-00://$20$!-.!&!3$6$98-2!82!9#$!C-P82$!$2RN7$>!0-//$,5-2382T!9-!/&CC89!5-,898-2!KEX>!9#$!

2:7C$/82T! ,N,9$7! 8,! ,#8.9$3! CN! )D! &,! 0-75&/$3! 9-! 9#$! /&CC89! $2RN7$?!_$!M866! :,$! C-P82$!

2:7C$/82T! 9#/-:T#-:9! 9#8,! 5&5$/4?! G$,589$! 9#$! /$6&98P$6N! 68789$3! /$,-6:98-2>! '?JK! h>! 9#$!

$6$09/-2! 3$2,89N! M&,! M$66! 3$.82$3! 1&,! &2! $O&756$>! ,$$! ;:556$7$29&/N! f8T?! ;X4>! M89#! 9#$!

$O0$598-2!-.!.$M!6--5,!&23!0-22$0982T!/$T8-2,!9#&9!&/$!.6$O8C6$?!*!7-6$0:6$!-.!*H++%+>!9#/$$!

38P&6$29!8-2,!1%&'(!-/!HT'(4!&23!-2$!c(!8-2!&/$!C-:23!9-!9#$!5/-9$82!82!9#$!,&7$!,89$,!&,!82!9#$!

/&CC89!$2RN7$!1f8T?!'4?!L2!9#$!.82&6!f-:/8$/)38..$/$20$!7&5>!9M-!$6$09/-2!3$2,898$,!#8T#$/!9#&2!

Xm! M$/$! ,9866! 5/$,$29?! \2$! M&,! -2! 9#$! 5/-9$82! ,:/.&0$! 06-,$! 9-! ,83$! 0#&82! -.! g62DEB>! 82! &!

5&/98&66N!#N3/-5#-C80!5&90#! 682$3!CN!9#$!,83$!0#&82,!-.!+#$BEB>!"/5DEV!&23!J@D!&23!n&6DEX!

1;:556$7$29&/N!f8T?!;K4?!"#$!-9#$/!M&,!06-,$!9-!9#$!,83$!0#&82!-.!*,2JBJ?! L2!C-9#!0&,$,!M$!

M$/$! :2&C6$! 9-! ,9&9$! 8.! 9#$N! 0-//$,5-23$3! 9-! &! 5-,9)9/&2,6&98-2&6! 7-38.80&98-2>! -/! 9-! 9#$!

C82382T! -.! ,7&66! 68T&23,>! 9&F$2! ./-7! 9#$! 98,,:$! C$.-/$! 5:/8.80&98-2! -/! 5/$,$29! 82! 9#$!

0/N,9&668R&98-2!7$38:7?!"#$!-26N!5-,9)9/&2,6&98-2&6!7-38.80&98-2!-.!;<=%*D&!3$9$09$3!,-!.&/!8,!

289/-,N6&98-2! &9! "N/D''! 1;#&/-P! $9! &6?>! 'EE'4>! M#86,9! ,$P$/&6>! 8206:382T! 289/-,N6&98-2>!

T6:9&9#8-6&98-2!&23!,:7-N6&98-2>!#&P$!C$$2!.-:23!82!;<=%*'&!./-7!#$&/9!7:,06$!1c2N:,#F-!

$9!&6?>!'EEKZ!*3&0#8!$9!&6?>!'EEXZ!c#-!$9!&6?>!'EDD4?!*2!$6$09/-2!3$2,89N!82!9#$!06$.9!.-/7$3!CN!

H'>!HX>!HA!&23!HJ!#$680$,!&9!9#$!0N9-,-6)7$7C/&2$!829$/.&0$>!8?$?!82!&!5-,898-2!06-,$!9-!9#$!

.-/7$/! -.! -:/! &33898-2&6! $6$09/-2! 3$2,898$,>! M&,! -C,$/P$3! 82! 9#$! /&CC89! <D?*H++%+!

7-2-068280!0/N,9&6!.-/7!&23!89!M&,!829$/5/$9$3!&,!&!5#-,5#&983N60#-682$!#$&3T/-:5!1+80&/3!$9!

&6?>!'EEV4?!"#8,!/$T8-2!#&,!&6,-!C$$2!5/-5-,$3!9-!/$5/$,$29!9#$!C82382T!,89$!-.!9#$!/$T:6&9-/N!

5$5983$! ,&/0-68582! 1*,&#8! $9! &6?>! 'EE@>! Q:..N! $9! &6?>! 'EE@4>! ,:55-/982T! 9#$! #N5-9#$,8,! -.! 9#$!

C82382T!-.!&!,7&66!68T&23?!

CRYSTAL STRUCTURE OF ENDOPLASMIC RETICULUM CA2+-ATPASE (SERCA) FROM BOVINE MUSCLE

49

!

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

!

!

F*.<!D<!/'$%*0!,8!$>'!AXPPJP!2*&+*&.!(*$'!*&!2,B*&'!HI7JA%C<!9>'!@),$'*&!*(!(>,:&!%(!%!"%)$,,&1!$>'!0*.%&+!%(!%!($*"Z!-,+'0<!I0'"$),&!+'&(*$;!8),-!%!3DF,2(?F"%0"5!-%@!:%(!",&$,#)'+!%$!C<D[!%),#&+!$>'!0*.%&+<!

50

2.4 DISCUSSION

! "#$!0/N,9&6!,9/:09:/$!5/$,$29$3!#$/$>!M89#!C-:23!%&'(!&23!*H++%+>!0&2!C$!06&,,8.8$3!

&,!0-//$,5-2382T!9-!9#$!<D?*H++%+!,9&9$!-.!;<=%*D&?!L2!.&09>!89!0-75&/$,!^:89$!M$66!M89#!9#$!

0-//$,5-2382T! 0/N,9&6! ,9/:09:/$,! -.! 9#$! /&CC89! $2RN7$! 82! 9#$! ,&7$! 0-2.-/7&98-2&6! ,9&9$!

1;-/$2,$2! $9! &6?>! 'EEXZ! "-N-,#87&! &23! H8R:9&28>! 'EEX4?! %-75&/$3! 9-! 9#$! /&CC89! $2RN7$!

0/N,9&668R$3!82!9#$!,&7$!7-2-068280!.-/7!1+GQ!LG!D"K;4!-/!0/N,9&668R$3!82!9#$!+'D!,5&0$!T/-:5!

M89#! 9M-!7-6$0:6$,! 82! 9#$! &,N77$9/80! :289! 1+GQ! LG! Dnf+4>! 9#$! 0/N,9&6! ,9/:09:/$! -.! C-P82$!

;<=%*D&!5/$,$29,!&!/?7?,?3?!C$9M$$2!$^:8P&6$29!%a!&9-7,!-.!9#$!0-/$!,9/:09:/$!-.!E?BK!h!82!

C-9#! 0&,$,?! ;8T28.80&29!38..$/$20$,! &/$!-C,$/P$3!-26N! 82! 9#/$$! /$T8-2,W! 6--5!KED)KEV>!M#80#!

0-22$09,!,9/&23,!YB!9-!YJZ!6--5!BE)B@>!M#80#!0-22$09,!a)#$68O!HD!9-!H'Z!&23!.82&66N>!/$T8-2!

BVX)BBD>!9#&9!8,!5&/9!-.!&!6-2T!,9/$90#!M#80#!0-22$09,!#$680$,!HV!&23!HB!1f8T?!@4!

"M$29N)9M-!/$,83:$,!38..$/!82!9#$!&782-!&083!,$^:$20$!-.!9#$!C-P82$!M89#!/$,5$09!9-!

9#$! /&CC89! $2RN7$! 1;:556$7$29&/N! f8T?! ;A4?! L2! &33898-2>! &2! &782-! &083! 3$6$98-2! -00:/,! &9!

5-,898-2!KE@>!82!&!6--5!0-22$0982T!a)#$680$,!YB!&23!YJ>!$O5-,$3!9-!9#$!,-6P$29!1f8T?!X*4!&23!

9#$/$.-/$!M89#!5/-C&C6N!2-!.:2098-2&6!$..$09?!"#8,!6--5!8,!38,-/3$/$3!82!7-3$6!D"K;>!M#86,9!89!8,!

M$66!3$.82$3!82!9#$!C-P82$!$2RN7$?!*7-2T!9#$!''!,:C,989:98-2,>!D'!&/$!0-2,$/P&98P$>!7&826N!

;$/!o))p!"#/!-/!I$:>! L6$!o))p!n&6?!\26N!DE!&/$!2-2)0-2,$/P&98P$!/$56&0$7$29,!&23!&66!C:9!9M-!

&/$! 06:,9$/$3! 82! 9M-! &/$&,! -.! 9#$! %)9$/782&6! 3-7&82! 9#&9! 5/-9/:3$,! 82! 9#$! 6:7$2! -.! 9#$!

,&/0-56&,780!/$980:6:7!1f8T?!K4?!"#$!9M-!8,-6&9$3!/$56&0$7$29,!&/$!g6NJ@V!&23!n&6J''>!M#80#!

/$56&0$!&!%N,! 82! 9#$! .8/,9!5-/98-2!-.!a)#$68O!HJ!&23!&!H$9! 82! 9#$! 6--5!/$T8-2!C$.-/$!a)#$68O!

HJ>!/$,5$098P$6N?!Q-9#!,:C,989:98-2,!&55$&/!9-!C$!8//$6$P&29!./-7!9#$!0-2.-/7&98-2&6!5-829!-.!

P8$M>!8?$?!9#$!,9/:09:/$,!-.!9#$!C-P82$!&23!/&CC89!$2RN7$,!&/$!,:5$/875-,&C6$!82!9#$,$!&/$&,?!

*! ,7&66! 06:,9$/! -.! 38..$/$20$,! 8,! /$5/$,$29$3! CN! 9#$! 0-2,$0:98P$! ,:C,989:98-2,! "JAXq! &23!

rJAKU?!"#$N!-00:/!&9!9#$!$23!-.!a)#$68O!HJ>!&9!9#$!.82&6!$23!-.!9#$!6858380!C86&N$/W!&T&82>!9#$N!

3-!2-9! ,$$7! 9-!5$/9:/C! 9#$! 9#/$$)387$2,8-2&6! ,9/:09:/$!-.! 9#$!$2RN7$?!U8,!JAK! ,83$! 0#&82!

5-829,! 829$/2&66N! 9-! 9#$! C:236$! -.! #$680$,>! M#86,9! 9#$! 7-/$! 0:7C$/,-7$! "#/! )p! "N/!

/$56&0$7$29!0&2!C$!$&,86N!&00-77-3&9$3>!,820$!9#$!,83$!0#&82!5-829,!9-M&/3,!9#$!,-6P$29?!!

CRYSTAL STRUCTURE OF ENDOPLASMIC RETICULUM CA2+-ATPASE (SERCA) FROM BOVINE MUSCLE

51

!

F*.<!S<!H$')',!B*':!,8!J\!%$,-(!,8!2,B*&'!-#("0'!HI7JA!3";%&1!$>*(!@%@')5!(#@')*-@,('+!$,!$:,!-,+'0(!,8!)%22*$!-#("0'!IC<AXPPJP!8,)-!3)'+1!P/]!G/!C9MH1!H,)'&('&!'$!%0<!DLLWV!;'00,:1!P/]!G/!C^PF1!9,;,(>*-%!%&+!X*_#$%&*1!DLLW5<!7'.*,&(!:>')'!,#)!-,+'0!+*88')(!(*.&*8*"%&$0;!8),-!$>'!,$>')(!%)'!0%2'0'+<!G&!$>*(!F*.#)'!%&+!*&!F*.#)'!`!%00!J\!%$,-(!:')'!(#@')*-@,('+<!

!

!

F*.<!W<! 3A5!H$')',!B*':!,8!%!+'$%*0!,8! 0,,@(!MLC?MLa<!J,0,)(!%)'!%(! *&!F*.<!S<!b&0;!J\!%$,-(!%)'!(>,:&1!:*$>! $>'!'U"'@$*,&!,8!(*+'!">%*&(!,8! $>'!2,B*&'!'&_;-'!3J!%$,-(! *&!.)''&5<!H')MLS1! $>'!%-*&,!%"*+!%2('&$! *&! $>'!2,B*&'!'&_;-'1!*(!0%2'0'+!*&!$>'!,$>')!$:,!-,+'0(<!3]5!H%-'!%(!3A5!8,)!0,,@!%&+!a`S?aaC<!!

52

!

F*.<!M<!J%)$,,&!)'@)'('&$%$*,&!,8!2,B*&'!HI7JA<!/,-%*&(!A1!c!%&+!P1!+'8*&'+!%"",)+*&.!$,!9,;,(>*-%!%&+!G&'(*!3DLLW51! %)'! ",0,)'+! ";%&1! 0*.>$! )'+! %&+! ,)%&.'1! )'(@'"$*B'0;<! H*+'! ">%*&(! ,8! %-*&,! %"*+(! $>%$! )'@)'('&$! &,&?",&(')B'+!-#$%$*,&(!*&!$>'!2,B*&'!:*$>!)'(@'"$!$,!$>'!)%22*$!@),$'*&!%)'!(>,:&!*&!;'00,:<!

CRYSTAL STRUCTURE OF ENDOPLASMIC RETICULUM CA2+-ATPASE (SERCA) FROM BOVINE MUSCLE

53

f82&66N>!9#$!/$7&8282T!,8O!38..$/$20$,!&/$!T/-:5$3!./-7!/$,83:$,!BA@!9-!BBD>!-2$!-.!9#$!

&/$&,! M#$/$! M$! -C,$/P$! &! 0-2.-/7&98-2&6! 38..$/$20$! 82! 9#$! 9M-! ,9/:09:/$,! 1f8T?! XQ4?! Y-!

$6$09/-2!3$2,89N! 8,!P8,8C6$! .-/! /$,83:$,! ./-7!BVX!9-!BBD>! 82380&982T! 9#&9!,:C,989:98-2,! 823:0$!

0-2.-/7&98-2&6!.6$O8C8689N?!L9!8,!M-/9#!2-98082T!9#&9!9M-!%N,!/$,83:$,!&/$!5/$,$29!82!9#8,!&/$&?!L9!

#&,! C$$2! ,#-M2! 9#&9! &! 38,:6.83$! C-23! C$9M$$2! 9#$,$! 9M-! %N,! /$,83:$,! 1%BVK)%BBV! 82! 9#$!

C-P82$>! %BVA)%BBB! 82! 9#$! /&CC89! $2RN7$4! 8,! /$^:8/$3! .-/! &098P89N! 1G&8#-! $9! &6?>! 'EED4?! L9,!

/$3:098-2! 82! -:/! 0/N,9&6! ,9/:09:/$! 8,! 68F$6N! 3:$! 9-! /$3:082T! &T$29,! 82! 9#$! C:..$/,! :,$3! .-/!

0/N,9&668R&98-2?!

g8P$2!9#$!T/$&9!,8786&/89N!C$9M$$2!9#$!,9/:09:/$,!-.!9#$!<D?*H++%+!.-/7,!-.!C-P82$!

&23!/&CC89!;<=%*>!9#$!$O56&2&98-2!.-/!9#$!,8T28.80&296N!38..$/$29!,5$08.80!&098P898$,!-.!9#$!9M-!

$2RN7$,!3-$,!2-9!&55$&/!9-!C$!-CP8-:,?!_$!0&22-9!$O06:3$!9#$!5-,,8C8689N!9#&9!5&/9!-.!9#8,!

38..$/$20$!/$.6$09,!&!5-9$298&66N!38..$/$29!5#-,5#-68583!$2P8/-27$29!-.!9#$!9M-!5/$5&/&98-2,>!

,820$! 9#$! 5/-0$3:/$,! :,$3! 9-! $O9/&09! 9#$! /&CC89! &23! C-P82$! $2RN7$,! 38..$/$3! ,68T#96N?!

U-M$P$/>! 9#$! 5-,,8C8689N! 9#&9! 9#$! $2P8/-27$29! M-:63! C$! /$,5-2,8C6$! .-/! ,:0#! &! 6&/T$!

38..$/$20$! ,$$7,! /$7-9$>! 82!5&/980:6&/! ,820$! 9#$!cE?K! .-/!%&'(! &098P&98-2! 82! 9#$! 9M-!*"+&,$,!

M&,!$,,$298&66N!9#$!,&7$?!_$!0&2!9#:,!0-2.83$296N!0-206:3$!9#&9!9#$!$2RN7$!,9/:09:/$!7:,9!

56&N!&!/-6$!82!9#$!38..$/$20$?!*782-!&083,!9#&9!38..$/!,8T28.80&296N!82!9#$!9M-!$2RN7$,!&23!9#&9!

5$/9:/C! 9#$! 9#/$$)387$2,8-2&6! ,9/:09:/$!&/$!5/&0980&66N! 0-2.82$3! 9-!-2$! ,5$08.80! /$T8-2>! 9#$!

6-2T! 6--5!#&9!5/-9/:3$,! 829-! 9#$! ;=! 6:7$2!&23!M#80#! 0-22$09,!a)#$680$,!HV!&23!HB?! "#8,!

&/$&! 8,!2-9! 82P-6P$3! 82!9#$!C82382T!-.!*"+!-/!-.!%&'(>!2-/! 82!9#$! 6&/T$!,#8.9,!9#&9! 82P-6P$!9#$!

0N9-56&,780!3-7&82,!&23!9#&9!&/$!9#$!C&,8,!.-/!9#$!9/&2,.$/!-.!%&'(!./-7!9#$!0N9-56&,7!9-!9#$!

6:7$2?!Y$P$/9#$6$,,>! &! ,:5$/5-,898-2!-.!C-P82$!<D! 9-! 9#$! /&CC89! <'! 0-2.-/7&98-2!-.! ;<=%*!

1f8T?!A4!,#-M,!9#&9!82!9#$!<'!,9&9$!9#$!6&/T$!7-P$7$29,!-.!9#$!0N9-56&,780!3-7&82,!5$/9:/C!

&6,-!9#$!/$T8-2!-.!9#$!829$/7$7C/&2$!#$680$,!&23!823:0$!&!0-2.-/7&98-2&6!/$&//&2T$7$29!-.!

9#$!&/$&!5/-9/:382T!829-!9#$!6:7$2?!L2!5&/980:6&/>!9#$!,#8.9!-.!5-,898-2!-.!9#$!6-2T!a)#$68O!H'!

&23!-.!#$68O!HD!8,!9/&2,7899$3!9-!#$68O!H@>!0&:,82T!&!,#8.9!-.!9#$!6--5!0-22$0982T!#$680$,!H@)

HX?! L2! 5&/&66$6>! 9#$! 6-2T! ,9/$90#! 0-22$0982T! #$680$,! HB! &23!HJ>! M#80#! 8,! 9#$! /$T8-2! 9#&9!

54

0-29&82,! 7-,9! -.! 9#$! /$,83:$,! 9#&9! 38..$/,! 82! 9#$! C-P82$! 5/-9$82>! :23$/T-$,! &! 5&/&66$6!

/$&//&2T$7$29>!0-782T!06-,$/!9-!9#$!5/$P8-:,!6--5>!,-!9#&9!9#$!,83$!0#&82!-.!g6:BVV!C$0-7$,!

06-,$!9-!;$/'BV>! .-/782T!&!U)C-23! 829$/&098-2?!g6:BVV! 8,!0-2,$/P$3>!C:9! /$,83:$,!5/$0$382T!

&23!.-66-M82T!89! 82!9#$!,$^:$20$!&/$!7:9&9$3!1rBVXc>!"BVA;>!GBVBU>!UBVJ;>!UBBDG4?!"#$,$!

38..$/$20$,! 82! 9#$! ,$^:$20$>!M#80#! &/$! &6,-! /$.6$09$3! 82! 9#$! $6$09/-,9&980! 5-9$298&6! ,:/.&0$!

1;:556$7$29&/N!f8T:/$!;V4>!0-:63!82.6:$20$!9#$!9/&2,898-2!./-7!9#$!<D!9-!9#$!<'!0-2.-/7&98-2>!

7&F82T! 89! ,68T#96N! 6$,,! .&P-:/$3! M89#! /$,5$09! 9-! 9#$! /&CC89! $2RN7$?! "#8,! 0-:63! S:,98.N! 9#$!

/$3:0$3!,5$08.80!&098P89N!-.!9#$!C-P82$!$2RN7$?!!

!

!

!

F*.<!`<!H$')',!)*22,&!+)%:*&.!,8!$>'!(#@')@,(*$*,&!,8!J\!%$,-(!,8!$>'!$)%&(-'-2)%&'!%&+!";$,(,0*"!@,)$*,&(!,8!ID!",&8,)-%$*,&!,8!)%22*$!HI7JA!3;'00,:1!P/]!G/!DJaR1! 3d'&('&!'$!%0<!DLL`55!%&+!,8!",&8,)-%$*,&!IC!,8!$>'!2,B*&'!'&_;-'<! 9>'! )'.*,&! a`S?a`C1! :>*">! ",&$%*&(! -,($! ,8! $>'! +*88')'&"'(! 2'$:''&! 2,B*&'! %&+! )%22*$! '&_;-'1! *(!0%2'0'+<!

!

CRYSTAL STRUCTURE OF ENDOPLASMIC RETICULUM CA2+-ATPASE (SERCA) FROM BOVINE MUSCLE

55

2.4.1 SERCA MUTATIONS

L2! %#8&282&! 0&996$>! 9#$! */T! 9-! U8,! ,:C,989:98-2! &9! 5-,898-2! DAX! -.! ;<=%*D! 6$&3,! 9-! &!

5,$:3-7N-9-28&! 1;&00#$99-! $9! &6?>! 'EEJ4?! %&996$! 5,$:3-7N-9-28&! &,,-08&9$3! M89#! *"+'*D!

T$2$!7:9&98-2,!#&,!C$$2!3$,0/8C$3!&6,-! 82!Q$6T8&2!Q6:$!C/$$3! 12&7$3!0-2T$289&6!7:,0:6&/!

3N,9-28&D4! 1%#&/68$/! $9! &6?>! 'EEB4! &23! &,! &! ,82T6$! 0&,$! 82! &! G:90#! 875/-P$3! =$3! &23!_#89$!

0/-,,)C/$$3!0&6.!1g/s2C$/T!$9!&6?>!'EDE4!82!M#80#!9#$!GY*!,$^:$2082T!/$P$&6$3!&2!*/T!9-!%N,!

,:C,989:98-2! &9! 5-,898-2! KKJ! 10-//$,5-2382T! 9-! /&CC89! KAE4?! L2! 9#$! 6&99$/>! */TKKJ! 38/$096N!

829$/&09,! M89#! 9#$! 2:06$-983$! &23! 89,! 7:9&98-2! &..$09,! 9#$! C82382T! -.! 9#$! 2:06$-983$?! L2!

%#8&282&!0&996$>!9#$!&7-:29!-.!5/-9$82!5/$,$29!82!9#$!;=!/$980:6:7!82!9#$!38,$&,$3!&287&6,!8,!

,8T28.80&296N! 3$0/$&,$3! M89#! /$,5$09! 9-! M863! 9N5$! 0-:29$/5&/9,>! 3$,589$! 9#$! .&09! 9#&9! 9#$!

7=Y*!0-382T!.-/!;<=%*D&!8,!5/$,$29!82!$^:8P&6$29!&7-:29,?!"#$!7:9&9$3!=DAXU!&782-!&083!

C$6-2T,!9-!9#$!*!3-7&82!-.!;<=%*>!M#80#!8,!0/8980&6!82!9#$!3$5#-,5#-/N6&98-2!5/-0$,,>!3:/82T!

M#80#!89!/-9&9$,!&23!&,,-08&9$,!M89#!9#$!+!3-7&82!9-!.-/7!9#$!0&9&6N980!,89$!.-/!*"+!#N3/-6N,8,?!

*!3$9&86!-.! 9#$!,9/:09:/$!-.! 9#$! /$T8-2!-.!3-7&82!*!-.!;<=%*D! 8,! 866:,9/&9$3! 82!f8T?!V?! L2! 9#$!

<D?*H++%+!,9&9$>!9#$!5/-9-2&9$3!,83$!0#&82!-.!*/TDAX!8,!0-:29$/C&6&20$3!CN!9#$!2$T&98P$6N!

0#&/T$3!g6:'?!L2!&33898-2>!9#$!*/T!,83$!0#&82!.-/7,!$O9$2,8P$!829$/&098-2,!M89#!9#$!0&/C-2N6!

-ONT$2!&9-7,!-.!&9!6$&,9!.-:/!,://-:2382T!/$,83:$,!1L6$DAK>!"#$DJD>!IN,V!&23!U8,K4>!&0982T!&,!

&!0$29/&6! t&20#-/!5-829t! .-/! 9#/$$!38..$/$29! ,9/$90#$,!-.! 9#$!*)3-7&82! .-63>!&23! 8,! 9#$/$.-/$!

5/-C&C6N!0$29/&6!9-!5/-5$/!.-6382T?!"#$!,:C,989:98-2!-.!9#$!,83$!0#&82!-.!9#$!&/T8282$!M89#!9#$!

8783&R-6$!-.!9#$!U8,!/$,83:$>!M#80#!8,!,7&66$/!&23!&9!5#N,8-6-T80!5U!0&2!C$!2$:9/&6>!0-:63!#&P$!

&! /-6$! 82! 38,.&P-/82T! &! 0-//$09! .-6382T?! "#8,! 0-:63! &..$09! 9#$! &7-:29!-.! ;<=%*! 9#&9! $,0&5$,!

5/-9$-6N980!3$T/&3&98-2!9-!C$!0-//$096N!82,$/9$3!829-!9#$!;=!C86&N$/?!

!

56

!

F*.<!E<!H$')',!B*':!,8!%!@,)$*,&!,8!+,-%*&!A!,8!IC<AXPPJP! 8,)-!,8! $>'!2,B*&'!'&_;-'<!H*+'!">%*&(!,8! )'(*+#'(!*&$')%"$*&.!:*$>!A).C`W!%)'!'U@0*"*$0;!(>,:&1!%0,&.!:*$>!Q0#D<!P,$'&$*%0!=?2,&+(!8,)-'+!2;!A).C`W!(*+'!">%*&!%)'!(>,:&! %(! +%(>'+! 0*&'(<! 9>'! +*($%&"'! 2'$:''&! ce! %&+! c=C! ,8! A).C`W! %&+! beD! ,8! Q0#D! %)'! `<D! 4! %&+! a<L! 41!)'(@'"$*B'0;<!

2.5 CONCLUSIONS

"#$!0/N,9&6!,9/:09:/$!-.!C-P82$!;<=%*D&!5/$,$29$3!82!9#8,!5&5$/!,#-M,!9#&9!9#$!-P$/&66!

0-2.-/7&98-2! -.! 9#$! $2RN7$! 8,! M$66! 0-2,$/P$3! C$9M$$2! 0&996$! &23! /&CC89>! 9#&9! 38P$/T$3!

,$P$/&6!78668-2,!N$&/!&T-!1U$3T$,!&23!c:7&/>!'EE@4?!L9!8,!M-/9#!2-98082T!9#&9!9#$!C82382T!,89$,!

.-/!8-2,!&23!.-/!9#$!2:06$-983$!&/$!P$/N!M$66!0-2,$/P$3>!&23!9#&9!9#$!0&608:7!C82382T!0-2,9&29!

8,! $,,$298&66N! 9#$! ,&7$! .-/! 9#$! 9M-! $2RN7$,?! QN! 0-29/&,9>! ,7&66! 38..$/$20$,! 0&2! &..$09! &23!

7-3:6&9$! 9#$! 9/&2,5-/9! &098P89N>!M#80#! /$68$,! -2! &! 0-756$O! 0-20$/9$3! $^:868C/8:7!C$9M$$2!

38..$/$29!0-2.-/7&98-2&6!,9&9$,?!*!.$M!7:9&98-2,!#&P$!$P83$296N!/$23$/$3!9#$!C-P82$!$2RN7$!

6$,,! $..808$29! 9#&2! 9#$! /&CC89! 0-:29$/5&/9>! &,! 0&2! C$! $&,86N! :23$/,9--3! 0-2,83$/82T! 9#$!

38..$/$29!,8R$,!&23!9#$!38..$/$29!5$/.-/7&20$,!/$^:8/$3!CN!9#$!7:,06$!-.!9#$!9M-!&287&6,?!*,!

3$7-2,9/&9$3!CN!5,$:3-7N-9-28&!82!%#8&282&!0&996$>!&!,82T6$!7:9&98-2!8,!,:..808$29!9-!5$/9:/C!

9#$!9#/$$!387$2,8-2&6!,9/:09:/$!&23!823:0$!&!T$2$980!38,$&,$?!

CRYSTAL STRUCTURE OF ENDOPLASMIC RETICULUM CA2+-ATPASE (SERCA) FROM BOVINE MUSCLE

57

2.6 ACCESSION NUMBERS

"#$! 0--/382&9$,! &23! ,9/:09:/$! .&09-/,! #&P$! C$$2! 3$5-,89$3! 82! 9#$! +/-9$82!G&9&! Q&2F!!

1#995WddMMM?53C?-/T4!.-/!877$38&9$!/$6$&,$!:23$/!&00$,,8-2!0-3$!@"IH?!

2.7 ACKNOWLEDGMENTS

_$!9#&2F!9#$!,9&..!-.!C$&7682$! LG'J!-.!<;=f>!g/$2-C6$>! .-/! 9$0#280&6!&,,8,9&20$!3:/82T!3&9&!

0-66$098-2?!_$!&0F2-M6$3T$! 9#$!5/$08-:,!#$65!-.!H/?!g8-P&228!%&5-/&6$?!_$! 9#&2F!*29#$&!

=-M6$/,-2! .-/! 0&/$.:66N! /$&382T! 9#$! 7&2:,0/859?! _$! &/$! $,5$08&66N! T/&9$.:6! 9-! g8&2982!

,6&:T#9$/#-:,$>!f-,,u! 1n<4! L9&6N?!"#8,!M-/F!M&,!,:55-/9$3!CN!f-:23&98-2!%&/85&/-! 1%&608:7!

,8T2&6682T!82!#$&69#!&23!38,$&,$4!&23!CN!9#$!j28P$/,89N!-.!+&3:&!*9#$2&$:7!+/-S$09!19-!f?H?4?!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

58

2.8 SUPPLEMENTARY FIGURES

!

!

F*.<!HC<!A5!H/H!.'0!'0'"$),@>,)'(*(!,8!)%22*$!%&+!2,B*&'!HI7JA!#('+!*&!$>'!K#%&$*8*"%$*,&!,8!$>'!'&_;-%$*"!%"$*B*$;<!R%&'(! C1!Xf! ($%&+%)+(V! 0%&'(! D1! S! %&+! W! )'@)'('&$! (%)",@0%(-*"! )'$*"#0#-!-'-2)%&'(! 'U$)%"$'+! 8),-! )%22*$!-#("0'1! 8,00,:*&.! $>'! @),"'+#)'! @)'B*,#(0;! +'(")*2'+! 3H%"">'$$,! '$! %0<1! DLLM5V! 0%&'(! M1! `! %&+! E! )'@)'('&$!(%)",@0%(-*"!)'$*"#0#-!-'-2)%&'(!,8!2,B*&'!HI7JA!'U$)%"$'+!%"",)+*&.!$,!3/'!X'*(!%&+!=%(('02%">1!CYEC5<!]5!F*&%00;!@#)*8*'+!HI7JA!'&_;-'!#('+!8,)!");($%00*_%$*,&<!9>'!)%22*$!'&_;-'!*(!*&!0%&'!C1!2,B*&'!*&!0%&'!D<!

CRYSTAL STRUCTURE OF ENDOPLASMIC RETICULUM CA2+-ATPASE (SERCA) FROM BOVINE MUSCLE

59

!

F*.<! HD<! J,&8,"%0! -*"),(",@;! ,8! 2,B*&'! "#$%&'#(! $)#&"*! -#("0'! ");,('"$*,&(<! H')*%0! $)%&(B')('! ('"$*,&(! :')'!*--#&,0%2'0'+!:*$>!-,&,"0,&%0!%&$*2,+*'(! $,!HI7JAC!%&+!HI7JAD! *(,8,)-(!,)!@>,(@>,0%-2%&! 3PR]5! 39>')-,!("*'&$*8*"5!%(!*&+*"%$'+<!H'"$*,&(!:')'!$>'&!*&"#2%$'+!:*$>!$>'!%@@),@)*%$'!('",&+%);!%&$*2,+*'(!",&g#.%$'+!:*$>!$'$)%-'$>;0)>,+%-*&'!*(,$>*,";%&%$'!397G9J5!%&+!'U%-*&'+!#(*&.!%!R'*"%!9JH?HPD!",&8,"%0!("%&&*&.!-*"),(",@'<!H"%0'!2%)T!CaE<M!--<!

60

!

F*.<! HS<! J%Dh?A9P%('! %"$*B*$;! ,8! (%)",@0%(-*"! )'$*"#0#-! -'-2)%&'(1! -'%(#)'+! %(! %! 8#&"$*,&! ,8! J%Dh!",&"'&$)%$*,&<!9>'!J%Dh?A9P%('!%"$*B*$;!:%(!-'%(#)'+!2;!(@'"$),@>,$,-'$)*"!+'$')-*&%$*,&!,8!cA/=!,U*+%$*,&!",#@0'+!$,!%&!A9P!)'.'&')%$*&.!(;($'-!%$!B%)*,#(!",&"'&$)%$*,&!,8!8)''!J%Dh<!/%$%!%)'!'U@)'(('+!%(!@')"'&$%.'!,8!-%U*-#&!B%0#'!3@J%!M5!%&+!%)'!$>'!-'%&!h!H/<!H;-2,0(T!"*)"0'!i!2,B*&'!(%)",@0%(-*"!)'$*"#0#-!-'-2)%&'(V!$)*%&.0'!i!)%22*$!(%)",@0%(-*"!)'$*"#0#-!-'-2)%&'(<!

!

!

CRYSTAL STRUCTURE OF ENDOPLASMIC RETICULUM CA2+-ATPASE (SERCA) FROM BOVINE MUSCLE

61

!

!

F*.<! HW<! H$')',!B*':!,8!%!@,)$*,&!,8! $>'!'0'"$),&!+'&(*$;!-%@1! (>,:*&.! 8,#)!,8! $>'! $)%&(-'-2)%&'!>'0*"'(<!9>'!-%@!:%(!"%0"#0%$'+!:*$>!3DF,2(?F"%0"5!",'88*"*'&$(1!",&$,#)(!%)'!+)%:&!%$!C[<!!!

!

!

!

F*.<!HM<!H$')',!B*':!,8!$>'!'0'"$),&!+'&(*$;!-%@1!"%0"#0%$'+!:*$>!",'88*"*'&$(!3F,2(?F"%0"51!,8!$>'!)'.*,&!"0,('!$,!)'(*+#'!jCLa<!A&!'0'"$),&!+'&(*$;1!@,((*20;!",))'(@,&+*&.!$,!%!(-%00!0*.%&+!2,#&+1!*(!+)%:&!%$!W<M[<!!!

62

F*.<!H`<!A0*.&-'&$!,8!$>'!%-*&,!%"*+!('K#'&"'!,8!2,B*&'!HI7JA%C!@#-@!3jL^JkL5!:*$>!$>%$!,8!$>'!)%22*$!'&_;-'!3Q'&2%&Z!XCMCMa<C5<!!

CRYSTAL STRUCTURE OF ENDOPLASMIC RETICULUM CA2+-ATPASE (SERCA) FROM BOVINE MUSCLE

63

!

!

F*.<! HE<! j#%0*$%$*B'! '0'"$),($%$*"! @,$'&$*%0! (#)8%"'! 3"%0"#0%$'+! 2;! (,8$:%)'! P;-,05! 8,)! 2,B*&'! 3$,@5! %&+! )%22*$!HI7JA! 32,$$,-5<! 9>'! 0'8$! %&+! )*.>$! B*':(!%)'! ),$%$'+!%@@),U*-%$'0;! CaL6! '%">!,$>')<! H-%00! +*88')'&"'(! "%&!2'!,2(')B'+!%$!$>'!2,$$,-1!",))'(@,&+*&.!$,!$>'!%)'%!@),$)#+*&.!*&$,!$>'!0#-'&<!

64

!

!

!

!

CHAPTER III

!

HETEROLOGOUS EXPRESSION AND AFFINITY

PURIFICATION OF HUMAN SERCA 2A IN

SACCHAROMYCES CEREVISIAE

!

!

!

66

CONTENTS

3.1 INTRODUCTION 67

3.2 MATERIALS AND METHODS 68

3.2.1 HETEROLOGOUS EXPRESSION OF HUMAN SERCA2AR863G IN S. CEREVISIAE 68

3.2.2 PROTEIN EXPRESSION 70

3.2.3 ISOLATION OF YEAST MEMBRANES 70

3.2.4 SOLUBILIZATION OF MEMBRANE FRACTIONS 71

3.2.5 FORMATION OF PHOSPHO-INTERMEDIATE ENZYME ON MEMBRANE FRACTION 71

3.2.6 PURIFICATION OF HSERCA2AR863G 72

3.2.7 BATCH PURIFICATION WITH AVIDINE AGAROSE 72

3.2.8 GEL-FILTRATION 72

3.2.9 PROTEIN RECONSTITUTION AND CRYSTALLIZATION TRIALS 73

3.2.10 SODIUM DODECYL SULFATE-POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE) 73

3.2.11 WESTERN BLOTTING 73

3.3 RESULTS AND DISCUSSION 74

3.3.1 OVER-EXPRESSION OF HSERCA2AR863G IN S. CEREVISIAE 74

3.3.2 HUMAN SERCA, ISOFORM 2A, PURIFICATION 77

3.3.3 CRYSTALLIZATION TRIALS 80

3.4 CONCLUSIONS 80

3.5 ACKNOWLEDGEMENTS 80

HETEROLOGOUS EXPRESSION AND AFFINITY PURIFICATION OF HUMAN SERCA 2A IN SACCHAROMYCES CEREVISIAE

67

3.1 INTRODUCTION

!"#$%&'()*+$,-./.01$,-$+$1#120+3#$40.5#,3$./$+2.65$778$9:+;$)-$+$1#12#0$./$5"#$(+*<$

4614-$ /+1,=>?$ ,5$ 4=+>-$ +$ 9#>$ 0.=#$ ,3$ 5"#$ @.350.=$ ./$ @+=@,61$ ".1#.-5+-,-$ ,3$ @+0A,+@$16-@=#?$

B"#0#$ ,5-$+2,=,5>$5.$0#1.C#$@+=@,61$,3A6@#-$16-@=#$0#=+D+5,.3;$ E3$"61+3-?$+2.65$FGH$./$5"#$

@>5.-.=,@$ (+*<$ 0#645+9#$ ,35.$ %'$ ,-$ 0#I6=+5#A$ 2>$ 5"#$ %&'()*+$ 4614;$ J.0#.C#0?$ 5",-$ 4614$

,3A,0#@5=>$@.350.=-$5"#$-5.0+I#$./$(+*<$,35.$%'?$B",@"$,-$0#-4.3-,2=#$/.0$5"#$@+0A,+@$@.350+@5,.3$

+@5,C+5,.3;$ (.3-#K6#35=>?$ 5"#$ %&'()*+$ ,-./.01$ 0#40#-#35-$ 5"#$1+L.0$ 4=+>#0$ ,3C.=C#A$ ,3$ 5"#$

0#I6=+5,.3$ ./$ 5"#$ #D@,5+5,.3M@.350+@5,.3$ @.64=,3I$ ./$ 5"#$ "#+05$ NO.30+A$ P;$ #5$ +=?$ *GGQR;$

&C,A#3@#-$ /0.1$ "61+3$ +3A$ #D4#0,1#35+=$ 1.A#=-$ ./$ "#+05$ /+,=60#$ "+C#$ A#1.3-50+5#A$ 5"+5$

+=5#0+5,.3-$,3$%'$@+=@,61$"+3A=,3I$+0#$+--.@,+5#A$B,5"$+3$,14+,0#A$@.350+@5,=,5>?$40.2+2=>$A6#$

5.$A#@0#+-#A$%&'()*+$40.5#,3$=#C#=-$+3AS.0$,3@0#+-#A$,3",2,5,.3$2>$5"#$4".-4.=+12+3$NTUVR$

0#I6=+5.0>$ 40.5#,3$ N&=,W+2#5"$ X+/,+A+9,?$ *GGYR;$ Z5"#0$ #C,A#3@#$ +=-.$ -##1-$ 5.$ -6II#-5$ 5"+5$

165+5,.3-$ ./$ 5"#$ ,-./.01$ *+$1+>$ 40#A,-4.-#$ 5.$ @+0A,+@$ A,-#+-#-;$ '#@#35=>?$ %&'()*+$ 4614$

I#3#$50+3-/#0$B+-$A#1.3-50+5#A$5.$2#$-+/#$+3A$#//#@5,C#$,3$0#-5.0,3I$@.350+@5,=#$/63@5,.3$C,+$

.C#0M#D40#--,.3$./$%&'()*+$63A#0$4">-,.=.I,@+=$+3A$4+5".M4">-,.=.I,@+=$@.3A,5,.3-$N[,+33,$:;$

#5$+=?$*GG8R;$

!"#$ ,3C.=C#1#35$ ./$ 5"#$ %&'()*+$ ,-./.01$ ,3$ 5"#$ @.350.=$ ./$ @+=@,61$ ".1#.-5+-,-$ ,3$

#69+0>.5,@$ @#==-$ +3A$ @.3-#K6#35=>$ ,5-$ 0.=#$ ,3$ 5"#$ 4+5".=.I,#-$ ./$ @+0A,+@$16-@=#$1+9#-$ ,5$ +3$

,14.05+35$5+0I#5$./$0#-#+0@"$,3C#-5,I+5,.3-;$!"#$A#5#01,3+5,.3$./$5"#$@0>-5+=$-506@560#$./$5"#$

%&'()*+$ @.6=A$ "#=4$ 5.$ #=6@,A+5#$ 5"#$ 1.=#@6=+0$ 1#@"+3,-1-$ 0#-4.3-,2=#$ /.0$ (+*<$ -,I3+=,3I$

A>-/63@5,.3$+-$B#==$+-$ 5.$A#-,I3$+3A$-56A>$-4#@,/,@$ ,3",2,5.0-$./$ 5"#$"#+05$%&'()*+$#3W>1#;$

P.0$5",-$0#+-.3?$B#$"+C#$#D5#3A#A$.60$,3C#-5,I+5,.3-$5.$5"#$-506@560+=$+3A$/63@5,.3+=$-56A>$./$

%&'()*+$+3A$./$5"#$165+35-$0#-4.3-,2=#$/.0$(+*<$-,I3+=,3I$A>-/63@5,.3;$$

E3$ .60$ B.09?$ 5"#$ "61+3$ %&'()*+$ B+-$ #D40#--#A$ ,3$ %+@@"+0.1>@#-$ @#0#C,-,+#$ +-$ +$

0#@.12,3+35$ 40.5#,3$ B,5"$ +$ 2,.5,3$ +@@#45.0$ A.1+,3$ N\):R$ =,39#A$ 5.$ 5"#$ (M5#01,36-$

N"%&'()*+M\):R$2>$+$5"0.12,3$@=#+C+I#$-,5#;$ZB,3I$5.$5"#$40#-#3@#$./$+$5"0.12,3$@=#+C+I#$

-,5#$B,5",3$5"#$40.5#,3$-#K6#3@#?$+$4.,35$165+35$N'Y]Q[R$B+-$I#3#0+5#A$+3A$5"#$40.5#,3$B+-$

68

-6@@#--/6==>$ #D40#--#A;$ E3$ C,C.$ >#+-5$ 2,.5,3>=+5,.3$ ./$ \):$ +AA#A$ +-$ +$ 5+I$ 5.$ %&'()*+$ "+-$

.//#0#A$2.5"$+$ /+-5$+3A$#//,@,#35$+//,3,5>$460,/,@+5,.3$-50+5#I>$+3A$+$4.-,5,C#$ -#=#@5,.3$./$ 5"#$

40.4#0=>$ /.=A#A$ #3W>1#;$ !.$ .25+,3$ -6//,@,#35$ +1.635$ ./$ 40.5#,3$ 5.$ 4#0/.01$ @0>-5+==,W+5,.3$

50,+=-?$ +$ 40.5.@.=$ /.0$ 2+5@"$ /#01#35+5,.3$ ./$ %;$ @#0#C,-,+#$ B+-$ .45,1,W#A$ ,3$ +$ ".1#$ 1+A#$

2,.0#+@5.0?$ +@@.0A,3I$ 5.$ 5"#$ 1#5".A$ ./$ (+0A,;$ N(+0A,$ :;$ #5$ +=?$ *G7GR;$ !"#$ 40.5#,3$ B+-$

-.=62,=,W#A$B,5"$+$26//#0$@.35+,3,3I$3MA.A#@>=$^M:M1+=5.-,A#$ N::JR$+5$ 5"#$+440.40,+5#$(J($

N@0,5,@+=$1,@#==+0$ @.3@#350+5,.3R;$ P,3+==>?$ 5"#$ #3W>1#$B+-$ 460,/,#A$ 2>$ +C,A,3M+//,3,5>$ -50+5#I>?$

6-,3I$5B.$A,//#0#35$460,/,@+5,.3$5..=-$N5"#$+C,A,3$0#-,3$+3A$5"#$+C,A,3$1+I3#5,@$3+3.4+05,@=#-R;$$

3.2 MATERIALS AND METHODS

3.2.1 HETEROLOGOUS EXPRESSION OF HUMAN SERCA2AR863G IN S. CEREVISIAE

!"#$@M:V)$@.A,3I$/.0$"61+3$%&'()*+$NE1+I#3#-$[12_?$\#0=,3?$[#01+3>R$B+-$+14=,/,#A$

2>$T('$+3A$@=.3#A$,35.$4`#:T]G$4=+-1,A$N9,3A=>$40.C,A#A$2>$J+0@$=#$J+,0#?$Na3,C#0-,5b$T+0,-M

%6A?$ PMc7dG8$Z0-+>?$ E3-5,565$ A#$ \,.=.I,#$ #5$ !#@"3.=.I,#-$ A#$ %+@=+>$ N,\,!#@M%R$ [,/M-60M`C#55#?$

+3A$a')$(V'%?$P0+3@#R$ ,3$5"#$-+1#$@.A,3I$/0+1#$./$5"0.12,3$@=#+C+I#$-,5#$+3A$\):$N2,.5,3$

+@@#45.0$A.1+,3R$-#K6#3@#-$2>$5"#$I+4M0#4+,0$@=.3,3I$1#5".A$N(",3.?$);$#5$+=?$*G7GR;$$

!"#$ /.0B+0A$ N8eM+5+$ @55$ @5+$ 5+I$ +@+$ @I@$ +++$ @+@$ +++$ 5+@$ +@+$ @+@$ 5++$ +55$ +@@$ I++$ 55@$

)![[)[))([([()()(())MQeR$ +3A$ 5"#$ 0#C#0-#$ 40,1#0-$ N8eM!!!)[([)!)![!!(![[!(!$ I@5$

+I@$55I$I55$@@+$+I+$II+$5@@$+@I$I@I$I@5$I@5$@@@$III$@@5$I@5$@@5MQeR?$B",@"$B#0#$40.4#0=>$A#-,I3#A$

5.$+==.B$5"#$".1.=.I.6-$0#@.12,3+5,.3$40.@#--$,3$5"#$>#+-5?$B#0#$6-#A$5.$4#0/.01$5"#$I+4M

0#4+,0$@=.3,3I$+-$A#-@0,2#A$2>$O,5+W.3.;$NO,5+W.3.?$);$);?$*GGcR;$

)$165+35$./$"%&'()*+$N'Y]Q[R$B+-$I#3#0+5#A$2>$T('$2+-#A$.3$5"#$f6,@9("+3I#$-,5#M

A,0#@5#A$165+I#3#-,-$ -50+5#I>$ N%50+5+I#3#R$ 5.$#=,1,3+5#$+$ 5"0.12,3$@=#+C+I#$-,5#$B,5",3$ 5"#$

40.5#,3$-#K6#3@#;$

(.14#5#35$%;$@#0#C,-,+#$@#==-$ N-50+,3$gQGQ;72$[+=dh*$N+?$ =#6*?$",-Q?$ 5047i$!'T7M[)U7GM

[)Ud?$ 60+Q?$ +A#*h7?$ @+30?$ @,0<R$ B#0#$ 50+3-/.01#A$ B,5"$ 5"#$ 4`#:T]G$ C#@5.0$ @.35+,3,3I$

HETEROLOGOUS EXPRESSION AND AFFINITY PURIFICATION OF HUMAN SERCA 2A IN SACCHAROMYCES CEREVISIAE

69

"%&'()M*+'Y]Q[$+3A$-#=#@5#A$.3$1,3,1+=$4=+5#-$+-$A#-@0,2#A$2>$[,#5W$+3A$g..A-$N:;$[,#5W?$

';$+3A$g..A-?$';$);R;$

$

$

!"#$% &$% '()*+",% -./012% 3*.,% 412% 5.0.21(1#13*% .672.**"18% 14% 59:;<=>);?@ABCD=E% "8% 9$% /.2.-"*").$% F2"% D)/0$G%

H)/0.2")(% 2.7("/)0"18% 12"#"8I% =E:>% )8,% J;=G% K.)*0% *.(./0"18% +)2L.2*I% =+7;G% H)/0.2")(% *.(./0"18% +)2L.2I% '21%

B=M&NC<O<&G%#)()/01*.C"8,3/"H(.%721+10.2I%P.2%'BQG%751*751#(K/.2)0.%L"8)*.%0.2+"8)012%*.R3.8/.I%D=EG%H"10"8%

)//.7012%,1+)"8I%P52G%0521+H"8%/(.)-)#.%*"0.G%:/1;SG%9)/SSG%T5.S%)8,%D)+USG%2.*02"/0"18%.8VK+.%*"0.*$

$

$

$

%

!"#$%>$%=("#8+.80%14%05.%)+"81%)/",%*.R3.8/.%14%53+)8%9:;<=>)%73+7%W"05%05)0%14%05.%9:;<=>);?@AB%7210."8$%

P5.% )+"81% )/",*% *.R3.8/.% 14% 9:;<=>);?@AB%)40.2% /(18"8#%W)*%)("#8.,%W"05% "0*%W"(0C0K7.% /1380.27)20% HK% 3*"8#%

<(3*0.2X% *140W)2.$% P5.% 0521+H"8% /(.)-)#.% *"0.% "*% 5"#5("#50.,% "8% ("#50% H(3.G% W5.2.)*% 05.% 71"80% +30)0"18% "*%

"8,"/)0.,%HK%)%H(3.%)221W$%

70

3.2.2 PROTEIN EXPRESSION

)$ 5.5+=$ ./$ 7G$1U$ ./$1,3,1+=$1#A,61$ NG;7H$BSC$ \+@5.$ (+-+1,3.$ +@,A-$ N\:$:,+I3.-5,@$

%>-5#1-?$Vj?$a;%;);R?$G;FH$BSC$>#+-5$3,50.I#3$2+-#?$*H$BSC$I=6@.-#?$*G$kIS1U$+A#3,3#R$B#0#$

,3.@6=+5#A$B,5"$5"#$-#=#@5#A$@=.3#$+3A$,3@62+5#A$+5$*Y$l($/.0$*d$";$!"#$40#@6=560#$B+-$5"#3$

A,=65#A$ ,3$7GG$1U$./$ /0#-"$1#A,61;$!"#$-#@.3A$40#M@6=560#$B+-$6-#A$5.$-5+05$ 5"#$@6=560#$ ,3$

`T[&$ 1#A,61$ N7H$ BSC$ >#+-5$ #D50+@5?$ G;8H$ BSC$ I=6@.-#?$ 7H$ BSC$ 2+@5.4#45.3#?$ *;FH$ CSC$

#5"+3.=R;$)/5#0$Q]$"$./$I0.B5"$+5$*Y$l(?$5"#$5#14#0+560#$./$5"#$@6=560#$B+-$=.B#0#A$5.$*G$l(;$

&D40#--,.3$ B+-$ ,3A6@#A$ 2>$ +AA,3I$ I+=+@5.-#$ 5.$ +$ /,3+=$ @.3@#350+5,.3$ ./$ *H$ BSC;$ )/5#0$

.C#03,I"5$ ,3@62+5,.3$ +5$ *G$ l(?$ +3$ +AA,5,.3+=$ ,3A6@5,.3$ B,5"$ I+=+@5.-#$ B+-$ 4#0/.01#A;$ !"#$

@6=560#$B+-$-5.44#A$+/5#0$]$";$!"#$@6=560#$B+-$5"#3$@.==#@5#A$+3A$@#350,/6I#A$+5$7GGGI+C$/.0$

78$1,365#-;$!"#$4#==#5$.25+,3#A$B+-$B+-"#A$B,5"$-5#0,=#$B+5#0?$@#350,/6I#A$+5$7GGG$I+C?$/0.W#3$

+3A$-5.0#A$+5$MYG$l(;$!"#$4#==#5-$B#,I"5$B+-$#-5,1+5#A$40,.0$5.$-5.0+I#;$

3.2.3 ISOLATION OF YEAST MEMBRANES

!"#$4#==#5$B+-$5"+B#A$+3A$0#-6-4#3A#A$,3$8G$1J$!'E%M_(=?$4_$F?8?$71J$&:!)?$G?]$J$

-.02,5.=?$ G?7$J$ O(=?$ +5$ +$ @.3@#350+5,.3$ ./$ +2.65$ *$ 1=SI$ ./$ >#+-5;$ T0.5#+-#$ ,3",2,5.0-$ B#0#$

+AA#A$5.$5"#$-6-4#3-,.3$N'.@"#$:,+I3.-5,@-?$\+-#=?$%B,5W#0=+3AR$N7$5+2=#5$./$@.14=#5#$&:!)M

/0##$+35,40.5#+-#$@.@95+,=$/.0$7GG$1=R$+3A$5"#$=>-,-$B+-$4#0/.01#A$B,5"$+$@#==$A,-0645.0$NZ3#$

%".5$ J.A#=?$ (.3-5+35$ %>-5#1-$ U5AR$ +5$ *?d$ 9\+0;$ !"#$ @#==$ A#20,-$ B+-$ -#4+0+5#A$ /0.1$ 5"#$

-6-4#3-,.3$2>$@#350,/6I+5,.3$+5$7GGG$I+C$+5$d$l($/.0$78$1,365#-;$!"#$-64#03+5+35$N%7R$B+-$5"#3$

@#350,/6I#A$+5$7Y?GGG$I+C;$!"#$4#==#5$.25+,3#A$NT*R?$@.35+,3,3I$5"#$"#+C>$1#120+3#$/0+@5,.3?$

B+-$0#-6-4#3A#A$,3$_#4#-M-6@0.-#$26//#0$N*G$1J$_#4#-M!0,-?$4_$F;d?$G?Q$J$-6@0.-#?$G?7$1J$

(+(=*R?$ /=+-"$ /0.W#3$ +3A$ -5.0#A$ +5$ MYG$ l($ /.0$ /605"#0$ +3+=>-,-;$ !"#$ -64#03+5+35$ N%*R$ B+-$

@#350,/6I#A$+5$*c?GGG$I+C$/.0$Q$".60$+5$7G$l($,3$.0A#0$5.$0#@.C#0$5"#$=,I"5$1#120+3#$/0+@5,.3$

NTQR?$B",@"$B+-$0#-6-4#3A#A$,3$_#4#-M-6@0.-#$26//#0$NG;*$1USI$./$>#+-5R$+3A$-5.0#A$+5$MYG$l($

+/5#0$/=+-"$/0.W#3;$

HETEROLOGOUS EXPRESSION AND AFFINITY PURIFICATION OF HUMAN SERCA 2A IN SACCHAROMYCES CEREVISIAE

71

3.2.4 SOLUBILIZATION OF MEMBRANE FRACTIONS

!"#$ 5.5+=$ 40.5#,3$ @.35#35$ B+-$ #-5,1+5#A$ 2>$ 5"#$ 2,@,3@".3,3,@$ +@,A$ 40.@#A60#;$ U,I"5$

1#120+3#-$NTQR$B#0#$A,=65#A$+5$8$1IS1=$./$5.5+=$40.5#,3-$,3$5"#$40#M-.=62,=,W+5,.3$26//#0$N8G$

1J$ JZT%M!0,-$ 4_$ F?$ 7GG$ 1J$ O(=?$ *GH$ [>@#0.=$ BSC?$ 71J$ (+(=*?$ 71J$ TJ%P?$ 71J$ ^M

1#0@+45.#5"+3.=$+3A$40.5#+-#$ ,3",2,5.0-$@.@95+,=R;$)/5#0$I#35=#$-5,00,3I?$ 5"#$ =,I"5$1#120+3#$

/0+@5,.3$B+-$@#350,/6I#A$+5$*c?GGG$#)-% /.0$7$".60$+5$7G$l(;$!"#$4#==#5$B+-$5"#3$0#-6-4#3A#A$

6-,3I$ +$ T.55#0M5>4#$ ".1.I#3,W#0$ ,3$ 5"#$ -.=62,=,W+5,.3$ 26//#0$ N-+1#$ @.14.-,5,.3$ +-$ 40#M

-.=62,=,W+5,.3$26//#0R$+3A$8MA.A#@>=M^MAM1+=5.-,A#$N::JR$NA#5#0I#35S40.5#,3$0+5,.$./$Qi7R;$!"#$

-6-4#3-,.3$ N!:JR$ B+-$ 9#45$ 63A#0$ I#35=#$ -5,00,3I$ /.0$ *G$ 1,365#-$ +5$ 0..1$ 5#14#0+560#;$

E3-.=62=#$1+5#0,+=-$B#0#$0#1.C#A$2>$@#350,/6I+5,.3$/.0$7$".60$+5$7Gl($+3A$7GG?GGG$#)-;$!"#$

-64#03+5+35$@.35+,3-$5"#$-.=62,=,W#A$40.5#,3-$N%:JR;$

3.2.5 FORMATION OF PHOSPHO-INTERMEDIATE ENZYME ON MEMBRANE FRACTION

P.01+5,.3$./$5"#$4".-4".#3W>1#$,35#01#A,+5#$/0.1$)!T$.3$1#120+3#$/0+@5,.3-$N7GkIR$

B+-$4#0/.01#A$,3$+$7GG$k=$0#+@5,.3$1,D560#$@.35+,3,3I$7]G$1J$O(=?$7F$1J$_#4#-?$4_$F;G?$7$

1J$:!!?$8$1J$V+VQ?$+3A$G;7$1J$(+(=*?$8G$1J$&[!)?$7kJ$!"+4-,I+0I,3;$

!"#$0#+@5,.3?$@+00,#A$.65$.3$ ,@#$ /.0$QG$-?$B+-$-5+05#A$2>$5"#$+AA,5,.3$./$7k=$./$*k(,Sk=$$$

mnMQQTo)!T$ N)1#0-"+1$\,.-@,#3@#-R$ +3A$ -5.44#A$2>$ +AA,3I$ ]H$ 50,@"=.0.+@#5,@$ +@,A?$ 7G$1J$

4".-4".0,@$+@,A?$+3A$7$1J$)!T;$!"#$-+14=#-$B#0#$9#45$.3$,@#$/.0$78$1,3$+3A$5"#3$4#==#55#A$

2>$@#350,/6I+5,.3$+5$78?GGG$I+C$/.0$Q$1,3$+5$dl(;$T#==#5-$B#0#$B+-"#A$5B.$5,1#-$,3$5"#$-+1#$

26//#0$+3A$/,3+==>$0#-6-4#3A#A$,3$1.A,/,#A$%:%MT)[&$-+14=#$26//#0$N7GG$1J$!0,-M_(=?$4_$Y?$

7;d$ J$ !M1#0@+45.#5"+3.=?$ dH$ %:%?$ 7$ 1J$ &:!)?$ Y$ J$ 60#+$ +3A$ G;G8H$ 20.14"#3.=$ 2=6#R;$

T".-4".0>=+5#A$40.5#,3-$B#0#$-#4+0+5#A$2>$#=#@50.4".0#-,-$.3$%:%$4.=>+@0,=+1>A#$I0+A,#35$

I#=-$ N8M7GHR?$+@@.0A,3I$5.$%+09+A,$#5$+=;$ N%+09+A,?$\;$#5$+=$7cY]R;$)/5#0$ /,D+5,.3$ ,3$F;8H$+@#5,@$

+@,A$+3A$A0>,3I?$ 5"#$I#=-$B#0#$+3+=>W#A$2>$+65.0+A,.I0+4">$ 5"0.6I"$(>@=.3#$T=6-$T".-4".0$

E1+I#0$NT#09,3&=1#0R;$

72

3.2.6 PURIFICATION OF HSERCA2AR863G

T60,/,@+5,.3$ ./$ 5"#$ "%#0@+*+'Y]Q[$ 40.5#,3$ B+-$ @+00,#A$ .65$ #,5"#0$ 2>$ +//,3,5>$

@"0.1+5.I0+4">$B,5"$+C,A,3$+I+0.-#$0#-,3$ N%./5=,39$%./5$'#=#+-#$)C,A,3$'#-,3?$T0.1#I+R$+3A$

B,5"$5"#$6-#$./$+C,A,3M@.+5#A$1+I3#5,@$3+3.4+05,@=#-$NJ+I0.?$J;$#5$+=?$*G7*R;$$

E3$ 5",-$ @"+45#0?$ .3=>$ 5"#$ 40.@#A60#$ ./$ +C,A,3M+//,3,5>$ @"0.1+5.I0+4">$ ,-$ 0#4.05#A;$ P.0$

1+I3#5,@$ -#4+0+5.0$ ->-5#1$B,5"$+C,A,3M@.+5#A$1+I3#5,@$3+3.4+05,@=#-?$ -##$ 5"#$4+4#0$ ,3$ 5"#$

+44#3A,D;$

3.2.7 BATCH PURIFICATION WITH AVIDINE AGAROSE

!"#$ -64#03+5+35$ .25+,3#A$ +/5#0$ -.=62,=,W+5,.3$ ./$ 5"#$ 40.5#,3$ B+-$ +44=,#A$ 5.$ 8$ 1=$

./$%./5=,39$%./5$'#=#+-#$)C,A,3$'#-,3?$40#C,.6-=>$#K6,=,20+5#A$B,5"$5"#$-.=62,=,W+5,.3$26//#0$+3A$

,3@62+5#A$.C#03,I"5$+5$d$l($63A#0$I#35=#$-5,00,3I;$!"#$-64#03+5+35$B+-$5"#3$@.==#@5#A$+3A$5"#$

0#-,3$B+-$B+-"#A$/,0-5$B,5"$7G$@.=613$C.=61#$N(XR$./$",I"$-+=5$B+-",3I$26//#0$N8G$1J$JZT%M

!0,-?$4_$F;G?$7J$O(=?$*GH$I=>@#0.=$NBSBR?$71J$(+(=*$+3A$G?8$1IS1=$::JR$+3A$=+5#0$B,5"$7G$

(X$./$=.B$-+=5$B+-",3I$26//#0$N8G$1J$JZT%M!0,-?$4_$F;G?$7GG$1J$O(=?$*GH$I=>@#0.=$NBSBR?$*?8$

1J$(+(=*$+3A$G?8$1IS1=$::JR;$!"#$0#-,3$B+-$5"#3$0#-6-4#3A#A$,3$*$1=$./$=.B$-+=5$B+-",3I$

26//#0$ @.35+,3,3I$!"0.12,3$ NQ8G$63,5-?$ %,I1+M)=A0,@"R$ +3A$ ,3@62+5#A$.C#03,I"5$ +5$ d$ l(;$ !"#$

40.5#+-#$+@5,C,5>$B+-$-5.44#A$2>$+AA,3I$*;8$1J$TJ%P$N4"#3>=1#5"+3#-6=/.3>=/=6.0,A#R$+3A$

5"#$-64#03+5+35$B+-$5"#3$@.==#@5#A;$$

3.2.8 GEL-FILTRATION

!"#$ +//,3,5>M460,/,#A$ "%&'()*+'Y]Q[$ .25+,3#A$ 2>$ +C,A,3$ 0#-,3$ @"0.1+5.I0+4">$ B+-$

@.3@#350+5#A$2>$X,C+-4,3M*G$N8G?GGG$JB$@65$.//?$%+05.0,6-R$+3A$+44=,#A$5.$+$%64#0A#D$*GGM_'$

7GSQGG$ N[&$ _#+=5"@+0#$ \,.M%@,#3@#-?$ a44-+=+?$ %B#A#3R$ +5$ G;8$ 1US1,3;$ !"#$ -.=C#35$ B+-$

@.3-5,565#A$./$8G$1J$J.4-M!0,-?$4_$F;G?$@.35+,3,3I$7GG$1J$O(=?$*GH$I=>@#0.=?$71J$(+(=*?$

+3A$G;8$1IS1=$./$(7*&Y$NA.A#@>=$.@5+#5">=#3#$I=>@.=$1.3.#5"#0R;$!"#$/0+@5,.3-$B#0#$4..=#A$

+3A$@.3@#350+5#A$2>$X,C+-4,3M*G$635,=$0#+@",3I$+$C.=61#$./$"$8G$µ=;$P0+@5,.3-$@.00#-4.3A,3I$

5.$1.3.1#0,@$"%#0@+*+'Y]Q[$B#0#$5"#0#/.0#$4..=#A$+3A$@.3@#350+5#A$5.$7*$1IS1=;$

HETEROLOGOUS EXPRESSION AND AFFINITY PURIFICATION OF HUMAN SERCA 2A IN SACCHAROMYCES CEREVISIAE

73

3.2.9 PROTEIN RECONSTITUTION AND CRYSTALLIZATION TRIALS

\#/.0#$ @0>-5+==,W+5,.3$ 50,+=-?$ 5"#$ -+14=#$ @.35+,3,3I$ 5"#$ %&'()*+$ 40.5#,3$ B+-$

-644=#1#35#A$B,5"$4".-4".=,4,A$:ZT($N7?*MA,.=#.>=M-3MI=,@#0.MQM4".-4".@".=,3#R$5.$0#+@"$+$

(7*&YS:ZT($0+5,.$./$Qi7$NBSBR?$7G$1J$(+(=*?$+3A$71J$)JTT(T$N!M#M1#5">=#3+A#3.-,3#M8eM

50,4".-4"+5#R;$ !"#$ -+14=#$ B+-$ #K6,=,20+5#A$ .C#03,I"5$ +5$ d$ l($ +3A$ 5"#3$ -62L#@5#A$ 5.$

6=50+@#350,/6I+5,.3$ N7YG?GGG$I+C$ /.0$7G$1,365#-R$ 5.$ 0#1.C#$+II0#I+5,.3;$(0>-5+==,W+5,.3$ 50,+=-$

B#0#$4#0/.01#A$2>$ 5"#$C+4.60$A,//6-,.3$1#5".A$ ,3$G;8$<$G;8$µ=$"+3I,3I$A0.4-$#K6,=,20+5,3I$

+I+,3-5$ 8GG$ µ=$ ./$ 26//#0$ @.35+,3,3I$ **G$ 1J$ -.A,61$ +@#5+5#?$ dH$ 5M265+3.=?$ 8$ 1J$ ^M

1#0@+45.#5"+3.=?$78H$I=>@#0.=?$YM7]H$T&[$]GGG;$

3.2.10 SODIUM DODECYL SULFATE-POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE)

%:%MT)[&$B+-$ 4#0/.01#A$ +-$ A#-@0,2#A$ 2>$ U+#11=,$ NU+#11=,?$ a;$ #5$ +=?$ 7cFGR?$ 6-,3I$ +$

7GH$4.=>+@0>=+1,A#$I#=$,3$+$C#05,@+=$-=+2$I#=$+44+0+56-$N_.#/#0$%@,#35,/,@$E3-5061#35R;$T0.5#,3$

-+14=#-$B#0#$40#4+0#A$,3$+$A#3+560,3I$-+14=#$26//#0$@.35+,3,3I$7;d$J$*M1#0@+45.#5"+3.=?$Y$

J$60#+$+3A$7$1J$&:!);$!"#$-+14=#-$N*G$kUR$B#0#$A,=65#A$,3$+3$#K6+=$C.=61#$./$A#3+560,3I$

-+14=#$26//#0$+3A$2.,=#A$+5$7GG$l($/.0$7$1,3;$&=#@50.4".0#-,-$B+-$4#0/.01#A$+5$7*G$X.=5$+3A$

*8$1)$/.0$7$";$!"#$063$B+-$-5.44#A$B"#3$5"#$A>#$/0.35$B+-$*$5.$Q$11$+B+>$/0.1$5"#$2.55.1$

#AI#$./$5"#$I#=;$!"#$I#=$B+-$5"#3$-5+,3#A$6-,3I$5"#$(..1+--,#$\0,==,+35$\=6#$NG;G8H$(..1+--,#$

2=6#$'?$dGH$1#5"+3.=?$7GH$+@#5,@$+@,AR$NV#6".//?$X;$#5$+=?$7cY8R;$ $:#-5+,3,3I$B+-$4#0/.01#A$

2>$B+-",3I$5"#$I#=-$-#C#0+=$5,1#-$B,5"$#,5"#0$B+5#0$.0$7GH$+@#5,@$+@,A;$

3.2.11 WESTERN BLOTTING

g#-5#03$ 2=.55,3I$ B+-$ 4#0/.01#A$ +@@.0A,3I$ 5.$ 5"#$1.A,/,#A$1#5".A$ ./$ !.B2,3$ #5$ +=;$

N!.B2,3$_;$ !;$ #5$ +=?$ 7cFcR$ )/5#0$ #=#@50.4".0#-,-?$ 5"#$ I#=$B+-$ -.+9#A$ ,3$ @.=A$ 50+3-/#0$ 26//#0$

NG;7c*$J$I=>@,3#?$*8$1J$50,-?$4_$Y;Q?$+3A$7;Q$1J$%:%R$/.0$7$"$5.$0#1.C#$%:%$+3A$+3>$#D@#--$

./$#=#@50.A#$26//#0;$)$-"##5$./$3,50.@#==6=.-#$1#120+3#$N4.0#$-,W#$G;d8$k1R$B+-$6-#A$N78$p$78$

@1R$ +3A$ 5"#3$B+-$ ,11#0-#A$ ,35.$ 5"#$ 50+3-/#0$ 26//#0;$ !.$ +C.,A$ @.35+1,3+5,.3?$ /.0@#4-$ +3A$

74

I=.C#-$B#0#$6-#A$B"#3$"+3A=,3I$5"#$1#120+3#;$T0.5#,3-$50+3-/#0$B+-$.25+,3#A$B,5"$+$J,3,M

!0+3-M\=.5$ &=#@50.4".0#5,@$ 50+3-/#0$ (#==$ N\,.M'+AR$ +5$ 7GG$ X$ +3A$ Q8G$ 1)$ /.0$ *$ ";$ )/5#0$ 5"#$

50+3-/#0?$5"#$3,50.@#==6=.-#$1#120+3#$B+-$I#35=>$0.@9#A$,3$2=.@9,3I$26//#0$@.3-5,565#A$./$QH$

NBSCR$\%)$,3$!\%$26//#0$N*G$1J$!0,-M_(=?$4_$F;]?$78G$1J$V+(=R$/.0$*$"$+5$0..1$5#14#0+560#$

5.$2=.@9$63.@@64,#A$-,5#-;$!"#$1#120+3#$B+-$5"#3$ ,3@62+5#A$B,5"$4.=>@=.3+=$+35,2.A>$+35,$

%#0@+$ N%&'()7S*SQ$ N_QGGR$%+35+M(06W$\,.5#@"3.=.I>R$+5$+$7i8GG$A,=65,.3$ ,3$!\%$.C#03,I"5$+5$

dl($,3$+$0.@9,3I$1.5,.3;$!"#$1#120+3#$B+-$B+-"#A$Q$5,1#-$B,5"$5"#$!\%$26//#0?$@.35+,3,3I$

G;8H$!B##3$*G;$!"#$1#120+3#$B+-$ 5"#3$ ,3@62+5#A$B,5"$1.6-#$+35,0+22,5$@.3L6I+5#A$B,5"$

".0-#0+A,-"$ 4#0.D,A+-#$ /.0$ *$ "$ +5$ 0..1$ 5#14#0+560#$ ,3$ +$ 7i*GGG$ A,=65,.3$ ,3$ !\%;$ )/5#0$ +3$

+AA,5,.3+=$B+-",3I$ -5#4$ NQ$ 5,1#-$B,5"$!\%$+3A$G;8H$!B##3$*GR?$ 5"#$2.63A$+35,2.A,#-$B#0#$

0#C#+=#A$B,5"$)1#0-"+1$&(U$0#+I#35$N[&$_#=5"@+0#$+3A$U,/#$%@,#3@#R$,3$+$O.A+9$E1+I#$%5+5,.3$

dGGGJJ$T0.$NO.A+9R;$!"#$-+1#$40.@#A60#$B+-$4#0/.01#A$/.0$A#5#@5,3I$+==$ 5"#$2,.5>3,=+5#A$

40.5#,3-?$B",@"$B+-$,3@62+5#A$B,5"$+C,A,3$4#0.D,A+-#$40.2#$N)TR$N%,I1+$)=A#0,@"R$+5$+$7i*GGG$

A,=65,.3;$

3.3 RESULTS AND DISCUSSION

3.3.1 OVER-EXPRESSION OF HSERCA2AR863G IN S. CEREVISIAE

_61+3$ %&'()$ ,-./.01$ *+$ N'Y]Q[R$ 40.5#,3$ B+-$ #D40#--#A$ ,3$ 9$$ /.2.-"*").?$ B",@"$ B+-$

40#C,.6-=>$6-#A$/.0$5"#$#D40#--,.3$./$.5"#0$(+*<M)!T+-#-$NU#3.,0?$[;$#5$+=?$*GG*R$+3A$/.0$0+22,5$

%&'()7+$ Nj,A#39.$ #5$ +=;?$ *GG]R;$ !",-$ "#5#0.=.I.6-$ ->-5#1$ +44#+0#A$ 5.$ 2#$ 5"#$ 1.0#$

+440.40,+5#$/.0$5"#$.C#0M#D40#--,.3$./$/63@5,.3+=$1+11+=,+3$1#120+3#$40.5#,3-?$-,3@#$2.5"$

5"#$ 4.-5M50+3-=+5,.3+=$ 1.A,/,@+5,.3$ ->-5#1$ +3A$ 5"#$ (+*<$ ".1#.-5+-,-$ 1#@"+3,-1$ +0#$

@.3-#0C#A$,3$>#+-5;$$

!"+39-$ 5.$ 5"#$ 4`#:T]G$ C#@5.0?$ 5"#$ "%&'()*+$ I#3#$ B+-$ ,3-#05#A$ ,3$ 5"#$ -+1#$ @.A,3I$

/0+1#$./$ !"0$ @=#+C+I#$ -,5#$ +3A$\):$ N2,.5,3$ +@@#45.0$ A.1+,3R$ -#K6#3@#-$2>$ 5"#$[+4M0#4+,0M

@=.3,3I$ N_.1.=.I.6-$ 0#@.12,3+5,.3R$ 5#@"3,K6#?$ 5.$ +==.B$ #D40#--,.3$ ./$ /6-,.3$ 40.5#,3$

HETEROLOGOUS EXPRESSION AND AFFINITY PURIFICATION OF HUMAN SERCA 2A IN SACCHAROMYCES CEREVISIAE

75

%#0@+*+M\):$ ,3$ 9$% /.2.-"*").;$ U+5#0?$ +$ 4.,35$ 165+5,.3$ B+-$ I#3#0+5#A$ 5.$ 0#1.C#$ +$ /605"#0$

5"0.12,3$@=#+C+I#$-,5#$B,5",3$5"#$-#K6#3@#;$

!"6-?$5"#$0#@.12,3+35$40.5#,3$B+-$#D40#--#A$63A#0$5"#$@.350.=$./$+$I+=+@5.-#M,3A6@,2=#$

40.1.5#0?$B"#0#+-$ 5"#$ 2,.5,3>=+5,.3$ 40.@#--$ ./$ 5"#$ 40.5#,3?$ .@@600,3I$ A,0#@5=>$ ,3$ >#+-5?$ "+-$

40.C,A#A$ +$ /+-5$ +3A$ #//,@,#35$ 460,/,@+5,.3$ -50+5#I>;$ !"#$ #D40#--,.3$ ./$ 5"#$ 40.5#,3$ B+-$

4#0/.01#A$#,5"#0$ ,3$ +$".1#$1+A#$2,.0#+@5.0$ NP,I60#$QR$ .0$ ,3$ *$ =$ /=+-9-$ @.35+,3,3I$#+@"$3.5$

1.0#$ 5"+3$8GG$1=?$ +@@.0A,3I$ 5.$ 5"#$40.5.@.=$ 0#4.05#A$2>$(+0A,;$ N(+0A,?$:;$ #5$ +=?$ *G7GR;$g#$

B#0#$+2=#$5.$0#@.C#0$+2.65$8G$I0+1-$./$>#+-5$/.0$=,5#0$./$@6=560#;$%,3@#$,3$C,C.$5"#$2,.5,3>=+5,.3$

0#+@5,.3$ .3=>$ .@@60-$ B,5"$ 40.4#0=>$ /.=A#A$ /6-,.3$ 40.5#,3?$ B#$ "+C#$ 2##3$ +2=#$ 5.$ -#=#@5$ 5"#$

+@5,C#$(+*<M)!T+-#-$1.=#@6=#-$+/5#0$>#+-5$#D40#--,.3$2>$6-,3I$5"#$+C,A,3$4#0.D,A+-#$40.2#;$E3$

+AA,5,.3?$5"#$)!TM+-#$+@5,C,5>$B+-$A#5#@5#A$2>$+65.0+A,.I0+4">;$

$

$

$

$

$

$

$

%

!"#$%A$%F-.2C.672.**"18%14%59:;<=>);?@AB%"8%9$%/.2.-"*").$%M)2#.C*/)(.%.672.**"18%5)*%H..8%7.2412+.,%HK%3*"8#%)%

51+.%+),.%2.)/012G%)((1W"8#%3*%01%*.0%05.%7)2)+.0.2*%14%/.((%#21W05%,32"8#%05.%).21H"/%#21W"8#%75)*.%)0%>?%Y<%

)8,%05.%)8).21H"/%.672.**"18%75)*.%)0%&?%Y<$%%

76

$

$

!"#$% Z$%X.*0.28% H(10% )8)(K*"*% 14% 42)/0"18*% 421+% 05.%+.+H2)8.% 72.7)2)0"18% HK% 3*"8#% )-","8CU;'% 721H.$% =((% 05.%

H"10"8K()0.,%7210."8*%W.2.%,.0./0.,%HK% 05.%721H.G% 2.-.)("8#% 0W1%.8,1#.813*%H"10"8K()0.,%7210."8*%.672.**.,% "8%

K.)*0% [7327(.% )221W*\$% 9)+7(.*% W.2.% (1),.,% )*% *51W8% H.(1W]% P<:G% 010)(% /23,.% .602)/0I% '&G% 7.((.0% &I% 9&G%

*37.28)0)80%&I%'>G%7.((.0%>G%/122.*718,"8#%01%05.%5"#5%+.+H2)8.*I%9>G%*37.28)0)80%>I%'AG%7.((.0%>G%/122.*718,"8#%

01% 05.% ("#50% +.+H2)8.*I% 9AG% *37.28)0)80% A% )8,%^G% +1(./3()2% W."#50% +)2L.2$% P5.% K.)*0% H"10"8K()0.,% 7210."8*%

/122.*718,% 01% =/.0K(C<1=% /)2H16K()*.% [=/1=$% /)2H$\% )8,% 7K23-)0.% /)2H16"()*.% [7K2$% /)2H$\$% P5.% H(3.% )221W%

"8,"/)0.*%05.%59:;<=>);?@ABCD=E%7210."8$%

!

$

!"#$%_$%!12+)0"18%14%751*751C"80.2+.,")0.%.8VK+.%18%05.%+.+H2)8.%42)/0"18$%<11+)**".%H(3.%*0)"8.,%9E9C'=B:%

[(.40\% )8,%)3012),"1#2)+% [2"#50\% 14% 05.% `aCAA'b%=P'C751*7512K()0.,%59.2/)>);?@AB%+.+H2)8.*% "8% 72.*.8/.% 14%

N$&%+^%<)<(>%[M)8.%&\G%_N%+^%:BP=%[M)8.%>\G%&c^%P5)7*"#)2#"8%[M)8.%A\$%%%

HETEROLOGOUS EXPRESSION AND AFFINITY PURIFICATION OF HUMAN SERCA 2A IN SACCHAROMYCES CEREVISIAE

77

3.3.2 HUMAN SERCA, ISOFORM 2A, PURIFICATION

)2.65$d$U$./$>#+-5$@6=560#$B#0#$6-#A$/.0$#+@"$460,/,@+5,.3$50,+=?$/0.1$B",@"$+2.65$*GG$I$

./$A0>$@#==$4#==#5$B+-$0#@.C#0#A;$!"#$#-5,1+5#A$5.5+=$40.5#,3$@.35#35$ ,3$ 5"#$ =,I"5$1#120+3#$

/0+@5,.3$B+-$+2.65$*]$1I;$

%,3@#$ 0#@.12,3+35$ "61+3$ %&'()*+$ N"%&'()*+'Y]Q[M\):R$ @.14#5#-$ B,5"$ 5"#$

#3A.I#3.6-$2,.5,3>=+5#A$40.5#,3-$/.0$5"#$2,3A,3I$5.$+C,A,3?$+3$+AA,5,.3+=$460,/,@+5,.3$-5#4$B+-$

0#K6,0#A$,3$.0A#0$5.$,3@0#+-#$5"#$0#@.C#0>$./$5"#$0#@.12,3+35$40.5#,3;$&=65,.3$./$5"#$40.5#,3$

B+-$+@",#C#A$2>$.C#03,I"5$ ,3@62+5,.3$./$ 5"#$40.5#,3M2.63A$0#-,3$B,5"$ 5"0.12,3;$!"#$ /6-,.3$

"%&'()*+'Y]Q[$ 40.5#,3$ B+-$ 5"#3$ 0#=#+-#A$ ,3$ 5"#$ -64#03+5+35?$ B",=#$ 5"#$ \):$ A.1+,3$

0#1+,3#A$,11.2,=,W#A$.35.$5"#$0#-,3;$)2.65$7$1I$./$8GH$460,/,#A$40.5#,3$B+-$.25+,3#A$/0.1$

5"#$+//,3,5>$460,/,@+5,.3;$(..1+--,#M-5+,3#A$T)[&M#=#@50.4".0#-,-$+3A$g#-5#03$2=.5$ /.==.B#A$

5"#$460,/,@+5,.3$-5#4-?$/0.1$@06A#$>#+-5-$=>-+5#$5.$5"#$I#=M/,=50+5,.3$460,/,#A$40.A6@5;$)-$-".B3$

,3$P,I60#$]?$+$1+L.0$2+3A$./$+2.65$YG$9:+$,-$C,-,2=#$,3$(..1+--,#M-5+,3#A$I#=-;$!",-$2+3A$B+-$

+=-.$ A#5#@5#A$ 2>$g#-5#03$ 2=.5$ +3+=>-#-$B,5"$ 0+22,5$ 4.=>@=.3+=$ +35,M%&'()$ NP,I60#$ FR$ +3A$ ,-$

5"#0#/.0#$ +550,265+2=#$ 5.$ "%&'()*+'Y]Q[;$ !"#$ A,//#0#3@#$ 2#5B##3$ 5"#$ +44+0#35$1.=#@6=+0$

B#,I"5$./$460,/,#A$%&'()*+'Y]Q[$NYG$9:+R$+3A$5"#$#D4#@5#A$B#,I"5$0#4.05#A$,3$5"#$=,5#0+560#$

N778$9:+R$,-$+550,265+2=#$5.$5"#$#//#@5$./$5"#$A#5#0I#35$.3$5"#$#=#@50.4".0#5,@$1.2,=,5>$./$5"#$

40.5#,3$ ,3$ %:%MT)[&?$ +-$ ./5#3$ 0#4.05#A$ /.0$ ">A0.4".2,@$ 40.5#,3-$ ,3$ 5"#$ 40#-#3@#$ ./$

A#5#0I#35-$N'+5"?$);$#5$+=?$*GGcR;$P,3+==>?$+$I#=M/,=50+5,.3$-5#4$NP,I60#-$Y$+3A$cR$B+-$4#0/.01#A$

5.$ ,3@0#+-#$ 40.5#,3$ 460,5>$ +3A$ 5.$ #D@"+3I#$ 5"#$ A#5#0I#35$ /.0$ @0>-5+==,W+5,.3$ 50,+=-;$ !"#$ /,3+=$

>,#=A$B+-$+2.65$8GG$kI$./$FGH$460,/,#A$40.5#,3;$!"#$+1.635$./$0#@.12,3+35$0+22,5$%&'()M7+$

B+-$ 40#C,.6-=>$ #-5,1+5#A$ 5.$ 2#$ +2.65$ QH$ ./$ 5"#$ 5.5+=$ 40.5#,3$ @.35#35$ ,3$ 5"#$ 1#120+3#$

/0+@5,.3$./$9$%/.2.-"*").%N(+0A,?$:;$#5$+=?$*G7GR$\#@+6-#$./$5"#$",I"$-#K6#3@#$-,1,=+0,5>$2#5B##3$

0+22,5$%&'()7+$+3A$"%&'()*+'Y]Q[M\):?$,5$,-$4.--,2=#$5.$+--61#$5"+5$5"#$#D40#--,.3$=#C#=-$

./$5"#$5B.$40.5#,3-$,3$>#+-5$+0#$5"#$-+1#;$!"#0#/.0#?$2+-#A$.3$5",-$+--6145,.3?$B#$@+=@6=+5#A$

+$>,#=A$,3$5"#$460,/,@+5,.3$40.@#--$./$+2.65$]dH;$$

78

$

!"#$%@$%'32"4"/)0"18%14%59:;<=>);?@AB%HK%)-","8%)44"8"0K%/521+)01#2)75K$%<11+)**".%H(3.%*0)"8"8#%9E9C'=B:%14%

*)+7(.*%/1((./0.,%,32"8#%)44"8"0K%732"4"/)0"18$%9)+7(.*%412%9E^%01%:Z%42)/0"18*%W.2.%&NC41(,$%9)+7(.*%W.2.%(1),.,%

)*%*51W8%H.(1W]%PE^G%+.+H2)8.%7.((.0$%9E^G%*1(3H"("V.,%42)/0"18$%!PG%4(1W05213#50$%U9%)8,%M9G%W)*5"8#%)0%&^%

)8,%_N+^%Q<(G%2.*7./0"-.(K$%;:9%2.*"8%W"05%H138,%9:;<=>);?@ABCD=E$%:&G%:>G%:A%)8,%:ZG%.(30.,%42)/0"18*%421+%

)44"8"0K%732"4"/)0"18$%^G%+1(./3()2%W."#50%+)2L.2$%D(3.%)221W*%"8,"/)0.%05.%71*"0"18%14%05.%59:;<=>);?@ABCD=E%

)8,%59:;<=>);?@AB%7210."8*$%%

$

$

!"#$% d$% '32"4"/)0"18% 14% 59:;<=>);?@AB% HK% )-","8% )44"8"0K% /521+)01#2)75K$%X.*0.28% H(10% )8,% "++381,.0./0"18%

3*"8#%)80"C9:;<=&e>eA%)80"H1,K$%9)+7(.*%412%9E^%01%;:9%42)/0"18*%W.2.%>NC41(,G%.(30.,%42)/0"18*%*)+7(.*%[:\%W)*%

711(.,%)8,%_NC41(,$%%

HETEROLOGOUS EXPRESSION AND AFFINITY PURIFICATION OF HUMAN SERCA 2A IN SACCHAROMYCES CEREVISIAE

79

%

%

!"#$% ?$% 9:<C!'M<%732"4"/)0"18% *0.7% 412% /2K*0)(("V)0"18%)00.+7*$% P5.% .(30"18%7214"(.% )0% >?N%8+%14% 59:;<=>);?@AB%

421+% *"V.% .6/(3*"18% /521+)01#2)75K% )40.2% )44"8"0K% /521+)01#2)75K$% P5.% )H*1270"18% 7.)L*% /122.*718,% 01%

59:;<=>);?@AB%)8,%0521+H"8G%2.*7./0"-.(K$%

%

$%

!"#$% f$% 9:<C!'M<% 732"4"/)0"18% *0.7% 412% /2K*0)(("V)0"18% )00.+7*$% <11+)**".% H(3.% *0)"8"8#% 9E9C'=B:% 14% 05.% .(30.,%

42)/0"18*%/122.*718,"8#%01%05.%)H*1270"18%7.)L%*51W*%05)0% 05.%59:;<=>);?@AB%73+7% "*%72.*.80% "8%132%7210."8%

*1(30"18%)0%dNg%14%732"0K$%%

80

3.3.3 CRYSTALLIZATION TRIALS

%,3@#$5"#$@0>-5+==,W+5,.3$@.3A,5,.3-$ /.0$%&'()7+$ ,-./.01$+0#$93.B3$+3A$0.65,3#=>$6-#A$

5.$.25+,3$@0>-5+=-$./$5"#$3+5,C#$0+22,5$%&'()$40.5#,3?$+3A$@.3-,A#0,3I$5"#$C#0>$=.B$+1.635$./$

460#$40.5#,3$.25+,3#A?$B#$A#@,A#A$5.$6-#$5"#-#$@.3A,5,.3-$5.$4#0/.01$-.1#$50,+=-$2>$"+3I,3IM

A0.4$ C+4.60MA,//6-,.3$ 5#@"3,K6#;$ a3/.0563+5#=>?$ -.$ /+0$ B#$ +0#$ 3.5$ +2=#$ 5.$ .25+,3$ -6,5+2=#$

@0>-5+=-$/.0$A,//0+@5,.3$+3+=>-,-;$

3.4 CONCLUSIONS

:#-4,5#$ -,I3,/,@+35$ +3A$ @.3-,A#0+2=#$ 0#@#35$ ,140.C#1#35-?$ 5"#$ #D40#--,.3$ +3A$ 5"#$

-62-#K6#35$ 460,/,@+5,.3$ ./$ /63@5,.3+==>$ /.=A#A$1#120+3#$ 40.5#,3-$ ,3$ -6//,@,#35$ +1.635-$ /.0$

/63@5,.3+=$+3A$ -506@560+=$ -56A,#-$ ,-$ -5,==$ +$ @"+==#3I,3I$ 5+-9q$B#$6-#A$ 5"#$40.4.-#A$ ->-5#1$ 5.$

460,/>$ +$ 1#120+3#$ 40.5#,3?$ 5"#$ 0#@.12,3+35$ "%&'()*+;$ P#B$ #D40#--,.3$ ->-5#1-$ +0#$

-6@@#--/6==>$ 6-#A$ 5.$ 40.A6@#$ 1,==,I0+1$ K6+35,5,#-$ ./$ 1#120+3#$ 40.5#,3-;$ E3$ 0#@#35$ >#+0-?$

>#+-5$"+-$2#@.1#$ 5"#$ -#@.3A$1.-5$4.46=+0$1#120+3#$40.5#,3-$#D40#--,.3$ ->-5#1?$+/5#0$:$%

/1(";$E5$,-$1.0#$@.-5M#//#@5,C#$5"+3$5"#$#D40#--,.3$,3$1+11+=,+3$.0$,3-#@5$@#==$=,3#-$+3A$,5$./5#3$

40.A6@#-$ ",I"#0$ >,#=A-;$ %506@560+=$ -56A,#-$ 0#K6,0#$ 5"+5$ 5"#$ 460,/,#A$ 1#120+3#$ 40.5#,3$ ,-$

@"#1,@+==>$ +3A$ @.3/.01+5,.3+==>$ ".1.I#3#.6-?$ -5+2=#$ +5$ 0#=+5,C#=>$ ",I"$ @.3@#350+5,.3-$ +3A$

+C+,=+2=#$ ,3$ 1,==,I0+1$ +1.635-;$ g#$ "+C#$ 2##3$ +2=#$ 5.$ 460,/>$ 5"#$ 0#@.12,3+35$ "%&'()*+?$

#D40#--#A$,3$>#+-5?$,3$5"#$40#-#3@#$./$.5"#0$@.14#5,5,C#$2,.5,3>=+5#A$40.5#,3-$+3A$A#5#0I#35-;$

!",-$ ->-5#1$+==.B#A$6-$ 5.$ 0#+@"$ 5"#$40.1,-,3I$ >,#=A$ ./$ 8GG$kI?$ +$ -6//,@,#35$ +1.635$ /.0$ 5"#$

@"+0+@5#0,W+5,.3$./$1#120+3#$40.5#,3-$2>$,3$C,50.$+440.+@"#-;$$

3.5 ACKNOWLEDGEMENTS

g#$B+35$5.$+AA0#--$-4#@,+=$5"+39-$5.$:0;$J+I0.$J;?$/0.1$:#4+051#35$./$(.14+0+5,C#$

\,.1#A,@,3#$+3A$P..A$%@,#3@#?$T+A6+?$ /.0$ 9,3A=>$40.C,A,3I$+C,A,3r3+3.4+05,@=#-$ +3A$ 5.$:0;$

X#3#0+3A.$);$/0.1$:#4+051#35$./$\,.1#A,@+=$%@,#3@#-?$T+A6+?$/.0$4#0/.01,3I$nMQQTM)!T+-#$

)--+>;$

!

CHAPTER IV

!

EXPRESSION AND PURIFICATION OF

SWIPROSIN1/EFHD2, A NOVEL HUMAN

TAU-ASSOCIATED PROTEIN

!

!

!

82

CONTENTS

4.1 INTRODUCTION 83

4.2 MATERIALS AND METHODS 83

4.2.2 HETEROLOGOUS EXPRESSION OF HUMAN EFHD2 IN E. COLI 83

4.2.3 IMAC PURIFICATION AND SIZE EXCLUSION CHROMATOGRAPHY 84

4.2.4 SDS-PAGE AND WESTER BLOT ANALYSIS 84

4.2.5 LIMITED PROTEOLYSIS 85

4.2.6 CRYSTALLIZATION 85

4.3 RESULTS AND DISCUSSION 86

!

!

!

!

!

EXPRESSION AND PURIFICATION OF SWIPROSIN1/EFHD2, A NOVEL HUMAN TAU-ASSOCIATED PROTEIN

83

4.1 INTRODUCTION

"#$%&! '(! )! *+,-.! /)./'01!2'*%'*3! 45+6-'*!1+5-! /+*(-5,-%! )1+*3! 6$-! (4-/'-(7! 8*! 9)/6!

6$-5-! )5-! 65)/-(! 95+1! !"# $%$&'()! 6+! *"# )'+,$()7! :5'3'*)..;<! 6$-! "#$%&! 45+6-'*! $)(! 2--*!

'%-*6'9'-%!'*!=>?!)*%!=>@!A!/-..(!)*%!1)(6!/-..(<!206!6$-!$'3$-(6!-B45-(('+*!+9!6$-!45+6-'*!$)(!

2--*! %-6-/6-%! '*! 6$-! /-*65).! *-5,+0(! (;(6-1<! C$-5-! '6! $)(! 2--*! 9+0*%! )((+/')6-%! C'6$!

4)6$+.+3'/).! 9+51(! +9! 6$-! 1'/5+6020.-D)((+/')6-%! 45+6-'*! 6)07! E4-/'9'/)..;<! "#$%&! 9+51(! )!

/+14.-B! C'6$! 6$-! $01)*! A)0FGHIJ! 106)*6! '*! 6$-! KLFJG! 6)0+4)6$;! 1+0(-! 1+%-.<! C$'/$!

%-,-.+4(! *-05+3-*-5)6'+*! '*! )3-D%-4-*%-*6! 1)**-57! A$'(! 2-$),'+05! '(! )2(-*6! '*! ;+0*3!

KLFJG!1'/-<! (033-(6'*3! 6$)6! 6$'(! )((+/')6'+*! '(! '*,+.,-%! '*! 6$-! *-05+%-3-*-5)6'+*! 45+/-((!

MN-3)<!87!"7!-6!).<!&HH@O7!A$-(-!%)6)!$),-!2--*!).(+!,).'%)6-%!'*!$01)*!)99-/6-%!2;!P.Q$-'1-5R(!

%'(-)(-<!C$-5-!6$-!)((+/')6'+*!2-6C--*!6)0!)*%!6$-!*+,-.!/)./'01D2'*%'*3!45+6-'*!C)(!9+0*%!

-*$)*/-%7! A$-! 6)0! 45+6-'*! 4.);(! )! S-;! 5+.-! '*! 6$-! )44-)5)*/-! +9! 6)0+4$)6$'-(<! C$'/$! )5-!

%-(/5'2-%! )(! )! 35+04! +9! *-05+.+3'/).! %'(+5%-5(! /$)5)/6-5'Q-%! 2;! 6$-! )335-3)6'+*! +9!

$;4-54$+(4$+5;.)6-%!)*%! 9'.)1-*6+0(! 6)0!45+6-'*(!+53)*'Q-%! '*!*-05+9'25'..)5;! 6)*3.-(7!A$-!

-B45-(('+*!)*%!)2-55)*6!1+%'9'/)6'+*(!+9!6)0!45+6-'*(!$),-!2--*!%-1+*(65)6-%!6+!4.);!)!5+.-!

'*!1-%')6'*3! 6$-! *-05+%-3-*-5)6'+*! 45+/-((7! >-(4'6-! 6$-! 6)0! 4$+(4$+5;.)6'+*! 45+/-((! $)(!

2--*! '*6-*(-.;! (60%'-%<! 6$-! 1+.-/0.)5! 1-/$)*'(1! 0*%-5.;'*3! 6$-! 6)0D1-%')6-%!

*-05+%-3-*-5)6'+*!'(!4++5.;!0*%-5(6++%7!A$-!'%-*6'9'/)6'+*!+9!6$-!*-C!6)0D)((+/')6-%!45+6-'*!

"#$%&!)*%!'6(!(650/605).!/$)5)/6-5'Q)6'+*!/+0.%!$-.4!6+!-.0/'%)6-!6$-!1-/$)*'(1(!5-(4+*('2.-!

9+5!6)0+4)6$'-(7!T-5-!C-!5-4+56!6$-!-B45-(('+*!)*%!405'9'/)6'+*!+9!6$-!"#$%&!45+6-'*!)'1-%!

)6!4-59+51'*3!(650/605).!(60%'-(7!!

4.2 MATERIALS AND METHODS

4.2.2 HETEROLOGOUS EXPRESSION OF HUMAN EFHD2 IN E. COLI

-"#./%,!UJ&IM>"GO!/+14-6-*6!/-..(!C-5-!65)*(9+51-%!C'6$!)!4.)(1'%!4-6&@2!/+*6)'*'*3!

6$-! "#$%&! /+%'*3! (-V0-*/-!C'6$! )! 4+.;$'(6'%'*-! 6)3! .'*S-%! 6+! 6$-!LD6-51'*0(7! A$-! 4.)(1'%!

84

0(-%!C)(!S'*%.;!45+,'%-%!2;!85,'*3!N-3)!95+1!6$-!>-4)561-*6!+9!U'+.+3;<!W*',-5('6;!+9!F0-56+!

X'/+7! P96-5! $-)6! ($+/S! 65)*(9+51)6'+*<! /-..(! C-5-! 35+C*! '*! )! (-.-/6',-! JU! 1-%'01!

(044.-1-*6-%!C'6$!IHH!Y3Z1J!)14'/'..'*7!P*!+,-5*'3$6!45-D'*+/0.)6'+*!C)(!6$-!(6)56'*3!4+'*6!

9+5! )! IJ! /0.605-! 4-59+51-%!)6! G[\=7! !]$-*! )2(+52)*/-!P^HH! 5-)/$-%! 6$-! ,).0-! H7^<! 45+6-'*!

-B45-(('+*!C)(!'*%0/-%!C'6$!H7_!1`!8FAa!)*%!2)/6-5')!C-5-!35+C*!9+5!I!)%%'6'+*).!$+05!)6!

G[\=7!A$-!/-..(!C-5-!$)5,-(6-%!)*%!6$-!1-%'01!-.'1'*)6-%!2;!/-*65'903)6'+*7!A$-!4-..-6!C)(!

5-(0(4-*%-%! '*! )! .;('(! 2099-5! /+*6)'*'*3<! _H!1`! AX8E! 4T[7?<! I_H!1`!L)=.<! I!1`! =)=.&<!

(044.-1-*6-%! C'6$! )! 45+6-)(-! '*$'2'6+5! /+/S6)'.! 6)2.-6! MX+/$-O7! A$-! .;('(! C)(! /)55'-%! +06!

0('*3!6$-!/-..!%'(5046+5!)6!I<G_!b2)57!=-..(!C-5-!6$-*!/-*65'903-%!)6!I@<HHH!3),!9+5!I_!1'*!'*!

+5%-5!6+!(-4)5)6-!6$-!(04-5*)6)*6!95+1!6$-!'*(+.02.-!95)/6'+*7

4.2.3 IMAC PURIFICATION AND SIZE EXCLUSION CHROMATOGRAPHY

A$-!(+.02.-!95)/6'+*!M/50%-!45+6-'*!1'B605-O!C)(!)44.'-%!6+!)!I1.!T'(D65)4!L'D/$-.)6-%!

/+.01*! Ma"!T-).6/)5-O! 9+5! 8`P=! M811+2'.'Q-%!`-6).! P99'*'6;! =$5+1)6+35)4$;O! 405'9'/)6'+*7!

A$-! /+.01*!C)(! 9'5(6.;! -V0'.'25)6-%!C'6$! )! 2099-5! /+*6)'*'*3! _H!1`!AX8E! 4T! [7?<! I_H!1`!

L)=.<! I! 1`! =)=.&7AC+! (02(-V0-*6! C)($'*3! (6-4(! C-5-! 4-59+51-%! 0('*3! 6$-! ()1-! 2099-5!

(044.-1-*6-%!C'6$!_!1`!81'%)Q+.-7!A$-!"#$%&!45+6-'*!C)(!6$-*!-.06-%!'*!)!35)%'-*6!5)*3'*3!

95+1!_!1`!6+!_HH1`! '1'%)Q+.-7! A$-! 95)/6'+*(! /+*6)'*'*3! 6$-!"#$%&!45+6-'*!C-5-!4++.-%<!

/+*/-*65)6-%! )*%! 9056$-5! 405'9'-%! +*! )! 3-.! 9'.65)6'+*! /+.01*! ME04-5%-B! [_! 45-4! 35)%-!

TXI^Z^Hc! a"! T-).6$/)5-O! -V0'.'25)6-%! C'6$! I_H!1`!L)=.<! _H!1`! AX8E! 4T! [7?! )*%! &!1`!

=)=.&!2099-57!

4.2.4 SDS-PAGE AND WESTER BLOT ANALYSIS

E>EDFPa"!C)(!4-59+51-%!+*!)!I?d!4+.;)/5;.)1'%-!3-.! '*!)!,-56'/).!(.)2!3-.!)44)5)60(!

MT+-9-5! E/'-*6'9'/! 8*(6501-*6O7! A$-! ()14.-(! M&H! YJO! C-5-! %'.06-%! '*! )*! -V0).! ,+.01-! +9!

%-*)605'*3! ()14.-! 2099-5! /+*6)'*'*3! I7?!`!&D1-5/)46+-6$)*+.<! @!`!05-)! )*%! I!1`!">AP!

)*%!2+'.-%!)6!IHH!\=!9+5!I!1'*7!P96-5!-.-/65+4$+5-('(!50**'*3!)6!I&H!N+.6!)*%!&_!1P!9+5!I!$<!

6$-! 3-.! C)(! (6)'*-%! 2;! 0('*3! 6$-! =++1)(('-! U5'..')*6! U.0-! MH7H_d! =++1)(('-! 2.0-! X<! ?Hd!

EXPRESSION AND PURIFICATION OF SWIPROSIN1/EFHD2, A NOVEL HUMAN TAU-ASSOCIATED PROTEIN

85

1-6$)*+.<!IHd!)/-6'/!)/'%O7!E-,-5).!C)($'*3!C'6$!-'6$-5!C)6-5!+5!IHd!)/-6'/!)/'%!%-(6)'*-%!

6$-!3-.7!P96-5!-.-/65+4$+5-('(<!6$-!3-.!C)(!65)*(9-5(!+*!)!*'65+/-..0.+(-!1-125)*-!M4+5-!('Q-!

H7?_!Y1O!C'6$!)!`'*'DA5)*(DU.+6!".-/65+4$+5-6'/!65)*(9-5!=-..!MU'+DX)%O!)6!IHH!N!)*%!G_H!1P!

9+5!I!$!'*!)!H7Ie&!`!3.;/'*-<!&_!1`!65'(<!4T!@7G<!)*%!I7G!1`!E>E!2099-57!P96-5!6$-!65)*(9-5<!

6$-!*'65+/-..0.+(-!1-125)*-!C)(!2.+/S-%!C'6$!)!Gd!MCZ,O!UEP!'*!AUE!2099-5!M&H!1`!A5'(DT=.<!

4T![7^<!I_H!1`!L)=.O!9+5!&!$!)6!5++1!6-14-5)605-7!A$-!1-125)*-!C)(!6$-*!'*/02)6-%!C'6$!

1+0(-! )*6'DT'(! 6)3! 1+*+/.+*).! )*6'2+%;! M=-..DU'+.)2(<! 8*/7O! )6! )! IfIHHH! %'.06'+*! '*! AUE!

+,-5*'3$6!)6!?\=!'*!)!5+/S'*3!1+6'+*7!A$-!1-125)*-!C)(!C)($-%!G!6'1-(!C'6$!6$-!AUE!2099-5!

)*%!C)(!6$-*!'*/02)6-%!C'6$!1+0(-!)*6'5)22'6!/+*g03)6-%!C'6$!$+5(-5)%'($!4-5+B'%)(-!9+5!&!

$!)6! 5++1!6-14-5)605-! '*!)!If&HHH!%'.06'+*! '*!AUE7!P96-5! (-,-5).!C)($'*3! (6-4(<! 6$-!2+0*%!

)*6'2+%'-(!C-5-! 5-,-).-%!C'6$!P1-5($)1!"=J! 5-)3-*6! Ma"!T-.6$/)5-!)*%! J'9-! E/'-*/-O! '*! )!

b+%)S!81)3-!E6)6'+*!?HHH``!F5+!Mb+%)SO7!

4.2.5 LIMITED PROTEOLYSIS

A$-! 45+6-'*! C)(! '*/02)6-%! C'6$! =$'1+65'4('*! '*! )! IfIHHH! ]Z]! 5)6'+! +9! 45+6-'*f!

45+6-)(-!'*!_H1`!A5'(<!4T!@7H<!H7_1`!&D`"<!I_H1`!L)=.!5-)/6'+*!2099-5!)6!?!\=!9+5!&<!I_<!GH!

)*%!^H!1'*7!A$-!6+6).!5-)/6'+*!,+.01-!C)(!I!1.7!A+!6-(6!6$-!)/6','6;!+9!6$-!45+6-+.'/!-*Q;1-!

+*! 6$-! 45+6-'*! '*! )2(-*/-! +9! /)./'01<! 6$-! 5-)/6'+*! 2099-5!C)(! (044.-1-*6-%!C'6$! H7&!1`!

">AP7! P6! 6$-! -*%! +9! 6$-! %'3-(6'+*! 4-5'+%<! 6$-! 5-)/6'+*! C)(! (6+44-%! 2;! )%%'*3! 6$-! ()1-!

)1+0*6!+9! .+)%'*3!2099-57!#'*)..;<!6$-!()14.-(!/+*6)'*'*3!6$-!"#$%&!95)31-*6(!C-5-!.+)%-%!

+*!I?d!E>EDFPa"!)*%!,'(0).'Q-%!2;!/++1)(('-!2.0-!(6)'*'*37!A$-!()1-!45+/-%05-!C)(!0(-%!

9+5!6-(6'*3!A$-51+.;('*!)/6','6;!'*!I!1.!+9!)!2099-5!/+*6)'*'*3!_H1`!A5'(<!4T!@7H<!IH1`!=)=.&<!

H7_1`!&D`"!)*%!I_H1`!L)=.7!

4.2.6 CRYSTALLIZATION

=5;(6)..'Q)6'+*! 65').(! C-5-! /)55'-%! +06! 0('*3! 6$-! ,)4+05! %'990('+*! 6-/$*'V0-! C$'6! )*!

:5;B@! /5;(6)..'Q)6'+*! %-,'/-! M>+03.)(! 8*(6501-*6(O7! >'99-5-*6! 45-/'4'6)*6! (+.06'+*(! 95+1!

86

(-,-5).! /5;(6)..'Q)6'+*! S'6(! ME650/605-! E/5--*! 8! )*%! 88! 2;!`+.-/0.)5! >'1-*('+*(<! FP=A! E0'6-<!

K=Ea!E0'6-<!F"a(!)*%!F"a(!88<!2;!h')3-*O!C-5-!(/5--*-%!2;!0('*3!6$-!$)*3'*3!%5+4!6-/$*'V0-7!!

8*! ('60! 45+6-+.;('(! C'6$! /$'1+65'4('*! C)(! 4-59+51-%! 6+! -*$)*/-! 6$-! 45+2)2'.'6;! 6+!

+26)'*!/5;(6).(!(6)56'*3!95+1!)!1+5-!(6)2.-!45+6-'*!(+.06'+*7!W*9+560*)6-.;!/5;(6).(!%'995)/6'*3!

C-..!$),-!*+6!2--*!+26)'*-%!;-67!T+C-,-5<!(+1-!(1)..!/5;(6).(!9+51-%!'*!45-(-*/-!+9!H7&!`!

/)./'01!/$.+5'%-<!H7I!`!L)!T"F"E!4T![7_!)*%!&@!d!,Z,!F"a!?HH7!A$-;!*--%!9056$-5!6-(6(7!

4.3 RESULTS AND DISCUSSION

"#$%&!'(!)!&?H!)1'*+D)/'%!45+6-'*!+9!&[!b>)!6$)6!-B$'2'6!)*!)44)5-*6!1+.-/0.)5!C-'3$6!

+9! GG! b>)<! )(! '*%'/)6-%! 2;! E>EDF)3-7! A$-! 45-%'/6-%! (-/+*%)5;! (650/605-! ($+C(! )! 45+6-'*!

/+*('(6'*3!+9!)!4+.;).)*'*-!1+6'9!.+/)6-%!)6!6$-!LD6-51'*0(<!6C+!"#D$)*%!1+6'9(!)*%!)!/+'.-%D

/+'.!%+1)'*!)6!6$-!=D6-51'*0(7!A$-!45-(-*/-!+9!4+.;).)*'*-!)*%!/+'.-%D/+'.!)5-!'*!)35--1-*6!

C'6$!6$-!"#$%&!(650/605).!9-)605-(!6+!45+1+6-!45+6-'*D45+6-'*!'*6-5)/6'+*(<!C$-5-)(!6$-!6C+!

"#D$)*%!1+6'9(!)6!6$-!/-*65-!+9!6$-!45+6-'*!(-V0-*/-!1-%')6-!/)./'01!2'*%'*37!A$-!45+6-'*!

(6)2'.'6;! '(!)((05-%!6$5+03$!6$-!/)./'01!2'*%'*3<!)(!%-(/5'2-%!.)6-57!A$-!5-/+12'*)*6!"#T>&!

45+6-'*!C)(!-B45-((-%!'*!-"#./%,!)(!4+.;$'(6'%'*-D6)33-%!90('+*!0*%-5!6$-!/+*65+.!+9!)*!8FAaD

'*%0/-%!45+1+6-57!P99'*'6;!405'9'/)6'+*!+9!"9$%&!C)(!)/$'-,-%!6$+03$!8`P=!/$5+1)6+35)4$;!

)*%!;'-.%-%!)2+06!&H!13!+9!45+6-'*!4-5! .!+9!-"#!/%,! /0.605-7! 8*'6').!405'9'/)6'+*!65').(!($+C-%!

6$)6!6$-!45+6-'*!'*!6$-!)2(-*/-!+9!=)./'01!0*%-5C-*6!45+6-+.;6'/!%-35)%)6'+*7!A$-!)%%'6'+*!

+9!=)./'01!(-)1-%! 6+! 5-%0/-! 6$-!45+6-+.;6'/!%-35)%)6'+*!)*%! 6+! '*/5-)(-! 6$-!405'6;!+9! 6$-!

45+6-'*! )96-5! 3-.D9'.65)6'+*! M(--! -.06'+*! 45+9'.-! C'6$! )*%! C'6$+06! =)./'01O7! A$'(! 2-$),'+05<!

C$'/$!'(!6;4'/).!+9!/)./'01!2'*3'*3!45+6-'*(!M6$-;!0*%-53+!('3*'9'/)*6!/+*9+51)6'+*).!/$)*3-(!

04+*! /)./'01! 2'*%'*3O<! '(! '*%'/)6',-! +9! 6$-! /+55-/6! 9+.%'*3! +9! 6$-! 45+6-'*7! L+*-6$-.-((! 6$-!

45-(-*/-!+9!%-35)%)6'+*!2)*%(!'*!6$-!E>EDFPa"!)96-5!3-.D9'.65)6'+*!'(!$)5%.;!/+14)6'2.-!C'6$!

/5;(6)..'Q)6'+*! 4054+(-(7! A+! '%-*6'9;! -B4+(-%! 5-3'+*(! (0(/-46'2.-! 6+! 45+6-'*! %-35)%)6'+*<! )!

.'1'6-%! 45+6-+.;('(! (65)6-3;! C)(! 4-59+51-%7! A$'(! 45+/-%05-! (033-(6-%! =$'1+65'4('*! )(! 6$-!

2-(6! -*Q;1-! )2.-! 6+! 5-1+,-! %'(+5%-5-%! )*%! 0*(6)2.-! 5-3'+*(! '*! +5%-5! 6+! 5-/+,-5! )! (6)2.-!

EXPRESSION AND PURIFICATION OF SWIPROSIN1/EFHD2, A NOVEL HUMAN TAU-ASSOCIATED PROTEIN

87

45+6-'*!(02%+1)'*<!)(! ($+C*!2;! 6$-!45-(-*/-!+9!)! ('*3.-!2)*%! '*! 6$-!E>EDFPa"! M#'305-!^O7!

A$'(! )..+C-%! 0(! 6+! 4-59+51-%! '*! ('60! 45+6-+.;('(! /5;(6)..'Q)6'+*! 65').(7! E+1-! (1)..! 45+6-'*!

/5;(6).(! $),-! 2--*! +2(-5,-%! '*! (4-/'9'/! /+*%'6'+*(! +9! 6$-! E650/605-! E/5--*! S'6<! 206!

0*9+560*)6-.;!6$-;!%+!*+6!%'995)/67!:46'1'Q'*3!6$-!/5;(6).!35+C6$!/+*%'6'+*(<!4-5$)4(!1)S'*3!

0(-! +9! )%%'6',-(<! /+0.%! -*$)*/-! 6$-! 45+2)2'.'6;! 6+! +26)'*! (0'6)2.-! /5;(6).(! 9+5! (650/605-!

%-6-51'*)6'+*7!

!

!

#

#

#

#

#

#

#

#

!

0,&# 1"# -2+3$)),/(# '(4# '55,(,67# +83,5,.'6,/(# /5# -094:"# ;(# 69$# %$56<# !//=')),$# >%8$# )6',(,(&# ?@?ABCD-# /5# .8%683$#

=$4,8=#>$5/3$#EAFG#'(4#'56$3#EHFG#,(48.6,/(#I,'#FBJD"#K,&96<#!//=')),$#>%8$#)6',(,(&#?@?ABCD-#/5#-094:#)'=+%$)#

53/=# F='.# C55,(,67# '(4# '56$3# $%86,/(# ,(# ,=,4'L/%$# )6$+)# &3'4,$(6# EMANMM#=OG"# ?'=+%$)# P$3$# %/'4$4# ')# )9/P(#

>$%/P<# 1G# !384$# +3/6$,(#=,2683$Q# :G# 5%/P# 693/8&9Q# RG#P')9,(&#P,69# N=O# ,=,4'L/%$Q# SATG# $%86$4# 53'.6,/()# 53/=#

,=,4'L/%$#)6$+)#&3'4,$(6"#

#

!

!

88

!

0,&"#:"#?-!A0BU!#+83,5,.'6,/(#)6$+#>7#8),(&#'#>855$3#P,69/86#!':H"#J9$#$%86,/(#+3/5,%$#'6#:VM#(=#/5#-094:#53/=#),L$#

$2.%8),/(#.93/='6/&3'+97#P,69#'#>855$3#P,69/86#!':#H"#

#

!

0,&"#R"# ?-!A0BU!#+83,5,.'6,/(# )6$+#>7#8),(&#'#>855$3#P,69#!':H"#J9$#$%86,/(#+3/5,%$#'6#:VM#(=#/5#-094:# 53/=#),L$#

$2.%8),/(#.93/='6/&3'+97#P,69#'#>855$3#./(6',(,(&#!':H"#

!

EXPRESSION AND PURIFICATION OF SWIPROSIN1/EFHD2, A NOVEL HUMAN TAU-ASSOCIATED PROTEIN

89

!

0,&"#S"#?-!A0BU!#+83,5,.'6,/(#)6$+"#!//=')),$#>%8$#)6',(,(&#?@?ABCD-#/5#69$#$%86$4#53'.6,/()Q#./33$)+/(4,(&#6/#69$#

-094:#'>)/3+6,/(#+$'W"#E)'=+%$)#XQ#TQ#VQ#YG"#

#

!

0,&"#N"#Z$)6$3(#>%/6#'(4#,==8(/4$6$.6,/(#8),(&#=/8)$#'(6,A*,)#6'&#=/(/.%/('%#'(6,>/47"#?'=+%$)#P$3$#%/'4$4#

')# )9/P(# >$%/P<# A# F# '(4# H# FG# )'=+%$)# >$5/3$# '(4# '56$3# ,(48.6,/(# I,'# FBJD[# 1G# .384$# +3/6$,(# =,2683$[# :G# 5%/P#

693/8&9[#RG#P')9,(&#P,69#N=O#,=,4'L/%$[#SG#=/%$.8%'3#P$,&96#='3W$3[#NG#$%86$4#53'.6,/(#53/=#FOC!#+83,5,.'6,/([#

XG#$%86$4#53'.6,/(#53/=#?-!A0BU!"##

90

#

0,&"# X"# !//=')),$# >%8$# )6',(,(&# ?@?ABCD-# /5# -094:# )'=+%$)# '56$3# %,=,6$4# +3/6$/%7),)"# ?'=+%$)#P$3$# ,(.8>'6$4#

P,69# P,69# !9,=/63,+),(# 5/3# :Q# 1NQ# RM# '(4# XM# =,(Q# 3$)+$.6,I$%7"# 1G# -594:# )'=+%$# '56$3# ?-!A0BU![# :ANG# )'=+%$)#

,(.8>'6$4#,(#'>)$(.$#/5#!':H[#XAYG#)'=+%$)#,(.8>'6$4#,(#+3$)$(.$#/5#!'

:H"#

#

0,&"# T"# !//=')),$# >%8$# )6',(,(&# ?@?ABCD-# /5# -094:# )'=+%$)# '56$3# %,=,6$4# +3/6$/%7),)"# ?'=+%$)#P$3$# ,(.8>'6$4#

P,69#J9$3=/%7),(#5/3#:Q#1NQ#RM#'(4#XM#=,(Q#3$)+$.6,I$%7"#1ASG#?'=+%$)#,(.8>'6$4#,(#'>)$(.$#/5#!':H[#NAVG#)'=+%$)#

,(.8>'6$4#,(#+3$)$(.$#/5#!':H[#YG#-594:#)'=+%$#'56$3#?-!A0BU!"#

APPENDIX

AVIDIN FUNCTIONALIZED MAGHEMITE NANOPARTICLES

AND THEIR APPLICATION FOR RECOMBINANT HUMAN

BIOTINYL-SERCA PURIFICATION

MASSIMILIANO MAGRO, ADELE FARALLI, DAVIDE BARATELLA, ILENIA BERTIPAGLIA, SARA

GIANNETTI, GABRIELLA SALVIULO, RADEK ZBORIL AND FABIO VIANELLO

!

!

!

!

Langmuir 28 (2012) 15392-15401

!

!

!

Avidin Functionalized Maghemite Nanoparticles and TheirApplication for Recombinant Human Biotinyl-SERCA Puri!cationMassimiliano Magro,† Adele Faralli,† Davide Baratella,† Ilenia Bertipaglia,‡ Sara Giannetti,‡

Gabriella Salviulo,§ Radek Zboril,! and Fabio Vianello*,†,!

†Department of Comparative Biomedicine and Food Science, ‡Department of Biomedical Sciences, §Department of Geosciences,University of Padua, Italy!Regional Centre of Advanced Technologies and Materials, Department of Physical Chemistry, Faculty of Science, Palacky Universityin Olomouc, Czech Republic

*S Supporting Information

ABSTRACT: We report on the surface characterization, functionalization, andapplication of stable water suspensions of novel surface active maghemitenanoparticles (SAMNs), characterized by a diameter of 11 ± 2 nm andpossessing peculiar colloidal properties and surface interactions. These featurespermitted the acquisition of titration curves and aqueous UV"vis spectra andsuggested a role played by surface under-coordinated iron atoms. This new classof nanoparticles was obtained through an easy, inexpensive, one-step, greenprocedure and functionalized with ligands of high biotechnological interest, suchas biotin and avidin, by simple incubation in aqueous solution. Bound avidin wasdetermined by measuring the disappearance of free avidin absorbance at 280 nm,as a function of increasing nanoparticle concentration, showing the presence of10 ± 3 avidin molecules per nanoparticle. The biological activity of the SAMN@avidin complex was evaluated and the number of available biotin binding sites wasdetermined, using biotinyl-!uorescein as a probe, showing that each bound avidinmolecule is able to bind 2.8 ± 0.8 biotin molecules, con"rming the maintenance of biological activity and excellent bindingcapacity of the SAMN@avidin complex. Furthermore a Langmuir isotherm model was used to describe the biomolecule speci"cmonolayer adsorption onto the particle surface, and in the case of avidin, the maximum adsorption capacity was 100 ± 27 !gavidin/mg SAMN, whereas the binding constant is 45.18 !L !g"1. The SAMN@avidin complex was characterized by UV"visspectroscopy, quartz crystal microbalance, FTIR spectroscopy, and transmission electron microscopy. Finally, SAMN@avidinwas applied for the large scale puri"cation of recombinant biotinylated human sarco/endoplasmic reticulum Ca2+-ATPase(hSERCA-2a), expressed by Saccharomyces cerevisiae. The protein was magnetically puri"ed, and about 500 !g of a 70% purehSERCA-2a were recovered from 4 L of yeast culture, with a puri"cation yield of 64%.

! INTRODUCTIONThe combination of nanotechnology, biochemistry, biotechnol-ogy, and molecular biology has developed into an emergingresearch area: nanobiotechnology, which o#ers excitingopportunities for developing new nanosized materials andtechnologies. In order to develop new hybrid nanostructures itis mandatory to understand surface nanostructure properties.Furthermore, hybrid nanostructures, which combine magneticnanoparticles with bioelements, such as antibodies, proteins, orother functionalities, lead to superparamagnetic biofunctionalnanoparticles exhibiting highly selective binding. As a result,these nanoparticles could have many applications in biologyand medicine, including drug delivery, medical imaging, andprotein puri"cation.1,2

Recently, a number of aqueous magnetic nanoparticledispersions have been reported, all coated by low or highmolecular weight organic polymers or inorganic shells as stericstabilizers in order to prevent the particle aggregation and tomaintain long-term stability, pH and electrolyte tolerance, and

proper surface chemistry. Many of the polymeric stabilizersreported only bind weakly to nanoparticle surfaces andeventually desorb or exchange with bulk solution, a#ectingthe stability of the resultant dispersions. Furthermore, processesto coat nanoparticles are often cumbersome, time-consuming,expensive, and with low yield and limiting massive productions.At last, nanoparticle coating reduces the average materialmagnetic moment by introducing nonmagnetic material in the"nal nanoparticles.3,4

Recently, we developed a novel synthesis of nanostructuredsuperparamagnetic material, totally carried out in water,without any organic solvent or surfactant.5,6 A wet reactiono#ers several advantages: simplicity, low cost, and high yieldscale and, above all, it is an organic solvent free process andthus ecologically green. This nanomaterial is composed of

Received: August 3, 2012Revised: October 5, 2012Published: October 11, 2012

Article

pubs.acs.org/Langmuir

© 2012 American Chemical Society 15392 dx.doi.org/10.1021/la303148u | Langmuir 2012, 28, 15392"15401

stoichiometric maghemite ("-Fe2O3), with peculiar surfacechemical behavior, called SAMNs (surface active magneticnanoparticles).5,6 SAMNs are synthesized in the dimensionrange around 10 nm without any super"cial modi"cation orcoating derivatization. Bare SAMNs are dispersible in water,and their suspensions are stable for several months. Because oftheir unique physical and chemical properties, these bare ironoxide nanoparticles present a high average magnetic momentand can be easily used to immobilize speci"c organicmolecules.6 Functionalization is carried out in water, withoutany chemical reactant, and the total derivatization process ismild, minimizing alteration of ligand macromolecular structure,low cost, and ecologically green. In the present manuscript,SAMN surface properties were studied by titration curves, UV"vis spectroscopy, and ferrocyanide absorption, and weattributed the main responsibility in the distinctive SAMNssurface chemistry to under-coordinated iron atoms.In biosciences and biotechnology, the isolation of proteins

and peptides is usually performed using a variety ofchromatographic, electrophoretic, ultra"ltration, or precipita-tion techniques, with a$nity chromatography being the mostimportant. Currently, a$nity ligand techniques represent themost powerful tool available to the downstream processingboth in terms of selectivity and recovery. The strength ofcolumn a$nity chromatography has been shown in thousandsof successful applications, especially in the laboratory scale.7

However, the disadvantage of all standard column liquidchromatography procedures is the impossibility to cope withsamples containing particulate material, so this technique is notsuitable for work in early stages of the isolation/puri"cationprocess, where suspended solid and fouling components arepresent in the sample.8 Among the existing protein puri"cationprotocols, magnetic separation and puri"cation seem to beconvenient methods for selective and reliable capture of speci"cproteins.4"9 Magnetic separation techniques have severaladvantages in comparison with standard separation procedures.These processes are usually very simple, with only a fewhandling steps. All of the puri"cation steps can take place inone single test tube or vessel, even on very large volumes.There is no need for expensive liquid chromatography systems,centrifuges, "lters, or other equipment. The separation processcan be performed directly on crude samples, containingsuspended solid material. Furthermore, separation of targetproteins using standard chromatography techniques often leadsto large volumes of diluted protein solutions. In this case,appropriate magnetic particles can be used for target proteinconcentration, instead of ultra"ltration, precipitation, etc.9

In order to propose a biotechnological application ofSAMNs, we functionalized their surface with ligands of highbiotechnological interest, such as biotin and avidin. Biotin andavidin represent an example of a molecular key-lock system inlife processes, and their most important feature consists of thespeci"city and the strength of their interaction (Ka # 1015

M"1). We tested the functionality of SAMN@biotin andSAMN@avidin nanostructures, toward avidin and biotin,respectively. Subsequently, we applied the SAMN@avidinsystem for the puri"cation of the recombinant sarcoplasmicreticulum Ca2+-ATPase (SERCA-2a). This membrane protein,belonging to the family of P-types ATP-ases, plays a crucial rolein the regulation of the excitation-contraction coupling inskeletal and cardiac muscle, thus making it an important targetfor research investigations.

! MATERIALS AND METHODSChemicals. Chemicals were purchased at the highest commercially

available purity, and they were used without further treatment.Iron(III) chloride hexahydrate (97%), sodium borohydride (NaBH4),tetramethylammonium hydroxide (TMA), biotin, perchloric acid,biotinylated !uorescein, phenylmethanesulfonyl!uoride (PMSF), andammonia solution (35% in water) were obtained from Aldrich (Sigma-Aldrich, Italy). Egg’s Avidin (cat. A9275; purity $98%) was fromAldrich (Sigma-Aldrich, Italy)

Instrumentation. Optical spectroscopy and !uorescence measure-ments were respectively performed in 1 cm quartz cuvettes using aCary 50 spectrophotometer and a Cary Eclipse !uorescencespectrometer (Varian Inc., Palo Alto, CA, U.S.A.).

FT-IR spectra were acquired using a Thermo Nicolet Nexus 670instrument. Nanoparticle samples were lyophilized, homogenized withKBr powder, and pelleted by an 8.0 tons hydraulic press.

Nanoparticles (2 g L"1) were suspended in Milli-Q grade water (3.5L) by treatment in an ultrasonic bath at 48 kHz, 50 W (Bransonic,mod. 221 at 48 kHz, 50 W), for at least 3 h, giving a stable colloidalsuspension.

Microscopic characterizations of the native maghemite particles, aswell as biotin and avidin coated particles, were performed bytransmission electron microscopy (TEM) using a FEI Tecnai 12microscope operating at 120 kV with a point-to-point resolution of 1.9Å. Before measurements, SAMN were dispersed in ethanol (50 mgL"1), and the suspension was treated by ultrasound for 10 min. A dropof a very dilute suspension was placed on a carbon-coated copper gridand allowed to dry by evaporation at room temperature.

Quartz crystal microbalance (QCMagic), from Elbatech (Marciana,LI, Italy), was interfaced to a driving PC by means of a USB port.QCMagic was equipped with a low-volume (20 !L) !ow-throughreaction chamber, which houses the oscillating crystal, tuned to workat 9.5 MHz.

Derivatization of the Piezoelectric Crystal. Piezoelectriccrystals (Elbatech, Marciana, LI, Italy) consist of a thin quartz diskwith gold electrodes plated on it, in which the acoustic wavepropagates in a direction perpendicular to the crystal surface. Asshown by Sauerbrey in 1959,10 changes in resonant frequency aresimply related to the mass accumulated on the crystal by the followingequation:

! "! = " !f mnf2 02

q q (1)

where #q and $q are the density and the viscosity of the quartz, n is theovertone number, f 0

2 is the basic oscillator frequency of the quartz,and !m is the mass adsorbed on the surface per unit/area. For an AT-cut quartz crystal, !f = "2.26 ! 10"6 f 0

2!m.Before the immobilization, the electrode surface of the quartz crystal

was cleaned with ethanol and Milli-Q water. The gold electrodes,plated on piezoelectric crystals, were derivatized as follows: freshlycleaned crystals were immersed in an unstirred ethanolic solution of 10mM 2-mercaptoethylamine at room temperature, in the dark, for 14 h.Crystals were then washed with ethanol and Milli-Q water to removethe excess of the thiol. In order to immobilize biotin on aminederivatized piezoelectric crystals, carbodiimide chemistry was used. Inparticular, amine modi"ed crystals were incubated in the presence of10 mM biotin, 50 mM N-hydroxysuccinimide, and 200 mM EDC inwater for 2 h. This solution must be prepared immediately before theuse. The crystals were "nally washed with Milli-Q water to remove theexcess of reactants.

Derivatized piezoelectric crystals were inserted in a !ow injectionanalysis system (P-500 pump, MV-7 injection valve and LC-500controller by Pharmacia, Uppsala, Sweden), equipped with a 200 !Lloop, at a !ow rate of 100 !L min"1. In this way, a QCM sensor,bearing solvent exposed biotin molecules on the surface, was prepared.The biotin modi"ed sensor was tested with SAMN@avidin complex.Alternatively, by injecting an avidin solution (50 !g/mL) in the !owQCM system, containing the biotinylated crystal, the crystal surfacewas covered by a monomolecular layer of avidin. Due to the presenceof 4 biotin binding sites on avidin molecules, the resulting crystal

Langmuir Article

dx.doi.org/10.1021/la303148u | Langmuir 2012, 28, 15392"1540115393

surface exposed biotin binding sites to the solvent.11,12 In this last case,the avidin modi"ed sensor was tested with SAMN@biotin complex.Synthesis of SAMNs. A typical nanoparticles synthesis was already

described5,6 and can be summarized as follows: FeCl3·6H2O (10.0 g,37 mmol) was dissolved in Milli-Q grade water (800 mL) undervigorous stirring at room temperature. NaBH4 solution (2 g, 53 mmol)in ammonia (3.5%, 100 mL, 4.86 mol/mol Fe) was then quickly addedto the mixture. Soon after the reduction reaction occurrence, thetemperature of the system was increased to 100 °C and kept constantfor 2 h under stirring. The material was cooled at room temperatureand aged in water, as prepared, for other 12 h. This product wasseparated by imposition of an external magnet, as described inMethod, for 60 min, and washed several times with water. Thismaterial can be transformed into a red brown powder ("nal synthesisproduct) by drying and curing at 400 °C for 2 h, obtaining individualnanoparticles after thermal treatment. The resulting nanopowdershowed a magnetic response upon exposure to a magnetic "eld. The"nal mass of product was 2.0 g (12.5 mmol) of Fe2O3 and a yield of68% was calculated.The obtained nanomaterial was characterized by zero "eld and in

"eld (5 T) Mo"ssbauer spectroscopy, FTIR spectroscopy, highresolution transmission electron microscopy, XRPD, magnetizationmeasurements5,6 and resulted constituted of stoichiometric maghemite("-Fe2O3) with a mean diameter of 11 ± 2 nm (see Figure S1), whichcan lead to the formation, upon sonication in water (Bransonic, model221, 48 kHz, 50 W) of a stable colloidal suspension, without anyorganic or inorganic coverage. Notwithstanding, the surface of thesebare maghemite nanoparticles shows peculiar binding properties andcan be reversibly derivatized with selected organic molecules. Wecalled these bare nanoparticles suface active maghemite nanoparticles(SAMNs).Magnetic Separation. A series of Nd"Fe"B magnets (N35,

263"287 kJ/m3 BH, 1170"1210 mT !ux density by Powermagnet,Germany) were used for the magnetic separations. Magnets wereapplied on the bottom of the reaction !asks, and depending on the!ask volume, supernatants were separated by suction after 30"60 min.Derivatization of SAMNs with Avidin. SAMNs can be

super"cially derivatized by simple incubation in water solutions inthe presence of avidin. In the present case avidin binding was carriedout in 50 mM tetramethylammonium perchlorate, pH 7.0. Theamount of bound avidin was calculated from the disappearance of theabsorbance at 280 nm in the supernatants (%280nm = 6.99 ! 104 M"1

cm"1). Alternatively, bound avidin was released from nanoparticlesurface by treatment with 0.5 M ammonia. The released protein wasevaluated by spectrophotometry.Heterologous Expression of Human SERCA-2a in S.

cerevisiae. The c-DNA coding for human SERCA-2a (ImagenesGmbH, Berlin, Germany) was ampli"ed by PCR and cloned intopYeDP60 plasmid (kindly provided by Marc le Maire, (Universite #Paris-Sud, F-91405 Orsay, Institut de Biologie et Technologies deSaclay (iBiTec-S) Gif-sur-Yvette, and URA CNRS, France) in thesame coding frame of thrombin cleavage site and BAD (biotinacceptor domain) sequences. A mutant of hSERCA-2a (R863G) wasgenerated by PCR based on the QuickChange site-directed muta-genesis strategy (Stratagene) to eliminate a thrombin cleavage sitewithin the protein sequence.Competent S. cerevisiae cells (strain W303.1b Gal4"2 (a, leu2, his3,

trp1::TRP1-GAL10-GAL4, ura3, ade2"1, canr, cir+) were transformedwith the pYeDP60 vector containing hSERCA-2a (R863G) andselected on minimal plates as described by Gietz and Woods.13

Protein Expression. A total of 10 mL of minimal medium (0.1%w/v Bacto Casamino acids (BD Diagnostic Systems, NJ, U.S.A.), 0.7%w/v yeast nitrogen base, 2% w/v glucose, 20 !g/mL adenine) wereinoculated with the selected clone and incubated at 28 °C for 24 h.The preculture was then diluted in 100 mL of fresh medium. Thesecond preculture was used to start the culture in YPGE medium (1%w/v yeast extract, 0.5% w/v glucose, 1% w/v bactopeptone, 2.7% v/vethanol). After 36 h of growth at 28 °C, the temperature of the culturewas lowered to 20 °C. Expression was induced by adding galactose to a"nal concentration of 2% w/v. After overnight incubation at 20 °C, an

additional induction with galactose was performed. The culture wasstopped after 6 h.14

Isolation and Solubilization of Membrane Fractions.Membranes were separated as described by Cardi et al.15 and thetotal protein content was estimated by the bicinchoninic acidprocedure.16 Protein solubilization was performed in a bu#ercontaining 50 mM MOPS-Tris, pH 7.0, containing 100 mM KCl,20% v/v glycerol, 1 mM CaCl2, 1 mM PMSF, 1 mM 2-mercaptoethanol, complete EDTA-free antiprotease cocktail (RocheDiagnostics, Basel, Switzerland) and n-dodecyl-&-D-maltoside (DDM)(detergent/protein ratio of 3:1). The suspension was kept undergentle stirring for 20 min at room temperature. Insoluble materialswere removed by centrifugation at 100,000g.

Puri!cation of hSERCA-2a and Its Mutant. The supernatant(180 mL) was mixed with SAMN@avidin (40 mL, 3.12 g/L) andgently stirred overnight at 4 °C. The magnetic nanoparticles wereseparated by exposure to an external magnet for 1 h at 4 °C andwashed twice with 80 mL of bu#er containing 0.05 M Tris, pH 7.0, 1M NaCl, 20% (w/v) glycerol, 1 mM CaCl2, 1 mM 2-mercaptoethanol,and 0.05% w/v DDM) to remove nonspeci"cally bound proteins. Afurther washing step was carried out with 80 mL of the bu#ercontaining 0.05 M Tris-HCl, pH 7.0, containing 0.15 M NaCl, 20% v/v glycerol, 2.5 mM CaCl2, 1 mM 2-mercaptoethanol, 0.05% w/vDDM. The removal of the BAD domain was achieved by thrombincleavage. The protease activity was stopped by adding 2.5 mM PMSF(phenylmethanesulfonyl!uoride). The nanoparticles were removed bymagnetic separation.

Gel-Filtration. The a$nity-puri"ed hSERCA-2a, obtained bySAMN@avidin puri"cation, was concentrated by Vivaspin-20 (50000 Mw cut o#, Sartorius) and applied to a Superdex 200-HR 10/300(GE Healthcare Bio-Sciences, Uppsala, Sweden) at 0.5 mL/min. Thesolvent was constituted of 50 mM Mops-Tris, pH 7.0, containing 100mM KCl, 20% glycerol, 1 mM CaCl2, and 0.5 g L"1 dodecylocta-ethylene glycol ether. The gel-"ltration was performed in order toincrease the protein purity.

Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophore-sis (SDS-PAGE). SDS-PAGE was performed as described byLaemmli,17 using a 12% polyacrylamide gel in a vertical slab gelapparatus (Hoefer Scienti"c Instrument). Protein samples wereprepared in a denaturing sample bu#er containing 1.4 M 2-mercaptoethanol, 8 M urea and 1 mM EDTA. The samples (20 !L)were diluted in an equal volume of denaturing sample bu#er andboiled at 100 °C for 1 min. Electrophoresis was performed at 120 mAand 25 mA for 1 h. The run was stopped when the dye front was 2 to 3mm away from the bottom edge of the gel. The gel was then stainedusing the Coomassie Brilliant Blue (0.05% Coomassie blue R, 40%methanol, 10% acetic acid).18 Destaining was performed by washingthe gels several times with either water or 10% acetic acid.

Western Blotting. Western blotting was performed according tothe modi"ed method of Towbin et al.19 After electrophoresis, the gelwas soaked in cold transfer bu#er (0.192 M glycine, 25 mM tris, pH8.3, and 1.3 mM SDS) for 1 h to remove SDS and any excess ofelectrode bu#er. A sheet of nitrocellulose membrane (pore size 0.45!m) was used (15 ! 15 cm) and then was immersed into the transferbu#er. To avoid contamination, forceps and gloves were used whenhandling the membrane.

Proteins transfer was obtained with a Mini-Trans-Blot Electro-phoretic transfer Cell (Bio-Rad) at 100 V and 350 mA for 2 h. Afterthe transfer, the nitrocellulose membrane was gently rocked inblocking bu#er constituted of 3% (w/v) BSA in TBS bu#er (20 mMTris-HCl, pH 7.6, 150 mM NaCl) for 2 h at room temperature toblock unoccupied sites. The membrane was then incubated withpolyclonal antibody anti Serca (SERCA1/2/3 (H300) Santa-CruzBiotechnology) at a 1:500 dilution in TBS overnight at 4 °C in arocking motion. The membrane was washed 3 times with the TBSbu#er, containing 0.5% Tween 20. The membrane was then incubatedwith mouse antirabbit conjugated with horseradish peroxidase for 2 hat room temperature in a 1:2000 dilution in TBS. After an additionalwashing step (3 times with TBS and 0.5% Tween 20), the bound

Langmuir Article

dx.doi.org/10.1021/la303148u | Langmuir 2012, 28, 15392"1540115394

antibodies were revealed with Amersham ECL reagent (GE Helthcareand Life Science) in a Kodak Image Station 4000MM Pro (Kodak).

! RESULTSIn order to characterize the surface of nanomaterials and topropose new nanobiotechnological applications, it is offundamental importance to work with stable colloidal watersuspensions and the excellent colloidal behavior of SAMNspermitted some informative characterizations. In the presentcase, maghemite nanoparticles (SAMNs), synthesized accord-ing to an innovative, already described method,5,6 were used.The synthetic mechanism of maghemite formation under ourexperimental conditions, brie!y described in the Materials andMethods section, comprises the reduction of iron(III) byborohydride in water, leading to zerovalent iron. The reaction isconducted in an ammonia containing, alkaline solution, whichgenerates very easily an unstable intermediate. This inter-mediate, right after its formation, is heated at 100 °C and agedin water, giving maghemite nanoparticles, with no traces ofother iron compounds. After curing this material at 400 °C, weobtain the "nal product, characterized for being stoichiometriccrystalline maghemite nanoparticles with peculiar surfaceproperties. The synthetic mechanism of maghemite formationunder our experimental conditions is under detailed study.The resulting nanoparticles were suspended in bidistilled

water by using an ultrasonic bath (Bransonic, model 221 at 48kHz, 50 W). Once formed, this colloidal suspension of baremaghemite nanoparticle was stable, without precipitation oraggregation phenomena, for more than 6 months, in contrastwith other maghemite nanoparticles described in literature.20,21

The remarkable aqueous suspensions stability of SAMNs wasexploited to obtain information on nanoparticle surfacebehavior by pH titration. An aliquot of SAMN colloidal watersuspension (50 mL, 200 mg/L) was brought at pH above 10.5with tetramethylammonium hydroxide and retro-titrated with 1M perchloric acid. Two di#erent pKa were evidenced (pKa1 =5.0 and pKa2 = 8.5), demonstrating the presence of di#erentionizable groups on SAMN surface, di#erently to data reportedin literature.22 From the same titration curve, 2.5 meq/gSAMNs for each ionizable group were estimated.In order to obtain deeper information on the nature of

nanoparticle surface, SAMNs (500 mg/L) were suspended in0.10 M K4Fe(CN)6 (50 mL) and stirred for about 30 min.Then, under continuous stirring, few drops of 6 M HCl wereadded, till pH 3.5. The resulting mixture turned to blue in fewseconds (see Figure 1A), forming the typical Prussian bluecolor, demonstrating the presence of under-coordinated Fe3+

functionalities on SAMN surface. In Figure 1B, the UV"visspectrum of bare and Fe(CN)6

4! modi"ed SAMNs is presented.The electronic absorption spectrum of bare SAMNs, acquiredin water, shows a wide band with a maximum at about 400 nm(Figure 1B) characterized by an extinction coe$cient of 1520M"1cm"1, expressed as Fe2O3 molar concentration. Further-more, we noticed that optical properties of SAMNs depend onthe presence of salts and on the pH of the suspension. In fact,the SAMN UV"vis spectrum acquired in 50 mM tetramethy-lammonium perchlorate, pH 7.0, resulted di#erent from thespectrum acquired in pure water see Figure 2A. The SAMNspectrum in tetramethylammonium perchlorate, pH 7.0, showsa wide absorption band characterized by two peaks, at 450 and500 nm, respectively. Optical properties of SAMN suspensionswere also analyzed as a function of pH, in the 200"800 nmspectral range. It was noticed that the wavelength of the

absorption maximum was constant, at 450 nm, in the 3.5 " 8.8pH range, and it decreased to 380 nm increasing the pH valuefrom 8.0 to 11.0 (see Figure 2B). The second peak, at 500 nm,gradually disappears with the increasing of pH, con"rming theinvolvement of surface properties on optical SAMN behavior.

SAMN Surface Functionalization with Biotin andAvidin. SAMN surface functionalization was accomplishedwith biotin and avidin by simple incubation of reactants in 50mM tetramethylammonium perchlorate, at pH 7.0. Inparticular, SAMN colloidal dispersion (50 mg/L) wereincubated with avidin (100 mg/L) or biotin (100 !M), underovernight end-over-end mixing at 4.0 °C. After the incubationperiod, nanoparticles were separated by the application of anexternal magnetic "eld and the presence of the biomolecule inthe supernatant was checked by spectrophotometry. SAMN@biotin or SAMN@avidin complexes were magnetically isolatedand washed several times with 50 mM tetramethylammoniumperchlorate, pH 7.0, and water. Biomolecule coverage onSAMNs was stable, without any loss in solution of biotin oravidin, as checked by spectrophotometry. Even the interactionof avidin and biotin with SAMN surface produced an alterationof nanoparticle optical properties. In this case, both the shapeand the position of maximum absorption were altered, furtherdemonstrating the in!uence of SAMN surface properties onoptical characteristics. In water, SAMN@avidin presents a

Figure 1. SAMNs super"cially derivatized with Fe(CN)64!. Photograph

of bare SAMNs and SAMN@Fe(CN)64! suspensions. Optical

spectrum of bare SAMN and SAMN@Fe(CN)64! suspension acquired

in a 1 cm quartz cuvette in water. (---) bare SAMN; (!) SAMN@Fe(CN)6

4!.

Langmuir Article

dx.doi.org/10.1021/la303148u | Langmuir 2012, 28, 15392"1540115395

single broad absorption peak, red-shifted by about 10 nm withrespect to bare SAMNs, whereas the spectrum of SAMN@biotin is characterized by two peaks, at 450 and 510 nm (seeFigure S2).SAMN@biomolecule complexes were also studied by

transmission electron microscopy (TEM) and FTIR. TEMmicroscopy images of the SAMN@biotin complex indicate thepresence of an organic matrix, as a 2"3 nm sized shell aroundiron oxide nanoparticles, characterized by a lower electrondensity, attributable to biotin bound molecules on the SAMNsurface.SAMN@biotin complex was characterized by FTIR spec-

troscopy and compared with underivatized SAMNs. Aremarkable change in the FTIR spectrum of SAMNs uponbiotin binding, recorded in the 400"4000 cm"1 range, con"rmsthe binding of biotin on the SAMN surface (see Figure 3). TheFTIR spectrum of free biotin shows two strong bands in theregion around 1700 cm"1: The most intense band at 1706 cm"1

is assigned to the asymmetric C!O stretching of theprotonated carboxylate group, whereas the band at 1684cm"1 is due to the C!O stretching vibration of the ureidogroup.23,24 It can be observed that the IR spectrum of theSAMN@biotin complex does not show any of the two IRbands, suggesting that both the carboxyl terminal group of thevaleric acid chain and the carbonyl of the ureido group areinvolved in the binding,25 possibly with under-coordinatediron(III) sites, as discussed by Chen and co-workers.26

As a low molecular weight ligand, such as biotin, couldcompletely adhere to the surface of nanoparticles, hindering itsrecognition by avidin, SAMN@biotin complex was tested byquartz crystal microbalance (QCM). In this case, the goldsurface of the piezoelectric crystal was derivatized with avidin,then 50 !g/mL SAMN@biotin complex was injected in theQCM !ow-through system. No variation of the resonancefrequency acquired by QCM was observed, con"rming that thebinding capacity of SAMN@biotin toward avidin wascompromised, and bound biotin cannot be recognized byavidin, as suggested by FTIR measurements. The unavailabilityof bound biotin for avidin binding lead us to exclude SAMN@biotin for the development of any further application.SAMN@avidin complex was prepared as already described

and characterized by TEM, FTIR spectroscopy and QCM.TEM images of SAMN@avidin showed the presence of an

organic shell coverage around the iron oxide nanoparticle (seeFigure 4), characterized by a shell thickness of about 5 nm, anda lower contrast of particles themselves, which are moreembedded in the organic matrix. The shell thickness is in goodagreement with avidin size (5.6 ! 5.0 ! 4.0 nm).27 Theaggregation phenomenon showed by the coated nanoparticlesis probably due to TEM sample pretreatment and drying on thecopper grid. In water suspensions SAMN@avidin still maintaintheir stable colloidal behavior.From the FTIR spectrum of SAMN@avidin (see Figure 5),

the presence of typical IR bands, attributable to proteinvibrational frequencies of C!C, C!O, and CH2" groups, inthe 1000"1700 cm"1 range, appeared,28 con"rming thepresence of avidin bound on nanoparticle surface. In particular,the characteristic protein amide I and amide II IR bands at 1654

Figure 2. Optical spectrum of SAMN suspension. Spectrum ofnanoparticles (50 mg/L), dispersed by sonication, acquired in a 1 cmquartz cuvette. (---) SAMN in water, pH 7.0; (!) SAMN in 50mM tetramethylammonium perchlorate, pH 7.0. Dependence of thewavelength of maximum absorption of a nanoparticle colloidaldispersion as a function of pH. Nanoparticle colloidal dispersion(100 mg/L) was prepared in 50 mM tetramethylammoniumperchorate. The pH was controlled by small additions of perchloricacid and tetramethylammonium hydroxide.

Figure 3. FTIR spectrum of the SAMN@biotin complex. Nano-particles samples were lyophilized, homogenized with KBr powder andpelleted by an 8.0 tons hydraulic press. (!) SAMN, (---) biotin,and (····) SAMN@biotin. Inset: Detail of the FTIR spectrum ofSAMN@biotin complex.

Langmuir Article

dx.doi.org/10.1021/la303148u | Langmuir 2012, 28, 15392"1540115396

and 1544 cm"129 are present in the SAMN@avidin FTIRspectrum (see Figure 5).As the interactions between proteins and solid surfaces could

lead to signi"cant changes in protein structure30 and,31 possiblyaltering protein functionality and biological activity, as well asmodifying ligand accessibility due to unproper orientation ofbound protein, SAMN@avidin binding properties were testedby quartz crystal microbalance (QCM), in which the goldsurface of the piezoelectric crystal was derivatized with biotin,as described in Methods. Upon injection of 100 !L of 100 mgL"1 SAMN@avidin suspension in the !ow-through QCMsystem, a 40 Hz decrease in the resonance frequency of thebiotin derivatized crystal was observed, indicating the bindingoccurrence and con"rming the binding capacity of theSAMN@avidin complex.Furthermore, data on avidin binding on SAMN surface were

analyzed according to the Langmuir isotherm model.32 Theanalysis was carried out on the assumptions that each bindingsite acts independently of other sites.33 The surface fractional

coverage of protein was calculated using the followingsaturation function:34,35

# = ## = +

K PK P[ ]

1 [ ]max (2)

where ' is the surface fractional coverage of bound protein,$max is the surface concentration of protein at the fullmonolayer coverage, K is the apparent binding constant, and$ is the surface concentration of associated proteins when thebulk concentration of protein is [P]. A linear plot of theexperimentally determined ' " 1 as a function of [P] " 1 yieldsthe value of the binding constant, K. In the case of the SAMN@avidin complex, $max was 100 !g mg"1 and K was 45.18 !L!g"1. The comparison with literature on nanoparticle surfacebinding of proteins showed comparable results.36 A value of$max 100 !g mg

"1 corresponds to 17 avidin molecules in a closepacked geometry. Bound avidin was also determined bymeasuring the disappearance of free avidin absorbance at 280nm (%280 nm = 6.99 ! 104 M"1 cm"1), as a function of increasingnanoparticle concentration, in the range 200"1800 mg L"1, in50 mM tetramethylammonium perchlorate, pH 7.0. Exper-imental data showed the presence of 12 ± 3 (n = 5) avidinmolecules per nanoparticle, in good agreement with themaximum coverage capacity calculated according to theLangmuir isotherm model. As a comparison, the possibletheoretical number of avidin molecules on SAMN surface,considering the geometry of the protein on a sphere of 5.5 nmradius, gives 11"16 avidin molecules per nanoparticle(considering di#erent protein orientations).The biological activity of SAMN@avidin complex was

evaluated and the number of available biotin binding siteswas determined, using biotinyl-!uorescein as a probe, showingthat each bound avidin molecule is able to bind 2.8 ± 0.8 biotinmolecules, con"rming the maintenance of biological activityand excellent binding capacity of SAMN@avidin.

Human SERCA, Isoform 2a, Puri!cation. Yeast culture(4 L) was used for each puri"cation trial, from which about 115g of dry cell pellet was recovered. The estimated total proteincontent in the membrane fraction was of about 26 mg.Since recombinant human SERCA-2a (hSERCA-2a-

(R863G)-BAD) competes with the endogenous biotinylatedproteins for the binding to avidin, a large excess (134 mg) ofSAMN@avidin was used for the puri"cation. Furthermore theCoomassie stained gels showed that a signi"cant amount of therecombinant protein was still present in the supernatant afterincubation with the nanoparticles (Figure 6). Therefore anadditional puri"cation step with SAMN@avidin was performed,by incubating the supernatant previously recovered with freshnanoparticles, to increase the recovery of the recombinantprotein. Elution of the protein was achieved by overnightincubation of the nanoparticles with thrombin. The fusionhSERCA-2a(R863G) protein was then released in the super-natant, while the BAD domain remained immobilized onto theSAMN@avidin surface. About 1 mg of protein was obtainedfrom magnetic a$nity puri"cation with SAMN@avidin. Thepuri"cation steps were followed by Coomassie stained PAGE-electrophoresis and Western blot, from the crude yeasts lysateto the gel "ltration puri"ed product. As shown in Figure 6, amajor band of about 80 kDa was visible in Coomassie stainedgels. This band was also detected by Western blot analyses withrabbit polyclonal anti-SERCA (Figure 7) and is thereforeattributable to hSERCA-2a(R863G). The di#erence between

Figure 4. TEM image of the SAMN@avidin complex.

Figure 5. FTIR spectrum of the SAMN@avidin complex. Nano-particles samples were lyophilized, homogenized with KBr powder andpelleted by an 8.0 tons hydraulic press. (!) SAMN, (---) avidin,and (····) SAMN@avidin.

Langmuir Article

dx.doi.org/10.1021/la303148u | Langmuir 2012, 28, 15392"1540115397

the apparent molecular weight of puri"ed SERCA-2a(R863G)(80 kDa) and the expected weight, reported in the literature(115 kDa), is attributable to the e#ect of the detergent on the

electrophoretic mobility of the protein in SDS-PAGE, as oftenreported for hydrophobic proteins in the presence ofdetergents.36 Finally, a gel-"ltration step (Figure S3) performedto increase protein purity and to eliminate excess thrombinyielded to 500 !g of puri"ed protein. The amount ofrecombinant rabbit SERCA-1a was previously estimated to beabout 3% of the total protein content in the membrane fractionof S. cerevisiae.15 Because of the high sequence similaritybetween rabbit SERCA-1a and hSERCA-2a(R863G)-BAD, it ispossible to assume that the expression levels of the two proteinsin yeast are the same. Therefore, based on this assumption, wecalculated a yield in the puri"cation process of about 64%.The stability of the SAMN@avidin complex was veri"ed.

SAMN@avidin complex was stored in sterile 50 mMtetramethylammonium perchlorate, pH 7.0, at 4 °C, and itwas successfully applied for hSERCA-2a(R863G) puri"cationwithin 6 months.

SAMN@avidin Regeneration. After hSERCA-2a(R863G)puri"cation, the biotin binding domain (BAD) remains boundSAMN@avidin (SAMN@avidin-BAD). The regeneration ofSAMN@avidin was successfully accomplished by using amodi"cation of the method proposed by Promega Corporationfor the Softlink Soft Release Avidin Resin. Brie!y, SAMN@avidin-BAD was incubated in 10% acetic acid, containing anexcess of biotin (1 mM), under continuous stirring at 4 °C, inorder to partially denature immobilized avidin and to competewith bound biotin binding domain (BAD) and otherbiotinylated proteins, derived by the yeast colture. A largeamount of biotin had been used in order to guarantee the totaland irreversible protein removal. After SAMN@avidin washingtwice with 1 mM biotin in 10% acetic acid, biotin was removedby washing SAMN@avidin twice with 10% acetic acid.Immobilized avidin was refolded in 0.1 M potassium phosphatebu#er, pH 7.0. The biological activity of the regeneratedSAMN@avidin was tested by titration of biotin binding siteswith biotinylated !uorescein, as described in Methods. Afterregeneration, each avidin molecule bound to SAMN surface isable to bind 2.0 ± 0.4 biotin molecules, indicating that afterhSERCA-2a puri"cation and regeneration, SAMN@avidinmaintain 60% of its puri"cation e$ciency.

! DISCUSSIONSurface characteristics of bare SAMNs confer the peculiarability to form colloidal suspensions, stable for months,suggesting a network of interactions with water moleculesand repulsive forces, inhibiting nanoparticle aggregation. At thesame time, nanoparticle surface is able to interact with organicmolecules in solution. In our previous work we presented asimple electrostatic model to explain SAMN peculiar surfaceproperties6 and in a following paper we used rhodamineisothiocyanate, as a !uorescent surface probe, suggesting amultiple point binding, involving both electrostatic interactionsand complex formation with under-coordinated iron atoms onSAMNs surface, generated by crystal truncation.38 In thepresent report we found further evidence of the involvement ofunder-coordinated iron atoms on SAMN surface in the bindingwith biological molecules. A strong evidence of the presence ofunder-coordinated iron atoms on SAMN surface was obtainedby Prussian Blue formation after incubation of SAMNs inK4Fe(CN)6 containing solutions. The UV"vis spectrum of theSAMN@Fe(CN)6

4! was similar to that presented by Zhao etal.39 (Figure 1) on magnetite nanoparticles covered by PrussianBlue. In our case no addiction of Fe3+ was necessary for the

Figure 6. Coomassie stained SDS-PAGE of the di#erent puri"cationsteps of hSERCA-2a(R863G) with SAMN@avidin. Collected sampleswere diluted in SDS-PAGE loading bu#er (20 !L of sample diluted in20 !L loading bu#er) and 20 !L of the resulting mixture were loadedon a 10% polyacrylamide gel as follow. 1: membrane pellet; 2:solubilized fraction; 3: supernatant after incubation with SAMN@avidin; 4: washing fraction (with 1 M KCl); 5: eluted fraction from themagnetic puri"cation with SAMN@avidin; 6: eluted fraction fromSEC-FPLC (size-exclusion chromatography-fast protein liquid chro-matography); 7: molecular weight markers.

Figure 7. Western blotting analyses of puri"ed fractions. Samples ofthe eluted fractions were diluted in loading bu#er (as previouslydescribed) and loaded on an SDS-PAGE acrylamide gel. Afterelectrophoresis, the proteins were transferred to nitrocellulosemembranes and hSERCA-2a was detected with rabbit polyclonalantibodies against SERCA (SERCA1/2/3, Santa Cruz Biothecnology)as primary antibody, and with mouse antirabbit conjugated with horseradish peroxidase (AMS Biotechnology ltd). 1: membrane pellet; 2:solubilized fraction; 3: supernatant after incubation with SAMN@avidin; 4: washing fraction (with 1 M KCl); 5: eluted fraction from themagnetic puri"cation with SAMN@avidin; 6: eluted fraction fromSEC-FPLC (size-exclusion chromatography-fast protein liquid chro-matography); 7: molecular weight markers.

Langmuir Article

dx.doi.org/10.1021/la303148u | Langmuir 2012, 28, 15392"1540115398

reaction taking place, con"rming both the presence of under-coordinated Fe3+ on SAMN surface and their availability towardchelating molecules. Up to author knowledge few reports canbe found in literature about optical characteristics of watersuspensions of bare nanocrystalline maghemite,40 probablybecause it is unusual to obtain stable colloidal suspensions ofthis kind of material. According to Sherman et al.41 iron oxideoptical properties, peculiar of semiconductor metal oxides, canbe explained considering that the valence band consists mostlyof O(2p)-like orbitals, together with the occupied Fe(3d)orbitals, and the conduction band consists of unoccupiedFe(3d) orbitals. Thus, the band gap corresponds to a ligand-to-metal charge-transfer (LMCT) transition, O(2p) ! Fe(3d).Although the band gap of maghemite is 2.01 eV (611 nm), thevisible transitions are thought to be indirect transitions (d ! dtype).38 Depending on the iron oxide material, directtransitions from O(2p) valence band orbitals to the conductionband edge occur in the range comprised between 3 and 4.7 eV(257"413 nm).42 As consequence, in agreement with literatureprediction, our 400 nm maximum absorption wavelength isattributable to the direct transitions from O(2p) valence bandorbitals to the conduction band edge. Furthermore, opticalproperties of metal oxide in the nanometer range size areexpected to be sensitive to surface characteristics.43 Conversely,the modi"cation of nanoparticle surface will re!ect on opticalspectrum, as we observed on SAMNs upon salt addition, pHvariations and biomolecule binding (see Figures 1, 2, and S2).Rajh et al43 found a comparable binding behavior of TiO2,

ZrO2, and Fe2O3 toward chelating ligands. The phenomenon isexclusively characteristic of metal oxide systems displayingcolloidal stability, high crystallinity, dimensions below 20 nm,and SAMNs perfectly adhere to these requirements. In this sizedomain the surface atoms adjust their coordination environ-ment to form under-coordinated metal sites and ligand bindingis favored because of the stability gained from ligand adsorptioninduces a restructuration of the nanoparticle surface. As aconsequence, surface modi"cation of nanocrystalline metaloxide particles alters nanoparticle optical properties.43 Avidinand biotin probably adjust the coordination geometry of thesurface Fe3+ atoms and shift the onset of absorption bandtoward the visible region of the spectrum, compared tounmodi"ed SAMNs. The solvent, as well, in!uences SAMNoptical absorption, by interacting with the under-coordinatedsites on SAMNs surface.The possibility to form stable interactions with selected

organic molecules leads us to propose the avidin"biotin couplefor SAMN derivatization. In particular, SAMN@biotin resultedunuseful for biotechnological application, even if informativeabout nanoparticle surface properties, possibly con"rming thepresence of under-coordinated iron(III) atoms on nanoparticlesurface, as already suggested.23 The higher complexity of FTIRspectrum of avidin did not allow us to distinguish about theinvolvement of speci"c protein functional groups in SAMNbinding. Nevertheless, avidin binds on nanoparticle surface by amonomolecular layer e#ectively and quickly, by simpleincubation in aqueous solution without any expensive reagentor cumbersome procedure, thus reducing the overallunoccupied surface area and, as a consequence, reducingnonspeci"c protein absorption phenomena and achieving ahigh speci"city.Protein structural changes upon binding on a solid surface

are well documented.31 These protein conformational mod-i"cation may negatively a#ect ligand accessibility and, in the

case of avidin, the biotin binding site recognition properties andavailability. For this reason, the biological activity of SAMN@avidin complex was studied, in terms of number of biotinylablesites, by using a !uorescent probe, namely biotinyl-!uorescein.From the experimental data, each avidin molecule immobilizedon SAMN surface is able to bind 2.8 ± 0.8 biotin molecules,indicating a good binding capacity of SAMN@avidin, and, asconsequence, the absence of signi"cant changes in proteinstructure and of its binding sites.Furthermore, SAMN@avidin complex was successfully

applied to the puri"cation of a membrane protein, namelyrecombinant human SERCA-2a(R863G), previously biotiny-lated in S. cerevisiae, which present a still unknown structure.The proposed system enabled the magnetic a$nity isolation ofhuman SERCA-2a(R863G), from yeast lysate, with anestimated 64% yield and SAMN@avidin, after the puri"cationprocedure, was regenerated by an optimized method.The high speci"city exhibited by SAMN on protein

separation suggests that these magnetic nanoparticles couldbe successfully used as a general and versatile system for proteinisolation, possibly feasible for other biological targets.

! CONCLUSIONSA new category of maghemite nanoparticles (SAMNs), with asize of about 10 nm, has been proposed and applied. DespiteXRD, low-temperature, and in-"eld Mo"ssbauer and FTIRspectroscopic data, con"rm that SAMNs are composed ofstochiometric maghemite,5,6 these particles, easily matchingwith the interest in biotechnology, revealed di#erent surfacecharacteristics from other reported maghemite nanoparticles.Beyond the peculiar dispersion properties, giving stable watercolloidal suspensions without any organic or inorganiccoverage, and the possibility to adsorb organic molecules, we"rst evidenced a unique titration behavior and peculiar UV"visspectrum. We pointed out the accessibility and availability ofunder-coordinated Fe3+ by a simple reaction with K4Fe(CN)6leading to Prussian Blue formation, and we illustrated thatSAMN spectral parameters appear to depend on the bu#er, onsuspension pH and on coupling biomolecules, indicating thatnanoparticle optical characteristics are governed by surfaceproperties, in agreement with surface reconstruction theory,43

probably justifying the peculiar behavior of SAMN suspensions,their high stability in water and their ability of adsorbingbiomolecules, features that lead us to propose a newbiotechnological device, such as SAMNs@avidin, which canbe successfully used to isolate and purify biotinylated proteins.Despite signi"cant and considerable recent improvements,

the expression and the subsequent puri"cation of functionallyfolded membrane proteins in su$cient amounts for functionaland structural studies is still a challenging task; we used theproposed system to purify a hydrophobic membrane protein,the recombinant hSERCA-2a, expressed for the "rst time inyeast. Few expression systems are successfully used to producemilligram quantities of membrane proteins, in recent years,yeasts have become the second most popular membraneproteins expression system, after E. coli, more cost-e#ectivethan expression in mammalian or insect cell lines and oftenshowing higher yields. Structural studies require that puri"edmembrane proteins should be chemically and conformationallyhomogeneous, stable at relatively high concentrations andavailable in milligram amounts, as consequence, high expressionrates are necessary. In this report we were able to purify for the"rst time recombinant hSERCA-2a, expressed in yeast, in the

Langmuir Article

dx.doi.org/10.1021/la303148u | Langmuir 2012, 28, 15392"1540115399

presence of a great amount of fouling agents, other competitivebiotinylated proteins and detergents. Our system allowed us toreach the promising yield of 500 !g, a su$cient amount for thecharacterization of membrane proteins by in vitro approaches.Moreover, the complete puri"cation process, from SAMNssynthesis to their application, is cost-e#ective, fast andecologically green.

! ASSOCIATED CONTENT*S Supporting InformationSize distribution of SAMNs (Figure S1), optical spectra ofSAMN@avidin and SAMN@biotin suspension (Figure S2),and chromatographic exclusion pro"le from SEC-FPLC ofhSERCA-2a(R863G) (Figure S3). This material is available freeof charge via the Internet at http://pubs.acs.org.

! AUTHOR INFORMATIONCorresponding Author*Tel.: 0039-049-8276863. Fax: 0039-049-8073310. E-mail:fabio.vianello@unipd.it.NotesThe authors declare no competing "nancial interest.

! ACKNOWLEDGMENTSThe authors gratefully acknowledge the support by theOperational Program Research and Development for Innova-tions, European Regional Development Fund (ProjectCZ.1.05/2.1.00/03.0058), the Operational Program Educationfor Competitiveness, European Social Fund (Project CZ.1.07/2.3.00/20.0155) of the Ministry of Education, Youth andSports of the Czech Republic, and the Grant Agency of theAcademy of Sciences of the Czech Republic (KAN115600801and KAN200380801). The present experimental work waspartially funded by Italian Institutional Ministry Grants Cod.60A06-7411 and 60A06-8055.

! REFERENCES(1) Gupta, A. K.; Gupta, M. Synthesis and surface engineering of ironoxide nanoparticles for biomedical applications. Biomaterials 2005, 26,3995"4021.(2) Thorek, D. L.; Chen, A. K.; Czupryna, J.; Tsourkas, A.Superparamagnetic iron oxide nanoparticle probes for molecularimaging. Ann. Biomed. Eng. 2006, 34, 23"38.(3) Mackay, M. E.; Tuteja, A.; Duxbury, P. M.; Hawker, C. J.; VanHorn, B.; Guan, Z.; Chen, G.; Krishnan, R. S. General Strategies forNanoparticle Dispersion. Science 2006, 311, 1740"1743.(4) Horak, D.; Babic, M.; Mackova, H.; Benes, M. J. Preparation andproperties of magnetic nano- and microsized particles for biologicaland environmental separations. J. Sep. Sci. 2007, 30, 1751"1772.(5) Magro, M.; Valle, G.; Russo, U.; Nodari, L.; Vianello, F.Maghemite nanoparticles and method for preparing thereof. Patent no.PCT/EP2010/060486, 2010.(6) Magro, M.; Sinigaglia, G.; Nodari, L.; Tucek, J.; Polakova, K.;Marusak, Z.; Cardillo, S.; Salviulo, G.; Russo, U.; Stevanato, R.; Zboril,R.; Vianello, F. Charge binding of rhodamine derivative to OH"stabilized nanomaghemite: universal nanocarrier for construction ofmagnetofluorescent biosensors. Acta Biomater. 2012, 8, 2068"2076.(7) Hage, D. S.; Cazes, J. Handbook of A!nity Chromatography, 2nded.; CRC Press, Taylor and Francis Group: Boca Raton, FL, 2005.(8) Turkova, J. A!nity chromatography; Elsevier Scienti"c PublishingCompany: Amsterdam, The Netherlands, 1978.(9) Safarik, I.; Safarikova, M. Magnetic techniques for the isolationand purification of proteins and peptides. Biomagn. Res. Technol. 2004,2, 7"24.

(10) Sauerbrey, G. Verwendung von Schwingquarzen zur Wagungdunner Schichtenund Microwagung. Z. Phys. 1959, 155, 206"222.(11) Laitinen, O. H.; Nordlund, H. R.; Hyto"nen, V. P.; Kulomaa, M.S. Brave new (strept)avidins in biotechnology. Trends Biotechnol. 2007,25, 269"277.(12) Livnah, O.; Bayer, E. A.; Wilchek, M.; Sussman, J. L. Three-dimentional structures of avidin and the avidin-biotin complex. Proc.Natl. Acad. Sci. U.S.A. 1993, 90, 5076"5080.(13) Gietz, R. D.; Woods, R. A. Transformation of yeast by Liac/SScarrier DNA/PEG method. Meth. Enzymol. 2002, 350, 87"96.(14) Jidenko, M.; Lenoir, G.; Fuentes, J. M.; le Maire, M.; Jaxel, C.Expression in yeast and purification of a membrane protein, SERCA1a,using a biotinylated acceptor domain. Prot. Expr. Purif. 2006, 48, 32"42.(15) Cardi, D.; Montigny, C.; Arnou, B.; Jidenko, M.; Marchal, E.; leMaire, M.; Jaxel, C. Heterologous expression and affinity purificationof eukaryotic membrane protein in view of functional and structuralstudies: The example of the sarcoplasmic reticulum Ca2+-ATPase.Methods Mol. Biol. 2010, 601, 247"267.(16) Smith, P. K.; Krohn, R. I.; Hermanson, G. T.; Mallia, A. K.;Gartner, F. H.; Provenzano, M. D.; Fujimoto, E. K.; Goeke, N. M.;Olson, B. J.; Klenk, D. C. Measurement of protein using bicinchoninicacid. Anal. Biochem. 1985, 150, 76"85.(17) Laemmli, U. K. Cleavage of structural proteins during theassembly of the heat of bacteriophage T4. Nature 1970, 227, 680"685.(18) Neuhoff, V.; Stamm, R.; Eibl, H. Clear background and highlysensitive protein staining with Coomassie Blue dyes in polyacrylamidegels: A systematic analysis. Electrophoresis. 1985, 6, 427"448.(19) Towbin, H. T.; Staehelin, T.; Gordon, T. Electrophoretictransfer of protein from polyacrylamide gels to nitrocellulose sheets:Procedure and applications. Proc. Natl. Acad. Sci. U.S.A. 1979, 76,4350"4354.(20) Harris, L. A.; Goff, J. D.; Carmichael, A. Y.; Riffle, J. S.; Harburn,J. J.; Pierre, T. G., St.; Saunder, S. M. Magnetite NanoparticleDispersions Stabilized with Triblock Copolymers. Chem. Mater. 2003,15, 1367"1377.(21) Jain, N.; Wang, Y.; Jones, S. K.; Hawkett, B. S.; Warr, G. G.Optimized Steric Stabilization of Aqueous Ferrofluids and MagneticNanoparticles. Langmuir 2010, 26, 4465"4472.(22) Simmons, G. W.; Beard, B. C. Characterization of Acid-BaseProperties of the Hydrated Oxides on Iron and Titanium MetalSurfaces. J. Phys. Chem. 1987, 91, 1143"1148.(23) Shindo, H.; Brown, T. L. Infrared Spectra of Complexes of L-Cysteine and Related Compounds with Zinc(II), Cadmium(II),Mercury(II), and Lead(II). J. Am. Chem. Soc. 1965, 87, 1904"1909.(24) Bellamy, L. J. Advances in infrared group frequencies; MethuenCo. Ltd.: London, 1968.(25) Hegde, S.; Kapoor, S.; Joshi, S.; Mukherjee, T. Self-assembly ofAg nanoparticle"biotin composites into long fiberlike microstructures.J. Colloid Interface Sci. 2006, 297, 637"643.(26) Chen, L. X.; Liu, T.; Thurnauer, M. C.; Csencsits, R.; Rajh, T.Fe2O3 nanoparticle structures investigated by X-ray absorption near-edge structure, surface modifications, and model calculations. J. Phys.Chem. B 2002, 106, 8539"8546.(27) Pugliese, L.; Coda, A.; Malcovati, M.; Bolognesi, M. Three-dimensional structure of the tetragonal crystal form of egg-white avidinin its functional complex with biotin at 2.7A° resolution. J. Mol. Biol.1993, 231, 698"710.(28) Stuart, B. H. Infrared Spectroscopy: fundamentals and applications;John Wiley & Sons: Hoboken, NJ, 2004.(29) Haris, P. I.; Severcan, F. FTIR spectroscopic characterization ofprotein structure in aqueous and non-aqueous media. J. Mol. Catal. B:Enzymatic 1999, 7, 207"221.(30) Aubin-Tam, M. E.; Hamad-Schifferli, K. Structure and functionof nanoparticle"protein conjugates. Biomed. Mater. 2008, 3, 034001.(31) Fenoglio, I.; Fubini, B.; Ghibaudi, E. M..; Turci, F. MultipleAspects of the interaction of biomacromolecules with inorganicsurfaces. Adv. Drug Delivery Rev. 2011, 63, 1186"1209.

Langmuir Article

dx.doi.org/10.1021/la303148u | Langmuir 2012, 28, 15392"1540115400

(32) Langmuir, I. The adsorption of gases on plane surfaces of glass,mica and platinum. J. Am. Chem. Soc. 1918, 40, 1361"1403.(33) Yang, J.; Swaminathan, C. P.; Huang, Y.; Guan, R.; Cho, S.;Kieke, M. C.; Kranz, D. M.; Mariuzza, R. A.; Sundberg, E. J. DissectingCooperative and Additive Binding Energetics in the AffinityMaturation Pathway of a Protein-Protein Interface. J. Biol. Chem.2003, 278, 50412"50421.(34) Pisarchick, M. L.; Thompson, N. L. Binding of a monoclonalantibody and its Fab fragment to supported phospholipid monolayersmeasured by total internal reflection fluorescence microscopy. Biophys.J. 1990, 58, 1235"1249.(35) Hong, M. Y.; Lee, D.; Kim, H. S. Kinetic and EquilibriumBinding Analysis of Protein-Ligand Interactions at Poly(amidoamine)Dendrimer Monolayers. Anal. Chem. 2005, 77, 7326"7334.(36) Sun, S.; Ma, M.; Qiu, N.; Huang, X.; Cai, Z.; Huang, Q.; Hu, X.Affinity adsorption and separation behaviors of avidin on biofunctionalmagnetic nanoparticles binding to iminobiotin. Coll. Surf. B:Biointerfaces 2011, 88, 246"253.(37) Rath, A.; Glibowicka, M.; Nadeau, V. G.; Chen, G.; Deber, C.M. Detergent binding explains anomalous SDS-PAGE migration ofmembrane proteins. Proc. Natl. Acad. Sci. 2009, 106, 1760"1765.(38) Sinigaglia, G.; Magro, M.; Miotto, G.; Cardillo, S.; Agostinelli,E.; Zboril, R.; Bidollari, E.; Vianello, F. Catalytically active bovineserum amine oxidase bound to fluorescent and magnetically drivablenanoparticles. Int. J. Nanomed. 2012, 7, 1"11.(39) Zhao, G.; Feng, J.; Zhang, Q.; Li, P.; Chen, H. Y. Synthesis andCharacterization of Prussian Blue Modified Magnetite Nanoparticlesand Its Application to the Electrocatalytic Reduction of H2O2. Chem.Mater. 2005, 17, 3154"3159.(40) Cherepy, N. J.; Liston, D. B.; Lovejoy, J. A.; Deng, H.; Zhang, J.Z. Ultrafast Studies of Photoexcited Electron Dynamics in "- and (-Fe2O3 Semiconductor Nanoparticles. J. Phys. Chem. B 1998, 102, 770"776.(41) Sherman, D. M. Electronic structures of Fe3+ coordination sitesin iron oxides; applications to spectra, bonding and magnetism. Phys.Chem. Miner. 1985, 12, 161"175.(42) Sherman, D. M.; Waite, T. D. Electronic spectra of Fe3+oxidesand oxide hydroxides in the near-IR to near-UV. Am. Mineral. 1985,70, 1262"1269.(43) Rajh, T.; Chen, L. X.; Lukas, K.; Liu, T.; Thurnauer, M. C.;Tiede, D. M. Surface Restructuring of Nanoparticles: An EfficientRoute for Ligand-Metal Oxide Crosstalk. J. Phys. Chem. B 2002, 106,10543"10552.

Langmuir Article

dx.doi.org/10.1021/la303148u | Langmuir 2012, 28, 15392"1540115401

REFERENCES

103

REFERENCES

!"#$%&'( )*'( +,-./01"'( 2*3*'( 4&5,67,-'( 8*2*'( 9&6:'( ;*'( <%#01='( >*<*'( ,7( #-*'( ?@@A*( <BC-D7#7%&1-#7&16( /E(F,01GE6&70&7,( #$7&=#7,.( <H2I!( "D0&6:( #07,0&#-( 0,-#G#7&16( /E( 6&70&$( 1G&",*( J#7D0,(3,"*( K@'( FF*( K?@@BK?@L*(

!"#5.'(4*8*'(!M16&6,'(4*>*'(ND6O1$P&'(C*'(I%,6'(>*N*'(8#=&.'(Q*+*'(,7(#-*(?@K@*(4RHJQST(#($15F0,%,6.&=,(4E7%16B/#.,"(.E.7,5(M10(5#$0151-,$D-#0(.70D$7D0,(.1-D7&16*(!$7#(I0E.7#--1:0*(<,$7*(8BN&1-*(I0E.7#--1:0*(UU'(FF*(?KVB??K(

!-/,0.'(2*(+*'(KWUL*(N&1$%,5&$#-(#.F,$7.(1M(#$7&=,(70#6.F107*(!66D*(2,=*(N&1$%,5*(VU'(L?LXLYU*((

!.#%&'( 3*'( <D:&7#'( 9*'( ZD0PE"-1[.O&'( Z*'( 8,( \,16'( <*'( )#"#'( 3*( ,7( #-*'( ?@@V*( <#0$1-&F&6( 0,:D-#7,.(.#0$1],6"1^F-#.5&$(0,7&$D-D5(I#?_B!)4#.,(]<H2I!^(/E(/&6"&6:(71(70#6.5,5/0#6,(%,-&$,.(#-16,(10(&6(#..1$&#7&16([&7%(F%1.F%1-#5/#6*(401$*(J#7-(!$#"*(<$&*(`<!'(K@@'(FF*(Y@A@aY@AY*(

!=0#5&"1D'(!*'(Z01$P,O'(I*'(\#6:'(I*'(<$%D%'(+*'(;#$O'(R*(3*'(b(3&,-,6P'(8*(]?@@L^*()%,(61=,-(#"#F710(F017,&6(.[&F01.&6BK(,6%#6$,.(NI2(.&:6#-.(#6"($1670&/D7,.(71(NI2B&6"D$,"(#F1F71.&.*(I,--(8,#7%(8&MM,0'(KA'(KWVUBKWAL*((

N#--#710,'(I*'(\,,'(>*(3*'(b()01c#61[.O&'(;*(d*(]?@@L^*()#DB5,"&#7,"(6,D01",:,6,0#7&16(&6(#-P%,&5,0e.("&.,#.,(#6"(0,-#7,"("&.10",0.*(J#7(2,=(J,D01.$&'(f'(UUVBUL?*((

N,00&":,'(3*( ;*'(KWWL*(H-,5,67#0E(#6"(:-1/#-(#.F,$7.(1M( $#-$&D5(.&:6#--&6:*( ;*(4%E.&1-*'(AWW'(FF*(?WKaV@U*(

N,00&":,'(3*(;*'(N1175#6'(3*(8*'(b(\&FF'(4*(]KWWf^*(I#-$&D5BB#(-&M,(#6"(",#7%(.&:6#-*(J#7D0,'(VWY'(UAYBUAf*((

N,00&":,'(3*(;*'(N1175#6'(3*(8*'(21",0&$O'(R*(\*'(?@@V*(I#-$&D5(.&:6#--&6:T("E6#5&$.'(%15,1.7#.&.(#6"(0,51",-&6:*(J#7*(2,=*(31-*(I,--(N&1-*'(A'(FF*(YKLaY?W*(

N,00&":,'(3*(;*'(N1175#6'(3*8*'(\&FF'(4*'(KWWf*(I#-$&D5(a(#(-&M,(#6"(",#7%(.&:6#-*(J#7D0,'(VWY'(FF*(UAYaUAf*(

N,00&":,'(3*(;*'(\&FF'(4*'(b(N1175#6'(3*(8*(]?@@@^*()%,(=,0.#7&-&7E(#6"(D6&=,0.#-&7E(1M($#-$&D5(.&:6#--&6:*(J#7(2,=(31-(I,--(N&1-'(K'(KKB?K*((

N0#6"-'(I*(;*'(",\,16'(<*'(3#07&6'(8*(2*(b(3#$\,66#6'(8*(R*'(KWfL*((!"D-7(M105.(1M(7%,(I#?_(!)4#.,(1M(.#0$1F-#.5&$(0,7&$D-D5*(HGF0,..&16(&6(",=,-1F&6:(.O,-,7#-(5D.$-,*(;*(N&1-*(I%,5*(?U?'(VLUfXVLLA*(

N0&6&'(3*'(I#0#M1-&'(H*'(?@@W*(I#-$&D5(FD5F.(&6(%,#-7%(#6"("&.,#.,*(4%E.&1-*(2,=*(fW'(FF*(KVAKBKVLf*(

N0D6:,0'(!*)*'(!"#5.'(4*8*'(I-10,'(C*3*'(8,\#61'(+*\*'(C01.'(4*'(,7(#-*'(KWWf*(I0E.7#--1:0#F%E(b(J32(.E.7,5T(!(6,[(.1M7[#0,(.D&7,(M10(5#$0151-,$D-#0(.70D$7D0,(",7,05&6#7&16*(!$7#(I0E.7#--1:0*(<,$7*(8BN&1-*(I0E.7#--1:0*(YA'(FF*(W@YBW?K*(

NDMME'(;*(;*'(ND$OBZ1,%671F'(N*(!*'(410$,--&'(g*'()0##.,7%'(J*(;*'()%15#.'(8*(8*(,7(#-*'(?@@U*(8,M&6&6:(7%,(&670#5,5/0#6,(/&6"&6:(5,$%#6&.5(1M(.#0$1-&F&6(71($#-$&D5(!)4#.,(D.&6:(.1-D7&16(J32(.F,$701.$1FE*(;*(31-*(N&1-*(VYf'(FF*(A?@aA?W*(

104

I#0#M1-&'( H*'( b( N0&6&'( 3*( ]?@@@^*( I#-$&D5( FD5F.T( <70D$7D0#-( /#.&.( M10( #6"( 5,$%#6&.5( 1M( $#-$&D5(70#6.5,5/0#6,(70#6.F107*(ID00,67(hF&6&16(&6(I%,5&$#-(N&1-1:E'(A]?^'(KY?BKUK*((

I#0#M1-&'(H*'(<#67,--#'(\*'(N0#6$#'(8*'(b(N0&6&'(3*(]?@@K^*(C,6,0#7&16'($16701-'(#6"(F01$,..&6:(1M($,--D-#0($#-$&D5(.&:6#-.*(I0&7(2,=(N&1$%,5(31-(N&1-'(VU'(K@LB?U@*((

I#0"&'(8*'(3167&:6E'(I*'(!061D'(N*'( ;&",6O1'(3*'(3#0$%#-'(H*'( -,(3#&0,'(3*'(,7(#-*( ]?@K@^*(R,7,01-1:1D.(,GF0,..&16( #6"( #MM&6&7E( FD0&M&$#7&16( 1M( ,DO#0E17&$( 5,5/0#6,( F017,&6.( &6( =&,[( 1M( MD6$7&16#-( #6"(.70D$7D0#-( .7D"&,.T()%,(,G#5F-,(1M( 7%,( .#0$1F-#.5&$( 0,7&$D-D5($#]?_^B!)4#.,*(3,7%1".( &6(31-,$D-#0(N&1-1:E(]I-&M716'(J*;*^'(U@K'(?ALB?UL*((

I%#0-&,0(I'(I1FF&,7,0.(+'(21--&6(g'(8,.5,$%7(8'(!:,0%1-5(;<'(,7(#-*'(?@@f*(R&:%-E(,MM,$7&=,(<J4B/#.,"(#..1$&#7&16(5#FF&6:(#6"(5#6#:,5,67(1M(0,$,..&=,(",M,$7.(&6(-&=,.71$O*(J#7(C,6,7*(A@'(FF*(AAWBAYA*(

I%,6'(\*'(<D5/&--#'(I*'(\,[&.'(8*'(i%16:'(\*'(<701$O'(I*'(Z&07-,E'(3*(H*'(#6"(Q6,.&'(C*'(KWWU*(;*(N&1-*(I%,5*(?LK'(K@LAYXK@LY?*(

I%,6'(i*'(!O&6'(N*(\*'(b(;16,.'(\*(2*(]?@@L^*(3,$%#6&.5(1M(0,=,0.#-(1M(F%1.F%1-#5/#6(&6%&/&7&16(1M(7%,($#0"&#$( I#?_B!)4#.,( /E( F017,&6( O&6#.,( !( #6"( /E( #67&BF%1.F%1-#5/#6( 5161$-16#-( #67&/1"E( ?8K?*(;1D06#-(1M(N&1-1:&$#-(I%,5&.70E'(?f?]?W^'(?@WUfB?@WLU*((

I%,6'(i*'(!O&6'(N*(\*'(b(;16,.'(\*(2*(]?@K@^*(I#?_(/&6"&6:(71(.&7,(Q(1M(7%,($#0"&#$(I#?_(FD5F(&.(.DMM&$&,67(71("&..1$&#7,(F%1.F%1-#5/#6*(;1D06#-(1M(N&1-1:&$#-(I%,5&.70E'(?fY]Y^'(V?YVBV?U@*((

I%,6'( i*'( !O&6'( N*( \*'( <71O,.'( 8*( \*'( b( ;16,.'( \*( 2*( ]?@@U^*( I01..B-&6O&6:( 1M( IB7,05&6#-( 0,.&"D,.( 1M(F%1.F%1-#5/#6(71(7%,(I#?_(FD5F(1M($#0"&#$(.#0$1F-#.5&$(0,7&$D-D5(71(F01/,(.F#7&#-(#6"(MD6$7&16#-(&67,0#$7&16.( [&7%&6( 7%,( 70#6.5,5/0#6,( "15#&6*( ;1D06#-( 1M( N&1-1:&$#-( I%,5&.70E'( ?fK]?@^'( KAKUVBKAKL?*((

I%&61'(!*'(+#7#6#/,'(Z*'(b(310&E#'(R*(]?@K@^*(4-#.5&"($16.70D$7&16(D.&6:(0,$15/&6#7&16(#$7&=&7E(&6(7%,(M&..&16(E,#.7(.$%&P1.#$$%#015E$,.(F15/,*(4-1<(h6,'(Y]V^'(,WUY?*((

I%D'( !*'( <#&71'( !*'( g-,&.$%,0'( <*'( KWfL*( 40,F#0#7&16( #6"( $%#0#$7,0&P#7&16( 1M( -16:&7D"&6#-( 7D/D-,.( 1M(.#0$1F-#.5&$(0,7&$D-D5(M015(M#.7(.O,-,7#-(5D.$-,*(!0$%*(N&1$%,5*(N&1F%E.*(?Yf'(FF*(KVB?V*(

I-#F%#5(8*H*(KWWY*(I#-$&D5(.&:6#--&6:*(I,--'(f@'(FF*(?YWa?Uf*(

I-#0O,'( 8*( 3*'( \11'( )*( +*( b( 3#$\,66#6'( 8*( R*'( KWW@*( gD6$7&16#-( $16.,jD,6$,.( 1M( 5D7#7&16.( 1M($16.,0=,"( #5&61( #$&".( &6( 7%,( /,7#B.70#6"( "15#&6( 1M( 7%,( I#?_B!)4#.,( 1M( .#0$1F-#.5&$( 0,7&$D-D5*( ;*(N&1-*(I%,5*(?UY'(KA@ffXKA@W?*(

I1--#/10#7&=,( I15FD7#7&16#-( 401c,$7'( JD5/,0( A'( KWWA*( )%,( II4A( .D&7,T( F01:0#5.( M10( F017,&6($0E.7#--1:0#F%E*(!$7#(I0E.7#--1:0*(8(N&1-*(I0E.7#--1:0*(Y@'(FF*(LU@BLUV*(

8#&%1'()*'( 9#5#.#O&'(Z*'( <#&61'()*'(Z#5&"1$%&'(3*'( <#71%'(Z*'( ,7(#-*( ?@@K*(3D7#7&16.(1M(,&7%,0(10(/17%(IE.fLU(#6"(IE.fff(0,.&"D,.(1M(.#0$1F-#.5&$(0,7&$D-D5(I#?_B!)4#.,(0,.D-7(&6(#($15F-,7,(-1..(1M(I#?_(70#6.F107( #$7&=&7E( [&7%1D7( #( -1..( 1M( I#?_B",F,6",67( !)4#.,( #$7&=&7E*( 21-,( 1M( 7%,( I9<fLUBI9<fff("&.D-M&",(/16"*(;*(N&1-*I%,5*(?LU'(FF*V?LLKBV?LLf*(

8#6&,-( C&,7P'( 2*'( b(+11".'( 2*( !*( )0#6.M105#7&16( 1M( E,#.7( /E( -&7%&D5( #$,7#7,k.&6:-,B.70#6","( $#00&,0(8J!kF1-E,7%E-,6,(:-E$1-(5,7%1"*(3,7%1".(&6(,6PE51-1:E(]FF*(fLBWU^(!$#",5&$(40,..*((

REFERENCES

105

8,(3,&.'(\*'(R#..,-/#$%'(+*'(KWLK*(!$,7E-(F%1.F%#7,(#.(.D/.70#7,(M10(I#?_(DF7#O,(&6(.O,-,7#-(5D.$-,(5&$01.15,.*(Q6%&/&7&16(/E(#-O#-&(&16.*(;*(N&1-*(I%,5*(?AU'(FF*(ALYWBALUV*(

8D77&6:'( <*'( N0#$%.'( <*'( b( 3&,-,6P'( 8*( ]?@KK^*( g0#7,06#-( 7[&6.T( <[&F01.&6BKkHg%"?( #6"( .[&F01.&6B?kHg%"K'( 7[1( %151-1:1D.( HgB%#6"( $167#&6&6:( $#-$&D5( /&6"&6:( #"#F710( F017,&6.( [&7%( "&.7&6$7(MD6$7&16.*(I,--(I155D6&$#7&16(#6"(<&:6#-&6:'(W]K^'(?*((

H5.-,E'(4*'(I1[7#6'(Z*'(?@@A*(I117T(51",-B/D&-"&6:(711-.(M10(51-,$D-#0(:0#F%&$.*(!$7#(I0E.7#--1:0*(<,$7*(8BN&1-*(I0E.7#--1:0*(U@'(FF*(?K?UB?KV?*(

H=#6.'(4*'(?@@U*(<$#-&6:(#6"(#..,..5,67(1M("#7#(jD#-&7E*(!$7#(I0E.7#--1:0*(8(N&1-*(I0E.7#--1:0*(U?'(FF*(L?Bf?*(

g1::&#'(\*'(b(R1=6#6&#6'(!*(]?@@A^*(I#-$&D5(FD5F("&.10",0.(1M(7%,(.O&6*(!5,0&$#6(;1D06#-(1M(3,"&$#-(C,6,7&$.*4#07(I'(<,5&6#0.(&6(3,"&$#-(C,6,7&$.'(KVKI]K^'(?@BVK*((

g0#6O'(Z*(g*'(Nl-$O'(N*'(H0"5#66'(H*'(b(<$%[&6:,0'(2*(R*(C*(]?@@V^*(<#0$1F-#.5&$(0,7&$D-D5(I#?_B!)4#.,(51"D-#7,.($#0"&#$($1670#$7&16(#6"(0,-#G#7&16*(I#0"&1=#.$D-#0(2,.,#0$%'((>1-*(YL]K^'(FF*(?@B?L*(

C&#66&'(8*'(I%#6'(;*'(C[#7%5,E'(;*(Z*'(",-(3167,'(g*'(R#cc#0'(2*(;*'(?@@Y*(<H2I!?#(&6(%,#07(M#&-D0,T(01-,(#6"(7%,0#F,D7&$(F01.F,$7.*(;(N&1,6,0:(N&15,5/0'(>1-*(VL]U^'(FF*(VLYBf@*(

C-#=,.'( ;*(4*'()0&,/,0'(I*(!*'(I,%1-.O&'(8*(Z*'(<71O,.'(8*(\*'(b(91D6:'(R*(<*( ]?@KK^*(4%1.F%10E-#7&16(#6"(5D7#7&16( 1M( F%1.F%1-#5/#6( #-7,0( F%E.&$#-( &67,0#$7&16.( [&7%( 7%,( .#0$1F-#.5&$( 0,7&$D-D5( $#-$&D5(FD5F*(;1D06#-(1M(31-,$D-#0(N&1-1:E'(A@Y]V^'(L@LBL?V*((

C1"&$'(!*'(Z101.,$'(N*'(3&-cO1=&$'( ;*'(Z#6.OE'(!*'(b(C-#=#$'(8*( ]?@K@^*(g1D0(61=,-(!)4?!?(5D7#7&16.( &6(.-1=,6&#6(F#7&,67.([&7%("#0&,0("&.,#.,*(;1D06#-(1M(7%,(!5,0&$#6(!$#",5E(1M(8,05#71-1:E'(U?]Y^'(fKWBf?V*((

C1D-"'(C*+*'(H#.7'(;*3*'(g01D"'(2*;*'(3$+%&07,0'(;*3*'(<7,M#61=#'(,7(#-*'(KWfU*(!(O&6,7&$(51",-(M10(7%,(I#?_(_(3:?_B#$7&=#7,"(!)4#.,(1M(.#0$1F-#.5&$(0,7&$D-D5*(N&1$%,5*(;*(?VL'(FF*(?KLB??L*(

C0#/#0,O'(i*(]?@@U^*(<70D$7D0#-(/#.&.(M10("&=,0.&7E(1M(7%,(HgB%#6"($#-$&D5B/&6"&6:(F017,&6.*(;1D06#-(1M(31-,$D-#0(N&1-1:E'(VYW]V^'(Y@WBY?Y*((

C0m6/,0:(+*'(<#$$%,771(2*'(+&c6/,0:(Q*'(J,&c,6%D&.(Z*'(3#.$#0,--1(g*'(,7(#-*'(?@K@*(4.,D"15E1716&#'(#(5D.$-,( MD6$7&16("&.10",0(#..1$&#7,"([&7%(#6( &6%,0&7,"(!)4?!K(]<H2I!K^(",M,$7( &6(#(8D7$%( Q5F01=,"(2,"(#6"(+%&7,($01..B/0,,"($#-M*((J,D015D.$*(8&.10"*(?@'(FF*(AULBAL@*(

R,":,.(<*N*'(ZD5#0'(<*'(?@@V*(C,615&$($-1$O.(#6"(,=1-D7&16#0E(7&5,.$#-,.*()2HJ8<(&6(C,6,7&$.(KW'(FF*(?@@B?@U*(

Q6,.&'(C*'(40#.#"'(!*(3*'(b(4&-#6O#77#'(2*( ]?@@f^*()%,(I#?_(!)4#.,(1M($#0"&#$(.#0$1F-#.5&$( 0,7&$D-D5T(4%E.&1-1:&$#-(01-,(#6"(0,-,=#6$,(71("&.,#.,.*(N&1$%,5&$#-(#6"(N&1F%E.&$#-(2,.,#0$%(I155D6&$#7&16.'(VUW]K^'(Kf?BKfL*((

;,6$O.'(+*(4*(`7&-&P#7&16(1M(/&6"&6:(,6,0:E(#6"($1DF-&6:(0D-,.(M10(#$7&=,(70#6.F107(#6"(17%,0($1DF-,"(=,$710&#-(F01$,..,.*(3,7%1".(H6PE51-*(KLK'(KAYaKUA(]KWfW^(

;,6.,6'(!*\*'(<10,6.,6'()*\*'(h-,.,6'(I*'(31--,0'(;*>*'(J&..,6'(4*'(?@@U*(31"D-#710E(#6"($#7#-E7&$(51",.(1M(!)4(/&6"&6:(/E(7%,($#-$&D5(FD5F*(H3Nh(;*(?Y'(FF*(?V@YB?VKA*(

106

;&",6O1'( 3*'( \,61&0'( C*'( gD,67,.'( ;*( 3*'( -,( 3#&0,'( 3*'( b( ;#G,-'( I*( ]?@@U^*( HGF0,..&16( &6( E,#.7( #6"(FD0&M&$#7&16( 1M( #( 5,5/0#6,( F017,&6'( <H2I!K#'( D.&6:( #( /&17&6E-#7,"( #$$,F710( "15#&6*( 4017,&6(HGF0,..&16(#6"(4D0&M&$#7&16'(Af]K^'(V?BA?*((

;&",6O1'( 3*'( J&,-.,6'( 2*( I*'( <10,6.,6'( )*( \*'( 31--,0'( ;*( >*'( -,( 3#&0,'( 3*'( J&..,6'( 4*'( ,7( #-*( ]?@@Y^*(I0E.7#--&P#7&16( 1M( #( 5#55#-&#6( 5,5/0#6,( F017,&6( 1=,0,GF0,..,"( &6( .#$$%#015E$,.( $,0,=&.&#,*(401$,,"&6:.( 1M( 7%,(J#7&16#-(!$#",5E(1M( <$&,6$,.( 1M( 7%,(`6&7,"( <7#7,.( 1M(!5,0&$#'( K@?]VV^'( KKUfLBKKUWK*((

Z#[#.#O&'(R*'(b(Z0,7.&6:,0'(2*(R*(]KWWY^*(I#-$&D5B/&6"&6:(F017,&6.(KT(HgB%#6".*(4017,&6(401M&-,'(?'(?WLBAW@*((

Z%1'(I*'(\,,'(!*'(;,16:'(8*'(h%'(;*C*'(I%##6&6,'(,7(#-*'(?@KK*(<`3hKB",F,6",67(51"D-#7&16(1M(<H2I!?#(&6(%,#07(M#&-D0,*(J#7D0,(ALL'(FF*(U@KBU@U*(

Z&7#P161'( !*( !*( ]?@@W^*( Q5F01=,"( :#FB0,F#&0( $-16&6:( 5,7%1"( 7%#7( D.,.( 1-&:16D$-,17&",.( 71( 7#0:,7($1:6#7,(.,jD,6$,.*(9,#.7'(?U]W^'(AWLBY@Y*((

Z6ED.%O1'( )*>*'( <%#01='( >*<*'( +&--&#5.'( )*8*'( <$%l6,&$%'( I*'( N&:,-1['( 8*;*( ?@@Y*( ?BJ&7017E01.&6,(51"&M&$#7&16( 1M( <H2I!?#( &6( 7%,( #:&6:( %,#07T( #( "&.7&6$7( .&:6#7D0,( 1M( 7%,( $,--D-#0( 0,"1G( ,6=&0165,67*(N&1$%,5&.70E(AA'(FF*(KV@LKBKV@fK*(

Z01$P,O'( I*'( \#6:'( I*'( N0#$%.'( <*'( C01%5#66'(3*'( 8D77&6:'( <*'( <$%[,&P,0'( !*'( ,7( #-*( ]?@K@^*( <[&F01.&6BKkHg%"?( $16701-.( N( $,--( 0,$,F710( .&:6#-&6:( 7%01D:%( 7%,( #..,5/-E( 1M( 7%,( N( $,--( 0,$,F710'( .EO'( #6"(F%1.F%1-&F#.,(I(:#55#?(&6(5,5/0#6,(0#M7.*(;(Q55D61-'(KfA'(VUUYBVULU*((

Zm%-/0#6"7'(+*'(?@@A*(N&1-1:E'(.70D$7D0,(#6"(5,$%#6&.5(1M(4B7EF,(!)4#.,.*(J#7D0,(2,=*(31-*(I,--(N&1-*(Y'(?f?X?WY*(

\#.O1[.O&'(2*!*'(3#$#07%D0'(3*+*'(31..'(8*<*'()%106716'( ;*3*'(KWWV*(401$%,$O( B(#(401:0#5(71(I%,$O(7%,(<7,0,1$%,5&$#-(dD#-&7E(1M(4017,&6(<70D$7D0,.*(;*(!FF-*(I0E.7#--1:0*(?U'(FF*(?fVB?WK*(

\#D0.,6'(3*'(ND/-&7P'(3*'(316$1j'(Z*'(h-,.,6'(I*'(3l--,0'(,7(#-*'(?@@W*(IE$-1F&#P16&$(#$&"(&.($15F-,G,"(71(#("&=#-,67(5,7#-( &16([%,6(/1D6"(71( 7%,(.#0$1F-#.5&$( 0,7&$D-D5(I#?_B!)4#.,*( ;*(N&1-*(I%,5*(?fA'(FF*(KVYKVBKVYKf*(

\,,'( >*( 3*'( C1,",07'( 3*'( b( )01c#61[.O&'( ;*( d*( ]?@@K^*( J,D01",:,6,0#7&=,( 7#D1F#7%&,.*( !66D( 2,=(J,D01.$&'(?A'(KK?KBKKYW*((

\,61&0'( C*'( 3,6:DE'( )*'( I100,'( g*'( 3167&:6E'( I*'( 4,",0.,6'( 4*( !*'( )%&6,.'( 8*'( ,7( #-*( ]?@@?^*(h=,0F01"D$7&16( &6( E,#.7( #6"( 0#F&"( #6"( ,MM&$&,67( FD0&M&$#7&16( 1M( 7%,( 0#//&7( <H2I!K#( $#]?_^B!)4#.,*(N&1$%&5&$#(H7(N&1F%E.&$#(!$7#'(KYU@]KB?^'(ULBfV*((

\,.-&,'( !*C*+*'( ?@@U*( )%,( &67,:0#7&16( 1M( 5#$0151-,$D-#0( "&MM0#$7&16( "#7#*( !$7#( I0E.7#--1:0*( 8( N&1-*(I0E.7#--1:0*(U?'(FF*(AfBYL*(

\,=E'( 8*'( <,&:6,D0,7'( 3*'( N-DP#7'( !*'( 2&:#D"'( ;*B\*( H=&",6$,( M10( F01716( $1D67,070#6.F107( /E( 7%,(.#0$1F-#.5&$(0,7&$D-D5(I#?_B!)4#.,("D0&6:($#-$&D5(70#6.F107( &6(0,$16.7&7D7,"(F017,1-&F1.15,.([&7%(-1[(&16&$(F,05,#/&-&7n*(;(N&1-(I%,5'(?UY(]KWW@^'(FF*(KWY?AaKWYVA(

\1[0E'( h*R*'( 21.,/01D:%'( J*;*'( g#00'( !*\*'( 2#6"#--'( 2*;*'( KWYK*( 4017,&6( 5,#.D0,5,67( [&7%( 7%,( g1-&6(F%,61-(0,#:,67*(;*(N&1-*(I%,5*(KWV'(FF*(?UYB?LY*(

REFERENCES

107

3#'(R*'(\,[&.'(8*'(SD'(I*'( Q6,.&'(C*'(b()1E1.%&5#'(I*( ]?@@Y^*(gD6$7&16#-(#6"(.70D$7D0#-( 01-,.(1M($0&7&$#-(#5&61( #$&".( [&7%&6( 7%,oJo'( o4o'( #6"( o!o( "15#&6.( 1M( 7%,( I#?_( !)4#.,( ]<H2I!^( %,#"F&,$,*(N&1$%,5&.70E'(AA]??^'(f@W@BfK@@*((

3#$\,66#6'( 8*( R*( ]?@@@^*( I#?_( .&:6#--&6:( #6"( 5D.$-,( "&.,#.,*( HD01F,#6( ;1D06#-( 1M( N&1$%,5&.70E( k(gHN<'(?UL]KL^'(Y?WKBY?WL*((

3#$\HJJ!J'( 8*( R*'( !<!RQ'( 3*'( b( )`4\QJC'( !*( 2*( ]?@@V^*( )%,( 0,:D-#7&16( 1M( <H2I!B7EF,( FD5F.( /E(F%1.F%1-#5/#6(#6"(.#0$1-&F&6*(!66#-.(1M(7%,(J,[(910O(!$#",5E(1M(<$&,6$,.'(WfU]K^'(AL?BAf@*((

3#$\,66#6'(8*(R*'(N0#6"-'(I*( ;*'(Z10$P#O'(N*(b(C0,,6'(J*(3*'(KWfY*(!5&61B#$&"(.,jD,6$,(1M(#(I#?_(_(3:?_B",F,6",67( !)4#.,( M015( 0#//&7( 5D.$-,( .#0$1F-#.5&$( 0,7&$D-D5'( ","D$,"( M015( &7.($15F-,5,67#0E(8J!(.,jD,6$,*(J#7D0,(VKU'(UWUXL@@((

3#$\,66#6'(8*R*(b( Z0#6&#.'( H*C*'( ?@@V*( 4%1.F%1-#5/#6T( #( $0D$&#-( 0,:D-#710( 1M( $#0"&#$( $1670#$7&-&7E*(J#7(2,=(31-*(I,--(N&1-*'(A'(FF*(YUUaYLL*(

3#$\,66#6'(8*R*'(N0#6"-'(I*;*'(Z10$P#O'(N*'(C0,,6'(J*3*'(KWfY*(!5&61B#$&"(.,jD,6$,(1M(#(I#?_(_(3:?_B",F,6",67(!)4#.,(M015(0#//&7(5D.$-,(.#0$1F-#.5&$(0,7&$D-D5'(","D$,"(M015(&7.($15F-,5,67#0E(8J!(.,jD,6$,*(J#7D0,(VKU'(FF*(UWUBL@@*(

3#:01'(3*'(g#0#--&'(!*'(N#0#7,--#'(N*'(N,07&F#:-&#'(Q*'(C&#66,77&'(<*'(<#-=&D-1'(C*'(i/10&-'(2*'(#6"(>&#6,--1(g'(?@K?*(!=&"&6(gD6$7&16#-&P,"(3#:%,5&7,(J#61F#07&$-,.(#6"()%,&0(!FF-&$#7&16(M10(2,$15/&6#67(RD5#6(N&17&6E-B<H2I!(4D0&M&$#7&16*(\#6:5D&0(?f(]AV^'(KYVW?BKYA@K*(

3#0DE#5#'(Z*'(3#$\,66#6'(8*R*'(KWff*(3D7#7&16(1M(#.F#07&$(#$&"BVYK'(-E.&6,BVY?'(#6"(-E.&6,BYKY(#-7,0.(7%,(I#?_(70#6.F107(#$7&=&7E(1M(7%,(I#?_B!)4#.,(,GF0,..,"(&6(Ih<BK($,--.*(401$*(J#7-*(!$#"*(<$&*(`*(<*(!*(fY'(FF*(VVKABVVKf*(

3$I1E'( !*;*'( C01..,BZD6.7-,=,'( 2*+*'( !"#5.'( 4*8*'( +&66'( 3*8*'( <71016&'( \*I*'( ,7( #-*'( ?@@L*( 4%#.,0($0E.7#--1:0#F%&$(.1M7[#0,*(;*(!FF-*(I0E.7#--1:0*(A@'(FF*(UYfBULA*(

3,&..6,0'( C*'( I166,0'( C*H*'( g-,&.$%,0'( <*'( KWLV*( Q.1-#7&16( 1M( .#0$1F-#.5&$( 0,7&$D-D5( /E( P16#-($,670&MD:#7&16(#6"(FD0&M&$#7&16(1M(I#?_BFD5F(#6"(I#?_B/&6"&6:(F017,&6.*(N&1$%&5*(N&1F%E.*(!$7#(?Wf'(FF*(?AUB?UW*(

31--,0'( ;*( >*'( \,61&0'( C*'( \,(3#&0,'(3*'( ;DD-'( N*( <*'(b( I%#5F,&-'( 4*( ]?@@V^*( 4017,1-E7&$( .7D"&,.( 16( 7%,(70#6."D$7&16(5,$%#6&.5(1M(.#0$1F-#.5&$(0,7&$D-D5(I#?_B!)4#.,T(I15516(M,#7D0,.([&7%(17%,0(4B7EF,(!)4#.,.*(!66#-.(1M(7%,(J,[(910O(!$#",5E(1M(<$&,6$,.'(WfU'(f?BfW*((

31--,0'(;*(>*'(\,61&0'(C*'(3#0$%#6"'(I*'(3167&:6E'(I*'(-,(3#&0,'(3*'()1E1.%&5#'(I*'(,7(#-*(]?@@?^*(I#-$&D5(70#6.F107(/E(.#0$1F-#.5&$(0,7&$D-D5($#]?_^B!)4#.,*(01-,(1M(7%,(!("15#&6(#6"(&7.(IB7,05&6#-(-&6O([&7%(7%,(70#6.5,5/0#6,(0,:&16*()%,(;1D06#-(1M(N&1-1:&$#-(I%,5&.70E'(?LL]AK^'(VfUALBVfUYW*((

31--,0'( ;*( >*'( J&..,6'( 4*'( <10,6.,6'( )*( \*'( b( -,( 3#&0,'( 3*( ]?@@Y^*( )0#6.F107( 5,$%#6&.5( 1M( 7%,(.#0$1F-#.5&$(0,7&$D-D5(I#?_(B!)4#.,(FD5F*(ID00,67(hF&6&16(&6(<70D$7D0#-(N&1-1:E'(KY]A^'(VfLBVWV*((

316$1j'(Z*'()0&,/,0'(I*!*'(91D6:'(R*<*'(?@@L*()%,(51-,$D-#0(/#.&.( M10($E$-1F&#P16&$(#$&"( &6%&/&7&16(1M(7%,(.#0$1F-#.5&$(0,7&$D-D5($#-$&D5(FD5F*(;*(N&1-*(I%,5*(?f?'(FF*(WLAfBWLYL*(

108

h/#0#'( Z*'( 3&E#.%&7#'( J*'( SD'( I*'( )1E1.%&5#'( Q*'( <D:&7#'( 9*'( ,7( #-*'( ?@@Y*( <70D$7D0#-( 01-,( 1M($1D67,070#6.F107(0,=,#-,"( &6(I#]?_^(FD5F($0E.7#-(.70D$7D0,( &6(7%,(#/.,6$,(1M(I#]?_^*(401$,,"&6:.(1M(7%,(J#7&16#-(!$#",5E(1M(<$&,6$,.(1M(7%,(`6&7,"(<7#7,.(1M(!5,0&$#(K@?'(FF*(KAAfWBKAAWU*(

h",05#77'(!*'(N#0716'(Z*'(Z%#66#'(>*Z*'(3#7%&,D'(;*'(H.$1-#0'(8*'(,7(#-*'(?@@@*()%,(5D7#7&16(1M(401LfW(71(\,D(0,"D$,.(7%,(#$7&=&7E(1M(7%,(M#.7B7[&7$%(.O,-,7#-(5D.$-,(.#0$1],6"1^F-#.5&$(0,7&$D-D5(I#?_(!)4#.,(]<H2I!K^(#6"(&.(#..1$&#7,"([&7%(N01"E("&.,#.,*(RD5*(C,6,7*(K@U'(FF*(Af?BAWK*(

h-,.,6'(I*'(4&$#0"'(3*'(+&67%,0'(!*(3*'(CE0DF'(I*'(3107%'( ;*(4*'(hG=&:'(I*'(,7(#-*( ]?@@L^*()%,(.70D$7D0#-(/#.&.(1M($#-$&D5(70#6.F107(/E(7%,($#-$&D5(FD5F*(J#7D0,'(AY@]LKL?^'(K@VUBK@A?*((

h-,.,6'(I*'(4&$#0"'(3*'(+&67%,0'(!*(3*'(CE0DF'(I*'(3107%'( ;*(4*'(hG=&:'(I*'(,7(#-*( ]?@@L^*()%,(.70D$7D0#-(/#.&.(1M($#-$&D5(70#6.F107(/E(7%,($#-$&D5(FD5F*(J#7D0,'(AY@]LKL?^'(K@VUBK@A?*((

h-,.,6'( I*'( 4&$#0"'( 3*'( +&67%,0'( !*3*'( CE0DF'( I*'( 3107%'( ;*4*'( ,7( #-*'( ?@@L*( )%,( .70D$7D0#-( /#.&.( 1M($#-$&D5(70#6.F107(/E(7%,($#-$&D5(FD5F*(J#7D0,(AY@'(FF*(K@VUBK@A?*(

h-,.,6'(I*'(<10,6.,6'()*( \*'(J&,-.,6'(2*(I*'(31--,0'( ;*(>*(b(J&..,6'(4*'(?@@A*(8,F%1.F%10E-#7&16(1M( 7%,($#-$&D5(FD5F($1DF-,"(71($1D67,0&16(1$$-D.&16*(<$&,6$,(V@U'(??YKa??YY*(

4&$#0"'(3*'(;,6.,6'(!*(3*'(<10,6.,6'()*(\*'(I%#5F,&-'(4*'(31--,0'(;*(>*'(b(J&..,6'(4*(]?@@L^*(I#?_(=,0.D.(3:?_($110"&6#7&16(#7(7%,(6D$-,17&",B/&6"&6:(.&7,(1M(7%,(.#0$1F-#.5&$(0,7&$D-D5(I#?_B!)4#.,*(;1D06#-(1M(31-,$D-#0(N&1-1:E'(VUf]K^'(KBL*((

4&$#0"'(3*'(;,6.,6'(\*!*B3*'(<p0,6.,6'()*(\*B3*'(I%#5F,&-'(4*'(3p--,0'(;*>*(,7(#-*(?@@L*(I#?_(=,0.D.(3:?_($110"&6#7&16( #7( 7%,( 6D$-,17&",B/&"&6:( .&7,( 1M( 7%,( .#0$1F-#.5&$( 0,7&$D-D5( I#?_B!)4#.,*( ;*(31-*( N&1-*(VUf'(FF*(KBL*(

41.7'( 2*( \*'( R,:E=#0E'( I*( b( ZD5,'( <*'( KWL?*( !$7&=#7&16( /E( #",61.&6,( 70&F%1.F%#7,( &6( 7%,(F%1.F%10E-#7&16( O&6,7&$.( 1M( .1"&D5( #6"( F17#..&D5( &16( 70#6.F107( #",61.&6,( 70&F%1.F%#7#.,*( ;*( N&1-*(I%,5*(?AL'(UYV@XUYA@*(

2#7%'(!*'(C-&/1[&$O#'(3*'(J#",#D'(>*(C*'(I%,6'(C*'(b(8,/,0'(I*(3*(]?@@W^*(8,7,0:,67(/&6"&6:(,GF-#&6.(#615#-1D.( <8<B4!CH( 5&:0#7&16( 1M( 5,5/0#6,( F017,&6.*( 401$,,"&6:.( 1M( 7%,( J#7&16#-( !$#",5E( 1M(<$&,6$,.'(K@U]U^'(KLU@BKLUY*((

<#$$%,771'(2*'(N,07&F#:-&#'(Q*'(C&#66,77&'(<*'(I,6"016'(\*'(3#.$#0,--1'(g*'(8#5&#6&'(H*'(,7(#-*(]?@K?^*(I0E.7#-(.70D$7D0,(1M( .#0$1F-#.5&$( 0,7&$D-D5(I#?_B!)4#.,( ]<H2I!^( M015(/1=&6,(5D.$-,*( ;1D06#-(1M( <70D$7D0#-(N&1-1:E'(KLf]K^'(VfBAA*((

<#$$%,771'( 2*'( N1=1'( H*'( 816,--#B8,#6#'(!*'(8#5&#6&'( H*'( ?@@Y*(C-E$1:,6B( #6"(44K$B7#0:,7&6:( .D/D6&7(C3( &.(F%1.F%10E-#7,"(#7( <,0Af(/E( .#0$1F-#.5&$( 0,7&$D-D5B/1D6"(I#?_B$#-51"D-&6(F017,&6( O&6#.,( &6(0#//&7(M#.7(7[&7$%(.O,-,7#-(5D.$-,*(;*(N&1-*(I%,5*(?f@'(FF*(LKALBLKYY*(

<#$$%,771'( 2*'( ),.716&'( <*'(C,67&-,'(!*'(8#5&#6&'( H*'( 21..&'( ,7( #-*'( ?@@W*(!(",M,$7&=,( <H2I!K(F017,&6( &.(0,.F16.&/-,(M10($16:,6&7#-(F.,D"15E1716&#(&6(I%&#6&6#($#77-,*(!5*(;*(4#7%1-*(KLA'(FF*(YUYBYLV*(

<#$$%,771'( 2*'( ),.716&'( <*'( C,67&-,'( !*'( 8#5&#6&'( H*'( 21..&'( 3*'( \&:D10&'( 2*'( ,7( #-*( ]?@@W^*( !( ",M,$7&=,(<H2I!K(F017,&6(&.(0,.F16.&/-,(M10($16:,6&7#-(F.,D"15E1716&#(&6($%&#6&6#($#77-,*()%,(!5,0&$#6(;1D06#-(1M(4#7%1-1:E'(KLA]?^'(YUYBYLV*((

REFERENCES

109

<#0O#"&'(N*'(H6E,"&'(!*'(gl-",.B4#FF'(i*'(b(Cq0"1.'(C*(]KWfU^*(31-,$D-#0($%#0#$7,0&P#7&16(1M(7%,(&6(.&7D(0,"( $,--( 5,5/0#6,( $#-$&D5( FD5F( /E( -&5&7,"( F017,1-E.&.*( ;1D06#-( 1M( N&1-1:&$#-( I%,5&.70E'( ?UK]?@^'(WYY?BWYYL*((

<%#01='(>*<*'(C#-,=#'(J*!*'(Z6ED.%O1'()*>*'(N&:,-1['(8*;*'(+&--&#5.'()*8*'(,7(#-*'(?@@?*()[1B"&5,6.&16#-(.,F#0#7&16(1M( 7%,(5,5/0#6,(F017,&6( .#0$1F-#.5&$( 0,7&$D-D5(I#B!)4#.,( M10(%&:%BF,0M105#6$,( -&jD&"($%015#71:0#F%EB7#6",5(5#..(.F,$7015,70E(#6#-E.&.(1M(F1.770#6.-#7&16#-(F017,&6(51"&M&$#7&16.*(!6#-*(N&1$%,5*(V@f'(FF*(V?fBVVY(

<p0,6.,6'()*(\*'(3p--,0'( ;*(>*(b(J&..,6'(4*'(?@@A*4%1.F%10E-( 70#6.M,0(#6"($#-$&D5(&16(1$$-D.&16( &6(7%,($#-$&D5(FD5F*(<$&,6$,(V@A'(KUL?XKULY*(

<10,6.,6'( )*'( 31--,0'( ;*>*'( J&..,6'( 4*'( ?@@A*( 4%1.F%10E-( 70#6.M,0( #6"( $#-$&D5( &16( 1$$-D.&16( &6( 7%,($#-$&D5(FD5F*(<$&,6$,(V@A'(FF*(KUL?BKULY*(

)#O#%#.%&'( 3*'( Z16"1D'( 9*'( )1E1.%&5#'( I*'( ?@@L*( Q67,0"15#&6( $155D6&$#7&16( &6( $#-$&D5( FD5F( #.(0,=,#-,"( &6( 7%,($0E.7#-( .70D$7D0,.([&7%( 70#6.5,5/0#6,( &6%&/&710.*(401$*(J#7-*(!$#"*(<$&*(`*(<*(!*(K@A'(FF*(Yf@@BYf@Y*(

)%E-D0'(2*(4*'(Z&5'(9*(8*'(Z[16'(3*(<*'(h%'(R*(3*'(Z[16'(R*(Z*'(Z&5'(<*(R*'(,7(#-*( ]?@@W^*(<[&F01.&6BK( &.(,GF0,..,"( &6( 5#.7( $,--.( #6"( DFB0,:D-#7,"( 7%01D:%( 7%,( F017,&6( O&6#.,( I( /,7#( Qk,7#( F#7%[#E*( ;( I,--(N&1$%,5'(K@f'(L@YBLKY*((

)17-#6"'(C*Z*'(Z0E=&'(R*'(KWWK*(8&.70&/D7&16(F#77,06.(1M(5D.$-,(M&/0,(7EF,.(&6(5#c10(5D.$-,.(1M(7%,(/D--(]N1.(7#D0D.^*(!6#7*(H5/0E1-*(]N,0-^(KfA'(FF*(AAKBAY@*(

)1E1.%&5#'( I*( ]?@@W^*( R1[(I#?_B!)4#.,( FD5F.( &16.( #$01..( 7%,( .#0$1F-#.5&$( 0,7&$D-D5(5,5/0#6,*(N&1$%&5&$#(H7(N&1F%E.&$#(!$7#'(KLWV]U^'(WAKBWAU*((

)1E1.%&5#'(I*(b(3&PD7#6&'()*'(?@@A*I0E.7#-(.70D$7D0,(1M(7%,($#-$&D5(FD5F([&7%(#(/1D6"(!)4(#6#-1:D,*(J#7D0,(AV@'(Y?WXYVY*(

)1E1.%&5#'( I*( b( J15D0#'( R*'( ?@@?*( <70D$7D0#-( $%#6:,.( &6( 7%,( $#-$&D5( FD5F( #$$15F#6E&6:( 7%,("&..1$&#7&16(1M($#-$&D5*(J#7D0,(AKf'(U@YXUKK*(

)1E1.%&5#'(I*'(b(Q6,.&'(C*(]?@@A^*(<70D$7D0#-(/#.&.(1M(&16(FD5F&6:(/E(I#?_B!)4#.,(1M(7%,(.#0$1F-#.5&$(0,7&$D-D5*(!66D#-(2,=&,[(1M(N&1$%,5&.70E'(LV'(?UWB?W?*((

)1E1.%&5#'( I*'( b( 3&PD7#6&'( )*( ]?@@A^*( I0E.7#-( .70D$7D0,( 1M( 7%,( $#-$&D5( FD5F( [&7%( #( /1D6"( !)4(#6#-1:D,*(J#7D0,'(AV@]UWWW^'(Y?WBYVY*((

)1E1.%&5#'(I*'( Q6,.&'(C*'(?@@A*(<70D$7D0#-(/#.&.(1M( &16(FD5F&6:(/E(I!]?_^B!)F#.,(1M(7%,(.#0$1F-#.5&$(0,7&$D-D5*(!66D*(2,=*(N&1$%,5*(LV'(FF*(?UWB?W?*(

)1E1.%&5#'(I*'(3&PD7#6&'()*'(?@@A*(I0E.7#-(.70D$7D0,(1M(7%,($#-$&D5(FD5F([&7%(#(/1D6"(!)4(#6#-1:D,*(J#7D0,(AV@'(FF*(Y?WBYVY*(

)1E1.%&5#'(I*'(J#O#.#O1'(3*'(J15D0#'(R*(b(h:#[#'(R*'(?@@@*(I0E.7#-(.70D$7D0,(1M(7%,($#-$&D5(FD5F(1M(.#0$1F-#.5&$(0,7&$D-D5(#7(?*U(r(0,.1-D7&16*(J#7D0,(A@Y'(UALaUYY*((

)1E1.%&5#'(I*'(J#O#.#O1'(3*'(J15D0#'(R*'(h:#[#'(R*'(?@@@*(I0E.7#-(.70D$7D0,(1M(7%,($#-$&D5(FD5F(1M(.#0$1F-#.5&$(0,7&$D-D5(#7(?*U(r(0,.1-D7&16*(J#7D0,(A@Y'(FF*(UALBUYY*(

110

)1E1.%&5#'( I*'( J15D0#'( R*'( ?@@?*( <70D$7D0#-( $%#6:,.( &6( 7%,( $#-$&D5( FD5F( #$$15F#6E&6:( 7%,("&..1$&#7&16(1M($#-$&D5*(J#7D0,(AKf'(FF*(U@YBUKK*(

)1E1.%&5#'(I*'(916,OD0#'(<*'().D,"#'(;*'( Q[#.#[#'(<*'(?@KK*()0&6&701F%,6E-(",0&=#7&=,.(/&6"("&MM,0,67-E(M015(F#0,67(#",6&6,(6D$-,17&",.(71(I#?_B!)4#.,(&6(7%,(#/.,6$,(1M(I#?_*(401$*(J#7-*(!$#"*(<$&*(`*(<*(!*(K@f'(FF*(KfVVBKfVf*(

>#M&#"#O&'( H*'( 4#F#-1DO#'( >*'( !0=#6&7&.'( 8*'( !*'( Z0#6&#.'( H*'( C*'( <#61D"1D'( 8*'( ?@@W*( )%,( 01-,( 1M(<H2I!?#k4\J( $15F-,G'( I#?_( %15,1.7#.&.'( #6"( #67&B#F1F717&$( F017,&6.( &6( ",7,05&6&6:( $,--( M#7,*(4M-m:,0.(!0$%&=(B(HD01F,#6(;1D06#-(1M(4%E.&1-1:E'(>1-*(AYL]V^'(FF(UfLBL@@*(

>#6",$#,7./,,O'(Q*'(I%0&.7,6.,6'(<*(N*'(\&D'(R*'(>#6(>,-"%1=,6'(4*(4*'(+#,-O,6.'(H*'(H::,05167'(;*'(,7(#-*(]?@KK^*( )%#F.&:#0:&6( #MM&6&7E( FD0&M&$#7&16( 1M( &670#$,--D-#0( 4]?!^B7EF,( $#]?_^( !)4#.,.*( N&1$%&5&$#( H7(N&1F%E.&$#(!$7#'((

>,:#'( Q*(H*'()0#=,0.1'(H*(H*'(g,00,0B!$1.7#'(9*'(3#71.'(H*'(I1-16'(3*'(C16P#-,P'(;*'(,7(#-*( ]?@@f^*(!(61=,-($#-$&D5B/&6"&6:(F017,&6(&.(#..1$&#7,"([&7%(7#D(F017,&6.(&6(7#D1F#7%E*(;(J,D01$%,5'(K@U'(WUBK@U*((

>D#",6.'( g*'( 2DM,0'( J*'( Z0,..'( !*'( I107%,.E'( 4*'( <$%6,&",0'( 4*'(b( )&..17'( ;*( 8*( ]?@@A^*( Q",67&M&$#7&16( 1M(.[&F01.&6(K(&6(%D5#6(-E5F%1$E7,.*(4017,15&$.'(A'(??KUB???@*((

+#6:'( <*( Bd*'( <16:'( \*( B<*'( \#O#77#'( H*( C*( b( I%,6:'( R*( I#?_( .&:6#--&6:( /,7[,,6( .&6:-,( \B7EF,( I#?_($%#66,-.(#6"(0E#61"&6,(0,$,F710.(&6(%,#07($,--.*(J#7D0,(AK@'(YW?aYWU(]?@@K^*(

+&67%,0'(!*\*'(\&D'(R*'(<1667#:'(9*'(h-,.,6'(I*'(\,(3#&0,'(3*'(,7(#-*'(?@K@*(I0&7&$#-(01-,.(1M(%E"01F%1/&$&7E(#6"( 10&,67#7&16( 1M( .&",( $%#&6.( M10( &6#$7&=#7&16( 1M( .#0$1F-#.5&$( 0,7&$D-D5( I#?_B!)4#.,( [&7%(7%#F.&:#0:&6(#6"(7%#F.&:#0:&6(#6#-1:.*(;*(N&1-*(I%,5*(?fY'(FF*(?fffVB?ffW?*(

SD'( I*'( 2&$,'( +*;*'( R,'( +*'( <71O,.'( 8*\*'( ?@@?*( !( .70D$7D0#-( 51",-( M10( 7%,( $#7#-E7&$( $E$-,( 1M( I#]?_^B!)4#.,*(;*(31-*(N&1-*(VKU'(FF*(?@KB?KK*(

iD1'( <*'( b( \D6"#%-'( 4*( ]?@@@^*( !( 5&$01B/0#"M10"( 5,5/0#6,( F017,&6( #..#E*( !6#-E7&$#-( N&1$%,5&.70E'(?fA]K^'(KU?BKUA*((

(

(

(

ACKNOWLEDGMENTS

111

ACKNOWLEDGMENTS

!"#$%&'"&()*"+$"*,-.*//"01"/(23*.*"4.5+(+%'*"+$"01"/%-*.6(/$."7.$89":(%/*--*";52$++("8$."

<(/"(265&%5=&*"/%--$.+"52'"5//(/+523*"'%.(24"01"7<>"-.$4.509"!"352"2*6*."+<52)"<(0"*2$%4<"

8$."+<*"$--$.+%2(+1"+$")2$#"52'"*2+*."(2+$"+<*"505?(24"#$.&'"$8"3.1/+5&&$4.5-<19"

!" #52+" +$" *,+*2'" 01" /-*3(5&" +<52)/" +$" >." !&*2(5" @*.+(-54&(5" 8$." /<5.*'" <*." -*./$25&"

*,-*.(*23*"#(+<"0*"52'" 8$."5&&"2(3*" +(0*"/-*2+" +$4*+<*.9"A(+<$%+"<*." 3$2/+52+" /%--$.+"52'"

*23$%.54*0*2+B"+<(/"'(//*.+5+($2"3$%&'"2$+"<56*"=**2"#.(++*29"C<52)"1$%D"

E" /-*3(5&" +<52)" +$" >.9" F5%.5" G*2'.$2" 8$." +<*" 4.*5+" <*&-" (2" 5//(/+(24" 01" .*/*5.3<"

*,-*.(0*2+/"#(+<"*2+<%/(5/0"52'")(2'2*//9""

C<52)/"+$"5&&"+<*"3$&&*54%*/"#(+<"#<$0"!"<5'"+<*"$--$.+%2(+1"+$"#$.)H"I52'.5B":($.4(5B"

F$.*2?5B" J%252B" I5.5B" 52'" J5.3$9" !" #$%&'" &()*" +$" +<52)/" 5&/$" F5%.5" >$2'(2(" 8$." <*."

-<1/($&$4(35&"52'"+*3<2(35&"5//(/+523*"'%.(24"+<*"53<(*6*0*2+"$8"+<(/"'(//*.+5+($29"

!" 8(25&&1" #52+" +$" +<52)" 01" -5.*2+/" 52'" 8.(*2'/" +<5+" <56*" 5&#51/" *23$%.54*'" 0*" +$"

-%./%*"01"/3(*2+(8(3"35.**.9"